<SEC-DOCUMENT>0001493152-24-045894.txt : 20241114
<SEC-HEADER>0001493152-24-045894.hdr.sgml : 20241114
<ACCEPTANCE-DATETIME>20241114161550
ACCESSION NUMBER:		0001493152-24-045894
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		46
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241114
DATE AS OF CHANGE:		20241114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Glucotrack, Inc.
		CENTRAL INDEX KEY:			0001506983
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				980668934
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41141
		FILM NUMBER:		241462551

	BUSINESS ADDRESS:	
		STREET 1:		301 RT 17 NORTH
		STREET 2:		SUITE 800
		CITY:			RUTHERFORD
		STATE:			NJ
		ZIP:			07070
		BUSINESS PHONE:		972 (8) 675-7878

	MAIL ADDRESS:	
		STREET 1:		301 RT 17 NORTH
		STREET 2:		SUITE 800
		CITY:			RUTHERFORD
		STATE:			NJ
		ZIP:			07070

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GlucoTrack, Inc.
		DATE OF NAME CHANGE:	20220328

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Integrity Applications, Inc.
		DATE OF NAME CHANGE:	20101203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:GCTK="http://glucotrack.com/20240930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_GCTK_glucotrack.com_20240930 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20240101_20240930 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DDocumentFiscalPeriodFocus_Q3 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001506983 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06F_Israel_0_iso4217%2D%2DILS -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000005" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000006" name="dei:EntityCentralIndexKey">0001506983</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="xdx2ixbrl0057" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0078" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:PromissoryNotesCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0081" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0084" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-12-31" id="xdx2ixbrl0087" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0102" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-09-30" id="xdx2ixbrl0107" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:MarketingExpense" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl0159" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:MarketingExpense" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0161" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl0179" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0181" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0249" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0250" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0251" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0252" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0257" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-01-012023-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0258" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted" contextRef="From2023-01-012023-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted" contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0273" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-07-012023-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-012023-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares" contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares" contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares" contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares" contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions" contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions" contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions" contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0426" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0434" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0435" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0470" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0475" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0476" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-07-012024-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0477" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0479" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0482" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2024-07-012024-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0486" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0490" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0492" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0493" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity" contextRef="From2024-07-012024-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0498" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0500" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfWarrant" contextRef="From2024-07-012024-09-30_custom_ReceiptsOnAccountOfSharesMember" id="xdx2ixbrl0507" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfWarrant" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0508" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfWarrant" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0509" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0553" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:RevaluationExpensesRelatedToDerivativeFinancialLiabilities" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0556" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0559" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0580" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0583" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0589" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0592" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0595" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:ProceedsFromConvertibleDebtPrivatePlacementTransaction" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0598" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:ProceedsReceivedFromUnderwrittenPublicOffering" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl0600" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0625" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:DeemedDividendUponTriggerOfDownRoundProtection" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl0630" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0634" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0637" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0684" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl0685" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl0686" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-07-012024-09-30_custom_PrefundedWarrantsMember" id="xdx2ixbrl0710" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-07-012024-09-30_custom_PrefundedWarrantsMember" id="xdx2ixbrl0712" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-012023-09-30_custom_PrefundedWarrantsMember" id="xdx2ixbrl0714" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-012023-09-30_custom_PrefundedWarrantsMember" id="xdx2ixbrl0716" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-09-30_custom_PrefundedWarrantsMember" id="xdx2ixbrl0718" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-09-30_custom_PrefundedWarrantsMember" id="xdx2ixbrl0720" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-012023-09-30_custom_PerformanceMilestoneMember" id="xdx2ixbrl0730" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-012023-09-30_custom_PerformanceMilestoneMember" id="xdx2ixbrl0732" unitRef="Shares" xs:nil="true"/>
  <ix:nonNumeric contextRef="AsOf2024-06-27" id="xdx2ixbrl0838" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2023-12-31_custom_JuneTwentySevenWarrantsMember" id="xdx2ixbrl0852" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2023-12-31_custom_JulyEighteenNotesMember" id="xdx2ixbrl0876" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2023-12-31_custom_JulyThirtyNotesMember" id="xdx2ixbrl0929" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-12-31" id="xdx2ixbrl0943" unitRef="USD" xs:nil="true"/>
  <ix:nonNumeric contextRef="AsOf2024-08-23_custom_AugustTwentyThreeWarrantMember" id="xdx2ixbrl0959" name="us-gaap:WarrantsAndRightsOutstandingTerm">P10Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-09-05_custom_SeptemberFiveWarrantsMember" id="xdx2ixbrl0987" name="us-gaap:WarrantsAndRightsOutstandingTerm">P10Y</ix:nonNumeric>
  <ix:nonFraction name="GCTK:DiscountAmortizationAndInterestExpensesOne" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl1040" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:DiscountAmortizationAndInterestExpensesOne" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl1042" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl1045" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl1047" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:DiscountAmortizationAndInterestExpensesTwo" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl1050" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:DiscountAmortizationAndInterestExpensesTwo" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl1052" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:RevaluationExpensesRelatedToDerivativeFinancialLiabilities" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl1055" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:RevaluationExpensesRelatedToDerivativeFinancialLiabilities" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl1057" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl1060" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GCTK:RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl1062" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl1070" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl1072" unitRef="USD" xs:nil="true"/>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="gctk-20240930.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ReceiptsOnAccountOfSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ReceiptsOnAccountOfSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_ReceiptsOnAccountOfSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ReceiptsOnAccountOfSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ReceiptsOnAccountOfSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ReceiptsOnAccountOfSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_ReceiptsOnAccountOfSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ReceiptsOnAccountOfSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ReceiptsOnAccountOfSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ReceiptsOnAccountOfSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_ReceiptsOnAccountOfSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ReceiptsOnAccountOfSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ReceiptsOnAccountOfSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_ReceiptsOnAccountOfSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ReceiptsOnAccountOfSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ReceiptsOnAccountOfSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ReceiptsOnAccountOfSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_ReceiptsOnAccountOfSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ReceiptsOnAccountOfSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_PerformanceMilestoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:PerformanceMilestoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_PerformanceMilestoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:PerformanceMilestoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_PerformanceMilestoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:PerformanceMilestoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_PerformanceMilestoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:PerformanceMilestoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-032024-01-03_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-03</xbrli:startDate>
        <xbrli:endDate>2024-01-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-13_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-132024-02-13_custom_ExchangeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:ExchangeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-13</xbrli:startDate>
        <xbrli:endDate>2024-02-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-13_custom_ExchangeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:ExchangeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-192024-02-19_us-gaap_LeaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-19</xbrli:startDate>
        <xbrli:endDate>2024-02-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-19_us-gaap_LeaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-222024-04-22_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-22</xbrli:startDate>
        <xbrli:endDate>2024-04-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-22_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-302024-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-30</xbrli:startDate>
        <xbrli:endDate>2024-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-27_custom_UnsecuredPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GCTK:UnsecuredPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-272024-06-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-27</xbrli:startDate>
        <xbrli:endDate>2024-06-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-18_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-182024-07-18_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-18</xbrli:startDate>
        <xbrli:endDate>2024-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-30_custom_ConvertiblePromissoryNotesMember_custom_WarrantsAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">GCTK:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:WarrantsAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-302024-07-30_custom_ConvertiblePromissoryNotesMember_custom_WarrantsAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">GCTK:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:WarrantsAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-30</xbrli:startDate>
        <xbrli:endDate>2024-07-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-302024-07-30_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">GCTK:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-30</xbrli:startDate>
        <xbrli:endDate>2024-07-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-30_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-302024-07-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-30</xbrli:startDate>
        <xbrli:endDate>2024-07-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-302024-07-30_custom_FirstWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:FirstWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-30</xbrli:startDate>
        <xbrli:endDate>2024-07-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-30_custom_FirstWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:FirstWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-302024-07-30_custom_SecondWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:SecondWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-30</xbrli:startDate>
        <xbrli:endDate>2024-07-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-30_custom_SecondWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:SecondWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-302024-07-30_custom_ThirdWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ThirdWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-30</xbrli:startDate>
        <xbrli:endDate>2024-07-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-30_custom_ThirdWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ThirdWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-232024-08-23_custom_JuneTwentySevenNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JuneTwentySevenNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-23</xbrli:startDate>
        <xbrli:endDate>2024-08-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-23_custom_JuneTwentySevenNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JuneTwentySevenNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-152024-10-15_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-15</xbrli:startDate>
        <xbrli:endDate>2024-10-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-232024-08-23_custom_AugustTwentyThreeWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:AugustTwentyThreeWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-23</xbrli:startDate>
        <xbrli:endDate>2024-08-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-23_custom_AugustTwentyThreeWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:AugustTwentyThreeWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-23_custom_AugustTwentyThreeWarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:AugustTwentyThreeWarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-23_custom_AugustTwentyThreeWarrantTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:AugustTwentyThreeWarrantTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-23_custom_AugustTwentyThreeWarrantThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:AugustTwentyThreeWarrantThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-052024-09-05_custom_JuneTwentySevenNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JuneTwentySevenNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-05</xbrli:startDate>
        <xbrli:endDate>2024-09-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-052024-09-05_custom_JulyEighteenNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JulyEighteenNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-05</xbrli:startDate>
        <xbrli:endDate>2024-09-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-23_custom_JulyTwentySevenNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JulyTwentySevenNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-152024-10-15_us-gaap_SubsequentEventMember_custom_JuneTwentySevenNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JuneTwentySevenNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-15</xbrli:startDate>
        <xbrli:endDate>2024-10-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-052024-09-05_custom_SeptemberFiveWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:SeptemberFiveWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-05</xbrli:startDate>
        <xbrli:endDate>2024-09-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-05_custom_SeptemberFiveWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:SeptemberFiveWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-05_custom_SeptemberFiveWarrantsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:SeptemberFiveWarrantsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-05_custom_SeptemberFiveWarrantsTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:SeptemberFiveWarrantsTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-05_custom_SeptemberFiveWarrantsThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:SeptemberFiveWarrantsThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_JuneTwentySevenWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JuneTwentySevenWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_JulyEighteenNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JulyEighteenNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_JulyThirteenNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JulyThirteenNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_LessThanOneYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">GCTK:LessThanOneYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_BetweenOneYearToTwoYearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">GCTK:BetweenOneYearToTwoYearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_MoreThanTwoYearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">GCTK:MoreThanTwoYearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_JuneTwentySevenWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JuneTwentySevenWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_JuneTwentySevenWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JuneTwentySevenWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_JulyEighteenNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JulyEighteenNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_JulyEighteenNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JulyEighteenNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_JulyThirtyNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JulyThirtyNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_JulyThirtyNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JulyThirtyNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_JulyThirtyNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JulyThirtyNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2004-03-04_custom_IsraeliInnovationAuthorityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">GCTK:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2004-03-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2004-03-032004-03-04_custom_IsraeliInnovationAuthorityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">GCTK:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2004-03-03</xbrli:startDate>
        <xbrli:endDate>2004-03-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2004-03-032004-03-04_custom_IsraeliInnovationAuthorityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">GCTK:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2004-03-03</xbrli:startDate>
        <xbrli:endDate>2004-03-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2004-03-04_custom_IsraeliInnovationAuthorityMember29980703">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">GCTK:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2004-03-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_IsraeliInnovationAuthorityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">GCTK:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-072022-10-07_custom_IntellectualPropertyPurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:IntellectualPropertyPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-07</xbrli:startDate>
        <xbrli:endDate>2022-10-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-072022-10-07_custom_IntellectualPropertyPurchaseAgreementMember_us-gaap_CommonStockMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:IntellectualPropertyPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-07</xbrli:startDate>
        <xbrli:endDate>2022-10-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-07_custom_IntellectualPropertyPurchaseAgreementMember_us-gaap_CommonStockMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:IntellectualPropertyPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-07_custom_IntellectualPropertyPurchaseAgreementMember_us-gaap_CommonStockMember_srt_MinimumMember_custom_TrueupSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:IntellectualPropertyPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GCTK:TrueupSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-012023-06-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-01</xbrli:startDate>
        <xbrli:endDate>2023-06-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-122024-11-12_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-12</xbrli:startDate>
        <xbrli:endDate>2024-11-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_SeriesACommonWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GCTK:SeriesACommonWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_SeriesBCommonWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GCTK:SeriesBCommonWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_PrefundedWarrantsMember29981921">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GCTK:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-122024-11-12_us-gaap_SubsequentEventMember_custom_JulyThirtyNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:JulyThirtyNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-12</xbrli:startDate>
        <xbrli:endDate>2024-11-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_JulyThirtyNotesMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:JulyThirtyNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_JulyThirtyNotesMember_custom_SeriesACommonWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:JulyThirtyNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:SeriesACommonWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_JulyThirtyNotesMember_custom_SeriesCommonWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:JulyThirtyNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:SeriesCommonWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_JulyThirtyNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:JulyThirtyNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Israel">
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="xdx2ixbrl0286" toRefs="Footnote000529"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90B_edei--DocumentType_c20240101__20240930_zXMXZcVsyUXb"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000013" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--DocumentQuarterlyReport_c20240101__20240930_ziXkupcqLL0d"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" format="ixt:booleantrue" id="Fact000014" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>QUARTERLY
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the quarterly period ended <span style="text-decoration: underline"><span id="xdx_901_edei--DocumentPeriodEndDate_c20240101__20240930_znJ1BDwR5241"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" format="ixt:datemonthdayyearen" id="Fact000015" name="dei:DocumentPeriodEndDate">September 30, <span id="xdx_90B_edei--DocumentFiscalYearFocus_c20240101__20240930_zfvwzBZ1lyVi"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000016" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--DocumentTransitionReport_c20240101__20240930_zSKj5llPeaYg"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" format="ixt:booleanfalse" id="Fact000017" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the transition period from ________________ to ________________</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number: <span id="xdx_90A_edei--EntityFileNumber_c20240101__20240930_z2xsRND6tk2i"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000018" name="dei:EntityFileNumber">001-41141</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90C_edei--EntityRegistrantName_c20240101__20240930_zNgqRcxmKxg5"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000019" name="dei:EntityRegistrantName">GLUCOTRACK,
INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20240101__20240930_zAtQ2UonoBWg"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" format="ixt-sec:stateprovnameen" id="Fact000020" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20240101__20240930_z92NSz7ORgla"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000021" name="dei:EntityTaxIdentificationNumber">98-0668934</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of <br/>
    incorporation or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer <br/>
    Identification No.)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityAddressAddressLine1_c20240101__20240930_zl1jgCHSn4Kj"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000022" name="dei:EntityAddressAddressLine1">301
    Route 17 North</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressAddressLine2_c20240101__20240930_z0BUXYr00gdk"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000023" name="dei:EntityAddressAddressLine2">Suite 800</ix:nonNumeric> </span><br/>
    <span id="xdx_905_edei--EntityAddressCityOrTown_c20240101__20240930_ztaSBBoIXzeh"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000024" name="dei:EntityAddressCityOrTown">Rutherford</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressStateOrProvince_c20240101__20240930_zDRSNoMKrHRg"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000025" name="dei:EntityAddressStateOrProvince">NJ</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--EntityAddressPostalZipCode_c20240101__20240930_z1fXgwcRZMqh"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000026" name="dei:EntityAddressPostalZipCode">07070</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--CityAreaCode_c20240101__20240930_z6eRrGPot0Bc"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000027" name="dei:CityAreaCode">(201)</ix:nonNumeric></span>
<span id="xdx_904_edei--LocalPhoneNumber_c20240101__20240930_z25HDAlruQV3"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000028" name="dei:LocalPhoneNumber">842-7715</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name, former address and former fiscal year, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(b) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--Security12bTitle_c20240101__20240930_zR7sjJQTdWR1"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000029" name="dei:Security12bTitle">Common
    Stock</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--TradingSymbol_c20240101__20240930_znZAOL68348d"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000030" name="dei:TradingSymbol">GCTK</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_900_edei--SecurityExchangeName_c20240101__20240930_zUDED70Yi8a2"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_900_edei--EntityCurrentReportingStatus_c20240101__20240930_zJniE5W0wny"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000032" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was required to submit and post such files). <span id="xdx_906_edei--EntityInteractiveDataCurrent_c20240101__20240930_zCYuE4Ehe9vd"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000033" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntityFilerCategory_c20240101__20240930_zY1DZVRkcimi"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" format="ixt-sec:entityfilercategoryen" id="Fact000034" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_90A_edei--EntitySmallBusiness_c20240101__20240930_zhmltX5UDcYb"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" format="ixt:booleantrue" id="Fact000035" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20240101__20240930_zrIfEThRcqC"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" format="ixt:booleanfalse" id="Fact000036" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <span id="xdx_903_edei--EntityShellCompany_dbF_c20240101__20240930_zbdYtWoblmLk"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" format="ixt:booleanfalse" id="Fact000037" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of November 3, 2024, <span id="xdx_90D_edei--EntityCommonStockSharesOutstanding_iI_pid_c20241103_zvm38g12YoAb"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-11-03" id="Fact000038" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,772,026</ix:nonFraction></span> shares of the Company&#8217;s common stock, par value $<span id="xdx_90D_edei--EntityListingParValuePerShare_c20240101__20240930_zNEA2DPt7Yz7"><ix:nonFraction name="dei:EntityListingParValuePerShare" contextRef="From2024-01-01to2024-09-30" id="Fact000039" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share, were outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; vertical-align: top"><a href="#b_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART I - FINANCIAL INFORMATION</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_005">Item 1. Financial Statements.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; vertical-align: top"><a href="#b_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Balance Sheets</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; vertical-align: top"><a href="#b_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; vertical-align: top"><a href="#b_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity (Deficit)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; vertical-align: top"><a href="#b_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Statements of Cash Flows</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; vertical-align: top"><a href="#b_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Condensed Consolidated Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_011">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_012">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_013">Item 4. Controls and Procedures.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#b_014">PART II - OTHER INFORMATION</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_015">Item 1. Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_016">Item 1A. Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_017">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_018">Item 3. Defaults Upon Senior Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_019">Item 4. Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_020">Item 5. Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_021">Item 6. Exhibits.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#b_021">EXHIBIT INDEX</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#b_022">SIGNATURES</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY
NOTE REGARDING FORWARD LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Quarterly Report on Form 10-Q includes forward-looking statements. These forward-looking statements include statements about our expectations,
beliefs or intentions regarding our product development efforts, business, financial condition, results of operations, strategies or
prospects. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q, including statements
regarding our future activities, events or developments, including such things as future revenues, product development, clinical trials,
regulatory approval, market acceptance, responses from competitors, capital expenditures (including the amount and nature thereof), business
strategy and measures to implement strategy, competitive strengths, goals, expansion and growth of our business and operations, plans,
references to future success, projected performance and trends, and other such matters, are forward-looking statements. The words &#8220;believe,&#8221;
&#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221;
&#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and other similar words and phrases or the negative
of such terms, are intended to identify forward-looking statements. The forward-looking statements made in this Quarterly Report on Form
10-Q are based on certain historical trends, current conditions and expected future developments, as well as other factors we believe
are appropriate in the circumstances. These statements relate only to events as of the date on which the statements are made and we undertake
no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise,
except as required by law. All of the forward-looking statements made in this Quarterly Report on Form 10-Q are qualified by these cautionary
statements and there can be no assurance that the actual results anticipated by us will be realized or, even if substantially realized,
that they will have the expected consequences to or effects on us or our business or operations. Whether actual results will conform
to our expectations and predictions is subject to a number of risks and uncertainties that may cause actual results to differ materially.
Risks and uncertainties, the occurrence of which could adversely affect our business, include the risks identified in our Annual Report
on Form 10-K for year ended December 31, 2023, under the caption &#8220;Risk Factors.&#8221; We undertake no obligation to publicly update
or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this report unless required
by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="b_004"></span><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>PART
I - FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="b_005"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
1. Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="b_006"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i<b>n
thousands of US dollars except share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_111_pn3n3_zkGUKeZ2VlS4" summary="xdx: Statement - Condensed Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240930_zbqnKXD1i6Xg" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20231231_zdJz7fM0yTCf" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsCurrentAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_maACz5I2_zDZpzbLM5Jhi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-09-30" id="Fact000047" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">346</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000048" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,492</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherAssetsCurrent_i01I_pn3n3_maACz5I2_zU0FVUePiYB9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2024-09-30" id="Fact000050" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">296</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000051" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">376</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsCurrent_i01TI_pn3n3_mtACz5I2_maAzJXn_zcWEmr4mLQ01" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-09-30" id="Fact000053" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">642</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000054" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,868</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_maAzJXn_zGYDVizviV96" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease right-of-use asset, net (Note 3C)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-09-30" id="Fact000056" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0057">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_maAzJXn_zUqrGCYrvola" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-09-30" id="Fact000059" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000060" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_maAzJXn_ziA6BneI3G2a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Restricted cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="AsOf2024-09-30" id="Fact000062" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="AsOf2023-12-31" id="Fact000063" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--Assets_iTI_pn3n3_mtAzJXn_zAqCrbQaaSO" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-09-30" id="Fact000065" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">826</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000066" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,905</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccountsPayableCurrent_i02I_pn3n3_maLCzzdb_ztzr3OpAaXU" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-09-30" id="Fact000074" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,857</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">839</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pn3n3_maLCzzdb_zCpKIwgk5OU3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating lease liability, current (Note 3C)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-09-30" id="Fact000077" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0078">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--PromissoryNotesCurrent_i02I_pn3n3_maLCzzdb_zlzFnnoNTzb5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Promissory notes (Note 3G and Note 3H)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:PromissoryNotesCurrent" contextRef="AsOf2024-09-30" id="Fact000080" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,988</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0081">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ConvertibleNotesPayableCurrent_i02I_pn3n3_maLCzzdb_z45M0dgM3kSb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Convertible promissory notes (Note 3F)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2024-09-30" id="Fact000083" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0084">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DerivativeLiabilities_i02I_pn3n3_maLCzzdb_z4USkuNXKJv1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Derivative financial liabilities (Note 3G and Note 3H)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-09-30" id="Fact000086" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0087">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherLiabilitiesCurrent_i02I_pn3n3_maLCzzdb_zIC1mazLsAR9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-09-30" id="Fact000089" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">699</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">673</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesCurrent_i02TI_pn3n3_mtLCzzdb_maLzCD8_zITFbkj06wD1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-09-30" id="Fact000092" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,611</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,512</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesNoncurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherLiabilitiesNoncurrent_i02I_pn3n3_maLzCD8_z4qTO7DJ8Fok" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loans from stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2024-09-30" id="Fact000098" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">197</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">196</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_pn3n3_maLzCD8_zsSxUpiRubyh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Operating lease liability, non-current (Note 3C)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-09-30" id="Fact000101" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0102">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Liabilities_i01TI_pn3n3_mtLzCD8_maLASEzMIZ_zA89c7sfyXqd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-09-30" id="Fact000104" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,848</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000105" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,708</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CommitmentsAndContingencies_i01I_pn3n3_maLASEzMIZ_zdWR9M7gxL8b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Commitments and contingent liabilities (Note 4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0107">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Common Stock of $ <span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240930_zXqvilWB5rSg" title="Common stock, par value"><span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zHDqbDKGPEji" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30" id="Fact000113" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000115" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value (&#8220;Common Stock&#8221;):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommonStockValue_i02I_pn3n3_maSEzLZO_zL9iEqWnczmg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify"><span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240930_ze2ky10nLtXa" title="Common stock, shares authorized"><span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_z12mA7tbCErb" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-09-30" id="Fact000120" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000122" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized as of September 30, 2024 and December 31, 2023; <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_pid_c20240930_z64F0heBHeAl" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240930_zluaN8j4fBil" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-09-30" id="Fact000124" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-09-30" id="Fact000126" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,772,026</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zMnVXtjqVGUd" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zh2FYDjmBK18" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000128" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000130" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,178,274</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-09-30" id="Fact000117" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000118" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommonStockValue_i02I_pn3n3_maSEzLZO_zGZH29remEmh" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Common Stock of $ 0.001 par value (&#8220;Common Stock&#8221;):100,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 5,772,190 and 4,178,274 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-09-30" id="Fact000132" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000133" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_pn3n3_maSEzLZO_zKegSUWWg455" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2024-09-30" id="Fact000135" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">118,223</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2023-12-31" id="Fact000136" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112,982</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ReceiptsOnAccountOfShares_i02I_pn3n3_maSEzLZO_zDFxtI7j75ni" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Receipts on account of shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:ReceiptsOnAccountOfShares" contextRef="AsOf2024-09-30" id="Fact000138" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:ReceiptsOnAccountOfShares" contextRef="AsOf2023-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_pn3n3_maSEzLZO_zH6SSQCw5T0c" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accumulated other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2024-09-30" id="Fact000141" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-12-31" id="Fact000142" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pn3n3_maSEzLZO_zCmXVpTlfxlc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-09-30" id="Fact000144" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">122,356</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000145" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">109,853</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--StockholdersEquity_i02TI_pn3n3_mtSEzLZO_maLASEzMIZ_zVmDBXiEfdmi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Total stockholders&#8217; (deficit) equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000147" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,022</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000148" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,197</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pn3n3_mtLASEzMIZ_zDgemjwvi1nd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000150" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">826</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,905</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed interim consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="b_007"></span><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US dollars except share data) (unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_113_pn3n3_zWXpZNw2Zcda" summary="xdx: Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240701__20240930_zs1ySKkznoc1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230701__20230930_zXraoGNaoOpd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20240930_zavCooevm4ie" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20230930_z6CKjv1VNGHe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Three-month period ended<br/>
 September 30,</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Nine-month period ended<br/>
 September 30,</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_maOEz8jw_zl1DCeCUHLJk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Research and development expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30" id="Fact000153" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,063</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30" id="Fact000154" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,693</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-09-30" id="Fact000155" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,800</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30" id="Fact000156" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,962</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--MarketingExpense_maOEz8jw_z9BwKVkX1i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketingExpense" contextRef="From2024-07-012024-09-30" id="Fact000158" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">125</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0159">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketingExpense" contextRef="From2024-01-01to2024-09-30" id="Fact000160" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">295</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0161">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_maOEz8jw_z8Cz2PxYApBc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-07-012024-09-30" id="Fact000163" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,063</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-07-012023-09-30" id="Fact000164" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">531</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-09-30" id="Fact000165" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,598</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-09-30" id="Fact000166" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,725</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingExpenses_iT_pn3n3_mtOEz8jw_msOILzcJl_zaQDo5EaLzXc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-07-012024-09-30" id="Fact000168" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,251</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-07-012023-09-30" id="Fact000169" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,224</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-01to2024-09-30" id="Fact000170" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,693</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-09-30" id="Fact000171" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,687</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingIncomeLoss_iNT_pn3n3_di_mtOILzcJl_maFINzkPq_zGvzaPIkmM5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact000173" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,251</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-07-012023-09-30" id="Fact000174" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,224</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-09-30" id="Fact000175" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,693</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-09-30" id="Fact000176" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,687</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherNonoperatingIncomeExpense_iN_di_maFINzkPq_zswofZy6Pyuh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-07-012024-09-30" id="Fact000178" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0179">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-01to2024-09-30" id="Fact000180" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0181">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--FinanceIncomeNet_iN_di_maFINzkPq_z5TmfkEnk6ol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Finance (income) expenses, net (Note 5)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="GCTK:FinanceIncomeNet" contextRef="From2024-07-012024-09-30" id="Fact000183" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,848</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="GCTK:FinanceIncomeNet" contextRef="From2023-07-012023-09-30" id="Fact000184" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="GCTK:FinanceIncomeNet" contextRef="From2024-01-01to2024-09-30" id="Fact000185" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,822</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="GCTK:FinanceIncomeNet" contextRef="From2023-01-012023-09-30" id="Fact000186" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_iNT_pn3n3_di_mtFINzkPq_maCINOTz4Ng_zXwbpdaX45Te" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact000188" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,087</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30" id="Fact000189" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,223</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-09-30" id="Fact000190" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,503</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30" id="Fact000191" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,685</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other comprehensive (income) loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_i01N_pn3n3_di_maCINOTz4Ng_zrKjmvD7G8p2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-07-012024-09-30" id="Fact000198" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-07-012023-09-30" id="Fact000199" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-01to2024-09-30" id="Fact000200" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-09-30" id="Fact000201" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ComprehensiveIncomeNetOfTax_i01NT_pn3n3_di_mtCINOTz4Ng_zArUNSiyyy0f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Comprehensive loss for the period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-07-012024-09-30" id="Fact000203" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,104</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-07-012023-09-30" id="Fact000204" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,217</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-01to2024-09-30" id="Fact000205" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,514</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-09-30" id="Fact000206" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,668</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per common stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_pid_c20240701__20240930_zBvu6S8mGtV2" title="Basic net loss per common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20240701__20240930_zVZKQVsdl2Lk" title="Diluted net loss per common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-07-012024-09-30" id="Fact000208" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-07-012024-09-30" id="Fact000210" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.91</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230701__20230930_z1MOFHsfl9N1" title="Basic net loss per common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_pid_c20230701__20230930_zUZOyVx7xjDl" title="Diluted net loss per common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-07-012023-09-30" id="Fact000212" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-07-012023-09-30" id="Fact000214" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.49</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_pid_c20240101__20240930_zGLFcL63j8Ij" title="EarningsPerShareDiluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20240930_z7KA1fHw0Uy3" title="Diluted net loss per common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-09-30" id="Fact000216" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-09-30" id="Fact000218" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.39</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_pid_c20230101__20230930_z9SpSKui4y9b" title="Basic net loss per common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230930_zs1ZkhhwYhC4" title="Diluted net loss per common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-09-30" id="Fact000220" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-09-30" id="Fact000222" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.38</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average number of common stock used in computing basic and diluted loss per common stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930_zrpPfuTgvQTb" title="Weighted average number of common stock outstanding used in computing basic net loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930_zSBqeKkPyyfd" title="Weighted average number of common stock outstanding used in computing diluted net loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-07-012024-09-30" id="Fact000224" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-07-012024-09-30" id="Fact000226" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,594,880</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930_zTnaaoOSwcVa" title="Weighted average number of common stock outstanding used in computing basic net loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930_zPgimZ3Edqvc" title="Weighted average number of common stock outstanding used in computing diluted net loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-012023-09-30" id="Fact000228" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-012023-09-30" id="Fact000230" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,593,733</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930_ztHU7qgvAA2c" title="Weighted average number of common stock outstanding used in computing basic net loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930_zEf0XxlaXnJk" title="Weighted average number of common stock outstanding used in computing diluted net loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-09-30" id="Fact000232" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-09-30" id="Fact000234" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,355,806</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930_zwupcoAQE03l" title="Weighted average number of common stock outstanding used in computing basic net loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930_zSemLd9JxGkf" title="Weighted average number of common stock outstanding used in computing diluted net loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-09-30" id="Fact000236" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-09-30" id="Fact000238" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,006,527</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed interim consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="b_008"></span><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars except share data) (unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_114_pn3n3_zCCA25fpZJah" summary="xdx: Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z1Uf8CrNvpua">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z6Vpgpd4ZWIb">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_custom--ReceiptsOnAccountOfSharesMember_zU14FSxcDSs4">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zlEsVGOSvOsj">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zvwlxqsYO7he">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4BF_zX1KNkeeZtNa">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="26" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In thousands of US Dollars (except share data)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Additional</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">Receipts <br/> </td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated <br/> Other</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Total<br/>
 Stockholders&#8217;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Numbers of <br/> Shares</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Paid-in <br/> Capital</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="margin-top: 0; margin-bottom: 0">on account</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">of shares</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Comprehensive <br/> Income</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated <br/> Deficit</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Equity<br/>
 (Deficit)</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_43E_c20230101__20230930_eus-gaap--StockholdersEquity_iS_zixRHv0qSDL7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; font-weight: bold">Balance as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXoUyjP5Bah4" title="Balance, shares" style="width: 5%; text-align: right">&#160;&#160;&#160;<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000247" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,099,982</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000240" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000241" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">103,107</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_ReceiptsOnAccountOfSharesMember" id="Fact000242" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000243" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000244" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">101,901</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000245" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,230</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_zeWiSRP3nQXc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss for the period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0249">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0250">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0251">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0252">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember" id="Fact000253" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,685</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30" id="Fact000254" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,685</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_zIcJVt0wlv3f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0256">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0257">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0258">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000259" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0260">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-01-012023-09-30" id="Fact000261" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_z6LOy1rVxDhe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0263">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000264" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">260</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0266">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-09-30" id="Fact000268" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">260</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted_zbTARxiV5gR5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deemed dividend resulted from trigger of down round protection feature of certain warrants granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted" contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000271" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">855</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0272">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0273">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GCTK:AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted" contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember" id="Fact000274" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">855</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0275">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zNY9sn8tyrBh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of Common Stock and pre-funded warrants upon completion of public offering, net of offering expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuW4usbkpMR6" title="Issuance of Common Stock and pre-funded warrants upon completion of public offering, net of offering expenses, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="Fact000284" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,075,294</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="Fact000277" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000278" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,729</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0280">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0281">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-09-30" id="Fact000282" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,730</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zqb7jppl50uh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Issuance of restricted shares as compensation towards directors</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3RuGR4Egkdl" title="Issuance of shares as compensation to the board of directors, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="Fact000293" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,998</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0286">-</span></span><span id="xdx_F2E_zIrG6k19Qif7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<span>*)</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000287" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-09-30_custom_ReceiptsOnAccountOfSharesMember" id="Fact000288" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-09-30" id="Fact000291" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20230101__20230930_eus-gaap--StockholdersEquity_iE_zeP0eHupU2V6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance as of September 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxJZgs48gWWe" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact000302" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,178,274</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact000295" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000296" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112,960</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000298" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" id="Fact000299" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">107,441</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" id="Fact000300" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,557</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_435_c20230701__20230930_eus-gaap--StockholdersEquity_iS_zUeYNTKozan1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Balance at July 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHY0DDinzmCj" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000311" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,178,274</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000304" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000305" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112,929</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000307" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" id="Fact000308" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">105,218</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" id="Fact000309" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,743</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_zbNRLt1WMLt5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss for the period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="Fact000317" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,223</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30" id="Fact000318" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,223</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_z24Drl9AF994" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0321">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000323" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-07-012023-09-30" id="Fact000325" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zuT3eZbY9kC6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000328" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-012023-09-30" id="Fact000332" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_433_c20230701__20230930_eus-gaap--StockholdersEquity_iE_z9hh8lz35Gzi" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance as of September 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqn17vDaqu5k" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact000341" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,178,274</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact000334" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000335" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112,960</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000337" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" id="Fact000338" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">107,441</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" id="Fact000339" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,557</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20240101__20240930_eus-gaap--StockholdersEquity_iS_zVQ0vxAbF24l" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Balance as of January 1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhGU8zwuMHI7" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000350" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,178,274</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000343" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000344" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_ReceiptsOnAccountOfSharesMember" id="Fact000345" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000346" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000347" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">109,853</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000348" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,197</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_z7qSgcs3t8hg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss for the period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember" id="Fact000356" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,503</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-09-30" id="Fact000357" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,503</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_zPASNP4VrY1a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0359">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0360">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000362" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2024-01-01to2024-09-30" id="Fact000364" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zybD5HAosTt5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000367" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">239</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0368">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0369">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-01to2024-09-30" id="Fact000371" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">239</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_z5ACLUvCaYrc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of restricted shares as compensation towards directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUGVikziz9Gh" title="Issuance of restricted shares as compensation towards directors, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="Fact000380" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">86,861</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_F22_zl0nfLo5YVt1" style="text-align: right">(*)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000374" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">126</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember" id="Fact000375" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">48</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0376">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2024-01-01to2024-09-30" id="Fact000378" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">78</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross_zJBNaQf0D1jd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted shares to be issued as compensation towards directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0382">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember" id="Fact000384" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0385">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-01to2024-09-30" id="Fact000387" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares_z6X3vg0jyEEf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercise of prefunded warrants into shares (Note 3A)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlNIfJhRFmIg" title="Exercise of prefunded warrants into shares (Note 3A), shares" style="text-align: right"><ix:nonFraction name="GCTK:StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="Fact000396" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">395,294</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_F23_zUoHBXzzdvPh" style="text-align: right">(*)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0390">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0392">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_z2CkiEw81gmh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exchange of warrants into shares (Note 3B)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zykVGfrAx1n7" title="Exchange of warrants into shares (Note 3B), shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="Fact000405" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">718,641</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="Fact000398" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000399" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0400">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0401">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0402">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z2Tjqtg9bJf2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of Common Stock upon private placement transaction (Note 3D)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuQwtAoTL6Eb" title="Issuance of Common Stock upon private placement transaction (Note 3D), shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="Fact000414" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">79,366</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_F22_zdiVX1Zw8HYi" style="text-align: right">(*)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000408" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0410">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-09-30" id="Fact000412" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions_z40XxQJ6DzJ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of detachable warrants through private placement transactions
(Note 3F and Note 3H)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Issuance of Common Stock upon private placement transaction (Note 3D), shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions" contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000417" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,635</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions" contextRef="From2024-01-01to2024-09-30" id="Fact000421" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,635</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_zwqqgYqPaxC8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of shares and warrants as settlement of financial liabilities
(Note 3I and Note 3J)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Issuance of Common Stock upon private placement transaction (Note 3D), shares" id="xdx_980_ecustom--StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2EoGCPVBo6l" style="text-align: right"><ix:nonFraction name="GCTK:StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="Fact000430" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">293,590</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="Fact000423" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000424" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,742</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0425">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0426">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" contextRef="From2024-01-01to2024-09-30" id="Fact000428" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,743</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b_zWtUjHaOWQjf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Issuance of restricted shares as payment for a previous achievement of milestone pursuant to purchase agreement (Note 4B)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRqsMDMFDsY9" title="Issuance of restricted shares as payment for a previous achievement of milestone pursuant to purchase agreement (Note 4B), shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="GCTK:StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="Fact000439" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">20,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0432">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0434">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0435">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0436">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0437">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_431_c20240101__20240930_eus-gaap--StockholdersEquity_iE_zisE4wGBG4v6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance as of September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfweUm1DcvTi" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000448" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,772,026</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000441" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000442" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">118,223</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_custom_ReceiptsOnAccountOfSharesMember" id="Fact000443" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000444" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" id="Fact000445" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">122,356</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000446" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,022</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_439_c20240701__20240930_eus-gaap--StockholdersEquity_iS_zS85DtCYaH3a" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Balance as of July 1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrJgNDKxQ1wi" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000457" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,478,436</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000450" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000451" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">113,903</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_custom_ReceiptsOnAccountOfSharesMember" id="Fact000452" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000453" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact000454" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">117,269</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000455" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,289</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_432_c20240701__20240930_eus-gaap--StockholdersEquity_iS_zEb5QSvi4qM8" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zefIZl1xUSoj" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000466" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,478,436</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000459" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000460" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">113,903</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_custom_ReceiptsOnAccountOfSharesMember" id="Fact000461" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000462" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact000463" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">117,269</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000464" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,289</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--NetIncomeLoss_zXU8ERCkIp38" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss for the period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0468">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0470">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0471">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="Fact000472" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,087</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact000473" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,087</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zOPaSmrkJFz4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0475">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0476">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0477">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000478" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0479">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-07-012024-09-30" id="Fact000480" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_zZt5EK0P0DVj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0482">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000483" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0484">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2024-07-012024-09-30" id="Fact000487" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross_z6KYKQGzV7ug" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted shares to be issued as compensation towards directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0489">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0490">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-07-012024-09-30_custom_ReceiptsOnAccountOfSharesMember" id="Fact000491" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0492">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0493">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-07-012024-09-30" id="Fact000494" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity_zbU41cgOifUk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of detachable warrants through private placement transactions
(Note 3F and Note 3H)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZq4n6Idzowj" title="Settlement of liabilities with equity, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0503">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0496">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000497" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,567</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0498">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0499">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0500">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity" contextRef="From2024-07-012024-09-30" id="Fact000501" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,567</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--StockIssuedDuringPeriodValueIssuanceOfWarrant_zpwB0iZIJZx4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Issuance of shares and warrants as settlement of financial liabilities
(Note 3I and Note 3J)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">293,590</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfWarrant" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact000505" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfWarrant" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000506" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,742</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0507">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0508">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0509">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="GCTK:StockIssuedDuringPeriodValueIssuanceOfWarrant" contextRef="From2024-07-012024-09-30" id="Fact000510" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,743</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43A_c20240701__20240930_eus-gaap--StockholdersEquity_iE_zTRg0a9mP4A9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance as of September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2HEdOcZHql5" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000519" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,772,026</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000512" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000513" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">118,223</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_custom_ReceiptsOnAccountOfSharesMember" id="Fact000514" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000515" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" id="Fact000516" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">122,356</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000517" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,022</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_436_c20240701__20240930_eus-gaap--StockholdersEquity_iE_zIZUbxPkSLV8" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk9LzGm92XP9" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000528" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,772,026</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000521" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000522" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">118,223</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_custom_ReceiptsOnAccountOfSharesMember" id="Fact000523" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000524" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" id="Fact000525" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">122,356</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000526" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,022</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F07_zvLhwFpeuGk6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F1E_zjLojD0exmqd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000529" xml:lang="en-US">Represents
    amount lower than $1.</ix:footnote></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed interim consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="b_009"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars) (Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_112_pn3n3_z4q5pF6CN4wd" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20240930_zTi8a3PvhPp" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20230930_zwcZe79XLNef" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine-month period ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_i01_pn3n3_maNCPBUzGtO_zJXxJTB1T6x9" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Loss for the period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-09-30" id="Fact000534" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,503</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30" id="Fact000535" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,685</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Depreciation_i02_pn3n3_maNCPBUzGtO_zajI09RzT3i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-09-30" id="Fact000540" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-09-30" id="Fact000541" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_i02_pn3n3_maNCPBUzGtO_zssOaReulI6j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-09-30" id="Fact000543" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">239</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-09-30" id="Fact000544" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">260</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors_i02_pn3n3_maNCPBUzGtO_z6KreQuzsdP3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of restricted shares as compensation towards directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" contextRef="From2024-01-01to2024-09-30" id="Fact000546" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">178</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" contextRef="From2023-01-012023-09-30" id="Fact000547" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--LinkageDifferenceOnPrincipalOfLoansFromStockholders_i02_pn3n3_maNCPBUzGtO_z49wkrgnPkK2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Linkage difference on principal of loans from stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:LinkageDifferenceOnPrincipalOfLoansFromStockholders" contextRef="From2024-01-01to2024-09-30" id="Fact000549" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:LinkageDifferenceOnPrincipalOfLoansFromStockholders" contextRef="From2023-01-012023-09-30" id="Fact000550" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities_i02_pn3n3_maNCPBUzGtO_zAm6Nra1kaNf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Revaluation expenses incurred from settlement of financial liabilities (Note 3I and Note 3J)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" contextRef="From2024-01-01to2024-09-30" id="Fact000552" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,505</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0553">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--RevaluationExpensesRelatedToDerivativeFinancialLiabilities_i02_pn3n3_maNCPBUzGtO_ztDTwu9enQDb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Revaluation expenses related to derivative financial liabilities (Note
3H)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:RevaluationExpensesRelatedToDerivativeFinancialLiabilities" contextRef="From2024-01-01to2024-09-30" id="Fact000555" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0556">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_pn3n3_maNCPBUzGtO_zzzXJlCHIgB8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Discount amortization and interest expenses related to promissory notes
(Note 3F, Note 3G and Note 3H)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2024-01-01to2024-09-30" id="Fact000558" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">330</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0559">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zXRbCwP2GEI8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Changes in assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOtherCurrentAssets_i03N_pn3n3_di_msNCPBUzGtO_zOsGglkP5HVe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2024-01-01to2024-09-30" id="Fact000564" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">80</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2023-01-012023-09-30" id="Fact000565" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">216</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_pn3n3_maNCPBUzGtO_zShNA9aKxu0b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-01-01to2024-09-30" id="Fact000567" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,129</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-012023-09-30" id="Fact000568" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">598</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_i03_pn3n3_maNCPBUzGtO_ziB3T8mX4DM6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2024-01-01to2024-09-30" id="Fact000570" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2023-01-012023-09-30" id="Fact000571" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">134</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pn3n3_mtNCPBUzGtO_maCCERCzAaH_zjxE1WY4iCV2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-09-30" id="Fact000573" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,991</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-09-30" id="Fact000574" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,147</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_pn3n3_di_msNCPBUzqTH_zNtXgj77g9f6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Purchase of property and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-01to2024-09-30" id="Fact000579" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">104</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0580">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pn3n3_mtNCPBUzqTH_maCCERCzAaH_zUHc74zRUf7k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash used in investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-09-30" id="Fact000582" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">104</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0583">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_i01_maNCPBUzB4f_zp6UG1OMePAg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds received from private placement transaction (Note 3D)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2024-01-01to2024-09-30" id="Fact000588" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0589">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromIssuanceOfWarrants_i01_pn3n3_maNCPBUzB4f_zpueesRMsmRj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance of promissory notes and detachable warrants through private placement
    transaction (Note 3F)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-01to2024-09-30" id="Fact000591" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0592">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromConvertibleDebt_i01_pn3n3_maNCPBUzB4f_zlnUujNjIqkl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of convertible promissory notes and bifurcated conversion feature
through private placement transaction (Note 3G)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2024-01-01to2024-09-30" id="Fact000594" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">360</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0595">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ProceedsFromConvertibleDebtPrivatePlacementTransaction_i01_pn3n3_maNCPBUzB4f_zy699zcfkzvl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance of convertible promissory note, bifurcated conversion and redemption
features and detachable warrants through private placement transaction (Note 3H)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:ProceedsFromConvertibleDebtPrivatePlacementTransaction" contextRef="From2024-01-01to2024-09-30" id="Fact000597" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0598">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ProceedsReceivedFromUnderwrittenPublicOffering_i01_pn3n3_maNCPBUzB4f_ziqy7T1JGMn3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Net proceeds received from underwritten U.S. public offering</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0600">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="GCTK:ProceedsReceivedFromUnderwrittenPublicOffering" contextRef="From2023-01-012023-09-30" id="Fact000601" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,730</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pn3n3_maCCERCzAaH_mtNCPBUzB4f_zdIYlBwzDP0j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-09-30" id="Fact000603" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,960</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-09-30" id="Fact000604" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,730</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_maCCERCzAaH_zCiQk4P8wAAj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Effect of exchange rate changes on cash and cash equivalents, and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2024-01-01to2024-09-30" id="Fact000606" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2023-01-012023-09-30" id="Fact000607" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pn3n3_mtCCERCzAaH_zfR54lQ75ufd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in cash and cash equivalents, and restricted cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-09-30" id="Fact000609" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,146</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-09-30" id="Fact000610" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,566</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Cash and cash equivalents, and restricted cash at beginning of the period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000612" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,502</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000613" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,331</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents, and restricted cash, end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-09-30" id="Fact000615" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">356</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-09-30" id="Fact000616" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,897</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Supplemental disclosure of cash flow activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InterestPaidAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">(a) Net cash (received) paid during the year for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--InterestPaidNet_i01N_pn3n3_di_zWvhufkEA7F" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-01to2024-09-30" id="Fact000624" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0625">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">(b) Non-cash investment and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeemedDividendUponTriggerOfDownRoundProtection_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Deemed dividend upon trigger of down round protection</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0630">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GCTK:DeemedDividendUponTriggerOfDownRoundProtection" contextRef="From2023-01-012023-09-30" id="Fact000631" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">855</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseCost_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Recognition of right for use asset against a lease liability (Note 3C)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-01-01to2024-09-30" id="Fact000633" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">79</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0634">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_i01_pn3n3_zCC2nIRsl9G3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GCTK:IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" contextRef="From2024-01-01to2024-09-30" id="Fact000636" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">238</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0637">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed interim consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="b_010"></span><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars, except share and per share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000639" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zn0fJ1kBrjhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 - <span id="xdx_825_zxsgLp8ybfod">GENERAL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glucotrack
    Inc. (the &#8220;Company&#8221;) was incorporated on May 18, 2010 under the laws of the State of Delaware. The Company is a medical
    device company, focused on development of an Implantable Continuous Glucose Monitor (CGM) for persons with Type 1 diabetes and insulin-dependent
    Type 2 diabetes (the &#8220;Glucotrack CBGM Product&#8221;).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
    and capital resources</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    date, the Company has not yet commercialized the Glucotrack CBGM Product. Further development and commercialization efforts are
    expected to require substantial additional expenditure. Therefore, the Company is dependent upon external sources for financing its
    operations. As of September 30, 2024, the Company has incurred an accumulated deficit of $<span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20240930_z6Z3fzOakOh"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-09-30" id="Fact000640" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">122,356</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
    in addition, the Company has generated operating losses and negative operating cash flow for all reported periods. As of September
    30, 2024, the balance of cash and cash equivalents amounted to $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20240930_zkcgNVTj1v9i" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-09-30" id="Fact000642" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">346</ix:nonFraction></span>,
    together with the net proceeds in total amount of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20240101__20240930_z0zWkCuuh5g" title="Net proceeds from public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-01-01to2024-09-30" id="Fact000644" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,873</ix:nonFraction></span> which expected to be received upon closing of a public offering through
    registration statements on Form S-1 (see also Note 6 below) on November 14, 2024.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company raised net proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_pn3n3_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zpKbIUIvAMZf"><ix:nonFraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_IPOMember" id="Fact000645" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,730</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">through completion of underwritten public offering.
Moreover, during the period of nine months ended September 30, 2024, the Company entered into (i) exchange agreement with certain shareholders
under which warrants with down round protection feature have been exchanged into shares of common stock in order to facilitate its equity
structure (see also Note 3B below), (ii) private placement agreement under which the Company raised proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_pn3n3_c20240101__20240930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zg1RZcGu6XNk"><ix:nonFraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="From2024-01-012024-09-30_us-gaap_PrivatePlacementMember" id="Fact000646" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(see also Note 3D below), (iii) <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unsecured promissory notes
and warrant agreements under which the Company raised proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromUnsecuredNotesPayable_pn3n3_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQfhEVgk4yZf" title="Unsecured promissory notes"><ix:nonFraction name="us-gaap:ProceedsFromUnsecuredNotesPayable" contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember" id="Fact000648" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></span> (see also Note 3F below), (iv) unsecured promissory notes under
which the Company raised proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromUnsecuredNotesPayable_pn3n3_c20240101__20240930_zM3dYnOomgo2" title="Unsecured promissory notes"><ix:nonFraction name="us-gaap:ProceedsFromUnsecuredNotesPayable" contextRef="From2024-01-01to2024-09-30" id="Fact000650" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">360</ix:nonFraction></span> (see also Note 3G below), (v) secured promissory note and warrant agreements under which the
Company raised proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromSecuredNotesPayable_pn3n3_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGVIM3egHdR1" title="Secured promissory notes"><ix:nonFraction name="us-gaap:ProceedsFromSecuredNotesPayable" contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember" id="Fact000652" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,000</ix:nonFraction></span> (see also Note 3H below) and (vi) conversion agreements under which certain financial liabilities have
been settled for issuance of shares of common stock and warrants of the Company (see also Note 3I and Note 3J below</span>).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company plans to finance its operations through the sale of equity securities (including shelf registration statement on Form S-3 was declared effective on October 3, 2023 by the Securities
and Exchange Commission (SEC) which allows the Company to register up to $<span id="xdx_90E_eus-gaap--DebtSecurities_iI_c20240930_zXydevKeSl6d"><ix:nonFraction name="us-gaap:DebtSecurities" contextRef="AsOf2024-09-30" id="Fact000653" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,000</ix:nonFraction></span> of certain equity and/or debt securities of
the Company through prospectus supplement) and/or debt securities. There can be no assurance that the Company
    will succeed in obtaining the necessary financing or generating sufficient revenue from sale of its Glucotrack CBGM Product in
    order to continue its operations as a going concern.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
    has considered the significance of such conditions in relation to the Company&#8217;s ability to meet its current obligations and
    to achieve its business targets and determined that these conditions raise substantial doubt about the Company&#8217;s ability to
    continue as a going concern.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    condensed interim consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000655" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zdjNiMPZU7ck" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 - <span id="xdx_821_zeS9LwxMHg55">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000657" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zBk6y2rc9TH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zE5VrcHnpgzg">Basis
    of Presentation</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    accompanying unaudited condensed interim consolidated financial statements and related notes should be read in conjunction with the
    Company&#8217;s consolidated financial statements and related notes included in the Company&#8217;s annual report on Form 10-K for
    the fiscal year ended December 31, 2023, as was filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 28,
    2024. The unaudited condensed interim consolidated financial statements have been prepared in accordance with the rules and regulations
    of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures
    normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial
    information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary
    to present fairly the results of the Company&#8217;s financial position and operating results for the interim periods. All such adjustments
    are of a normal recurring nature.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    results for the period of three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected
    for the year ending December 31, 2024 or for any other interim period or for any future period.</span></td></tr>
</table>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000659" name="us-gaap:UseOfEstimates"><p id="xdx_84B_eus-gaap--UseOfEstimates_zRBBoArUAa42" style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z7LpEpyqQxfl">Use
    of Estimates in the Preparation of Financial Statements</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates
    and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities
    at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could
    differ from those estimates. As applicable to these interim financial statements, the most significant estimates and assumptions include identification and measurement of financial instruments.</span></td></tr>
</table>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000661" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zmLrlRp17BSa" style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zttyu0kFfb0a">Principles
    of Consolidation</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    condensed interim consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany
    balances and transactions have been eliminated in consolidation.</span></td></tr>
</table>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000663" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zdGHStKilDFl" style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_ztmSw1zOzLMh">Cash
    and Cash Equivalents</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    equivalents are short-term highly liquid investments which include short-term bank deposits (up to three months from date of deposit),
    that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as
    of the date acquired.</span></td></tr>
</table>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000665" name="GCTK:ModificationOfEquityClassifiedContractsPolicyTextBlock"><p id="xdx_84D_ecustom--ModificationOfEquityClassifiedContractsPolicyTextBlock_z8qXmJM3USR6" style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_z1Av9IYetR81">Modification
    of equity-classified contracts</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    modification or exchange of equity-classified contracts, such as warrants that were classified as equity before the modification
    or exchange and remained eligible for equity classification after the modification, is accounted for in a similar manner to a modification
    of stock-based compensation. Accordingly, the incremental fair value from the modification or exchange (the change in the fair value
    of the instrument before and after the modification or exchange) is recognized as a reduction of retained earnings of increase of
    accumulated deficit as a deemed dividend. Modifications or exchanges that result in a decrease in the fair value of an equity-classified
    share-based payment awards are not recognized. In addition, the amount of the deemed dividend is also recognized as an adjustment
    to earnings available to common shareholders for purposes of calculating earnings per share.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000667" name="GCTK:ConvertiblePromissoryNotesPolicyTextBlock"><p id="xdx_84A_ecustom--ConvertiblePromissoryNotesPolicyTextBlock_zkZ8o3MQtn6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zLDCavFUdVDf">Convertible Promissory Notes</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    initial recognition of convertible promissory notes and similar instruments, the Company considers the provisions of ASC 815-40,
    &#8220;Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity&#8221; (&#8220;ASC 815-40&#8221;) in order to determine whether
    the conversion features embedded within the convertible instrument should be separated from the host instrument.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
    it is determined that an embedded derivative required to be bifurcated (such as embedded conversion feature that does not qualify
    for equity classification), the Company recognized the embedded derivative bifurcated as a separate derivative liability upon
    initial recognition and on subsequent periods at fair value. The remaining consideration amount received or allocated to the entire
    convertible instrument is allocated to the host debt instrument. The difference between the face value of the host and such an
    allocated amount represents a discount which is amortized as finance expense to profit or loss using an effective interest method
    over the term of the note until its stated maturity.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
    it is determined that the embedded conversion feature qualifies for equity classification (such when the embedded conversion option,
    if it were freestanding, is not qualified as a derivative in accordance with the provisions of ASC 815-10, &#8220;Derivatives and
    Hedging&#8221; since its terms did not require or permit net settlement or when the embedded conversion option is indexed to the
    entity&#8217;s own stock), the conversion option is not bifurcated. When bifurcation is not required, the Company considers whether
    the debt instrument involves a significant premium (i.e. when the proceeds received or allocated upon issuance exceed the principal
    amount that will be paid at maturity). When it is determined that a substantial premium exists, the entire premium is allocated to
    paid-in capital and when it is determined, otherwise no additional accounting is required and the convertible promissory note is
    accounted for at amortized cost using effective interest method over the term of the note until its stated maturity.</span></p></td></tr>
  </table>
</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000669" name="GCTK:AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock"><p id="xdx_847_ecustom--AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock_zskbeHi3THyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zwlQGZrpQPe7">Allocation
    of proceeds and related issuance costs</span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
    multiple instruments are issued in a single transaction (package issuance), the total net proceeds from the transaction are allocated
    among the individual freestanding instruments identified. The allocation occurs after identifying all freestanding instruments and
    the subsequent measurement basis for those instruments.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    instruments that are required to be subsequently measured at fair value (such as derivative liabilities) are measured at fair value
    and the remaining consideration is allocated to other financial instruments that are not required to be subsequently measured at
    fair value (such as liabilities measured at amortized cost, common shares and warrants eligible for equity classification), based
    on the relative fair value basis for such instruments.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    costs allocated to financial instruments that are required to be subsequently measured at fair value immediately expensed. Issuance
    costs allocated to shares and warrants classified as equity components and are recorded as a reduction of additional paid-in capital.
    Issuance costs allocated to financial liabilities measured at amortized cost are recorded as a discount and accreted over the contractual
    term of the financial instrument using the effective interest method.</span></p></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000671" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_840_eus-gaap--DerivativesPolicyTextBlock_zTw3FWwKVhEd" style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zjqH5CCt7BB">Warrants</span></b></span></td></tr>
  </table>
<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    warrants that were issued to several holders are classified as a component of permanent equity since they are freestanding financial
    instruments that are legally detachable and separately exercisable, do not embody an obligation for the Company to repurchase its
    own shares, and permit the holders to receive a fixed number of Ordinary Shares upon exercise for a fixed exercise price and thus,
    are considered as indexed to the Company&#8217;s own shares. As such warrants were issued together with financial instruments that
    are not subsequently measured at fair value and the warrants were measured based on allocation of the proceeds received by the Company
    in accordance with the relative fair value basis. When applicable, direct issuance expenses that were allocated to certain warrants
    were deducted from additional paid-in capital.</span></td></tr>
</table>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000673" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_840_eus-gaap--LesseeLeasesPolicyTextBlock_zHAYzcA7DY9f" style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zRB01wOYGo4b">Leases</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company applies ASC Topic 842, &#8220;Leases&#8221; (&#8220;ASC 842&#8221;) under which the Company determines if an arrangement
    is a lease at inception.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
    are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following
    criteria are met: (i) the lease transfers ownership of the asset by the end of the lease term, (ii) the lease contains an option
    to purchase the asset that is reasonably certain to be exercised, (iii) the lease term is for a major part of the remaining useful
    life of the asset, (iv) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset,
    or (v) the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end
    of lease term. A lease is classified as an operating lease if it does not meet any one of these criteria. Since all the Company&#8217;s
    lease contracts for premises do not meet any of the criteria above, the Company concluded that all its lease contracts should be
    classified as operating leases.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    of Use (&#8220;ROU&#8221;) assets and liabilities are recognized on the commencement date based on the present value of remaining
    lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the
    time of commencement. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its Incremental Borrowing
    Rate (&#8220;IBR&#8221;) based on the information available on the commencement date in determining the present value of lease payments.
    The Company&#8217;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments
    and in economic environments where the leased asset is located. The ROU asset also includes any lease payments made prior to commencement
    and is recorded net of any lease incentives received. Moreover, the ROU asset may also include initial direct costs, which are incremental
    costs of a lease that would not have been incurred if the lease had not been obtained. The Company uses the long-lived assets impairment
    guidance in ASC 360-10, &#8220;Property, Plant, and Equipment - Overall&#8221;, to determine whether a ROU asset is impaired, and
    if so, the amount of the impairment loss to recognize. Certain leases include options to extend or terminate the lease. An option
    to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain
    that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company
    will not exercise the option.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000675" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zYpF2IOulXnk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zajuTRwUQnY8">Basic
    and diluted loss per share</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
                                                         loss per share is computed by dividing the loss for the period applicable (after considering the effect of deemed dividend related
                                                         to trigger of down round protection feature) for Common Stockholders by the weighted average number of shares of Common Stock
                                                         outstanding and shares of Common Stock to be issued upon achievement of certain performance milestones during the period <span style="background-color: white">and
                                                         upon </span>exercise of pre-funded warrants. In computing, diluted loss per share, basic earnings per share are adjusted to reflect
                                                         the potential dilution that could occur upon the exercise of options or warrants issued or granted using the &#8220;treasury stock
                                                         method&#8221; and using the if-converted method with respect to certain convertible promissory notes and bifurcated redemption
feature accounted for as derivative financial liability, if the effect of each of such financial instruments is dilutive. In computing diluted loss per share, the average
                                                         stock price for the period is used in determining the number of Common Stock assumed to be purchased from the proceeds to be
                                                         received from the exercise of stock options or stock warrants.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    to be issued upon exercise of all options and warrants, convertible promissory notes and bifurcated redemption feature, have been excluded from the calculation of the diluted net loss
    per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as result
    of the exercise or conversion of these instruments was anti-dilutive.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    net loss and the weighted average number of shares of Common Stock used in computing basic and diluted net loss per Common Stock
    for the period of three and nine months ended September 30, 2024 and 2023, is as follows:</span></td></tr>
  </table>
<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000677" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zECRBfAsXP8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zlH3UMgBCy09" style="display: none">SCHEDULE
OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240701__20240930_zY1fwQEntJ1j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230701__20230930_zyh7Jwyw3RX4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20240930_zk8T6rrK77Zk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230930_zGuY6kLIwKf7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">US dollars (except share data)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">US dollars (except share data)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three-month period ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine-month
period ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_iN_pn3n3_di_maNILATzfsR_z3h5F4HaMWLd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 44%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact000679" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,087</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30" id="Fact000680" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,223</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-09-30" id="Fact000681" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,503</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30" id="Fact000682" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,685</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature_iN_pn3n3_di_maNILATzfsR_zLtm2Uj52lz3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Deemed dividend related to trigger of down round protection feature</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0684">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0685">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0686">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="GCTK:DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature" contextRef="From2023-01-012023-09-30" id="Fact000687" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">855</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iNT_pn3n3_di_mtNILATzfsR_zzJULLVnGMdh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Net loss attributable to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-07-012024-09-30" id="Fact000689" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,087</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-07-012023-09-30" id="Fact000690" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,223</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-01to2024-09-30" id="Fact000691" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,503</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-09-30" id="Fact000692" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,540</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Shares of Common Stock used in computing basic and diluted net loss per common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zVmjIIryPAmh" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zoZOdvODAwxd" title="Ordinary shares used in computing diluted net loss per common stock"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact000694" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact000696" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,564,880</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zKGeyIxhq1n7" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zNtDgyEEgYN" title="Ordinary shares used in computing diluted net loss per common stock"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="Fact000698" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="Fact000700" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,593,733</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_z7D7t5EV2Tld" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zZ2dQIclzRx7" title="Ordinary shares used in computing diluted net loss per common stock"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="Fact000702" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="Fact000704" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,340,532</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_ztUZlocG5Z42" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zSgMwvqxjys" title="Ordinary shares used in computing diluted net loss per common stock"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="Fact000706" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="Fact000708" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,758,590</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Shares of Common Stock to be issued upon exercise of pre-funded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zefuTJYCqzc" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zWheIw9VGqE6" title="Ordinary shares used in computing basic net loss per common stock"><span style="-sec-ix-hidden: xdx2ixbrl0710"><span style="-sec-ix-hidden: xdx2ixbrl0712">-</span></span></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zkBxULuZabwb" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zHNW06k4Cbta" title="Ordinary shares used in computing diluted net loss per common stock"><span style="-sec-ix-hidden: xdx2ixbrl0714"><span style="-sec-ix-hidden: xdx2ixbrl0716">-</span></span></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zDyS5M8xO2Og" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zGjWmtb2Havc" title="Ordinary shares used in computing diluted net loss per common stock"><span style="-sec-ix-hidden: xdx2ixbrl0718"><span style="-sec-ix-hidden: xdx2ixbrl0720">-</span></span></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zZoCHb218dwf" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_z18oaHPtHo4j" title="Ordinary shares used in computing diluted net loss per common stock"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-09-30_custom_PrefundedWarrantsMember" id="Fact000722" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-09-30_custom_PrefundedWarrantsMember" id="Fact000724" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">241,246</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Shares of Common Stock to be issued upon achievement of performance milestones</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_z1RWeBPjSvWl" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zg9ykkrfTP58" title="Ordinary shares used in computing diluted net loss per common stock"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-07-012024-09-30_custom_PerformanceMilestoneMember" id="Fact000726" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-07-012024-09-30_custom_PerformanceMilestoneMember" id="Fact000728" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zD7rw58jVuB2" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zRDWvYLlWlO7" title="Ordinary shares used in computing diluted net loss per common stock"><span style="-sec-ix-hidden: xdx2ixbrl0730"><span style="-sec-ix-hidden: xdx2ixbrl0732">-</span></span></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_ziP4Gvys9mb8" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_z0W0wTgEHEx4" title="Ordinary shares used in computing diluted net loss per common stock"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-09-30_custom_PerformanceMilestoneMember" id="Fact000734" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-09-30_custom_PerformanceMilestoneMember" id="Fact000736" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,275</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zr59VvXkLhbe" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zR2GCY4Jyrhj" title="Ordinary shares used in computing diluted net loss per common stock"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-09-30_custom_PerformanceMilestoneMember" id="Fact000738" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-09-30_custom_PerformanceMilestoneMember" id="Fact000740" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,691</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average number of Common Stock outstanding used in computing basic and diluted net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930_zyw8P5D5hxPe" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930_z30ArI9toSR8" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-07-012024-09-30" id="Fact000742" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-07-012024-09-30" id="Fact000744" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,594,880</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930_zQs2xS3Sy7lg" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930_znjWzcAjwsXd" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-012023-09-30" id="Fact000746" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-012023-09-30" id="Fact000748" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,593,733</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930_zn2Qx0dJPtVh" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930_zNEM4narGaFe" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-09-30" id="Fact000750" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-09-30" id="Fact000752" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,355,806</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930_zOjdbevyrhHb" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930_zOQXvVfVxnR5" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-09-30" id="Fact000754" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-09-30" id="Fact000756" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,006,527</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per common stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240701__20240930_z91DnSu7T2Ka" title="Diluted net loss per common stock"><span id="xdx_906_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240701__20240930_zuRoixSV9Nua" title="Diluted net loss per common stock">(<ix:nonFraction name="GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones" contextRef="From2024-07-012024-09-30" id="Fact000758" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones" contextRef="From2024-07-012024-09-30" id="Fact000760" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.91</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230701__20230930_zchev55s3gn" title="Diluted net loss per common stock"><span id="xdx_90D_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230701__20230930_z5Pvp7a8vFg4" title="Diluted net loss per common stock">(<ix:nonFraction name="GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones" contextRef="From2023-07-012023-09-30" id="Fact000762" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones" contextRef="From2023-07-012023-09-30" id="Fact000764" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.49</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240101__20240930_zNUAReKKbO7" title="Diluted net loss per common stock"><span id="xdx_90D_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240101__20240930_zxIeGyO6KKO3" title="Diluted net loss per common stock">(<ix:nonFraction name="GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones" contextRef="From2024-01-01to2024-09-30" id="Fact000766" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones" contextRef="From2024-01-01to2024-09-30" id="Fact000768" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.39</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230101__20230930_zowndlo5mvYd" title="Diluted net loss per common stock"><span id="xdx_909_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230101__20230930_zXz74f5ovqRg" title="Diluted net loss per common stock">(<ix:nonFraction name="GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones" contextRef="From2023-01-012023-09-30" id="Fact000770" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones" contextRef="From2023-01-012023-09-30" id="Fact000772" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.38</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zEuqK0oVDPO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

</ix:nonNumeric><p id="xdx_858_zdCThtqixkGb" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000774" name="GCTK:SignificantTransactionsTextBlock"><p id="xdx_802_ecustom--SignificantTransactionsTextBlock_z7r92uxTpit6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 - <span id="xdx_822_zqACE4jkYJr9">SIGNIFICANT TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
    of pre-funded warrants</b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    January 3, 2024, <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20240103__20240103__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zvUMykTLeWlc" title="Pre-funded warrants"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-032024-01-03_custom_PrefundedWarrantsMember" id="Fact000776" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">395,294</ix:nonFraction></span> pre-funded warrants granted through underwritten public offering in April 2023 have been fully
    exercised into the same number of shares of Common Stock of the Company. </span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exchange
    Agreement</b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    February 13, 2024, the Company entered into an Exchange Agreement with certain warrant holders (the &#8220;Holders&#8221;), pursuant
    to which the Company and the Holders agreed to exchange (the &#8220;Exchange&#8221;) warrants with down round protection feature
    exercisable to common shares (the &#8220;Warrants&#8221;) owned by the Holders for shares of Common Stock to be issued by the
    Company. On February 15, 2024, <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pid_c20240213_z7xBRoTYBUcl" title="Shares of Common Stock"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-02-13" id="Fact000778" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">718,641</ix:nonFraction></span> shares of Common Stock have been issued in exchange for <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20240213__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zI5RNUfzJWu1" title="Shares of Common Stock"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-02-13_us-gaap_WarrantMember" id="Fact000780" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">876,391</ix:nonFraction></span> Warrants (the &#8220;Shares&#8221;).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
    was also agreed that the Holders will not, during the period (&#8220;Lock-Up Period&#8221;) (i) offer, pledge, announce the intention
    to sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option,
    right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Shares, (ii) enter into any swap or
    other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Shares of, whether any
    such transaction described in clause (i) or (ii) above is to be settled by delivery of Shares or such other securities, in cash or
    otherwise, (iii) make any demand for or exercise any right with respect to, the registration of any Shares or any security convertible
    into or exercisable or exchangeable for shares of common stock, or (iv) publicly announce an intention to effect any transaction
    specific in clause (i), (ii) or (iii) above, provided that the Holder, during the Lock-Up Period, may<span id="xdx_900_ecustom--LockUpPeriodDescription_c20240213__20240213__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zWEYX8w2NVEh" title="Lock-up period conditions"> <ix:nonNumeric contextRef="From2024-02-132024-02-13_custom_ExchangeAgreementMember" id="Fact000782" name="GCTK:LockUpPeriodDescription">(a) sell or contract
    to sell Shares at a price higher than $0.50 per Share on any trading day up to 10% of the daily volume of Shares or (b) sell or contract
    to sell Shares at a price higher than $0.80 per Share on any trading day with no volume limitation.</ix:nonNumeric></span></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Lock-Up Period shall expire at the earliest of (i) 365 days after the date hereof or (ii) until the Shares traded above $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20240213__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zFDzbdvxhtne" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-02-13_custom_ExchangeAgreementMember" id="Fact000784" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per
    Share for five consecutive trading days.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company accounted for the Exchange of the aforesaid warrants with shares as deemed dividend which was calculated at the closing date
    by the management using the assistance of external appraiser as the excess of fair value of the share to be issued after taking into
    consideration a discount for lack of marketability at a rate of 16.81% over the Lock-Up Period over the fair value of the original
    equity instrument (i.e. warrants which included down round protection feature). However, since the fair value of the new equity
    instrument (common shares) was estimated as lesser than the fair value of the replaced equity instrument, deemed dividend was not
    recorded.</span></p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lease
    Agreement</b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    February 19, 2024, the Company entered into Lease Agreement (the &#8220;Agreement&#8221;) with Tapsak Enterprises LLC dba Virginia
    Analytical (the &#8220;Landlord&#8221;) under which it was agreed that the Company will lease from the Landlord a premises located
    in Front Royal, Virginia area for a monthly rental fee of $<span id="xdx_904_eus-gaap--OperatingLeasePayments_pn2n3_c20240219__20240219__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zWEPgI704uA4" title="Monthly rental fee"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-02-192024-02-19_us-gaap_LeaseAgreementsMember" id="Fact000786" format="ixt:numdotdecimal" decimals="-2" scale="3" unitRef="USD">2.5</ix:nonFraction></span> over a period of <span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20240219__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zwseJGRqKbB" title="Lessee term of contract"><ix:nonNumeric contextRef="AsOf2024-02-19_us-gaap_LeaseAgreementsMember" format="ixt-sec:duryear" id="Fact000788" name="us-gaap:LesseeOperatingLeaseTermOfContract">3</ix:nonNumeric></span>-years commencing March 1, 2024 through February
    28, 2027 (the &#8220;Initial Lease Period&#8221;). Security deposit of $<span id="xdx_908_eus-gaap--SecurityDeposit_iI_pn2n3_c20240219__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zYKYu0ivesP3" title="Security deposit"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2024-02-19_us-gaap_LeaseAgreementsMember" id="Fact000790" format="ixt:numdotdecimal" decimals="-2" scale="3" unitRef="USD">2.5</ix:nonFraction></span> which represents payment of one month is held by the
    Landlord which will be return to the Company at the end of the Initial Lease Period.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Company has an option to renew the Initial Lease Period for another two additional periods of 3-years each following the
Initial Lease Period (the &#8220;Option Term&#8221;), following advanced notice as defined in the Agreement. The monthly rental fee over
the Option Term shall be the fair market rate determined as what is a comparable cost for similar property in Front Royal, Virginia area.</span></p>
                                                                              <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                              <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance
                                                                              with the provision of ASC 842, Leases, at the commencement date of the Agreement, the Company recognized the right to use asset
                                                                              equals to lease liability in total amount of $<span id="xdx_90D_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20240219_zUEtACXcKmf5" title="Lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-02-19" id="Fact000792" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">79</ix:nonFraction></span>. The lease liability was measured at the present value of the future lease
                                                                              payments, which are discounted based on an estimate of the incremental interest rate that the Company would be required to pay to
                                                                              borrow a similar amount for a similar period in order to obtain a similar amount on the initial recognition date of the lease.</span></p>
                                                                              <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
                                                                              <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the leasing period, the Company considered only the Initial Lease Period as the realization of the option
to extend the period was not considered as reasonably certain.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 - SIGNIFICANT TRANSACTIONS (CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lease
    Agreement (Cont.)</b></span></td></tr>
</table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000794" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_897_eus-gaap--LeaseCostTableTextBlock_zIzel0VXWKy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_z3vDuEBqrYq6" style="display: none">SCHEDULE
OF OPERATING
LEASE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240930_zZZP4RDv7wKg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zsaPUwH9wOCa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left; padding-bottom: 2.5pt">Operating right-of-use asset</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 18%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-09-30" id="Fact000796" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zyV0tTXRkczh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Current operating lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-09-30" id="Fact000798" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zsi5QhiaesRb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Non-Current operating lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-09-30" id="Fact000800" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zsWg4xTRsw31" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000802" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zjcYrVnemZJ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturity
analysis of the Company&#8217;s lease liability:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_ztlO01gzXIGk" style="display: none">SCHEDULE
OF MATURITY
ANALYSIS OF LEASE LIABILITY</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240930_zhZxTL7nJvg3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_hus-gaap--LeaseContractualTermAxis__custom--LessThanOneYearMember_zXc3Tv74rw9c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Less than one year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-09-30_custom_LessThanOneYearMember" id="Fact000804" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_hus-gaap--LeaseContractualTermAxis__custom--BetweenOneYearToTwoYearsMember_zC0BaIt2ItC1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Between 1-2 years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-09-30_custom_BetweenOneYearToTwoYearsMember" id="Fact000806" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_hus-gaap--LeaseContractualTermAxis__custom--MoreThanTwoYearsMember_zUYBx9ixmCL2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">More than 2 years</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-09-30_custom_MoreThanTwoYearsMember" id="Fact000808" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zR8mOjemPfEj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total operating lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-09-30" id="Fact000810" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">73</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--LesseeOperatingLeaseLiabilityImputedInterest_iNI_di_zDVgdFWJRpO7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="GCTK:LesseeOperatingLeaseLiabilityImputedInterest" contextRef="AsOf2024-09-30" id="Fact000812" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_zrTAHbTQkpxb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-09-30" id="Fact000814" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zIP5L8OLIHc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Additional
information on lease</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000816" name="GCTK:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock"><p id="xdx_892_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock_zZMEFboNQckj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the weighted average remaining lease terms and discount rate for the lease:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zg2FCIS7FFqb" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Lease term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240930_zE2X8TvuDZW1" title="Lease term (years)"><ix:nonNumeric contextRef="AsOf2024-09-30" format="ixt-sec:duryear" id="Fact000818" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.42</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20240930_zxtunKEZIuh9" title="Weighted average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-09-30" id="Fact000820" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.03</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zhcJ7QICHX1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Private
    Placement Agreement</b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    April 22, 2024, the Company entered into a private placement agreement under which the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240422__20240422__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z02OXS5tWxCl" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-04-222024-04-22_us-gaap_PrivatePlacementMember" id="Fact000822" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">79,366</ix:nonFraction></span> shares of its common
    stock at a price of $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240422__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zGVygKaVHZY" title="Common stock share price"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-04-22_us-gaap_PrivatePlacementMember" id="Fact000824" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.30</ix:nonFraction></span> per share for aggregate gross proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20240422__20240422__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zo4ISivbb5A6" title="Aggregate gross proceeds offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-04-222024-04-22_us-gaap_PrivatePlacementMember" id="Fact000826" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction> </span>(the &#8220;Offering&#8221;). The Offering included participation
    of certain members of the Company&#8217;s executive management, Board of Directors and existing shareholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Adoption
    of 2024 Equity Incentive Plan and Reverse Share Split</b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    April 26, 2024, the Company held its Annual Meeting of Shareholders (the &#8220;Annual Meeting&#8221;) under which the Company&#8217;s
    stockholders approved, inter alia, the following proposals: (i) adoption of the Company&#8217;s 2024 Equity Incentive Plan and (ii)
    an amendment to Article IV of the Company&#8217;s Certificate of Incorporation, to effect a reverse stock split of the Company&#8217;s
    Common Stock at a ratio of between one-for-five and one-for-thirty, with such ratio to be determined at the sole discretion of the
    Board of Directors. Following the Annual Meeting, on April 30, 2024, the Company&#8217;s Board of Directors approved a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20240430__20240430_zI4eRcuuZfv3" title="Reverse stock split"><ix:nonNumeric contextRef="From2024-04-302024-04-30" id="Fact000828" name="us-gaap:StockholdersEquityReverseStockSplit">one-for-five</ix:nonNumeric></span>
    reverse stock split of the Company&#8217;s issued and outstanding shares of common stock (the &#8220;Reverse Stock Split&#8221;).
    On May 17, 2024, the Company filed a Certificate of Amendment to the Company&#8217;s Certificate of Incorporation with the Secretary
    of State of the State of Delaware which effected the Reverse Stock Split.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    accounting purposes, all shares, options and warrants to purchase shares of common stock and loss per share amounts have been adjusted
    to give retroactive effect to the Reverse Share Split for all periods presented in these interim consolidated financial statements.
    Any fractional shares resulting from the Reverse Share Split were rounded up to the nearest whole share.</span></p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 - SIGNIFICANT TRANSACTIONS (CONT.)</b></span></p>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
    and Warrant Purchase Agreements</b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                                         June 27, 2024, the Company entered into note and warrant purchase agreements (the &#8220;Purchase Agreement&#8221;) with certain
                                                         investors (the &#8220;June 27 Investors&#8221;), providing for the private placement of unsecured promissory notes in the aggregate
                                                         principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240627__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNotesMember_zOhRbwCA6P52" title="Aggregate principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-06-27_custom_UnsecuredPromissoryNotesMember" id="Fact000830" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></span>
                                                         (the &#8220;June 27 Notes&#8221; and each a &#8220;June 27 Note&#8221;) and warrants to purchase up to an aggregate of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240627_zKAYWNYv4bP1" title="Aggregate of shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-06-27" id="Fact000832" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">300,000</ix:nonFraction></span>
                                                         shares of the Company&#8217;s Common Stock (the &#8220;June 27 Warrants&#8221;).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShortTermDebtDescription_c20240627__20240627_zsH3tYKPYR06" title="Notes payable description"><ix:nonNumeric contextRef="From2024-06-272024-06-27" id="Fact000834" name="us-gaap:ShortTermDebtDescription">The
    June 27 Notes bear simple interest at a rate of 3% per annum and are due and payable in cash on the earlier of: (a) 12 months
    from the date of the June 27 Note; or (b) the date the Company raises third-party equity capital in an amount equal to or in excess
    of $1,000 (the &#8220;Maturity Date&#8221;). The Company may prepay the June 27 Notes at any time prior to the Maturity Date without
    penalty. If an event of default occurs, the then-outstanding principal amount of the June 27 Notes plus any unpaid accrued interest
    will accelerate and become immediately payable in cash.</ix:nonNumeric></span></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    of June 27 Warrants has an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240627_zriHWWg9YRhk" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-27" id="Fact000836" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.95</ix:nonFraction></span>
    per share. The June 27 Warrants are immediately exercisable and have a <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20240627_zGREZ9zlCaZ4" title="Warrants term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0838">5-year</span></span>
    term.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon initial recognition, the management allocated the gross cash proceeds received based on the relative fair value
of the June 27 Notes and the detachable June 27 Warrants in total amount of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfDebt_pn3n3_c20240627__20240627_zJngEYUKS1ga" title="Proceeds from notes"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2024-06-272024-06-27" id="Fact000840" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20240627__20240627_zz49PcCQcMLh" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-06-272024-06-27" id="Fact000842" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">85</ix:nonFraction></span>, respectively. The fair value of the June 27 Note
was determined based on a rating model using a debt discount rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20240627_zBw0S6KB0Nog" title="Debt discount rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2024-06-27" id="Fact000844" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">28.65</ix:nonFraction></span>% which represented the Company&#8217;s applicable rate of risk.
The fair value of the June 27 Warrants was determined by using Black-Scholes pricing model taking into account, inter alia, expected stock
price volatility of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240627__20240627_zwAzZcOMetV8" title="Price volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-06-272024-06-27" id="Fact000846" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">245</ix:nonFraction></span>% and risk-free interest rate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240627__20240627_zhS0SwSVZhVa" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-06-272024-06-27" id="Fact000848" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.52</ix:nonFraction></span>%. The amount allocated to June 27 Warrants was classified as a component
of permanent equity (as their terms permit the holders to receive a fixed number of shares of common stock upon exercise for a fixed exercise
price).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    June 27 Notes are accounted for as a financial liability measured at amortized cost. In subsequent periods, the Company recognized a
    discount and interest expense over the economic life of the June 27 Notes based on the effective interest rate method.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tabular presentation reflects the reconciliation of the carrying amount of the June 27 Notes during
the period of nine months ended September 30, 2024:&#160;</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-09-30_custom_JuneTwentySevenWarrantsMember" escape="true" id="Fact000850" name="GCTK:ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenWarrantsMember_ztHe4s0Y6vC" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zmhwp7QEQiti" style="display: none">SCHEDULE
OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenWarrantsMember_zq6138sou90d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine-month period ended<br/>
 September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>(Unaudited)</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_zqYDDjqLHFkl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Open balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0852">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfWarrants_pn3n3_zyhzU0eZMena" style="vertical-align: bottom; background-color: White">
    <td>Total proceeds received</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-012024-09-30_custom_JuneTwentySevenWarrantsMember" id="Fact000854" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ProceedsFromAllocatedWarrantsAtInitialRecognition_pn3n3_zX9355DzW9V4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
proceeds allocated to June 27 Warrants at initial recognition</span></td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 18%">(<ix:nonFraction name="GCTK:ProceedsFromAllocatedWarrantsAtInitialRecognition" contextRef="From2024-01-012024-09-30_custom_JuneTwentySevenWarrantsMember" id="Fact000856" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">85</ix:nonFraction></td><td style="text-align: left; width: 1%">)</td></tr>
  <tr id="xdx_409_ecustom--DiscountAmortizationAndInterestExpenses_pn3n3_zE75HDXl0Vsd" style="vertical-align: bottom; background-color: White">
    <td>Discount amortization and interest expenses related to <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
27 Notes (Note 5 below)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:DiscountAmortizationAndInterestExpenses" contextRef="From2024-01-012024-09-30_custom_JuneTwentySevenWarrantsMember" id="Fact000858" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--PartialConversionNotesAndAccruedInterest_pn3n3_zT1rqNwyyTs5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Partial conversion <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 27 Notes and accrued
Interest (Note 3I and Note 3J below)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="GCTK:PartialConversionNotesAndAccruedInterest" contextRef="From2024-01-012024-09-30_custom_JuneTwentySevenWarrantsMember" id="Fact000860" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">26</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--WarrantsAndRightsOutstanding_iE_pn3n3_zhz6ftz91vk2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2024-09-30_custom_JuneTwentySevenWarrantsMember" id="Fact000862" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_z0tPSidYjd83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the period commencing the issuance date through September 30, 2024,
none of the June 27 Warrants have been exercised.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 - SIGNIFICANT TRANSACTIONS (CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-size: 10pt"><b>G.</b></span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><b>Convertible Promissory Notes</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                                         July 18, 2024, the Company entered into a series of convertible promissory notes with three directors, and one member of the
                                                         Company&#8217;s executive management (the &#8220;July 18 Investors&#8221;), providing for the private placement of unsecured
                                                         convertible promissory notes in the aggregate principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240718__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z7fJNvPujgik" title="Debt instrument face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-07-18_us-gaap_ConvertibleNotesPayableMember" id="Fact000864" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">360</ix:nonFraction></span>
                                                         (the &#8220;July 18 Notes&#8221; and each a &#8220;July 18 Note&#8221;).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    July 18 Notes bear simple interest at a rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240718__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z1HHp0TCjWbj" title="Debt instrument interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-07-18_us-gaap_ConvertibleNotesPayableMember" id="Fact000866" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>%
    per annum. Interest on the outstanding principal will accrue and, unless converted earlier as set forth below, be due and payable on
    (i) the 12-month anniversary of the date hereof, or (ii) the closing date of a Qualified Financing, as defined herein (the
    &#8220;Maturity Date&#8221;).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
    regarding the conversion of the July 18 Notes as discussed below, the Company may not prepay the July 18 Notes without the written
    consent of the July 18 Investors. If not sooner repaid, all outstanding principal and accrued but unpaid interest on the July 18
    Notes (the &#8220;July 18 Note Balance&#8221;), as of the close of business on the day immediately preceding the date of the closing
    of the next issuance and sale of capital stock of the Company, in a single transaction or series of related transactions, to
    investors resulting in gross proceeds to the Company of at least $<span id="xdx_902_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20240718__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zsXQiQu4rIZ8" title="Gross proceeds from notes conversion"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2024-07-18_us-gaap_ConvertibleNotesPayableMember" id="Fact000868" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></span>
    (excluding indebtedness converted in such financing) (a &#8220;Qualified Financing&#8221;), will automatically be converted into
    that number of shares of equity securities of the Company sold in the Qualified Financing equal to the number of shares calculated
    by dividing (X) the July 18 Note Balance by (Y) an amount equal to the price per share or other unit of equity securities issued in
    such Qualified Financing, and otherwise on the same terms as the security issued in the Qualified Financing, provided that the
    conversion price per share shall not be lower than $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240718__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z4eUBxeoaARb" title="Conversion price per share"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2024-07-18_us-gaap_ConvertibleNotesPayableMember" id="Fact000870" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.56</ix:nonFraction></span>.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    the occurrence of an Event of Default (as defined below), each July 18 Investors may, by written notice to the Company, declare the
    July 18 Note to be due immediately and payable with respect to the July 18 Note Balance. An &#8220;Event of Default&#8221; means (i)
    failure by the Company to pay the July 18 Note Balance on the Maturity Date, (ii) voluntary bankruptcy, or (iii) involuntary
    bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii) above, the July 18 Note Balance shall automatically
    and immediately become due and payable, in all cases without any action on the part of any July 18 Investors.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon initial date, the management measured the fair value of the embedded
conversion feature which is accounted for as embedded derivative liability. The difference between the total gross cash proceeds received
and the fair value of the embedded conversion feature is allocated to July 18 Notes that are measured at amortized cost under which in
subsequent periods the Company recognizes a discount expense over the economic life of the July 18 Notes based on the effective interest
rate method. However, the fair value of the embedded derivative liability related to the conversion feature was determined by the management
at an insignificant amount since upon closing of a Qualified Financing the conversion will be done based on market conditions (i.e. conversion
price will be equal to the fair value of the share upon conversion) and thus all proceeds received of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_pid_c20240718__20240718__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zpDthaLemiE2" title="Conversion price"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2024-07-182024-07-18_us-gaap_ConvertibleNotesPayableMember" id="Fact000872" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">360</ix:nonFraction></span> were allocated to the July
18 Notes.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tabular presentation reflects the reconciliation of the carrying
amount of the July 18 Notes during the period of nine months ended September 30, 2024:&#160;</span></p></td></tr>
</table>

<ix:nonNumeric contextRef="From2024-01-012024-09-30_custom_JulyEighteenNotesMember" escape="true" id="Fact000874" name="GCTK:ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock"><p id="xdx_89F_ecustom--ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--JulyEighteenNotesMember_z1cKGNZR7vUa" style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zwhuunhzDGij" style="display: none">SCHEDULE
OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--JulyEighteenNotesMember_z5oURXRylszg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine-month period ended <br/>
September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ConvertibleDebt_iS_pn3n3_z2iF2SE7fnzd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Open balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfDebt_pn3n3_zF7GWCyQYXw" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Total proceeds allocated to July 18 Notes at initial recognition</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2024-01-012024-09-30_custom_JulyEighteenNotesMember" id="Fact000878" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">360</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestExpense_pn3n3_zpZevaxptRE3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expenses related to July 18 Notes (Note 5 below)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-012024-09-30_custom_JulyEighteenNotesMember" id="Fact000880" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PartialConversionAndAccruedInterest_pn3n3_zv1dVDK0cmVl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Partial conversion July 18 Notes and accrued Interest (Note 3J below)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="GCTK:PartialConversionAndAccruedInterest" contextRef="From2024-01-012024-09-30_custom_JulyEighteenNotesMember" id="Fact000882" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">101</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--ConvertibleDebt_iE_z4h2ISWrdvL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2024-09-30_custom_JulyEighteenNotesMember" id="Fact000884" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">264</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A8_zvjwyH7nOxb" style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 - SIGNIFICANT TRANSACTIONS (CONT.)</b></span></p>


<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-size: 10pt"><b>H.</b></span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><b>Convertible Promissory Note and Warrant Agreements</b></span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    July 30, 2024, the Company entered into a convertible promissory note and three warrant agreements (the &#8220;July 30
    Warrants&#8221;) with an existing investor (the &#8220;July 30 Holder&#8221;), providing for the private placement of a secured
    convertible promissory note in the aggregate principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240730__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--WarrantsAgreementMember_z38Rua6Xufea" title="Debt instrument face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-07-30_custom_ConvertiblePromissoryNotesMember_custom_WarrantsAgreementMember" id="Fact000886" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,000</ix:nonFraction></span>
    (the &#8220;July 30 Note&#8221;). The July 30 Note is not convertible until and unless approved at a meeting of the Company&#8217;s
    stockholders (the &#8220;Stockholder Approval&#8221;). </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
July 30 Note bears simple interest at a rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240730__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--WarrantsAgreementMember_zVKre55BlA8i" title="Debt instrument interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-07-30_custom_ConvertiblePromissoryNotesMember_custom_WarrantsAgreementMember" id="Fact000888" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>%
per annum and is due and payable in cash on earlier of: <span id="xdx_909_eus-gaap--DebtInstrumentDescription_c20240730__20240730__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--WarrantsAgreementMember_z3mjP06wK9Mj" title="Debt instrument description"><ix:nonNumeric contextRef="From2024-07-302024-07-30_custom_ConvertiblePromissoryNotesMember_custom_WarrantsAgreementMember" id="Fact000890" name="us-gaap:DebtInstrumentDescription">(i)
12 months anniversary of July 30 Note, or (ii) closing date of a Sale Transaction (defined below) (the &#8220;Maturity
Date&#8221;)</ix:nonNumeric></span>. The July 30 Note is secured by a first-priority security interest on all Company&#8217;s assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
regarding the conversion of the July 30 Note or a Sale Transaction as discussed below, the Company may not prepay the July 30 Note
without the written consent of the July 30 Holder. If Stockholder Approval is obtained, the July 30 Note <span id="xdx_90F_eus-gaap--DebtInstrumentDescription_c20240730__20240730__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zGGr5AJGdj7l" title="Debt instrument description"><ix:nonNumeric contextRef="From2024-07-302024-07-30_custom_ConvertiblePromissoryNotesMember" id="Fact000892" name="us-gaap:DebtInstrumentDescription">(i)
is convertible at the discretion of the July 30 Holder at a price equal to the closing price of the Common Stock on the date of
conversion and, (ii) if the Closing Price of the Common stock exceeds $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20240730__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_ztZiSbU2C6Xj" title="Sale of stock issued price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-07-30_us-gaap_ConvertibleNotesPayableMember" id="Fact000894" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></span>
per share for a period of 5 consecutive trading days, will automatically convert at a price equal to the 5 daily Volume Weighted
Average Price (&#8220;VWAP&#8221;) of the Common Stock (subject to adjustment for any stock split, stock dividend, reverse stock
split, combination or similar transaction).</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
Sale Transaction on or prior to the Maturity Date, the Company will repay the July 30 Holder, at the July 30 Holder&#8217;s
election, as follows: <span id="xdx_907_eus-gaap--SaleOfStockDescriptionOfTransaction_c20240730__20240730__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zjf1zIUFekU7" title="Sale of stock description of transaction"><ix:nonNumeric contextRef="From2024-07-302024-07-30_custom_ConvertiblePromissoryNotesMember" id="Fact000896" name="us-gaap:SaleOfStockDescriptionOfTransaction">(i)
cash equal to 200% of the Note balance, or (ii) transaction consideration in the amount to be received by the Holder in such Sale
Transaction if the July 30 Note was converted pursuant to an optional conversion. &#8220;Sale Transaction&#8221; means a merger or
consolidation of the Company with or into any other entity, or a sale of all or substantially all of the Company&#8217;s assets, or any other transaction or series of related transactions in which the Company&#8217;s stockholders immediately prior
to such transaction(s) receive cash, securities or other property in exchange for their shares and, immediately after such
transaction(s), own less than 50% of the equity securities of the surviving corporation or its parent.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the occurrence of an Event of Default (defined below), the July 30 Holder may, by written notice to the Company, declare the Note to
be due immediately and payable with respect to the July 30 Note balance. An &#8220;Event of Default&#8221; means <span id="xdx_906_eus-gaap--DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault_c20240730__20240730_zfJPzROqFKAj" title="Debt description of notice of default"><ix:nonNumeric contextRef="From2024-07-302024-07-30" id="Fact000898" name="us-gaap:DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault">(i)
failure by the Company to pay the July 30 Note balance on the Maturity Date, (ii) the Company becomes subject to a judgement of more
than $<span id="xdx_904_eus-gaap--DebtDefaultLongtermDebtAmount_iI_pn3n3_c20240730_zP2KMCyVHcE6" title="Debt default long term debt amount"><ix:nonFraction name="us-gaap:DebtDefaultLongtermDebtAmount" contextRef="AsOf2024-07-30" id="Fact000900" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50,000</ix:nonFraction></span>,
(iii) voluntary bankruptcy, or (iv) involuntary bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii)
above, the July 30 Note balance shall automatically and immediately become due and payable, in all cases without any action on the
part of the July 30 Holder.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
July 30 Warrant becomes exercisable 12 months after its issuance and has term of <span id="xdx_901_eus-gaap--DebtInstrumentTerm_dtY_c20240730__20240730_zJduixxhgpdk"><ix:nonNumeric contextRef="From2024-07-302024-07-30" format="ixt-sec:duryear" id="Fact000901" name="us-gaap:DebtInstrumentTerm">10</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years. The July 30 Warrants are exercisable for
cash only and have no price-based antidilution. The first July 30 Warrant is for <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240730__20240730__us-gaap--StatementEquityComponentsAxis__custom--FirstWarrantMember_zqTbmwV8W7kc"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-07-302024-07-30_custom_FirstWarrantMember" id="Fact000902" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,133,334</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240730__us-gaap--StatementEquityComponentsAxis__custom--FirstWarrantMember_z8ZsNrZqH5Zd" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-07-30_custom_FirstWarrantMember" id="Fact000904" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.875</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The second July 30 Warrant is for
<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240730__20240730__us-gaap--StatementEquityComponentsAxis__custom--SecondWarrantMember_zhP7ZBPUM3z"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-07-302024-07-30_custom_SecondWarrantMember" id="Fact000905" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,523,810</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares at $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240730__us-gaap--StatementEquityComponentsAxis__custom--SecondWarrantMember_zdDCUegw3YBe" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-07-30_custom_SecondWarrantMember" id="Fact000907" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.625</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The third July 30 Warrant is for <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240730__20240730__us-gaap--StatementEquityComponentsAxis__custom--ThirdWarrantMember_zYV4mNMoM6M2"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-07-302024-07-30_custom_ThirdWarrantMember" id="Fact000908" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,185,186</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares at $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240730__us-gaap--StatementEquityComponentsAxis__custom--ThirdWarrantMember_zbLOxZG0Utj" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-07-30_custom_ThirdWarrantMember" id="Fact000910" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.375</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the initial date, the Company has issued two instruments that include (i) a financial instrument that is considered as &#8220;host&#8221;
which comprised of July 30 Note and two embedded derivative financial instruments (i.e. an embedded conversion feature and an embedded
redemption feature to receive cash equals to <span id="xdx_90F_ecustom--EmbeddedConversionFeaturePercentage_iI_pid_dp_c20240730_zHpOGMbkvSf2" title="Embedded conversion feature percentage"><ix:nonFraction name="GCTK:EmbeddedConversionFeaturePercentage" contextRef="AsOf2024-07-30" id="Fact000912" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">200</ix:nonFraction></span>% of July 30 Note balance upon Sale Transaction) and (ii) three series of detachable
warrants. At the initial date, the Company is required to estimate the fair value of both two instruments and allocate the total gross
proceeds received between them based on that relative fair value identified. The fair value of the embedded derivative financial instruments
(i.e. the conversion right and the redemption right) should be bifurcated from the host instrument and remeasured on recurring basis
at each reporting period under marked to market approach, the July 30 Note is accounted for under carrying amount whereby discount and
interest expenses are recorded over the economic life of the July 30 Note based on the effective interest rate method and the July 30
Warrants are classified into equity without any further subsequent measurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 - SIGNIFICANT TRANSACTIONS (CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible
    Promissory Note and Warrant Agreements (Cont.)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
                                                         initial recognition, the management by using the assistance of an external appraiser allocated the gross cash proceeds received
                                                         based on the relative fair value of the July 30 Note and the detachable July 30 Warrants in total amount of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfDebt_c20240730__20240730_zcvcskdIz6L" title="Proceeds from notes"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2024-07-302024-07-30" id="Fact000914" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,450</ix:nonFraction></span>
                                                         and $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20240730__20240730_zBb7XG2JF2rc" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-07-302024-07-30" id="Fact000916" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,550</ix:nonFraction></span>,
                                                         respectively. The fair value of the convertible note was determined by using hybrid method that includes conversion
                                                         scenario and liquidation scenario taking into account, inter alia, a debt discount rate of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20240730_zr46TEhAsdIk" title="Debt discount rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2024-07-30" id="Fact000918" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">28.65</ix:nonFraction></span>%.
                                                         The fair value of the July 30 Warrants was determined by using Black-Scholes pricing model taking into account, inter alia, expected
                                                         stock price volatility of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240730__20240730_z7P6OiQpLtof" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-07-302024-07-30" id="Fact000920" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">122.8</ix:nonFraction></span>%
                                                         and risk-free interest rate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240730__20240730_za4oQLVx6iI5" title="Risk- free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-07-302024-07-30" id="Fact000922" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.78</ix:nonFraction></span>%.
                                                         The amount allocated to July 30 Warrants was classified as a component of permanent equity (as their terms permit the holders to
                                                         receive a fixed number of shares of common stock upon exercise for a fixed exercise price).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
it was determined that the embedded conversion feature and embedded redemption feature are required to be bifurcated from the host loan
instrument. The fair value of the bifurcated derivatives was determined by the management using the assistance of an external appraiser
in a total amount of $<span id="xdx_903_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_pn3n3_c20240730_zhLPZmjp7eU3" title="Fair value of embedded derivative liability"><ix:nonFraction name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" contextRef="AsOf2024-07-30" id="Fact000924" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon initial recognition and in subsequent periods
as derivative liability at fair value through profit and loss. The remaining amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240730_z41X6Q5ys25k"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-07-30" id="Fact000925" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,415</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">was allocated to the host loan instrument which
in subsequent periods is accounted for using the effective interest method over the term of the loan, until its stated maturity.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    following tabular presentation reflects the reconciliation of the carrying amount of the July 30 Note during the period of nine months
    ended September 30, 2024:</span></p></td></tr>
  </table>
<ix:nonNumeric contextRef="From2024-01-012024-09-30_custom_JulyThirteenNotesMember" escape="true" id="Fact000927" name="GCTK:ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock"><p id="xdx_898_ecustom--ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--JulyThirteenNotesMember_zYc0P3ckmT7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="display: none"><span id="xdx_8B2_z3vRAylczGji">SCHEDULE
OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY  30 NOTES</span></span></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--JulyThirtyNotesMember_zdScknDfgcK7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine-month period ended <br/>
September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ConvertibleDebt_iS_pn3n3_z52nzxn0zku7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Open balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromIssuanceOfDebt_pn3n3_zL8inGKJRWpb" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Total proceeds received</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2024-01-012024-09-30_custom_JulyThirtyNotesMember" id="Fact000931" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_zqFwYLU1yITe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total proceeds allocated to July 30 Warrants at initial recognition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-09-30_custom_JulyThirtyNotesMember" id="Fact000933" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,550</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_pn3n3_zv82Po9flfcg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total proceeds allocated to embedded redemption feature at initial recognition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" contextRef="From2024-01-012024-09-30_custom_JulyThirtyNotesMember" id="Fact000935" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">35</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--DiscountAmortizationAndInterestExpenses_pn3n3_zW1ptRHkBZxf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Amortization of discount and interest expenses related to July 30 Note (Note 5 below)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="GCTK:DiscountAmortizationAndInterestExpenses" contextRef="From2024-01-012024-09-30_custom_JulyThirtyNotesMember" id="Fact000937" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">309</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ConvertibleDebt_iE_pn3n3_zC5jJ7G5R526" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2024-09-30_custom_JulyThirtyNotesMember" id="Fact000939" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,724</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zESJf0AQXKE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000941" name="GCTK:ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock"><p id="xdx_89E_ecustom--ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock_zXF9TfCc680g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tabular presentation reflects the reconciliation of the fair value of the embedded conversion feature and embedded redemption
feature during the period of nine months ended September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zuF3YLAqrakf" style="display: none">SCHEDULE
OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20240930_zt5zN59dkSx8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine-month period ended <br/>
September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DerivativeLiabilities_iS_zozdHaCn3yp4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Open balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0943">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_pn3n3_zP200s6qmuRd" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Proceeds allocated to embedded redemption feature at initial recognition</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" contextRef="From2024-01-01to2024-09-30" id="Fact000945" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--RevaluationExpensesRelatedToEmbeddedRedemptionFeature_pn3n3_zihVxNPa8Od1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Revaluation expenses related to embedded redemption feature (Note 5 below)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="GCTK:RevaluationExpensesRelatedToEmbeddedRedemptionFeature" contextRef="From2024-01-01to2024-09-30" id="Fact000947" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DerivativeLiabilities_iE_zkchSUvzHfM1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-09-30" id="Fact000949" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zapTcKaPmV92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 24, 2024, the Company held a special meeting of its stockholders under which shares of common stock issuable by the Company
upon conversion of the July 30 Note and exercise of the July 30 Warrants has been approved. However, through September 30, 2024, July
30 Holder has not elected to trigger the conversion of July 30 Note or the exercise of the July 30 Warrants into shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 - SIGNIFICANT TRANSACTIONS (CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>August 23
    Conversion</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    August 23, 2024 (the &#8220;Commitment Date&#8221;), the Company and two of June 27 Investors entered into conversion agreement,
    under which the Company agreed to convert the principal nominal amount plus any accrued but unpaid interest pursuant to each of June
    27 Notes, totalling approximately $<span id="xdx_90F_eus-gaap--InterestExpense_pn3n3_c20240823__20240823__us-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenNotesMember_zWxpyAz6cV45" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-08-232024-08-23_custom_JuneTwentySevenNotesMember" id="Fact000951" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></span> each (the &#8220;Debt&#8221;), held by the Investors to Common Stock at a conversion price
    of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240823__us-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenNotesMember_zVdF1YSkjFs9" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2024-08-23_custom_JuneTwentySevenNotesMember" id="Fact000953" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.02</ix:nonFraction></span> per share. On October 15, 2024, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20241015__20241015__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIHLNVy4FjEb" title="Stock issued during period shares issued for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-10-152024-10-15_us-gaap_SubsequentEventMember" id="Fact000955" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">19,682</ix:nonFraction></span> shares of common stock for each of the two of the June 27 Investors
    in respect of each respective Debt converted.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    satisfaction of the Debt, the Company also issued to each of the two June 27 Investors three warrants (each an &#8220;August 23 Warrant&#8221;).
    Each August 23 Warrant becomes exercisable on <span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240823__20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantMember_zOolTvNjVPF8" title="Warrants exercisable"><ix:nonNumeric contextRef="From2024-08-232024-08-23_custom_AugustTwentyThreeWarrantMember" format="ixt:datemonthdayyearen" id="Fact000957" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">August 16, 2025</ix:nonNumeric></span> and has term of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantMember_zPIvgDc6Wy7a" title="Warrants and rights outstanding term::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0959">10</span></span> years. The August 23 Warrants are exercisable for
    cash only and have no price-based antidilution. The first August 23 Warrant is for <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantOneMember_zgKCXWgB51w2" title="Class of warrant or right number of securities called by warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-08-23_custom_AugustTwentyThreeWarrantOneMember" id="Fact000961" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">10,707</ix:nonFraction></span> shares of Common Stock and is exercisable
    at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantOneMember_zqHZ1Vlj9dPb" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-08-23_custom_AugustTwentyThreeWarrantOneMember" id="Fact000963" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.875</ix:nonFraction></span> per share. The second August 23 Warrant is for <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantTwoMember_zT1svfPEATIc" title="Class of warrant or right number of securities called by warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-08-23_custom_AugustTwentyThreeWarrantTwoMember" id="Fact000965" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">7,648</ix:nonFraction></span> shares of Common Stock, exercisable at $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantTwoMember_zMDZF2QlRRbe" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-08-23_custom_AugustTwentyThreeWarrantTwoMember" id="Fact000967" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.625</ix:nonFraction></span> per share. The third
    August 23 Warrant is for <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantThreeMember_zcJiiOjJZ0Ja" title="Class of warrant or right number of securities called by warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-08-23_custom_AugustTwentyThreeWarrantThreeMember" id="Fact000969" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,948</ix:nonFraction></span> shares of Common Stock, exercisable at $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantThreeMember_zBHRahYCFjc2" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-08-23_custom_AugustTwentyThreeWarrantThreeMember" id="Fact000971" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.375</ix:nonFraction></span> per share.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    above transaction was accounted for as settlements of financial liabilities under which the instruments issued or to be issued to
    the June 27 Investors (i.e. shares of common stock and August 23 Warrants) are eligible for equity classification and thus both have
    been recorded as part of the permanent equity based on the total fair value of $<span id="xdx_904_eus-gaap--EquityFairValueDisclosure_iI_pn3n3_c20240823_zZiLMCIoNcoh" title="Equity fair value disclosure"><ix:nonFraction name="us-gaap:EquityFairValueDisclosure" contextRef="AsOf2024-08-23" id="Fact000973" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">238</ix:nonFraction></span> at the Commitment Date. The difference between
    the fair value of these equity instruments and the carrying amount of each of the respective Debt at the Commitment Date amounted
    to $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240823_zsJluKmFvjaa" title="Debt instrument face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-08-23" id="Fact000975" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></span> was charged immediately to the finance expenses (see also Note 5 below).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the period commencing the issuance date through September 30, 2024, none of the August 23 Warrants have been exercised.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sep 5 Conversion</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    September 5, 2024 (the &#8220;Commitment Date&#8221;), the Company and one of June 27 Investors and July 18 Investors entered into
    a conversion agreement, under which the Company agreed to convert outstanding board fees amounted $<span id="xdx_90F_eus-gaap--InterestExpense_pn3n3_c20240905__20240905__us-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenNotesMember_zhbP7e0kpav1" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-09-052024-09-05_custom_JuneTwentySevenNotesMember" id="Fact000977" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">113</ix:nonFraction></span> and the principal nominal
    amount plus any accrued but unpaid interest pursuant to June 27 Note and July 18 Note, totalling $<span id="xdx_909_eus-gaap--InterestExpense_pn3n3_c20240905__20240905__us-gaap--StatementEquityComponentsAxis__custom--JulyEighteenNotesMember_zooXaIH17PN7" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-09-052024-09-05_custom_JulyEighteenNotesMember" id="Fact000979" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">146</ix:nonFraction></span> (referring together as a &#8220;Debt&#8221;),
    held by the Investor to Common Stock at a conversion price of $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240823__us-gaap--StatementEquityComponentsAxis__custom--JulyTwentySevenNotesMember_zsDO7fWyYe1g" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2024-08-23_custom_JulyTwentySevenNotesMember" id="Fact000981" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.02</ix:nonFraction></span> per share. On October 15, 2024, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20241015__20241015__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenNotesMember_zeUrn5PRxDO9" title="Stock issued during period shares issued for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-10-152024-10-15_us-gaap_SubsequentEventMember_custom_JuneTwentySevenNotesMember" id="Fact000983" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">254,226</ix:nonFraction></span> shares
    of common stock for the June 27 Investor in respect of the Debt converted.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    satisfaction of the Debt, the Company also issued to June 27 Investor and July 18 Investor three warrants (each an &#8220;September
    5 Warrant&#8221;). Each September 5 Warrant becomes exercisable on <span id="xdx_904_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240905__20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsMember_zkAfYk20Ghab" title="Warrants exercisable"><ix:nonNumeric contextRef="From2024-09-052024-09-05_custom_SeptemberFiveWarrantsMember" format="ixt:datemonthdayyearen" id="Fact000985" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">August 16, 2025</ix:nonNumeric></span> and has term of <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsMember_zV8yWD4JRDWh" title="Warrants and rights outstanding term::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0987">10</span></span> years. The September 5 Warrants
    are exercisable for cash only and have no price-based antidilution. The first September 5 Warrant is for <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsOneMember_zMPLfHDDzBx4" title="Class of warrant or right number of securities called by warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-09-05_custom_SeptemberFiveWarrantsOneMember" id="Fact000989" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">138,299</ix:nonFraction></span> shares of Common
    Stock and is exercisable at $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsOneMember_z77WflL0Wfy8" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-09-05_custom_SeptemberFiveWarrantsOneMember" id="Fact000991" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.875</ix:nonFraction></span> per share. The second September 5 Warrant is for <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsTwoMember_z2GIl1yqeUb2" title="Class of warrant or right number of securities called by warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-09-05_custom_SeptemberFiveWarrantsTwoMember" id="Fact000993" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">98,785</ix:nonFraction></span> shares of Common Stock, exercisable at
    $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsTwoMember_zz1Ym84sgTie" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-09-05_custom_SeptemberFiveWarrantsTwoMember" id="Fact000995" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.625</ix:nonFraction></span> per share. The third September 5 Warrant is for <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsThreeMember_zaKm6gzzUXv5" title="Class of warrant or right number of securities called by warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-09-05_custom_SeptemberFiveWarrantsThreeMember" id="Fact000997" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">76,833</ix:nonFraction></span> shares of Common Stock, exercisable at $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsThreeMember_zShYVelRWV1e" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-09-05_custom_SeptemberFiveWarrantsThreeMember" id="Fact000999" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.375</ix:nonFraction></span> per share.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    above transaction was accounted for as settlements of financial liabilities under which the instruments issued or to be issued to
    the July 18 Investor (i.e. shares of common stock and September 5 Warrants) are eligible for equity classification and thus both
    have been recorded as part of permanent equity based on the total fair value of $<span id="xdx_901_eus-gaap--EquityFairValueDisclosure_iI_pn3n3_c20240905_zIQnmVLV7pRd" title="Equity fair value disclosure"><ix:nonFraction name="us-gaap:EquityFairValueDisclosure" contextRef="AsOf2024-09-05" id="Fact001001" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,505</ix:nonFraction></span> at the Commitment Date. The difference between
    the fair value of these equity instruments and the carrying amount of the Debt at the Commitment Date amounted to $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240905_znjTytI72ePi" title="Debt instrument face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-09-05" id="Fact001003" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">227</ix:nonFraction></span> was charged
    immediately to the finance expenses (see also Note 5 below).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the period commencing the issuance date through September 30, 2024, none of the September 5 Warrants have been exercised.</span></p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact001005" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zCOc37QMoXDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 - <span id="xdx_822_zdDaUGCzfqad">COMMITMENTS AND CONTINGENT LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    2004, the Israeli Innovation Authority (IIA) provided Integrity Israel with a grant of approximately $<span id="xdx_908_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember_zaHViVdRghJ1"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2004-03-04_custom_IsraeliInnovationAuthorityMember" id="Fact001006" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">93</ix:nonFraction></span>
    (NIS <span id="xdx_90E_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pp0p0_uIsrael_c20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember_zhBK2jlcIrLh"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2004-03-04_custom_IsraeliInnovationAuthorityMember" id="Fact001007" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Israel">420,000</ix:nonFraction></span>),
    for develop a non-invasive blood glucose monitor (the &#8220;Development Plan&#8221;). Integrity Israel is required to pay royalties
    to IIA at a rate ranging between <span id="xdx_90B_ecustom--RoyaltyPercentage_pid_dp_uPure_c20040303__20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember__srt--RangeAxis__srt--MinimumMember_zunJ0lR75WF5" title="Royalty percentage minimum"><ix:nonFraction name="GCTK:RoyaltyPercentage" contextRef="From2004-03-032004-03-04_custom_IsraeliInnovationAuthorityMember_srt_MinimumMember" id="Fact001009" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span>-<span id="xdx_903_ecustom--RoyaltyPercentage_pid_dp_uPure_c20040303__20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember__srt--RangeAxis__srt--MaximumMember_zxphyp4Enfx8" title="Royalty percentage maximum"><ix:nonFraction name="GCTK:RoyaltyPercentage" contextRef="From2004-03-032004-03-04_custom_IsraeliInnovationAuthorityMember_srt_MaximumMember" id="Fact001011" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
    of the proceeds from sale of the Company&#8217;s products arising from the Development Plan up to an amount equal to $<span id="xdx_906_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pp0p0_c20040304__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember_zPm8IVWj1hOj" title="Business combination contingent consideration liability"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2004-03-04_custom_IsraeliInnovationAuthorityMember29980703" id="Fact001013" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">93</ix:nonFraction></span>,
    plus interest at LIBOR from the grant date. As to replacement of the LIBOR benchmark rate, even though the IIA has not
    declared the alternative benchmark rate to replace the LIBOR, the Company does not believe it will have a significant impact. As of
    September 30, 2024, the remaining contingent liability with respect to royalty payment on future sales equals approximately $<span id="xdx_90D_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pp0p0_c20240930__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember_zGM71gfi1iJ4" title="Contingent consideration liability"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2024-09-30_custom_IsraeliInnovationAuthorityMember" id="Fact001015" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">73</ix:nonFraction></span>,
    excluding interest. Such contingent obligation has no expiration date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    October 7, 2022 (&#8220;the Closing Date&#8221;), the Company entered into Intellectual Property Purchase Agreement (the &#8220;Agreement&#8221;)
    with Paul Goode, which is the Company&#8217;s Chief Executive Officer (the &#8220;Seller&#8221;), under which it was agreed that
    on and subject to the terms and conditions of the Agreement, at the Closing Date, Seller sold and assigned to the Company, all of Seller&#8217;s right, title and interest in and to the following assets, properties and rights (collectively,
    the &#8220;Purchased Assets&#8221;): (i) all rights, title, interests in all current and future intellectual
property, including, but not limited to patents, trademarks, trade secrets, industry know-how and other IP rights relating to an implantable
continuous glucose sensor (collectively, the &#8220;Conveyed Intellectual Property&#8221;); and (ii) all the goodwill relating to the
Purchased Assets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    consideration for the sale of the Purchased Assets to the Company, at the Closing Date, the Company paid to Seller cash
    in the amount of one dollar and obligated to issue up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221007__20221007__us-gaap--TypeOfArrangementAxis__custom--IntellectualPropertyPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXEZOIwXqj5i" title="Number of common shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-10-072022-10-07_custom_IntellectualPropertyPurchaseAgreementMember_us-gaap_CommonStockMember" id="Fact001017" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> shares of Common Stock to be issued based upon specified performance
    milestones as set forth in the Agreement (the &#8220;Purchase Price&#8221;). In addition, if upon the final issuance, the aggregate
    <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221007__20221007__us-gaap--TypeOfArrangementAxis__custom--IntellectualPropertyPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zrtE6UgOrJne" title="Number of common shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-10-072022-10-07_custom_IntellectualPropertyPurchaseAgreementMember_us-gaap_CommonStockMember_srt_MinimumMember" id="Fact001019" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> shares represent less than <span id="xdx_905_ecustom--AggregateSalesPriceOfUnitsPercentage_iI_pid_dp_uPure_c20221007__us-gaap--TypeOfArrangementAxis__custom--IntellectualPropertyPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zCCi3QJaefZ3" title="Commission as a percentage of aggregate sales price"><ix:nonFraction name="GCTK:AggregateSalesPriceOfUnitsPercentage" contextRef="AsOf2022-10-07_custom_IntellectualPropertyPurchaseAgreementMember_us-gaap_CommonStockMember_srt_MinimumMember" id="Fact001021" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.5</ix:nonFraction></span>% of the then outstanding Common Stock of the Company, the final issuance will include such
    number of additional shares so that the total aggregate issuance equals <span id="xdx_900_ecustom--AggregateSalesPriceOfUnitsPercentage_iI_pid_dp_uPure_c20221007__us-gaap--TypeOfArrangementAxis__custom--IntellectualPropertyPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__custom--TrueupSharesMember_z9Vfinwd0cze" title="Commission as a percentage of aggregate sales price"><ix:nonFraction name="GCTK:AggregateSalesPriceOfUnitsPercentage" contextRef="AsOf2022-10-07_custom_IntellectualPropertyPurchaseAgreementMember_us-gaap_CommonStockMember_srt_MinimumMember_custom_TrueupSharesMember" id="Fact001023" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.5</ix:nonFraction></span>% of the outstanding shares (the &#8220;True-Up Shares&#8221;).
    All shares of Common Stock of the Company that will be issued under the agreement shall be (i) restricted over a limited period
    as defined in the Agreement and (ii) subject to the lockup provisions.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
    the Company acquires net assets that do not constitute a business, as defined under ASU 2017-01 Business Combinations (Topic 805)
    Clarifying the Definition of a Business (such when there is no substantive process in the acquired entity) the transaction is accounted
    for as asset acquisition and no goodwill is recognized. The acquired In-Process Research and Development intangible asset (&#8220;IPR&amp;D&#8221;)
    to be used in research and development projects which have been determined not to have alternative future use at the acquisition
    date, is expensed immediately.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    the Closing Date, it was determined that the asset acquisition represents the purchase of IPR&amp;D with no alternative future use.
    However, the achievement of each of the performance milestones is considered as a contingent event outside the Company&#8217;s
    control and thus the contingent consideration which is equal to the fair value of the Purchase Price as measured at the Closing Date
    will be recognized when it becomes probable that each target will be achieved within the reasonable period. Such additional
    contingent consideration will be recognized in subsequent periods if and when the contingency (the achievement of targets) is
    resolved.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    June 2023, the Company achieved the first performance milestone out of the five performance milestones outlined in the Agreement
    executed between the Company and the Seller as of the Closing Date. As a result, upon the date of the fulfilment of the first performance
    milestone the Company was committed to issue <span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesRestrictedStock_pid_c20230601__20230620_z25ocrgRy8S8" title="Restricted shares to the seller"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesRestrictedStock" contextRef="From2023-06-012023-06-20" id="Fact001025" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span> restricted shares to the Seller. Accordingly, the Company recorded an amount
    of $<span id="xdx_906_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_c20240101__20240930_zSuklHwUuhGb" title="Research and development expenses"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-09-30" id="Fact001027" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">131</ix:nonFraction></span> as research and development expenses with a similar amount as an increase to additional paid-in capital. The first performance
    milestone shares were issued on February 6, 2024.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    May 2024, the Company achieved the second performance milestone out of the five performance milestones outlined in the Agreement
    executed between the Company and the Seller as of the Closing Date. As result, the Company is committed to issue <span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesRestrictedStock_pid_c20240501__20240531_z0lpNVaxB1S6" title="Restricted shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesRestrictedStock" contextRef="From2024-05-012024-05-31" id="Fact001029" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></span> restricted
    shares to the Seller. Accordingly, the Company recorded stock-based compensation expenses amounted to $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZzAsjd0Z9tl" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="Fact001031" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">192</ix:nonFraction></span> which represents the
    quoted price of its Common Stock at the Closing Date, after taking into consideration a discount for lack of marketability in a rate
    of <span id="xdx_906_ecustom--MarketabilityDiscountRate_pid_dp_uPure_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSM3uI0t0A02" title="Discount rate"><ix:nonFraction name="GCTK:MarketabilityDiscountRate" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="Fact001033" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30</ix:nonFraction></span> % over the applicable restriction period. As of September 30, 2024, the second performance milestone shares were not yet issued.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of September 30, 2024, the achievement of all other remaining performance milestones was not considered probable and thus no
    stock-based compensation expenses were recorded with respect to thereof.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact001035" name="us-gaap:FinancialInstrumentsDisclosureTextBlock"><p id="xdx_809_eus-gaap--FinancialInstrumentsDisclosureTextBlock_zwBry1e2Aijg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 - <span id="xdx_82D_z1HgvlIKamTb">FINANCE (INCOME) EXPENSES, NET</span></b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact001037" name="srt:ScheduleOfCondensedFinancialStatementsTableTextBlock"><p id="xdx_893_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zauJhdSM0g7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zDk8QpTWxw05" style="display: none">SCHEDULE
OF FINANCE EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20240701__20240930_zFF3zx8ch3R" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20230701__20230930_zuGbgWYkprh8" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20240101__20240930_zGqfKKbestH2" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20230101__20230930_z6aWwu5CAgM5" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three-month period ended<br/>
 September
    30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine-month period ended<br/>
 September
    30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_ecustom--DiscountAmortizationAndInterestExpensesOne_msFINztjv_zhyhrts5GOFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; width: 40%; text-align: left">Discount amortization and interest expenses related to June 27 Notes</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="GCTK:DiscountAmortizationAndInterestExpensesOne" contextRef="From2024-07-012024-09-30" id="Fact001039" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1040">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="GCTK:DiscountAmortizationAndInterestExpensesOne" contextRef="From2024-01-01to2024-09-30" id="Fact001041" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1042">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InterestExpense_msFINztjv_zlTcp83Lkpjj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expenses related to July 18 Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-07-012024-09-30" id="Fact001044" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1045">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-01to2024-09-30" id="Fact001046" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DiscountAmortizationAndInterestExpensesTwo_msFINztjv_z9b63atu2dth" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; text-indent: -10pt">Discount amortization and interest expenses related to July 30 Note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:DiscountAmortizationAndInterestExpensesTwo" contextRef="From2024-07-012024-09-30" id="Fact001049" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">309</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:DiscountAmortizationAndInterestExpensesTwo" contextRef="From2024-01-01to2024-09-30" id="Fact001051" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">309</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--RevaluationExpensesRelatedToDerivativeFinancialLiabilities_pn3n3_msFINztjv_zezxB21JZ20i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; text-indent: -10pt">Revaluation expenses related to derivative financial liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:RevaluationExpensesRelatedToDerivativeFinancialLiabilities" contextRef="From2024-07-012024-09-30" id="Fact001054" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1055">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:RevaluationExpensesRelatedToDerivativeFinancialLiabilities" contextRef="From2024-01-01to2024-09-30" id="Fact001056" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1057">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities_pn3n3_msFINztjv_zmxtjfjUkxt3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; text-indent: -10pt">Revaluation expenses incurred from settlement of financial liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" contextRef="From2024-07-012024-09-30" id="Fact001059" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,505</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GCTK:RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" contextRef="From2024-01-01to2024-09-30" id="Fact001061" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,505</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InterestExpenseDeposits_pn3n3_msFINztjv_zXVl7imz3jTk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest on bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseDeposits" contextRef="From2024-07-012024-09-30" id="Fact001064" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseDeposits" contextRef="From2023-07-012023-09-30" id="Fact001065" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseDeposits" contextRef="From2024-01-01to2024-09-30" id="Fact001066" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseDeposits" contextRef="From2023-01-012023-09-30" id="Fact001067" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherExpenses_pn3n3_msFINztjv_zd1FJnu5PiL" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; text-indent: -10pt">Exchange rate differentials, bank commissions and miscellaneous</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2024-07-012024-09-30" id="Fact001069" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1070">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2024-01-01to2024-09-30" id="Fact001071" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--FinanceIncomeNet_iNT_pn3n3_di_mtFINztjv_zV1QX83jCJJ6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance (income) expenses,
    net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GCTK:FinanceIncomeNet" contextRef="From2024-07-012024-09-30" id="Fact001074" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,848</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="GCTK:FinanceIncomeNet" contextRef="From2023-07-012023-09-30" id="Fact001075" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GCTK:FinanceIncomeNet" contextRef="From2024-01-01to2024-09-30" id="Fact001076" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,822</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="GCTK:FinanceIncomeNet" contextRef="From2023-01-012023-09-30" id="Fact001077" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact001079" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zFTwVRbQnGqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 - <span id="xdx_82B_zqoEpMyZAPt">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed interim consolidated financial statements were available to be issued. Based upon this review, the Company did not identify any other significant subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below.</span></p>



<p style="margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Completion
of underwritten U.S. public offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2024, the Company completed a public offering (the &#8220;Offering&#8221;) under which the Company received gross proceeds
of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20241112__20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpSI7AiY6Yh3" title="Gross proceeds from public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-11-122024-11-12_us-gaap_SubsequentEventMember" id="Fact001081" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,000</ix:nonFraction></span> in exchange for issuance of an aggregate of (i) <span id="xdx_90A_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1tP9c9SG7M" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" id="Fact001083" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,437,340</ix:nonFraction></span> shares (the &#8220;Shares&#8221;) of its Common Stock, (ii) <span id="xdx_90B_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zXoTQPrrcpu5" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_PrefundedWarrantsMember" id="Fact001085" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,756,900</ix:nonFraction></span>
pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to an aggregate of <span id="xdx_90B_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z1bGPQv2CdIa" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_PrefundedWarrantsMember" id="Fact001087" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,756,900</ix:nonFraction></span> shares of Common Stock (the &#8220;Pre-Funded
Warrant Shares&#8221;) in lieu of Shares, (iii) Series A Warrants (the &#8220;Series A Warrants&#8221;) to purchase up to <span id="xdx_909_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesACommonWarrantMember_zSc1j3V7lBt4" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_SeriesACommonWarrantMember" id="Fact001089" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,194,240</ix:nonFraction></span> shares
of Common Stock (the &#8220;Series A Warrant Shares&#8221;) and (iv) Series B Warrants (the &#8220;Series B Warrants&#8221; and, together
with the Series A Warrants, the &#8220;Common Warrants&#8221;) to purchase up to <span id="xdx_90C_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBCommonWarrantMember_zCY3WAecN04a" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_SeriesBCommonWarrantMember" id="Fact001091" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,194,240</ix:nonFraction></span> shares of Common Stock (&#8220;the &#8220;Series
B Warrant Shares&#8221; together with the Series A Warrant Shares, the &#8220;Warrant Shares&#8221;). Each Share or Pre-Funded Warrant,
as applicable, was sold together with one Series A Warrant to purchase one share of Common Stock and one Series B Warrant to purchase
one Common Share. The public offering price for each Share and accompanying Common Warrants was $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--PrefundedWarrantsMember_zzpcZaXFd25" title="Shares issued, per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_PrefundedWarrantsMember29981921" id="Fact001093" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.39</ix:nonFraction></span>, and the public offering price
for each Pre-Funded Warrant and accompanying Common Warrants was $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z668fmof9Om7" title="Shares issued, per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_us-gaap_IPOMember" id="Fact001095" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.389</ix:nonFraction></span> (the &#8220;Offering Price&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Pre-Funded Warrants have an exercise price of $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zsVYEpqkpIf7" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_PrefundedWarrantsMember" id="Fact001097" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share, are exercisable immediately and expire when exercised in full. Each Series
A Common Warrant will have an exercise price per share of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesACommonWarrantMember_zXzfJApE7vL4" title="Warrant, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_SeriesACommonWarrantMember" id="Fact001099" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.81</ix:nonFraction></span> and will be exercisable beginning on the date on which Stockholder
Approval (as defined below) is received and deemed effective (the &#8220;Initial Exercise Date&#8221; or the &#8220;Stockholder Approval
Date&#8221;). The Series A Warrants will expire on the five-year anniversary of the Initial Exercise Date. The Series B Warrants will
have an exercise price per share of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBCommonWarrantMember_z4d9LMCKojVg" title="Warrant, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_SeriesBCommonWarrantMember" id="Fact001101" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.81</ix:nonFraction></span> and will be exercisable beginning on the Initial Exercise Date. The Series B Warrants
will expire on the two and one-half year anniversary of the Initial Exercise Date. The issuance of Common Warrant Shares upon exercise
of the Common Warrants is subject to stockholder approval under applicable rules and regulations of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;)
(&#8220;Stockholder Approval&#8221; and the date on which Stockholder Approval is received and deemed effective, the &#8220;Stockholder
Approval Date&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price of Series A Warrants and Series B Warrants is subject to certain adjustments. If at the time of exercise there is no effective
registration statement registering, or the prospectus contained therein is not available for the issuance of the Series A Warrants Shares
and Series B Warrant Shares to the holders, then the Series A Warrants and Series B Warrants may also be exercised, in whole or in part,
at such time by means of a &#8220;cashless exercise&#8221;. In addition, the holders are entitled to an option to require the Company
to purchase the Series A Warrants and Series B Warrants for cash in an amount equal to their Black-Scholes Option Pricing Model value,
in the event that certain fundamental transactions (which some of them are not considered solely within the control of the Company) as
defined in the Series B Warrants agreement, occur. Additionally, holders of Series B Warrants may also effect an &#8220;alternative cashless
exercise&#8221; at any time while the Series B Warrants are outstanding following the Initial Exercise Date. Under the alternate cashless
exercise option, the holder of the Series B Warrant has the right to receive an aggregate number of shares equal to the product of (i)
the aggregate number of shares of Common Stock that would be issuable upon a cashless exercise of the Series B Warrant and (ii) 3.0.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
incremental and direct issuance costs are estimated at the total amount of $<span id="xdx_90A_eus-gaap--PaymentsOfDebtIssuanceCosts_pn3n3_c20241112__20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPu6cLA8K3w9" title="Incremental and direct issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2024-11-122024-11-12_us-gaap_SubsequentEventMember" id="Fact001103" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,127</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
closing of the public offering occurred on November 14, 2024 (the &#8220;Closing Date&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a private placement offering completed&#160; concurrently with the completion of the public offering, the July 30 Investor voluntarily
converted &#160;approximately $<span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn3n3_c20241112__20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--JulyThirtyNotesMember_z9NM5WmfsPJ4" title="Debt conversion converted instrument amount"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2024-11-122024-11-12_us-gaap_SubsequentEventMember_custom_JulyThirtyNotesMember" id="Fact001105" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,089</ix:nonFraction></span> of Debt, which represents the outstanding minimal amount of principal and accrued interest under
the July 30 Note as of November 12, 2024, on substantially the same terms as the public offering, resulting in the issuance of <span id="xdx_906_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--JulyThirtyNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zILd82iiKKig" title="Stock issuance"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_JulyThirtyNotesMember_us-gaap_CommonStockMember" id="Fact001107" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,640,717</ix:nonFraction></span>
shares of Common Stock (plus <span id="xdx_908_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--JulyThirtyNotesMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesACommonWarrantMember_zJv0FEwEYMm3" title="Stock issuance"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_JulyThirtyNotesMember_custom_SeriesACommonWarrantMember" id="Fact001109" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,640,717</ix:nonFraction></span> accompanying Series A Warrants and <span id="xdx_90C_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--JulyThirtyNotesMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCommonWarrantMember_zhrDrbg04nW7" title="Stock issuance"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_JulyThirtyNotesMember_custom_SeriesCommonWarrantMember" id="Fact001111" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,640,717</ix:nonFraction></span> accompanying Series B Common Warrants), based on
a conversion price of $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--JulyThirtyNotesMember_zoxmTKBDtus" title="Conversion price, per share"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_JulyThirtyNotesMember" id="Fact001113" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.55</ix:nonFraction></span> per share.</span></p>
</ix:nonNumeric><p id="xdx_811_z1FiH4O2kWs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="b_011"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cautionary
Note Regarding Forward-Looking Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
Quarterly Report on Form 10-Q contains forward-looking statements. These forward-looking statements include statements about our expectations,
beliefs or intentions regarding our product development efforts, business, financial condition, results of operations, strategies and
prospects. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q, including statements
regarding our future activities, events or developments, including such things as future revenues, capital raising and financing, product
development, clinical trials, regulatory approval, market acceptance, responses from competitors, capital expenditures (including the
amount and nature thereof), business strategy and measures to implement strategy, competitive strengths, goals, expansion and growth
of our business and operations, plans, references to future success, projected performance and trends, and other such matters, are forward-looking
statements. The words &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221;
&#8220;plan,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and other similar
words and phrases, are intended to identify forward-looking statements. The forward-looking statements made in this Quarterly Report
on Form 10-Q are based on certain historical trends, current conditions and expected future developments as well as other factors we
believe are appropriate in the circumstances. These statements relate only to events as of the date on which the statements are made
and we undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events
or otherwise, except as required by law. All of the forward-looking statements made in this Quarterly Report on Form 10-Q are qualified
by these cautionary statements and there can be no assurance that the actual results anticipated by us will be realized or, even if substantially
realized, that they will have the expected consequences to or effects on us or our business or operations. Whether actual results will
conform to our expectations and predictions is subject to a number of risks and uncertainties that may cause actual results to differ
materially. Risks and uncertainties, the occurrence of which could adversely affect our business, include the risks identified under
the caption &#8220;Risk Factors&#8221; included in our annual report on Form 10-K for the year ended December 31, 2023. The following
discussion should be read in conjunction with the condensed consolidated financial statements and the notes thereto included in Item
1 of this Quarterly Report on Form 10-Q.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a medical device company focused on the design, development and commercialization of novel technologies for use by people with diabetes.
We are currently developing an Implantable CBGM for those with Type 1 diabetes and insulin-dependent Type 2 diabetes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was founded with a mission to develop Glucotrack&#174;, a non-invasive glucose monitoring device designed to help people with diabetes
and pre-diabetics obtain glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot
finger stick devices. The first generation Glucotrack, which successfully received CE Mark approval, obtained glucose measurements via
a small sensor clipped onto one&#8217;s earlobe. A limited release beta test in Europe and the Middle East demonstrated the need for
an updated product with improved accuracy and human factors. As the glucose monitoring landscape rapidly moved away from point-in-time
measurement to continuous measurement since then, the Company recently determined that it would focus its efforts on developing its Implantable
CBGM. As such, we have since withdrawn our CE Mark for Glucotrack and are no longer pursuing commercialization of this product or development
of any further iterations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is currently developing an Implantable CBGM for use by Type 1 diabetes patients as well as insulin-dependent Type 2
patients. Implant longevity is key to the success of such a device. We have continued to evolve our sensor chemistry following our
successful in-vitro feasibility study demonstrating that a minimum two-year implant life is highly probable with the current sensor
design. Recently we announced a 3-year longevity is feasible leveraging both in-vitro and in-silico test results. We have also
completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant
procedure, good functionality, and safety. The Company has also successfully demonstrated continuous glucose sensing in the
epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, good functionality, and
safety. This latter approach is of importance for patients with painful diabetic neuropathy contemplating spinal cord
stimulation therapy for their condition. The results of these animal trials were recently presented in poster form at the American Diabetes Association, the
Diabetes Technology Society, and the DiabetesMine annual conferences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A regulatory submission has been made for a first in human study. This will be an acute study intended to demonstrate
device performance and safety. All preparatory clinical activities are complete and the study is expected to initiate in Q4 2024, pending
regulatory approval. In parallel, the Company is also preparing for a long-term clinical trial expected to begin in late Q2 2024. As part
of this effort, the Company is working towards ISO13485 certification, an internationally agreed-upon standard of quality system requirements
for the design, production, distribution, and sale of medical devices. The Company has successfully completed the first audit and is scheduled
to complete the second audit in December 2024. A successful second audit results in certification of compliance to the standard, which
is recognized and accepted by the FDA, the European Union, and many other geographies worldwide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We believe our technology, if successful, has the potential to be more accurate, more
convenient and have a longer duration than other implantable glucose monitors that are either in the market or currently under
development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Senior Management team includes; CEO and President, Paul V. Goode PhD, who has a decorated career developing innovative medical technologies,
including at Dexcom and MiniMed, CFO, James Cardwell, CPA who has over 16 years of experience as a Chief Financial Officer and Chief
Operating Officer with a concentration in both SEC financial reporting and tax compliance, James P. Thrower PhD, Vice President of Engineering,
a seasoned executive formerly of Sterling Medical Devices, Mindray DS USA and Dexcom, Inc., Mark Tapsak PhD, Vice President of Sensor
Technology, a medical research scientist who brings over 25 years of experience in the diabetes industry, including previous senior roles
at Dexcom and Medtronic, Drinda Benjamin, Vice President of Marketing, a medical device professional with over 20 years of experience
in the medical device and diabetes industry with senior roles at Intuity Medical, Senseonics, Abbott Diabetes, and Medtronic Diabetes, Vincent Wong, Vice President of Quality, a medical device professional with 15 years of experience in quality system
for implantable medical device manufacturing with senior roles at Cirtec Medical and TOMZ, and Sandie Martha, Vice President Clinical
Operations, a medical device professional with over 20 years of experience in the medical device and diabetes industry with senior roles
at Dexcom and GlySens.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andy
Balo, formerly of Dexcom and St Jude Medical (now Abbott) and John Ballantyne, founder and formerly of Aldeveron have joined as
independent board members. Several highly talented and accomplished executives joined the Company as senior advisors to the Board.
These include Daniel McCaffrey MBA MA, a world-renowned behavioral scientist and digital health expert formerly at Samsung Health
and Dexcom, Inc., and Dr. David C. Klonoff, world renowned endocrinologist and diabetes technology thought leader. We intend to
continue to invest in our talent and to expand and strengthen all areas within the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 22, 2024, we entered into a private placement agreement under which we issued 79,366 shares of our common stock at a price of $6.3
per share for aggregate gross proceeds of $500,000 to certain members of our executive management, Board of Directors and existing shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 26, 2024, we held our Annual Meeting of Shareholders (the &#8220;Annual Meeting&#8221;) under which our stockholders approved,
inter alia, the following proposals: (i) adoption of our 2024 Equity Incentive Plan; (ii) approved of an amendment to Article IV of our
Certificate of Incorporation, as amended, to effect a reverse stock split of the Company&#8217;s Common Stock at a ratio of between one-for-five
and one-for-thirty, with such ratio to be determined at the sole discretion of the Board of Directors. Following the Annual Meeting,
on April 30, 2024, the Board of Directors approved a one-for-five reverse split of our issued and outstanding shares of Common Stock
(the &#8220;Reverse Stock Split&#8221;). On May 17, 2024, we filed a Certificate of Amendment to the Company&#8217;s Certificate of Incorporation
with the Secretary of State of the State of Delaware which effected the Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 27, 2024, the Board of Directors approved us to enter into note and warrant purchase agreements with certain investors, providing
for the private placement of unsecured promissory notes in the aggregate principal amount of $100,000 (the &#8220;Notes&#8221;) and warrants
(the &#8220;Warrants&#8221;) to purchase up to an aggregate of 300,000 shares of our Common Stock. The closing of the private placement
occurred on July 1, 2024. The Notes bear simple interest at the rate of 3% per annum and are due and payable in cash on the earlier of:
(a) twelve months from the date of the Note; or (b) the date we raise third-party equity capital in an amount equal to or in excess of
$1,000,000 (the &#8220;Maturity Date&#8221;). We may prepay the Notes at any time prior to the Maturity Date without penalty. If an event
of default occurs, the then-outstanding principal amount of the Notes plus any unpaid accrued interest will accelerate and become immediately
payable in cash. Each Warrant has an exercise price of $4.95 per share. The Warrants are immediately exercisable and have a five-year
term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 18, 2024, we entered into a series of convertible promissory notes with certain investors which including three of our directors and one member of our executive management, providing for the private placement
of unsecured convertible promissory notes in the aggregate principal amount of $360,000 (the &#8220;Notes&#8221; and each a
&#8220;Note&#8221;). The Notes bear simple interest at the rate of 8% per annum and are due and payable in cash on the earlier of:
(a) the twelve-month anniversary of Note, or (b) the date of closing of a Qualified Financing (as defined above). Interest will be
computed on the basis of a 365-day year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 30, 2024, we entered into a convertible promissory note and three warrant agreements (the &#8220;Warrants&#8221;) with an
existing investor (the &#8220;Holder&#8221;), providing for the private placement of a secured convertible promissory note in the
aggregate principal amount of $4,000,000 (the &#8220;Note&#8221;). The Note was not convertible until and the approval at a meeting
of our stockholders. The Note bears simple
interest at the rate of 8% per annum and is due and payable in cash on the earlier of: (i) 12 months anniversary of Note, or (ii)
the date of closing of a Sale Transaction (as defined above) (the &#8220;Maturity Date&#8221;). The Note is secured by a
first-priority security interest on all our assets. Each Warrant becomes exercisable 12 months after its issuance and has term of 10
years. The Warrants are exercisable for cash only and have no price-based antidilution. The first Warrant is for 2,133,334 shares at
$1.875 per share. The second Warrant is for 1,523,810 shares at $2.625 per share. The third Warrant is for 1,185,186 shares at
$3.375 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 23, 2024, two of the June 27 Investors entered into conversion agreements with us, pursuant to which we
agreed to convert the principal amount, plus any accrued but unpaid interest pursuant to each of the June 27 Notes, totalling approximately
$20,076 each, held by the Investors to Common Stock at a conversion price of $1.02 per share. On October 15, 2024, we issued 19,682 shares
of common stock for each of the two of the June 27 Investors in respect of each respective debt converted. In satisfaction of the debt,
we also issued to each of the two June 27 Investors three warrants (each an &#8220;August 23 Warrant&#8221;). Each August 23 Warrant becomes
exercisable on August 16, 2025 and has term of 10 years. The August 23 Warrants are exercisable for cash only and have no price-based
antidilution. The first August 23 Warrant is for 10,707 shares of Common Stock and is exercisable at $1.875 per share. The second August
23 Warrant is for 7,648 shares of Common Stock, exercisable at $2.625 per share. The third August 23 Warrant is for 5,948 shares of Common
Stock, exercisable at $3.375 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 5, 2024, one of the June 27 Investors and July 18 Investors entered into a conversion agreement with
us, pursuant to which we agreed to convert outstanding board fees and the principal amount, plus any accrued but unpaid interest pursuant
to the June 27 Investor&#8217;s June 27 Note, totalling $259,300, held by the Investor to Common Stock at a conversion price of $1.02
per share. On October 15, 2024, we issued 254,226 shares of common stock for the June 27 Investor in respect of the Debt converted. In
satisfaction of the debt, we issued to the July 18 Investor three warrants (each an &#8220;September 5 Warrant&#8221;). Each September
5 Warrant becomes exercisable on August 16, 2025 and has term of 10 years. The September 5 Warrants are exercisable for cash only and
have no price-based antidilution. The first September 5 Warrant is for 138,299 shares of Common Stock and is exercisable at $1.875 per
share. The second September 5 Warrant is for 98,785 shares of Common Stock, exercisable at $2.625 per share. The third September 5 Warrant
is for 76,833 shares of Common Stock, exercisable at $3.375 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary of our significant accounting policies is included under Item 7 - Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations of our fiscal 2023 Form 10-K. An accounting policy is deemed to be critical if it requires an accounting estimate
to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably
could have been used, or if changes in the estimate that are reasonably possible could materially impact the financial statements. There
have been no material changes to the critical accounting policies and estimates as filed in such report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated any revenues and have experienced net losses and negative cash flows from our activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our incorporation, we have devoted substantially all our resources to research and product development and providing general and administrative
support for these activities. Since our incorporation, we have incurred significant losses and negative cash flows from operations. During
the nine months ended September 30, 2024, we incurred a net loss of approximately $12.5 million and used $9.0 million of cash in our
operations. As of September 30, 2024, we had an accumulated deficit of approximately $122.7 million. We expect to continue to incur significant
and increasing losses and do not expect positive cash flows from operations for the foreseeable future, and our net losses may fluctuate
significantly from period to period depending on the timing of and expenditures on our research and development activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2024, the balance of cash and cash equivalents of approximately $346,000, together with the net proceeds in total
amount of $8,873 which expected to be received upon closing of a public offering through registration statements on Form S-1 on
November 14, 2024, is insufficient for the Company to realize its business plans for the twelve-month period subsequent to the
reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion of our operating results explains material changes in our results of operations for the three and nine months ended
September 30, 2024 compared with the same periods ended September 30, 2023. The discussion should be read in conjunction with the financial
statements and related notes included elsewhere in this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Results of Operations for the Three Months Ended September 30, 2024 and 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Research
and development expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses were approximately $2.1 million for the three-month period ended September 30, 2024, as compared to approximately
$1.7 million for the prior-year period. The increase is attributable to ramping up product development actives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of salaries and other personnel-related expenses, materials, animal trials, production labor
and other expenses. We expect research and development expenses to increase in 2025 and beyond, primarily due to hiring additional
personnel, as well clinical trials for the Glucotrack CBGM; however, we may adjust or allocate the level of our research and development
expenses based on available financial resources and based on our commercial needs, including the FDA registration process, specific requirements
from customers, development of new Glucotrack CBGM models and others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Marketing
expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing
expenses were approximately $0.1 million <span style="background-color: white">for the three-month period ended </span>September <span style="background-color: white">30,
2024, as compared to </span>$0 <span style="background-color: white">for the prior-year period. This increase is primarily attributable
to business development personnel and professional marketing services.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General
and administrative expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses were approximately $1.1 million for the three-month period ended September 30, 2024, as compared to approximately
$0.5 million for the prior-year period. The increase is attributable to professional fees we accrued during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of professional services, salaries, consulting fees, insurance, travel expenses and other
related expenses for executive, finance and administrative personnel, including stock-based compensation expenses. Other general and
administrative costs and expenses include facility-related costs not otherwise included in research and development costs and expenses,
and professional fees for legal and accounting services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Finance (income)
expenses net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
expenses, net was approximately $1.9 million for the three-month period ended September 30, 2024, as compared to finance income of
approximately $0.001 million for the prior-year period. This increase was primarily due to $1.5 million in revaluation expenses
incurred from settlement of financial liabilities and $0.3 million in discount amortization and interest expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Net
Loss</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss was approximately $5.1 million for the three-month period ended September 30, 2024, as compared to approximately $2.2 million for
the prior-year period. The increase in net loss is attributable primarily to the increase in our operating expenses, as described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Results of Operations for the Nine Months Ended September 30, 2024 and 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Research
and development expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses were approximately $7.8 million for the nine-month period ended September 30, 2024, as compared to approximately
$3.0 million for the prior-year period. The increase is attributable to professional fees we accrued during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of salaries and other personnel-related expenses, materials, animal trials and other expenses.
We expect research and development expenses to increase in 2025 and beyond, primarily due to hiring additional personnel,
as clinical trials for the Glucotrack CBGM; however, we may adjust or allocate the level of our research and development expenses based
on available financial resources and based on our commercial needs, including the FDA registration process, specific requirements from
customers, development of new Glucotrack CBGM models and others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Marketing
expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing
expenses were approximately $0.3 million <span style="background-color: white">for the nine-month period ended September 30, 2024, as compared
to </span>$0 <span style="background-color: white">for the prior-year period. This increase is primarily attributable to business development
personnel and professional marketing services.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General
and administrative expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses were approximately $2.6 million for the nine-month period ended <span style="background-color: white">September
</span>30, 2024, as compared to approximately $1.7 million for the prior-year period. The increase is attributable to professional fees
we accrued during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of professional services, salaries, consulting fees, insurance, travel expenses and other
related expenses for executive, finance and administrative personnel, including stock-based compensation expenses. Other general and
administrative costs and expenses include facility-related costs not otherwise included in research and development costs and expenses,
and professional fees for legal and accounting services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Finance
(income) expenses, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
expenses, net was approximately $1.8 million for the nine-month period ended September 30, 2024, as compared to finance income, net
of approximately $0.002 million for the prior-year period. This increase was primarily due to $1.5 million in revaluation expenses
incurred from settlement of financial liabilities <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</span> $0.3 million in discount amortization and interest expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Net
Loss</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss was approximately $12.5 million for the nine-month period ended <span style="background-color: white">September </span>30, 2024,
as compared to approximately $4.7 million for the prior-year period. The increase in net loss is attributable primarily to the increase
in our operating expenses, as described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows for the Nine Months Ended September 30, 2024 and 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Operating
Activities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities for the nine-month period ended September 30, 2024 was approximately $9.0 million primarily due to
the net loss of approximately $12.5 million offset by non-cash charges of $2.3 million and an increase in working capital excluding cash
of $1.2 million. Net cash used in operating activities for the nine-month periods ended September 30, 2023 was approximately $4.1 million
primarily due to the net loss of $4.7 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Investing
Activities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities was $0.1 million and $0 for the nine-month periods ended September 30, 2024 and 2023, respectively. Net
cash used in investing activities primarily reflects the purchasing of fixed assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Financing
Activities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was approximately $5.0 million and $8.7 million for the nine-month periods ended September 30,
2024 and 2023, respectively. Net cash provided by financing activities primarily reflects the proceeds received from private placement
transaction in 2024 versus net proceeds received upon completion of public offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2024, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations discuss our financial statements, which have
been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).
In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events
and apply judgments that affect the reported amounts of assets, liabilities, expenses and the related disclosures. We base our assumptions,
estimates and judgments on historical experience, current trends and other factors that management believes to be relevant at the time
our condensed consolidated financial statements are prepared. On a regular basis, management reviews the accounting policies, assumptions,
estimates and judgments to ensure that our financial statements are presented fairly and in accordance with U.S. GAAP. However, because
future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates,
and such differences could be material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 49.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern Uncertainty</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of the implantable continuous glucose sensor product is expected to require substantial further expenditures. We remain dependent
upon external sources for financing our operations. Since inception, we have incurred substantial accumulated losses and negative operating
cash flow and have a significant accumulated deficit. We do not have any committed external source of funds or other support for our
development efforts, and we cannot be certain that additional funding will be available on acceptable terms, or at all. Until we can
generate sufficient revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through
a combination of public or private equity offerings, debt financings, collaborations, government funding, strategic alliances, licensing
arrangements, and other marketing or distribution arrangements, any of which may include terms that may adversely affect our stockholders&#8217;
rights. If we are unable to raise additional capital in sufficient amounts or on acceptable terms, we may have to significantly delay,
scale back or discontinue our development or commercialization initiatives. Any of the above events could significantly harm our business,
prospects, financial condition and results of operations and cause the price of our common stock to decline. We believe that our cash on hand as of September 30, 2024, <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">together with
the net proceeds expected to be received upon closing of a public offering through registration statements on Form S-1 on November 14,
2024, </span> will not provide sufficient working capital to fund its current operations and animal trial program
for the development of its Implantable CGM for a period of twelve-months subsequent to the reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="b_012"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
3. Quantitative and Qualitative Disclosures About Market Risk.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
required for smaller reporting companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="b_013"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
4. Controls and Procedures.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Evaluation
of Disclosure Controls and Procedures</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, with the participation of our Principal Executive Officer and Chief Financial Officer, has evaluated the effectiveness of
our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September
30, 2024 (the &#8220;Evaluation Date&#8221;). Based on such evaluation, those officers have concluded that, as of the Evaluation Date,
our disclosure controls and procedures are ineffective in recording, processing, summarizing and reporting, on a timely basis, information
required to be included in periodic filings under the Exchange Act and that such information is not accumulated and communicated to management,
including our principal executive and financial officers, in a manner sufficient to allow timely decisions regarding required disclosure,
due to the material weaknesses in internal control over financial reporting related to lack of sufficient internal accounting personnel,
segregation of duties, and lack of sufficient internal controls (including IT general controls) that encompass the Company as a whole
with respect to entity and transactions level controls in order to ensure complete documentation of complex and non-routine transactions
and adequate financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has identified corrective actions to remediate such material weaknesses, which includes hiring additional employees and engaging in external
financial reporting consultants. Management intends to implement procedures to remediate such material weaknesses during the fiscal year
2025; however, the implementation of these initiatives may not fully address any material weaknesses that we may have in our internal
control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected,
or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><span id="b_014"></span><b>PART
II - OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="b_015"></span>Item
1. Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time in the ordinary course of business, the Company may be subject to various claims, charges, and litigation. At September
30, 2024, except as described in the preceding paragraph, the Company did not have any pending claims, charges or litigation that were
expected to have a material adverse impact on its financial position, results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="b_016"></span>Item
1A. Risk Factors.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should carefully consider the factors discussed in Part I, Item 1A., &#8220;Risk Factors&#8221; in our Annual Report for the fiscal year
ended December 31, 2023, which could materially affect our business, financial position, or future results of operations. The risks described
in our Annual Report for the fiscal year ended December 31, 2023, are not the only risks we face. Additional risks and uncertainties
not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial position,
or future results of operations. We may disclose changes to such factors or disclose additional factors from time to time in our future
filings with the SEC. The risk factor set forth below supplements and updates the risk factors previously disclosed and should be read
together with the risk factors described in our Annual Report for the fiscal year ended December 31, 2023 and with any risk factors we
may include in subsequent periodic filings with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the current momentum for continuous glucose monitoring (&#8220;CGM&#8221;) in the diabetes market, we have announced our decision to
reset our priorities, improve our commercial outlook and refine our business strategy to focus on our implantable CGM technology. Should
our efforts to focus on CGM not be successful, we will need to further evaluate our business strategy and, as a result, our Board of
Directors may decide that it is in the best interest of our stockholders to dissolve our Company and liquidate our assets or otherwise
modify our strategy in the future. In this regard, we may, from time to time, focus our product development efforts on different product
candidates or may delay, suspend or terminate the future development of a product candidate at any time for strategic, business, financial
or other reasons. As a result of changes in our strategy, we have and may in the future change or refocus our existing product development,
commercialization and manufacturing activities. This could require changes in our facilities and our personnel. Any product development
changes that we implement may not be successful. In particular, we may fail to select or capitalize on the most scientifically, clinically
or commercially promising or profitable product candidates. Our decisions to allocate our research and development, management and financial
resources toward particular product candidates may not lead to the development of viable commercial products and may divert resources
from better opportunities. Similarly, our decisions to delay or terminate product development programs may also prove to be incorrect
and could cause us to miss valuable opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
failure to maintain compliance with Nasdaq&#8217;s continued listing requirements could result in the delisting of our Common Stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is currently listed for trading on The Nasdaq Stock Market LLC. We must satisfy the continued listing requirements of Nasdaq,
to maintain the listing of our common stock on The Nasdaq Stock Market LLC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 26, 2023, we received notice from the Staff indicating that, based upon the closing bid price of our common stock for the prior 30
consecutive business days, we were not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share
for continued listing on Nasdaq as set forth in Nasdaq Listing Rule 5550(a)(2) (the &#8220;Bid Price Rule&#8221;). We had 180 days from
May 26, 2023, or through November 22, 2023, to regain compliance with the Bid Price Rule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 24, 2023, we received a second letter from Nasdaq notifying the Company that it had been granted an additional 180 calendar
days, or until May 20, 2024 (the &#8220;Extended Compliance Period&#8221;), to regain compliance with the Minimum Bid Price Requirement
in accordance with Nasdaq Listing Rule 5810(c)(3)(A).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 21, 2024, we received a third letter from Nasdaq (the &#8220;Letter&#8221;) notifying us that it had not regained compliance with
the Minimum Bid Price Requirement during the Extended Compliance Period. The Letter also notified us that our Form 10-Q for the period
ended March 31, 2024, indicates that we no longer meet the $2,500,000 minimum stockholders&#8217; equity requirement for continued listing
set forth under Listing Rule 5550(b)(1) (the &#8220;Minimum Stockholders&#8217; Equity Requirement&#8221;). Pursuant to Listing Rule
5810(d)(2), the failure to comply with the Minimum Stockholders&#8217; Equity Requirement has become an additional and separate basis
for delisting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we were under review for failure to meet the Minimum Bid Price Requirement, we were not eligible to submit a plan to regain compliance.
Accordingly, unless we would request an appeal of this determination by May 28, 2024, trading of our common stock would be suspended
at the opening of business on May 30, 2024, and a Form 25-NSE would be filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;).
We timely requested a hearing before a Nasdaq Hearings Panel (the &#8220;Panel&#8221;). The hearing request would result in a stay of
any suspension or delisting action pending the hearing. On August 5, 2024, we received the decision of the Panel, and they granted us
an extension to November 18, 2024 to regain compliance with the Minimum Stockholders&#8217; Equity Requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 17, 2024, in order to regain compliance with the Minimum Bid Price Requirement, we filed a Certificate of Amendment to the Company&#8217;s
Certificate of Incorporation with the Secretary of State of the State of Delaware which effected, as of 4:30 p.m. Eastern Time, on May
17, 2024, a one-for-five Reverse Stock Split of our issued and outstanding shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that we are unable to regain and sustain compliance with all applicable requirements for continued listing on the Nasdaq, our
Common Stock may be delisted from Nasdaq. If our Common Stock were delisted from Nasdaq, trading of our common stock would most likely
take place on an over-the-counter market established for unlisted securities, such as the OTCQB or the Pink Market maintained by OTC
Markets Group Inc. An investor would likely find it less convenient to sell, or to obtain accurate quotations in seeking to buy, our
common stock on an over-the-counter market, and many investors would likely not buy or sell our common stock due to difficulty in accessing
over-the-counter markets, policies preventing them from trading in securities not listed on a national exchange or other reasons. In
addition, as a delisted security, our common stock would be subject to SEC rules as a &#8220;penny stock,&#8221; which impose additional
disclosure requirements on broker-dealers. The regulations relating to penny stocks, coupled with the typically higher cost per trade
to the investor of penny stocks due to factors such as broker commissions generally representing a higher percentage of the price of
a penny stock than of a higher-priced stock, would further limit the ability of investors to trade in our common stock. In addition,
delisting would materially and adversely affect our ability to raise capital on terms acceptable to us, or at all, and may result in
the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities. For these
reasons and others, delisting would adversely affect the liquidity, trading volume and price of our common stock, causing the value of
an investment in us to decrease and having an adverse effect on our business, financial condition and results of operations, including
our ability to attract and retain qualified employees and to raise capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely on third parties to manufacture and supply our product.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own or operate manufacturing facilities for clinical or commercial production of Glucotrack CBGM, other than a prototype lab.
We have no experience in medical device manufacturing and lack the resources and the capability to manufacture the Glucotrack CBGM on
a commercial scale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our manufacturing partners are unable to produce our products in the amounts, timing or pricing that we require, we may not be able to
establish a contract and obtain a sufficient alternative supply from another supplier on a timely basis and in the quantities or pricing
we require. We expect to depend on third-party contract manufacturers for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glucotrack
CBGM does, and our future product candidates, if any, likely will require precise, high quality manufacturing. Any of our contract manufacturers
will be subject to ongoing periodic unannounced inspections by the FDA and other non-U.S. regulatory authorities to ensure strict compliance
with quality system regulations, including current good manufacturing practices and other applicable government regulations and corresponding
standards. If our contract manufacturers fail to achieve and maintain high manufacturing standards in compliance with quality system
regulations, we may experience manufacturing errors resulting in patient injury or death, product recalls or withdrawals, delays or interruptions
of production or failures in product testing or delivery, delay or prevention of filing or approval of marketing applications for our
products, cost overruns or other problems that could seriously harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
performance failure on the part of our contract manufacturers could delay clinical development or regulatory clearance or approval of
our product candidates or commercialization of our future product candidates, depriving us of potential product revenue and resulting
in additional losses. In addition, our dependence on a third-party for manufacturing may adversely affect our future profit margins.
Our ability to replace an existing manufacturer may be difficult because the number of potential manufacturers is limited, and the FDA
must approve any replacement manufacturer before it can begin manufacturing our product candidates. Such approval would require additional
non-clinical testing and compliance inspections. It may be difficult or impossible for us to identify and engage a replacement manufacturer
on acceptable terms in a timely manner, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="b_017"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
2. Unregistered Sales of Equity Securities and Use of Proceeds.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Except as disclosed below, during the quarter ended September 30, 2024, there were no unregistered sales of our securities that were
not reported in a Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 23, 2024, two investors entered into conversion agreements (the &#8220;Conversion Agreements&#8221;) with the Company, pursuant
to which the Company agreed to convert the principal amount, plus any accrued but unpaid interest pursuant to two outstanding promissory
notes, totalling $20,076 each (the &#8220;Debt&#8221;), held by the Investors to Common Stock at a conversion price of $1.02 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
in satisfaction of the Debt and pursuant to the Conversion Agreement, the Company issued to each of the two Investors three warrants
(each an &#8220;August 23 Warrant&#8221;). Each August 23 Warrant becomes exercisable on August 16, 2025, and has term of 10 years. The
August 23 Warrants are exercisable for cash only and have no price-based antidilution. The first August 23 Warrant is for 10,707 shares
of Common Stock and is exercisable at $1.875 per share. The second August 23 Warrant is for 7,648 shares of Common Stock, exercisable
at $2.625 per share. The third August 23 Warrant is for 5,948 shares of Common Stock, exercisable at $3.375 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
August 23 Warrants and the shares issued in satisfaction of the Debt were issued in reliance on the exemption from registration requirements
thereof provided by Section 4(a)(2) of the Securities Act and Regulation D promulgated under the Securities Act. The Company relied on
this exemption from registration based in part on representations made by the investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Not applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="b_018"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
3. Defaults Upon Senior Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="b_019"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
4. Mine Safety Disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="b_020"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
5. Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="b_021"></span><b>Item
6. Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000114420411048873/v232648_ex3-1.htm" style="-sec-extract: exhibit">Certificate of Incorporation of Integrity Applications, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on August 22, 2011)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000114420411048873/v232648_ex3-2.htm" style="-sec-extract: exhibit">Certificate of Amendment to Certificate of Incorporation of Integrity Applications, Inc. (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on August 22, 2011)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000114420411048873/v232648_ex3-3.htm" style="-sec-extract: exhibit">Bylaws of Integrity Applications, Inc. (incorporated by reference to Exhibit 3.3 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on August 22, 2011)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000149315220006997/ex99-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to Certificate of Incorporation of Integrity Applications, Inc. (incorporated by reference to Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on April 23, 2020)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000149315222008417/ex3-7.htm" style="-sec-extract: exhibit">Amendments to The Company&#8217;s Certificate of Incorporation (incorporated by reference to Exhibit 3.7 to the Company&#8217;s Annual Report on Form 10-K, filed with the SEC on March 31, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000149315224020548/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on May 17, 2024 (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with SEC on May 20, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000149315224024427/ex3-01.htm" style="-sec-extract: exhibit">First Amendment to Bylaws (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on June 20, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000149315224025858/ex4-1.htm" style="-sec-extract: exhibit">Form of Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with SEC on July 1, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000149315224029775/ex10-2.htm" style="-sec-extract: exhibit">Form of Warrant (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with SEC on July 31, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000149315224025858/ex10-1.htm" style="-sec-extract: exhibit">Form of Note and Warrant Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with SEC on July 1, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000149315224025858/ex10-2.htm" style="-sec-extract: exhibit">Form of Promissory Note (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with SEC on July 1, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000149315224028635/ex10-1.htm" style="-sec-extract: exhibit">Form of Promissory Note (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with SEC on July 22, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000149315224029775/ex10-1.htm" style="-sec-extract: exhibit">Form of Convertible Promissory Note (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with SEC on July 31, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished
    herewith.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="b_022"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
November 14, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GLUCOTRACK,
    INC. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    James Cardwell</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Cardwell</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>




















































<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a)
OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Paul Goode, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2024 of Glucotrack, Inc.;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 14, 2024</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Paul Goode</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Goode</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a)
OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, James Cardwell, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2024 of Glucotrack, Inc.;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 14, 2024</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ James Cardwell</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Cardwell</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Quarterly Report on Form 10-Q of Glucotrack, Inc. (the &ldquo;<U>Company</U>&rdquo;) for the period ended September
30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;<U>Report</U>&rdquo;), I, Paul Goode, Principal
Executive Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that, to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Report fully complies
    with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the information contained
    in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Paul Goode</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Goode</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 14, 2024</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Quarterly Report on Form 10-Q
of Glucotrack, Inc. (the &ldquo;<U>Company</U>&rdquo;) for the period ended September 30, 2024, as filed with the Securities and Exchange
Commission on the date hereof (the &ldquo;<U>Report</U>&rdquo;), I, James Cardwell, Principal Financial Officer, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ James Cardwell</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Cardwell</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Dated:</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> November 14, 2024</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>gctk-20240930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaSEybP9z5Z8KekhvWB/bYn6bywvVorMKCTyG19WMV4P -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:GCTK="http://glucotrack.com/20240930" elementFormDefault="qualified" targetNamespace="http://glucotrack.com/20240930">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://glucotrack.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" id="StatementOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/General" id="General">
          <link:definition>00000007 - Disclosure - GENERAL</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/SignificantTransactions" id="SignificantTransactions">
          <link:definition>00000009 - Disclosure - SIGNIFICANT TRANSACTIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/CommitmentsAndContingentLiabilities" id="CommitmentsAndContingentLiabilities">
          <link:definition>00000010 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/FinanceIncomeExpensesNet" id="FinanceIncomeExpensesNet">
          <link:definition>00000011 - Disclosure - FINANCE (INCOME) EXPENSES, NET</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000012 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>00000014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/SignificantTransactionsTables" id="SignificantTransactionsTables">
          <link:definition>00000015 - Disclosure - SIGNIFICANT TRANSACTIONS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/FinanceIncomeExpensesNetTables" id="FinanceIncomeExpensesNetTables">
          <link:definition>00000016 - Disclosure - FINANCE (INCOME) EXPENSES, NET (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/GeneralDetailsNarrative" id="GeneralDetailsNarrative">
          <link:definition>00000017 - Disclosure - GENERAL (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails" id="ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails">
          <link:definition>00000018 - Disclosure - SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails" id="ScheduleOfOperatingLeaseDetails">
          <link:definition>00000019 - Disclosure - SCHEDULE OF OPERATING LEASE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails" id="ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails">
          <link:definition>00000020 - Disclosure - SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails" id="ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails">
          <link:definition>00000021 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails" id="ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails">
          <link:definition>00000022 - Disclosure - SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails" id="ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails">
          <link:definition>00000023 - Disclosure - SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureDetails" id="ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureDetails">
          <link:definition>00000024 - Disclosure - SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" id="SignificantTransactionsDetailsNarrative">
          <link:definition>00000025 - Disclosure - SIGNIFICANT TRANSACTIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" id="CommitmentsAndContingentLiabilitiesDetailsNarrative">
          <link:definition>00000026 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails" id="ScheduleOfFinanceExpensesDetails">
          <link:definition>00000027 - Disclosure - SCHEDULE OF FINANCE EXPENSES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://glucotrack.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000028 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="gctk-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="gctk-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="gctk-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="gctk-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="GCTK_ReceiptsOnAccountOfSharesMember" name="ReceiptsOnAccountOfSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_PrefundedWarrantsMember" name="PrefundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_PerformanceMilestoneMember" name="PerformanceMilestoneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_ExchangeAgreementMember" name="ExchangeAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_UnsecuredPromissoryNotesMember" name="UnsecuredPromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_ConvertiblePromissoryNotesMember" name="ConvertiblePromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_WarrantsAgreementMember" name="WarrantsAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_FirstWarrantMember" name="FirstWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_SecondWarrantMember" name="SecondWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_ThirdWarrantMember" name="ThirdWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_JuneTwentySevenNotesMember" name="JuneTwentySevenNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_AugustTwentyThreeWarrantMember" name="AugustTwentyThreeWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_AugustTwentyThreeWarrantOneMember" name="AugustTwentyThreeWarrantOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_AugustTwentyThreeWarrantTwoMember" name="AugustTwentyThreeWarrantTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_AugustTwentyThreeWarrantThreeMember" name="AugustTwentyThreeWarrantThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_JulyEighteenNotesMember" name="JulyEighteenNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_JulyTwentySevenNotesMember" name="JulyTwentySevenNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_SeptemberFiveWarrantsMember" name="SeptemberFiveWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_SeptemberFiveWarrantsOneMember" name="SeptemberFiveWarrantsOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_SeptemberFiveWarrantsTwoMember" name="SeptemberFiveWarrantsTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_SeptemberFiveWarrantsThreeMember" name="SeptemberFiveWarrantsThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_JuneTwentySevenWarrantsMember" name="JuneTwentySevenWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_JulyThirteenNotesMember" name="JulyThirteenNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_LessThanOneYearMember" name="LessThanOneYearMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_BetweenOneYearToTwoYearsMember" name="BetweenOneYearToTwoYearsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_MoreThanTwoYearsMember" name="MoreThanTwoYearsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_JulyThirtyNotesMember" name="JulyThirtyNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_IsraeliInnovationAuthorityMember" name="IsraeliInnovationAuthorityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_IntellectualPropertyPurchaseAgreementMember" name="IntellectualPropertyPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_TrueupSharesMember" name="TrueupSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_SeriesACommonWarrantMember" name="SeriesACommonWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_SeriesBCommonWarrantMember" name="SeriesBCommonWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_SeriesCommonWarrantMember" name="SeriesCommonWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_PromissoryNotesCurrent" name="PromissoryNotesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_ReceiptsOnAccountOfShares" name="ReceiptsOnAccountOfShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_FinanceIncomeNet" name="FinanceIncomeNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted" name="AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" name="StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares" name="StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares" name="StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions" name="StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" name="StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" name="StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" name="StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" name="StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity" name="StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity" name="StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant" name="StockIssuedDuringPeriodValueIssuanceOfWarrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" name="IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_LinkageDifferenceOnPrincipalOfLoansFromStockholders" name="LinkageDifferenceOnPrincipalOfLoansFromStockholders" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" name="RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities" name="RevaluationExpensesRelatedToDerivativeFinancialLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_ProceedsFromConvertibleDebtPrivatePlacementTransaction" name="ProceedsFromConvertibleDebtPrivatePlacementTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_ProceedsReceivedFromUnderwrittenPublicOffering" name="ProceedsReceivedFromUnderwrittenPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_DeemedDividendUponTriggerOfDownRoundProtection" name="DeemedDividendUponTriggerOfDownRoundProtection" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" name="IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_DisclosureSignificantTransactionsAbstract" name="DisclosureSignificantTransactionsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_SignificantTransactionsTextBlock" name="SignificantTransactionsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_ModificationOfEquityClassifiedContractsPolicyTextBlock" name="ModificationOfEquityClassifiedContractsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_ConvertiblePromissoryNotesPolicyTextBlock" name="ConvertiblePromissoryNotesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock" name="AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock" name="ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock" name="ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock" name="ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature" name="DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones" name="EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_LesseeOperatingLeaseLiabilityImputedInterest" name="LesseeOperatingLeaseLiabilityImputedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_ProceedsFromAllocatedWarrantsAtInitialRecognition" name="ProceedsFromAllocatedWarrantsAtInitialRecognition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_DiscountAmortizationAndInterestExpenses" name="DiscountAmortizationAndInterestExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_PartialConversionNotesAndAccruedInterest" name="PartialConversionNotesAndAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_PartialConversionAndAccruedInterest" name="PartialConversionAndAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_RevaluationExpensesRelatedToEmbeddedRedemptionFeature" name="RevaluationExpensesRelatedToEmbeddedRedemptionFeature" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_LockUpPeriodDescription" name="LockUpPeriodDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_EmbeddedConversionFeaturePercentage" name="EmbeddedConversionFeaturePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_RoyaltyPercentage" name="RoyaltyPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_AggregateSalesPriceOfUnitsPercentage" name="AggregateSalesPriceOfUnitsPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_MarketabilityDiscountRate" name="MarketabilityDiscountRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_DiscountAmortizationAndInterestExpensesOne" name="DiscountAmortizationAndInterestExpensesOne" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_DiscountAmortizationAndInterestExpensesTwo" name="DiscountAmortizationAndInterestExpensesTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_SeptemberFiveTwoThousandTwentyFourWarrantOneMember" name="SeptemberFiveTwoThousandTwentyFourWarrantOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_SeriesAWarrantSharesMember" name="SeriesAWarrantSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GCTK_SeriesBWarrantSharesMember" name="SeriesBWarrantSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>gctk-20240930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://glucotrack.com/role/Cover" xlink:href="gctk-20240930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/BalanceSheets" xlink:href="gctk-20240930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/BalanceSheetsParenthetical" xlink:href="gctk-20240930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="gctk-20240930.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" xlink:href="gctk-20240930.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/StatementsOfCashFlows" xlink:href="gctk-20240930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/General" xlink:href="gctk-20240930.xsd#General" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="gctk-20240930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SignificantTransactions" xlink:href="gctk-20240930.xsd#SignificantTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/CommitmentsAndContingentLiabilities" xlink:href="gctk-20240930.xsd#CommitmentsAndContingentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/FinanceIncomeExpensesNet" xlink:href="gctk-20240930.xsd#FinanceIncomeExpensesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SubsequentEvents" xlink:href="gctk-20240930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gctk-20240930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="gctk-20240930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SignificantTransactionsTables" xlink:href="gctk-20240930.xsd#SignificantTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/FinanceIncomeExpensesNetTables" xlink:href="gctk-20240930.xsd#FinanceIncomeExpensesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/GeneralDetailsNarrative" xlink:href="gctk-20240930.xsd#GeneralDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails" xlink:href="gctk-20240930.xsd#ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails" xlink:href="gctk-20240930.xsd#ScheduleOfOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails" xlink:href="gctk-20240930.xsd#ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails" xlink:href="gctk-20240930.xsd#ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails" xlink:href="gctk-20240930.xsd#ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails" xlink:href="gctk-20240930.xsd#ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureDetails" xlink:href="gctk-20240930.xsd#ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" xlink:href="gctk-20240930.xsd#SignificantTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:href="gctk-20240930.xsd#CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails" xlink:href="gctk-20240930.xsd#ScheduleOfFinanceExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SubsequentEventsDetailsNarrative" xlink:href="gctk-20240930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaapRestrictedCashNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapRestrictedCashNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PromissoryNotesCurrent" xlink:label="loc_GCTKPromissoryNotesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_GCTKPromissoryNotesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ReceiptsOnAccountOfShares" xlink:label="loc_GCTKReceiptsOnAccountOfShares" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_GCTKReceiptsOnAccountOfShares" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaapMarketingExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapMarketingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_FinanceIncomeNet" xlink:label="loc_GCTKFinanceIncomeNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_GCTKFinanceIncomeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" xlink:label="loc_GCTKIssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GCTKIssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_LinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:label="loc_GCTKLinkageDifferenceOnPrincipalOfLoansFromStockholders" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GCTKLinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" xlink:label="loc_GCTKRevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GCTKRevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities" xlink:label="loc_GCTKRevaluationExpensesRelatedToDerivativeFinancialLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GCTKRevaluationExpensesRelatedToDerivativeFinancialLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ProceedsFromConvertibleDebtPrivatePlacementTransaction" xlink:label="loc_GCTKProceedsFromConvertibleDebtPrivatePlacementTransaction" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_GCTKProceedsFromConvertibleDebtPrivatePlacementTransaction" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ProceedsReceivedFromUnderwrittenPublicOffering" xlink:label="loc_GCTKProceedsReceivedFromUnderwrittenPublicOffering" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_GCTKProceedsReceivedFromUnderwrittenPublicOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/General" xlink:title="00000007 - Disclosure - GENERAL" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SignificantTransactions" xlink:title="00000009 - Disclosure - SIGNIFICANT TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/CommitmentsAndContingentLiabilities" xlink:title="00000010 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/FinanceIncomeExpensesNet" xlink:title="00000011 - Disclosure - FINANCE (INCOME) EXPENSES, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SubsequentEvents" xlink:title="00000012 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SignificantTransactionsTables" xlink:title="00000015 - Disclosure - SIGNIFICANT TRANSACTIONS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/FinanceIncomeExpensesNetTables" xlink:title="00000016 - Disclosure - FINANCE (INCOME) EXPENSES, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/GeneralDetailsNarrative" xlink:title="00000017 - Disclosure - GENERAL (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails" xlink:title="00000018 - Disclosure - SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature" xlink:label="loc_GCTKDeemedDividendRelatedToTriggerOfDownRoundProtectionFeature" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_GCTKDeemedDividendRelatedToTriggerOfDownRoundProtectionFeature" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails" xlink:title="00000019 - Disclosure - SCHEDULE OF OPERATING LEASE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails" xlink:title="00000020 - Disclosure - SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails" xlink:title="00000021 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails" xlink:title="00000022 - Disclosure - SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails" xlink:title="00000023 - Disclosure - SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureDetails" xlink:title="00000024 - Disclosure - SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" xlink:title="00000025 - Disclosure - SIGNIFICANT TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:title="00000026 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails" xlink:title="00000027 - Disclosure - SCHEDULE OF FINANCE EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_FinanceIncomeNet" xlink:label="loc_GCTKFinanceIncomeNet" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DiscountAmortizationAndInterestExpensesOne" xlink:label="loc_GCTKDiscountAmortizationAndInterestExpensesOne" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GCTKFinanceIncomeNet" xlink:to="loc_GCTKDiscountAmortizationAndInterestExpensesOne" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GCTKFinanceIncomeNet" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DiscountAmortizationAndInterestExpensesTwo" xlink:label="loc_GCTKDiscountAmortizationAndInterestExpensesTwo" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GCTKFinanceIncomeNet" xlink:to="loc_GCTKDiscountAmortizationAndInterestExpensesTwo" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities" xlink:label="loc_GCTKRevaluationExpensesRelatedToDerivativeFinancialLiabilities" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GCTKFinanceIncomeNet" xlink:to="loc_GCTKRevaluationExpensesRelatedToDerivativeFinancialLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" xlink:label="loc_GCTKRevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GCTKFinanceIncomeNet" xlink:to="loc_GCTKRevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDeposits" xlink:label="loc_us-gaapInterestExpenseDeposits" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GCTKFinanceIncomeNet" xlink:to="loc_us-gaapInterestExpenseDeposits" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GCTKFinanceIncomeNet" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000028 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>gctk-20240930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://glucotrack.com/role/Cover" xlink:href="gctk-20240930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/BalanceSheets" xlink:href="gctk-20240930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/BalanceSheetsParenthetical" xlink:href="gctk-20240930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="gctk-20240930.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" xlink:href="gctk-20240930.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/StatementsOfCashFlows" xlink:href="gctk-20240930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/General" xlink:href="gctk-20240930.xsd#General" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="gctk-20240930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SignificantTransactions" xlink:href="gctk-20240930.xsd#SignificantTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/CommitmentsAndContingentLiabilities" xlink:href="gctk-20240930.xsd#CommitmentsAndContingentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/FinanceIncomeExpensesNet" xlink:href="gctk-20240930.xsd#FinanceIncomeExpensesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SubsequentEvents" xlink:href="gctk-20240930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gctk-20240930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="gctk-20240930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SignificantTransactionsTables" xlink:href="gctk-20240930.xsd#SignificantTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/FinanceIncomeExpensesNetTables" xlink:href="gctk-20240930.xsd#FinanceIncomeExpensesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/GeneralDetailsNarrative" xlink:href="gctk-20240930.xsd#GeneralDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails" xlink:href="gctk-20240930.xsd#ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails" xlink:href="gctk-20240930.xsd#ScheduleOfOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails" xlink:href="gctk-20240930.xsd#ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails" xlink:href="gctk-20240930.xsd#ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails" xlink:href="gctk-20240930.xsd#ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails" xlink:href="gctk-20240930.xsd#ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureDetails" xlink:href="gctk-20240930.xsd#ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" xlink:href="gctk-20240930.xsd#SignificantTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:href="gctk-20240930.xsd#CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails" xlink:href="gctk-20240930.xsd#ScheduleOfFinanceExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SubsequentEventsDetailsNarrative" xlink:href="gctk-20240930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ReceiptsOnAccountOfSharesMember" xlink:label="loc_GCTKReceiptsOnAccountOfSharesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKReceiptsOnAccountOfSharesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted" xlink:label="loc_GCTKAdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKAdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_GCTKStockToBeIssuedDuringPeriodValueRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockToBeIssuedDuringPeriodValueRestrictedStockAwardGross_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares" xlink:label="loc_GCTKStockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares" xlink:label="loc_GCTKStockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions" xlink:label="loc_GCTKStockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" xlink:label="loc_GCTKStockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" xlink:label="loc_GCTKStockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" xlink:label="loc_GCTKStockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" xlink:label="loc_GCTKStockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity" xlink:label="loc_GCTKStockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity" xlink:label="loc_GCTKStockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant" xlink:label="loc_GCTKStockIssuedDuringPeriodValueIssuanceOfWarrant_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockIssuedDuringPeriodValueIssuanceOfWarrant_70" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/General" xlink:title="00000007 - Disclosure - GENERAL" />
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SignificantTransactions" xlink:title="00000009 - Disclosure - SIGNIFICANT TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/CommitmentsAndContingentLiabilities" xlink:title="00000010 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/FinanceIncomeExpensesNet" xlink:title="00000011 - Disclosure - FINANCE (INCOME) EXPENSES, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SubsequentEvents" xlink:title="00000012 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SignificantTransactionsTables" xlink:title="00000015 - Disclosure - SIGNIFICANT TRANSACTIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JuneTwentySevenWarrantsMember" xlink:label="loc_GCTKJuneTwentySevenWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKJuneTwentySevenWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JulyEighteenNotesMember" xlink:label="loc_GCTKJulyEighteenNotesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKJulyEighteenNotesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JulyThirteenNotesMember" xlink:label="loc_GCTKJulyThirteenNotesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKJulyThirteenNotesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseCostTableTextBlock_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock" xlink:label="loc_GCTKScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock" xlink:label="loc_GCTKScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock" xlink:label="loc_GCTKScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/FinanceIncomeExpensesNetTables" xlink:title="00000016 - Disclosure - FINANCE (INCOME) EXPENSES, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/GeneralDetailsNarrative" xlink:title="00000017 - Disclosure - GENERAL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromUnsecuredNotesPayable" xlink:label="loc_us-gaapProceedsFromUnsecuredNotesPayable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromUnsecuredNotesPayable_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSecuredNotesPayable" xlink:label="loc_us-gaapProceedsFromSecuredNotesPayable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromSecuredNotesPayable_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecurities" xlink:label="loc_us-gaapDebtSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtSecurities_60" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails" xlink:title="00000018 - Disclosure - SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PrefundedWarrantsMember" xlink:label="loc_GCTKPrefundedWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKPrefundedWarrantsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PerformanceMilestoneMember" xlink:label="loc_GCTKPerformanceMilestoneMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKPerformanceMilestoneMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature" xlink:label="loc_GCTKDeemedDividendRelatedToTriggerOfDownRoundProtectionFeature_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKDeemedDividendRelatedToTriggerOfDownRoundProtectionFeature_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones" xlink:label="loc_GCTKEarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKEarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_170" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails" xlink:title="00000019 - Disclosure - SCHEDULE OF OPERATING LEASE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails" xlink:title="00000020 - Disclosure - SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaapLesseeLeaseDescriptionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_LessThanOneYearMember" xlink:label="loc_GCTKLessThanOneYearMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_GCTKLessThanOneYearMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_BetweenOneYearToTwoYearsMember" xlink:label="loc_GCTKBetweenOneYearToTwoYearsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_GCTKBetweenOneYearToTwoYearsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_MoreThanTwoYearsMember" xlink:label="loc_GCTKMoreThanTwoYearsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_GCTKMoreThanTwoYearsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_LesseeOperatingLeaseLiabilityImputedInterest" xlink:label="loc_GCTKLesseeOperatingLeaseLiabilityImputedInterest_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_GCTKLesseeOperatingLeaseLiabilityImputedInterest_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails" xlink:title="00000021 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails" xlink:title="00000022 - Disclosure - SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JuneTwentySevenWarrantsMember" xlink:label="loc_GCTKJuneTwentySevenWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKJuneTwentySevenWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JulyEighteenNotesMember" xlink:label="loc_GCTKJulyEighteenNotesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKJulyEighteenNotesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ProceedsFromAllocatedWarrantsAtInitialRecognition" xlink:label="loc_GCTKProceedsFromAllocatedWarrantsAtInitialRecognition_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKProceedsFromAllocatedWarrantsAtInitialRecognition_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DiscountAmortizationAndInterestExpenses" xlink:label="loc_GCTKDiscountAmortizationAndInterestExpenses_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKDiscountAmortizationAndInterestExpenses_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PartialConversionNotesAndAccruedInterest" xlink:label="loc_GCTKPartialConversionNotesAndAccruedInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKPartialConversionNotesAndAccruedInterest_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleDebt_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpense_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PartialConversionAndAccruedInterest" xlink:label="loc_GCTKPartialConversionAndAccruedInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKPartialConversionAndAccruedInterest_70" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails" xlink:title="00000023 - Disclosure - SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JulyThirtyNotesMember" xlink:label="loc_GCTKJulyThirtyNotesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKJulyThirtyNotesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleDebt_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaapEmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DiscountAmortizationAndInterestExpenses" xlink:label="loc_GCTKDiscountAmortizationAndInterestExpenses_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKDiscountAmortizationAndInterestExpenses_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureDetails" xlink:title="00000024 - Disclosure - SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" xlink:title="00000025 - Disclosure - SIGNIFICANT TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PrefundedWarrantsMember" xlink:label="loc_GCTKPrefundedWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKPrefundedWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_FirstWarrantMember" xlink:label="loc_GCTKFirstWarrantMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKFirstWarrantMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SecondWarrantMember" xlink:label="loc_GCTKSecondWarrantMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKSecondWarrantMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ThirdWarrantMember" xlink:label="loc_GCTKThirdWarrantMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKThirdWarrantMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JuneTwentySevenNotesMember" xlink:label="loc_GCTKJuneTwentySevenNotesMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKJuneTwentySevenNotesMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_AugustTwentyThreeWarrantMember" xlink:label="loc_GCTKAugustTwentyThreeWarrantMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKAugustTwentyThreeWarrantMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_AugustTwentyThreeWarrantOneMember" xlink:label="loc_GCTKAugustTwentyThreeWarrantOneMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKAugustTwentyThreeWarrantOneMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_AugustTwentyThreeWarrantTwoMember" xlink:label="loc_GCTKAugustTwentyThreeWarrantTwoMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKAugustTwentyThreeWarrantTwoMember_340" xlink:type="arc" order="341" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_AugustTwentyThreeWarrantThreeMember" xlink:label="loc_GCTKAugustTwentyThreeWarrantThreeMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKAugustTwentyThreeWarrantThreeMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JulyEighteenNotesMember" xlink:label="loc_GCTKJulyEighteenNotesMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKJulyEighteenNotesMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JulyTwentySevenNotesMember" xlink:label="loc_GCTKJulyTwentySevenNotesMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKJulyTwentySevenNotesMember_390" xlink:type="arc" order="391" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeptemberFiveWarrantsMember" xlink:label="loc_GCTKSeptemberFiveWarrantsMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKSeptemberFiveWarrantsMember_410" xlink:type="arc" order="411" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeptemberFiveWarrantsOneMember" xlink:label="loc_GCTKSeptemberFiveWarrantsOneMember_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKSeptemberFiveWarrantsOneMember_430" xlink:type="arc" order="431" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeptemberFiveWarrantsTwoMember" xlink:label="loc_GCTKSeptemberFiveWarrantsTwoMember_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKSeptemberFiveWarrantsTwoMember_440" xlink:type="arc" order="441" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeptemberFiveWarrantsThreeMember" xlink:label="loc_GCTKSeptemberFiveWarrantsThreeMember_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKSeptemberFiveWarrantsThreeMember_450" xlink:type="arc" order="451" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ExchangeAgreementMember" xlink:label="loc_GCTKExchangeAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GCTKExchangeAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaapLeaseAgreementsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapLeaseAgreementsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_WarrantsAgreementMember" xlink:label="loc_GCTKWarrantsAgreementMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GCTKWarrantsAgreementMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_UnsecuredPromissoryNotesMember" xlink:label="loc_GCTKUnsecuredPromissoryNotesMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GCTKUnsecuredPromissoryNotesMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ConvertiblePromissoryNotesMember" xlink:label="loc_GCTKConvertiblePromissoryNotesMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_GCTKConvertiblePromissoryNotesMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_480" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_480" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_LockUpPeriodDescription" xlink:label="loc_GCTKLockUpPeriodDescription_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_GCTKLockUpPeriodDescription_480" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharePrice_480" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_480" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_480" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSecurityDeposit_480" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_480" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_480" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_480" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_480" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_480" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_480" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_480" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtDescription" xlink:label="loc_us-gaapShortTermDebtDescription_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShortTermDebtDescription_480" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_480" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_480" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt_480" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_480" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_480" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_480" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_480" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_480" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_480" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_480" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_480" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription_480" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_480" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaapSaleOfStockDescriptionOfTransaction_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSaleOfStockDescriptionOfTransaction_480" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault" xlink:label="loc_us-gaapDebtDefaultLongtermDebtDescriptionOfNoticeOfDefault_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtDefaultLongtermDebtDescriptionOfNoticeOfDefault_480" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDefaultLongtermDebtAmount" xlink:label="loc_us-gaapDebtDefaultLongtermDebtAmount_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtDefaultLongtermDebtAmount_480" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm_480" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_EmbeddedConversionFeaturePercentage" xlink:label="loc_GCTKEmbeddedConversionFeaturePercentage_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_GCTKEmbeddedConversionFeaturePercentage_480" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="loc_us-gaapEmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapEmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_480" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpense_480" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_480" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_480" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaapEquityFairValueDisclosure_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapEquityFairValueDisclosure_480" xlink:type="arc" order="37" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:title="00000026 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="loc_us-gaapLegalEntityTypeOfCounterpartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="loc_us-gaapLegalEntityTypeOfCounterpartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="loc_us-gaapLegalEntityTypeOfCounterpartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="loc_us-gaapLegalEntityTypeOfCounterpartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_IsraeliInnovationAuthorityMember" xlink:label="loc_GCTKIsraeliInnovationAuthorityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLegalEntityTypeOfCounterpartyDomain" xlink:to="loc_GCTKIsraeliInnovationAuthorityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_IsraeliInnovationAuthorityMember" xlink:label="loc_GCTKIsraeliInnovationAuthorityMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_GCTKIsraeliInnovationAuthorityMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_IntellectualPropertyPurchaseAgreementMember" xlink:label="loc_GCTKIntellectualPropertyPurchaseAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GCTKIntellectualPropertyPurchaseAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_TrueupSharesMember" xlink:label="loc_GCTKTrueupSharesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GCTKTrueupSharesMember_80" xlink:type="arc" order="84" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_RoyaltyPercentage" xlink:label="loc_GCTKRoyaltyPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GCTKRoyaltyPercentage_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_AggregateSalesPriceOfUnitsPercentage" xlink:label="loc_GCTKAggregateSalesPriceOfUnitsPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GCTKAggregateSalesPriceOfUnitsPercentage_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesRestrictedStock_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesRestrictedStock_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensation_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_MarketabilityDiscountRate" xlink:label="loc_GCTKMarketabilityDiscountRate_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GCTKMarketabilityDiscountRate_140" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails" xlink:title="00000027 - Disclosure - SCHEDULE OF FINANCE EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000028 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PrefundedWarrantsMember" xlink:label="loc_GCTKPrefundedWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKPrefundedWarrantsMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeriesACommonWarrantMember" xlink:label="loc_GCTKSeriesACommonWarrantMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKSeriesACommonWarrantMember_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeriesCommonWarrantMember" xlink:label="loc_GCTKSeriesCommonWarrantMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKSeriesCommonWarrantMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeriesACommonWarrantMember" xlink:label="loc_GCTKSeriesACommonWarrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GCTKSeriesACommonWarrantMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeriesBCommonWarrantMember" xlink:label="loc_GCTKSeriesBCommonWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GCTKSeriesBCommonWarrantMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PrefundedWarrantsMember" xlink:label="loc_GCTKPrefundedWarrantsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GCTKPrefundedWarrantsMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JulyThirtyNotesMember" xlink:label="loc_GCTKJulyThirtyNotesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GCTKJulyThirtyNotesMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharesIssued_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharePrice_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_130" xlink:type="arc" order="6" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>gctk-20240930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ReceiptsOnAccountOfSharesMember" xlink:label="GCTK_ReceiptsOnAccountOfSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ReceiptsOnAccountOfSharesMember" xlink:to="GCTK_ReceiptsOnAccountOfSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_ReceiptsOnAccountOfSharesMember_lbl" xml:lang="en-US">Receipts on Account of Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PrefundedWarrantsMember" xlink:label="GCTK_PrefundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_PrefundedWarrantsMember" xlink:to="GCTK_PrefundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_PrefundedWarrantsMember_lbl" xml:lang="en-US">Prefunded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PerformanceMilestoneMember" xlink:label="GCTK_PerformanceMilestoneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_PerformanceMilestoneMember" xlink:to="GCTK_PerformanceMilestoneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_PerformanceMilestoneMember_lbl" xml:lang="en-US">Performance Milestone [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ExchangeAgreementMember" xlink:label="GCTK_ExchangeAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ExchangeAgreementMember" xlink:to="GCTK_ExchangeAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_ExchangeAgreementMember_lbl" xml:lang="en-US">Exchange Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="us-gaap_LeaseAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xml:lang="en-US">Lease Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_UnsecuredPromissoryNotesMember" xlink:label="GCTK_UnsecuredPromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_UnsecuredPromissoryNotesMember" xlink:to="GCTK_UnsecuredPromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_UnsecuredPromissoryNotesMember_lbl" xml:lang="en-US">Unsecured Promissory Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ConvertiblePromissoryNotesMember" xlink:label="GCTK_ConvertiblePromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ConvertiblePromissoryNotesMember" xlink:to="GCTK_ConvertiblePromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_ConvertiblePromissoryNotesMember_lbl" xml:lang="en-US">Convertible Promissory Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_WarrantsAgreementMember" xlink:label="GCTK_WarrantsAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_WarrantsAgreementMember" xlink:to="GCTK_WarrantsAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_WarrantsAgreementMember_lbl" xml:lang="en-US">Warrants Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_FirstWarrantMember" xlink:label="GCTK_FirstWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_FirstWarrantMember" xlink:to="GCTK_FirstWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_FirstWarrantMember_lbl" xml:lang="en-US">First Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SecondWarrantMember" xlink:label="GCTK_SecondWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_SecondWarrantMember" xlink:to="GCTK_SecondWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_SecondWarrantMember_lbl" xml:lang="en-US">Second Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ThirdWarrantMember" xlink:label="GCTK_ThirdWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ThirdWarrantMember" xlink:to="GCTK_ThirdWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_ThirdWarrantMember_lbl" xml:lang="en-US">Third Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JuneTwentySevenNotesMember" xlink:label="GCTK_JuneTwentySevenNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_JuneTwentySevenNotesMember" xlink:to="GCTK_JuneTwentySevenNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_JuneTwentySevenNotesMember_lbl" xml:lang="en-US">June Twenty Seven Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_AugustTwentyThreeWarrantMember" xlink:label="GCTK_AugustTwentyThreeWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_AugustTwentyThreeWarrantMember" xlink:to="GCTK_AugustTwentyThreeWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_AugustTwentyThreeWarrantMember_lbl" xml:lang="en-US">August Twenty Three Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_AugustTwentyThreeWarrantOneMember" xlink:label="GCTK_AugustTwentyThreeWarrantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_AugustTwentyThreeWarrantOneMember" xlink:to="GCTK_AugustTwentyThreeWarrantOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_AugustTwentyThreeWarrantOneMember_lbl" xml:lang="en-US">August Twenty Three Warrant One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_AugustTwentyThreeWarrantTwoMember" xlink:label="GCTK_AugustTwentyThreeWarrantTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_AugustTwentyThreeWarrantTwoMember" xlink:to="GCTK_AugustTwentyThreeWarrantTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_AugustTwentyThreeWarrantTwoMember_lbl" xml:lang="en-US">August Twenty Three Warrant Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_AugustTwentyThreeWarrantThreeMember" xlink:label="GCTK_AugustTwentyThreeWarrantThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_AugustTwentyThreeWarrantThreeMember" xlink:to="GCTK_AugustTwentyThreeWarrantThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_AugustTwentyThreeWarrantThreeMember_lbl" xml:lang="en-US">August Twenty Three Warrant Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JulyEighteenNotesMember" xlink:label="GCTK_JulyEighteenNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_JulyEighteenNotesMember" xlink:to="GCTK_JulyEighteenNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_JulyEighteenNotesMember_lbl" xml:lang="en-US">July Eighteen Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JulyTwentySevenNotesMember" xlink:label="GCTK_JulyTwentySevenNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_JulyTwentySevenNotesMember" xlink:to="GCTK_JulyTwentySevenNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_JulyTwentySevenNotesMember_lbl" xml:lang="en-US">July Twenty Seven Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeptemberFiveWarrantsMember" xlink:label="GCTK_SeptemberFiveWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_SeptemberFiveWarrantsMember" xlink:to="GCTK_SeptemberFiveWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_SeptemberFiveWarrantsMember_lbl" xml:lang="en-US">September Five Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeptemberFiveWarrantsOneMember" xlink:label="GCTK_SeptemberFiveWarrantsOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_SeptemberFiveWarrantsOneMember" xlink:to="GCTK_SeptemberFiveWarrantsOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_SeptemberFiveWarrantsOneMember_lbl" xml:lang="en-US">September Five Warrants One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeptemberFiveWarrantsTwoMember" xlink:label="GCTK_SeptemberFiveWarrantsTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_SeptemberFiveWarrantsTwoMember" xlink:to="GCTK_SeptemberFiveWarrantsTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_SeptemberFiveWarrantsTwoMember_lbl" xml:lang="en-US">September Five Warrants Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeptemberFiveWarrantsThreeMember" xlink:label="GCTK_SeptemberFiveWarrantsThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_SeptemberFiveWarrantsThreeMember" xlink:to="GCTK_SeptemberFiveWarrantsThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_SeptemberFiveWarrantsThreeMember_lbl" xml:lang="en-US">September Five Warrants Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JuneTwentySevenWarrantsMember" xlink:label="GCTK_JuneTwentySevenWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_JuneTwentySevenWarrantsMember" xlink:to="GCTK_JuneTwentySevenWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_JuneTwentySevenWarrantsMember_lbl" xml:lang="en-US">June Twenty Seven Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JulyThirteenNotesMember" xlink:label="GCTK_JulyThirteenNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_JulyThirteenNotesMember" xlink:to="GCTK_JulyThirteenNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_JulyThirteenNotesMember_lbl" xml:lang="en-US">July Thirteen Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_LessThanOneYearMember" xlink:label="GCTK_LessThanOneYearMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_LessThanOneYearMember" xlink:to="GCTK_LessThanOneYearMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_LessThanOneYearMember_lbl" xml:lang="en-US">Less Than One Year [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_BetweenOneYearToTwoYearsMember" xlink:label="GCTK_BetweenOneYearToTwoYearsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_BetweenOneYearToTwoYearsMember" xlink:to="GCTK_BetweenOneYearToTwoYearsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_BetweenOneYearToTwoYearsMember_lbl" xml:lang="en-US">Between 1 - 2 Years [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_MoreThanTwoYearsMember" xlink:label="GCTK_MoreThanTwoYearsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_MoreThanTwoYearsMember" xlink:to="GCTK_MoreThanTwoYearsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_MoreThanTwoYearsMember_lbl" xml:lang="en-US">More Than 2 Years [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JulyThirtyNotesMember" xlink:label="GCTK_JulyThirtyNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_JulyThirtyNotesMember" xlink:to="GCTK_JulyThirtyNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_JulyThirtyNotesMember_lbl" xml:lang="en-US">July 30 Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_IsraeliInnovationAuthorityMember" xlink:label="GCTK_IsraeliInnovationAuthorityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_IsraeliInnovationAuthorityMember" xlink:to="GCTK_IsraeliInnovationAuthorityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_IsraeliInnovationAuthorityMember_lbl" xml:lang="en-US">Israeli Innovation Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_IntellectualPropertyPurchaseAgreementMember" xlink:label="GCTK_IntellectualPropertyPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_IntellectualPropertyPurchaseAgreementMember" xlink:to="GCTK_IntellectualPropertyPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_IntellectualPropertyPurchaseAgreementMember_lbl" xml:lang="en-US">Intellectual Property Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_TrueupSharesMember" xlink:label="GCTK_TrueupSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_TrueupSharesMember" xlink:to="GCTK_TrueupSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_TrueupSharesMember_lbl" xml:lang="en-US">Trueup Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeriesACommonWarrantMember" xlink:label="GCTK_SeriesACommonWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_SeriesACommonWarrantMember" xlink:to="GCTK_SeriesACommonWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_SeriesACommonWarrantMember_lbl" xml:lang="en-US">Series A Common Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeriesBCommonWarrantMember" xlink:label="GCTK_SeriesBCommonWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_SeriesBCommonWarrantMember" xlink:to="GCTK_SeriesBCommonWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_SeriesBCommonWarrantMember_lbl" xml:lang="en-US">Series B Common Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeriesCommonWarrantMember" xlink:label="GCTK_SeriesCommonWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_SeriesCommonWarrantMember" xlink:to="GCTK_SeriesCommonWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_SeriesCommonWarrantMember_lbl" xml:lang="en-US">Series Common Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingParValuePerShare" xlink:label="dei_EntityListingParValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingParValuePerShare" xlink:to="dei_EntityListingParValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingParValuePerShare_lbl" xml:lang="en-US">Entity Listing, Par Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset, net (Note 3C)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability, current (Note 3C)</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PromissoryNotesCurrent" xlink:label="GCTK_PromissoryNotesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_PromissoryNotesCurrent" xlink:to="GCTK_PromissoryNotesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_PromissoryNotesCurrent_lbl" xml:lang="en-US">Promissory notes (Note 3G and Note 3H)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible promissory notes (Note 3F)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Derivative financial liabilities (Note 3G and Note 3H)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Loans from stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, non-current (Note 3C)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingent liabilities (Note 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock of $ 0.001 par value (&#8220;Common Stock&#8221;):100,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 5,772,190 and 4,178,274 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ReceiptsOnAccountOfShares" xlink:label="GCTK_ReceiptsOnAccountOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ReceiptsOnAccountOfShares" xlink:to="GCTK_ReceiptsOnAccountOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_ReceiptsOnAccountOfShares_lbl" xml:lang="en-US">Receipts on account of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; (deficit) equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingExpense" xlink:label="us-gaap_MarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingExpense" xlink:to="us-gaap_MarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingExpense_lbl" xml:lang="en-US">Marketing expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_FinanceIncomeNet" xlink:label="GCTK_FinanceIncomeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_FinanceIncomeNet" xlink:to="GCTK_FinanceIncomeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GCTK_FinanceIncomeNet_lbl" xml:lang="en-US">Finance (income) expenses, net (Note 5)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Other comprehensive (income) loss:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss for the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net loss per common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss per common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of common stock outstanding used in computing basic net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of common stock outstanding used in computing diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Loss for the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted" xlink:label="GCTK_AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted" xlink:to="GCTK_AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted_lbl" xml:lang="en-US">Deemed dividend resulted from trigger of down round protection feature of certain warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of Common Stock upon private placement transaction (Note 3D)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of Common Stock upon private placement transaction (Note 3D), shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of restricted shares as compensation towards directors</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of shares as compensation to the board of directors, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xml:lang="en-US">Issuance of restricted shares as compensation towards directors</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted shares as compensation towards directors, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="GCTK_StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="GCTK_StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted shares to be issued as compensation towards directors</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares" xlink:label="GCTK_StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares" xlink:to="GCTK_StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares_lbl" xml:lang="en-US">Exercise of prefunded warrants into shares (Note 3A)</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares" xlink:label="GCTK_StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares" xlink:to="GCTK_StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares_lbl" xml:lang="en-US">Exercise of prefunded warrants into shares (Note 3A), shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Exchange of warrants into shares (Note 3B)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Exchange of warrants into shares (Note 3B), shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions" xlink:label="GCTK_StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions" xlink:to="GCTK_StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions_lbl" xml:lang="en-US">Issuance of detachable warrants through private placement transactions (Note 3F and Note 3H)</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" xlink:label="GCTK_StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" xlink:to="GCTK_StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_lbl" xml:lang="en-US">Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J)</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" xlink:label="GCTK_StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" xlink:to="GCTK_StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GCTK_StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_lbl" xml:lang="en-US">Issuance of Common Stock upon private placement transaction (Note 3D), shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" xlink:label="GCTK_StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" xlink:to="GCTK_StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b_lbl" xml:lang="en-US">Issuance of restricted shares as payment for a previous achievement of milestone pursuant to purchase agreement (Note 4B)</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" xlink:label="GCTK_StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" xlink:to="GCTK_StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b_lbl" xml:lang="en-US">Issuance of restricted shares as payment for a previous achievement of milestone pursuant to purchase agreement (Note 4B), shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity" xlink:label="GCTK_StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity" xlink:to="GCTK_StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GCTK_StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity_lbl" xml:lang="en-US">Issuance of detachable warrants through private placement transactions (Note 3F and Note 3H)</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity" xlink:label="GCTK_StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity" xlink:to="GCTK_StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity_lbl" xml:lang="en-US">Settlement of liabilities with equity, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant" xlink:label="GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant" xlink:to="GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant_lbl" xml:lang="en-US">Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" xlink:label="GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" xlink:to="GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors_lbl" xml:lang="en-US">Issuance of restricted shares as compensation towards directors</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_LinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:label="GCTK_LinkageDifferenceOnPrincipalOfLoansFromStockholders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_LinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:to="GCTK_LinkageDifferenceOnPrincipalOfLoansFromStockholders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_LinkageDifferenceOnPrincipalOfLoansFromStockholders_lbl" xml:lang="en-US">Linkage difference on principal of loans from stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" xlink:label="GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" xlink:to="GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities_lbl" xml:lang="en-US">Revaluation expenses incurred from settlement of financial liabilities (Note 3I and Note 3J)</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities" xlink:label="GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities" xlink:to="GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities_lbl" xml:lang="en-US">Revaluation expenses related to derivative financial liabilities (Note 3H)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Discount amortization and interest expenses related to promissory notes (Note 3F, Note 3G and Note 3H)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds received from private placement transaction (Note 3D)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Issuance of promissory notes and detachable warrants through private placement transaction (Note 3F)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Issuance of convertible promissory notes and bifurcated conversion feature through private placement transaction (Note 3G)</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ProceedsFromConvertibleDebtPrivatePlacementTransaction" xlink:label="GCTK_ProceedsFromConvertibleDebtPrivatePlacementTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ProceedsFromConvertibleDebtPrivatePlacementTransaction" xlink:to="GCTK_ProceedsFromConvertibleDebtPrivatePlacementTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_ProceedsFromConvertibleDebtPrivatePlacementTransaction_lbl" xml:lang="en-US">Issuance of convertible promissory note, bifurcated conversion and redemption features and detachable warrants through private placement transaction (Note 3H)</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ProceedsReceivedFromUnderwrittenPublicOffering" xlink:label="GCTK_ProceedsReceivedFromUnderwrittenPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ProceedsReceivedFromUnderwrittenPublicOffering" xlink:to="GCTK_ProceedsReceivedFromUnderwrittenPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_ProceedsReceivedFromUnderwrittenPublicOffering_lbl" xml:lang="en-US">Net proceeds received from underwritten U.S. public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents, and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Change in cash and cash equivalents, and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents, and restricted cash at beginning of the period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and cash equivalents, and restricted cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidAbstract" xlink:label="us-gaap_InterestPaidAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidAbstract" xlink:to="us-gaap_InterestPaidAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidAbstract_lbl" xml:lang="en-US">(a) Net cash (received) paid during the year for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">(b) Non-cash investment and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DeemedDividendUponTriggerOfDownRoundProtection" xlink:label="GCTK_DeemedDividendUponTriggerOfDownRoundProtection" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_DeemedDividendUponTriggerOfDownRoundProtection" xlink:to="GCTK_DeemedDividendUponTriggerOfDownRoundProtection_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_DeemedDividendUponTriggerOfDownRoundProtection_lbl" xml:lang="en-US">Deemed dividend upon trigger of down round protection</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Recognition of right for use asset against a lease liability (Note 3C)</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" xlink:label="GCTK_IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" xlink:to="GCTK_IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GCTK_IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_lbl" xml:lang="en-US">Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">GENERAL</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DisclosureSignificantTransactionsAbstract" xlink:label="GCTK_DisclosureSignificantTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_DisclosureSignificantTransactionsAbstract" xlink:to="GCTK_DisclosureSignificantTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_DisclosureSignificantTransactionsAbstract_lbl" xml:lang="en-US">Significant Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SignificantTransactionsTextBlock" xlink:label="GCTK_SignificantTransactionsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_SignificantTransactionsTextBlock" xlink:to="GCTK_SignificantTransactionsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_SignificantTransactionsTextBlock_lbl" xml:lang="en-US">SIGNIFICANT TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US">FINANCE (INCOME) EXPENSES, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates in the Preparation of Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ModificationOfEquityClassifiedContractsPolicyTextBlock" xlink:label="GCTK_ModificationOfEquityClassifiedContractsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ModificationOfEquityClassifiedContractsPolicyTextBlock" xlink:to="GCTK_ModificationOfEquityClassifiedContractsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_ModificationOfEquityClassifiedContractsPolicyTextBlock_lbl" xml:lang="en-US">Modification of equity-classified contracts</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ConvertiblePromissoryNotesPolicyTextBlock" xlink:label="GCTK_ConvertiblePromissoryNotesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ConvertiblePromissoryNotesPolicyTextBlock" xlink:to="GCTK_ConvertiblePromissoryNotesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_ConvertiblePromissoryNotesPolicyTextBlock_lbl" xml:lang="en-US">Convertible Promissory Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock" xlink:label="GCTK_AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock" xlink:to="GCTK_AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock_lbl" xml:lang="en-US">Allocation of proceeds and related issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and diluted loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OPERATING LEASE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock" xlink:label="GCTK_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock" xlink:to="GCTK_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock" xlink:label="GCTK_ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock" xlink:to="GCTK_ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock" xlink:label="GCTK_ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock" xlink:to="GCTK_ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FINANCE EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Net proceeds from public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromUnsecuredNotesPayable" xlink:label="us-gaap_ProceedsFromUnsecuredNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromUnsecuredNotesPayable" xlink:to="us-gaap_ProceedsFromUnsecuredNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromUnsecuredNotesPayable_lbl" xml:lang="en-US">Unsecured promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSecuredNotesPayable" xlink:label="us-gaap_ProceedsFromSecuredNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSecuredNotesPayable" xlink:to="us-gaap_ProceedsFromSecuredNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSecuredNotesPayable_lbl" xml:lang="en-US">Secured promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecurities" xlink:label="us-gaap_DebtSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecurities" xlink:to="us-gaap_DebtSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecurities_lbl" xml:lang="en-US">Debt Securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature" xlink:label="GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature" xlink:to="GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature_lbl" xml:lang="en-US">Deemed dividend related to trigger of down round protection feature</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average number of Common Stock outstanding used in computing basic net loss per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted average number of Common Stock outstanding used in computing diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones" xlink:label="GCTK_EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones" xlink:to="GCTK_EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GCTK_EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_lbl" xml:lang="en-US">Diluted net loss per common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_DisclosureSignificantTransactionsAbstract" xlink:to="GCTK_DisclosureSignificantTransactionsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GCTK_DisclosureSignificantTransactionsAbstract_2_lbl" xml:lang="en-US">Schedule Of Operating Lease</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating right-of-use asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Current operating lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Non-Current operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total operating lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_LesseeOperatingLeaseLiabilityImputedInterest" xlink:label="GCTK_LesseeOperatingLeaseLiabilityImputedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_LesseeOperatingLeaseLiabilityImputedInterest" xlink:to="GCTK_LesseeOperatingLeaseLiabilityImputedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GCTK_LesseeOperatingLeaseLiabilityImputedInterest_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_DisclosureSignificantTransactionsAbstract" xlink:to="GCTK_DisclosureSignificantTransactionsAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="GCTK_DisclosureSignificantTransactionsAbstract_3_lbl" xml:lang="en-US">Schedule Of Weighted Average Remaining Lease Terms And Discount Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Lease term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Open balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xml:lang="en-US">Total proceeds received</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ProceedsFromAllocatedWarrantsAtInitialRecognition" xlink:label="GCTK_ProceedsFromAllocatedWarrantsAtInitialRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ProceedsFromAllocatedWarrantsAtInitialRecognition" xlink:to="GCTK_ProceedsFromAllocatedWarrantsAtInitialRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_ProceedsFromAllocatedWarrantsAtInitialRecognition_lbl" xml:lang="en-US">Total proceeds allocated to June 27 Warrants at initial recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DiscountAmortizationAndInterestExpenses" xlink:label="GCTK_DiscountAmortizationAndInterestExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_DiscountAmortizationAndInterestExpenses" xlink:to="GCTK_DiscountAmortizationAndInterestExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_DiscountAmortizationAndInterestExpenses_lbl" xml:lang="en-US">Discount amortization and interest expenses related to June 27 Notes (Note 5 below)</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PartialConversionNotesAndAccruedInterest" xlink:label="GCTK_PartialConversionNotesAndAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_PartialConversionNotesAndAccruedInterest" xlink:to="GCTK_PartialConversionNotesAndAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_PartialConversionNotesAndAccruedInterest_lbl" xml:lang="en-US">Partial conversion June 27 Notes and accrued Interest (Note 3I and Note 3J below)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Open balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Total proceeds allocated to July 18 Notes at initial recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expenses related to July 18 Notes (Note 5 below)</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PartialConversionAndAccruedInterest" xlink:label="GCTK_PartialConversionAndAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_PartialConversionAndAccruedInterest" xlink:to="GCTK_PartialConversionAndAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_PartialConversionAndAccruedInterest_lbl" xml:lang="en-US">Partial conversion July 18 Notes and accrued Interest (Note 3J below)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ConvertibleDebt_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_2_lbl" xml:lang="en-US">Total proceeds received</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Total proceeds allocated to July 30 Warrants at initial recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_lbl" xml:lang="en-US">Total proceeds allocated to embedded redemption feature at initial recognition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_DiscountAmortizationAndInterestExpenses" xlink:to="GCTK_DiscountAmortizationAndInterestExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GCTK_DiscountAmortizationAndInterestExpenses_2_lbl" xml:lang="en-US">Amortization of discount and interest expenses related to July 30 Note (Note 5 below)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeLiabilities_2_lbl" xml:lang="en-US">Open balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_2_lbl" xml:lang="en-US">Proceeds allocated to embedded redemption feature at initial recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_RevaluationExpensesRelatedToEmbeddedRedemptionFeature" xlink:label="GCTK_RevaluationExpensesRelatedToEmbeddedRedemptionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_RevaluationExpensesRelatedToEmbeddedRedemptionFeature" xlink:to="GCTK_RevaluationExpensesRelatedToEmbeddedRedemptionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_RevaluationExpensesRelatedToEmbeddedRedemptionFeature_lbl" xml:lang="en-US">Revaluation expenses related to embedded redemption feature (Note 5 below)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeLiabilities_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Pre-funded warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Shares of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_LockUpPeriodDescription" xlink:label="GCTK_LockUpPeriodDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_LockUpPeriodDescription" xlink:to="GCTK_LockUpPeriodDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_LockUpPeriodDescription_lbl" xml:lang="en-US">Lock-up period conditions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Monthly rental fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lessee term of contract</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock share price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xml:lang="en-US">Aggregate gross proceeds offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt instrument face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of warrant or right number of securities called by warrants or rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtDescription" xlink:label="us-gaap_ShortTermDebtDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtDescription" xlink:to="us-gaap_ShortTermDebtDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtDescription_lbl" xml:lang="en-US">Notes payable description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants and rights outstanding term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_3_lbl" xml:lang="en-US">Proceeds from notes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Debt discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk- free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt instrument interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Gross proceeds from notes conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">Debt instrument description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock issued price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xml:lang="en-US">Sale of stock description of transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault" xlink:label="us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault" xlink:to="us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault_lbl" xml:lang="en-US">Debt description of notice of default</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDefaultLongtermDebtAmount" xlink:label="us-gaap_DebtDefaultLongtermDebtAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDefaultLongtermDebtAmount" xlink:to="us-gaap_DebtDefaultLongtermDebtAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDefaultLongtermDebtAmount_lbl" xml:lang="en-US">Debt default long term debt amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt Instrument, Term</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_EmbeddedConversionFeaturePercentage" xlink:label="GCTK_EmbeddedConversionFeaturePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_EmbeddedConversionFeaturePercentage" xlink:to="GCTK_EmbeddedConversionFeaturePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_EmbeddedConversionFeaturePercentage_lbl" xml:lang="en-US">Embedded conversion feature percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xml:lang="en-US">Fair value of embedded derivative liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock issued during period shares issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="us-gaap_EquityFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueDisclosure" xlink:to="us-gaap_EquityFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityFairValueDisclosure_lbl" xml:lang="en-US">Equity fair value disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Contingent consideration liability</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_RoyaltyPercentage" xlink:label="GCTK_RoyaltyPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_RoyaltyPercentage" xlink:to="GCTK_RoyaltyPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_RoyaltyPercentage_lbl" xml:lang="en-US">Royalty percentage maximum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Number of common shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_AggregateSalesPriceOfUnitsPercentage" xlink:label="GCTK_AggregateSalesPriceOfUnitsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_AggregateSalesPriceOfUnitsPercentage" xlink:to="GCTK_AggregateSalesPriceOfUnitsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_AggregateSalesPriceOfUnitsPercentage_lbl" xml:lang="en-US">Commission as a percentage of aggregate sales price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:label="us-gaap_WeightedAverageNumberOfSharesRestrictedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:to="us-gaap_WeightedAverageNumberOfSharesRestrictedStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesRestrictedStock_lbl" xml:lang="en-US">Restricted shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_MarketabilityDiscountRate" xlink:label="GCTK_MarketabilityDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_MarketabilityDiscountRate" xlink:to="GCTK_MarketabilityDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_MarketabilityDiscountRate_lbl" xml:lang="en-US">Discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DiscountAmortizationAndInterestExpensesOne" xlink:label="GCTK_DiscountAmortizationAndInterestExpensesOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_DiscountAmortizationAndInterestExpensesOne" xlink:to="GCTK_DiscountAmortizationAndInterestExpensesOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_DiscountAmortizationAndInterestExpensesOne_lbl" xml:lang="en-US">Discount amortization and interest expenses related to June 27 Notes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_3_lbl" xml:lang="en-US">Interest expenses related to July 18 Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DiscountAmortizationAndInterestExpensesTwo" xlink:label="GCTK_DiscountAmortizationAndInterestExpensesTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_DiscountAmortizationAndInterestExpensesTwo" xlink:to="GCTK_DiscountAmortizationAndInterestExpensesTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_DiscountAmortizationAndInterestExpensesTwo_lbl" xml:lang="en-US">Discount amortization and interest expenses related to July 30 Note</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities" xlink:to="GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities_2_lbl" xml:lang="en-US">Revaluation expenses related to derivative financial liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" xlink:to="GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities_2_lbl" xml:lang="en-US">Revaluation expenses incurred from settlement of financial liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDeposits" xlink:label="us-gaap_InterestExpenseDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDeposits" xlink:to="us-gaap_InterestExpenseDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDeposits_lbl" xml:lang="en-US">Interest on bank deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Exchange rate differentials, bank commissions and miscellaneous</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_FinanceIncomeNet" xlink:to="GCTK_FinanceIncomeNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="GCTK_FinanceIncomeNet_2_lbl" xml:lang="en-US">Finance (income) expenses, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_3_lbl" xml:lang="en-US">Gross proceeds from public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Stock issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrant, exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Incremental and direct issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Debt conversion converted instrument amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_2_lbl" xml:lang="en-US">Conversion price, per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ReceiptsOnAccountOfShares" xlink:to="GCTK_ReceiptsOnAccountOfShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_ReceiptsOnAccountOfShares_doc" xml:lang="en-US">Receipts on account of shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_FinanceIncomeNet" xlink:to="GCTK_FinanceIncomeNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_FinanceIncomeNet_doc" xml:lang="en-US">Finance income net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ReceiptsOnAccountOfSharesMember" xlink:to="GCTK_ReceiptsOnAccountOfSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_ReceiptsOnAccountOfSharesMember_doc" xml:lang="en-US">Receipts on Account of Shares [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted" xlink:to="GCTK_AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted_doc" xml:lang="en-US">Adjustments to additional paid in capital deemed dividend resulted from trigger of down round protection feature of certain warrants granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="GCTK_StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross_doc" xml:lang="en-US">Stock to be issued during period value restricted stock award gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" xlink:to="GCTK_StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b_doc" xml:lang="en-US">Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement .</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares" xlink:to="GCTK_StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares_doc" xml:lang="en-US">Exercise of prefunded warrants into shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant" xlink:to="GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant_doc" xml:lang="en-US">Stock issued during period value issuance of warrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity" xlink:to="GCTK_StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity_doc" xml:lang="en-US">Stock issued during period value settlement of liabilities with equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity" xlink:to="GCTK_StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity_doc" xml:lang="en-US">Stock issued during period shares settlement of liabilities with equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares" xlink:to="GCTK_StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares_doc" xml:lang="en-US">Exercise of prefunded warrants into shares ,shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" xlink:to="GCTK_StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b_doc" xml:lang="en-US">Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement ,shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" xlink:to="GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors_doc" xml:lang="en-US">Issuance of restricted shares as compensation to the board of directors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_LinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:to="GCTK_LinkageDifferenceOnPrincipalOfLoansFromStockholders_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_LinkageDifferenceOnPrincipalOfLoansFromStockholders_doc" xml:lang="en-US">Linkage difference on principal of loans from stockholders .</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ProceedsReceivedFromUnderwrittenPublicOffering" xlink:to="GCTK_ProceedsReceivedFromUnderwrittenPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_ProceedsReceivedFromUnderwrittenPublicOffering_doc" xml:lang="en-US">Proceeds received from underwritten public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_DeemedDividendUponTriggerOfDownRoundProtection" xlink:to="GCTK_DeemedDividendUponTriggerOfDownRoundProtection_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_DeemedDividendUponTriggerOfDownRoundProtection_doc" xml:lang="en-US">Deemed dividend upon trigger of down round protection.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature" xlink:to="GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature_doc" xml:lang="en-US">Deemed dividend related to trigger of down round protection feature.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_PrefundedWarrantsMember" xlink:to="GCTK_PrefundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_PrefundedWarrantsMember_doc" xml:lang="en-US">Prefunded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones" xlink:to="GCTK_EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_doc" xml:lang="en-US">Earnings per share diluted including warrants and performance milestones.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ExchangeAgreementMember" xlink:to="GCTK_ExchangeAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_ExchangeAgreementMember_doc" xml:lang="en-US">Exchange Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_LockUpPeriodDescription" xlink:to="GCTK_LockUpPeriodDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_LockUpPeriodDescription_doc" xml:lang="en-US">Lock up period description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_LesseeOperatingLeaseLiabilityImputedInterest" xlink:to="GCTK_LesseeOperatingLeaseLiabilityImputedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_LesseeOperatingLeaseLiabilityImputedInterest_doc" xml:lang="en-US">Lessee operating lease liability imputed interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock" xlink:to="GCTK_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock_doc" xml:lang="en-US">Schedule Of Weighted Average Remaining Lease Terms And Discount Rate [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_UnsecuredPromissoryNotesMember" xlink:to="GCTK_UnsecuredPromissoryNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_UnsecuredPromissoryNotesMember_doc" xml:lang="en-US">Unsecured Promissory Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ConvertiblePromissoryNotesMember" xlink:to="GCTK_ConvertiblePromissoryNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_ConvertiblePromissoryNotesMember_doc" xml:lang="en-US">Convertible Promissory Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_WarrantsAgreementMember" xlink:to="GCTK_WarrantsAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_WarrantsAgreementMember_doc" xml:lang="en-US">Warrants Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_FirstWarrantMember" xlink:to="GCTK_FirstWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_FirstWarrantMember_doc" xml:lang="en-US">First Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_SecondWarrantMember" xlink:to="GCTK_SecondWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_SecondWarrantMember_doc" xml:lang="en-US">Second Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ThirdWarrantMember" xlink:to="GCTK_ThirdWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_ThirdWarrantMember_doc" xml:lang="en-US">Third Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_IsraeliInnovationAuthorityMember" xlink:to="GCTK_IsraeliInnovationAuthorityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_IsraeliInnovationAuthorityMember_doc" xml:lang="en-US">Israeli Innovation Authority [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_RoyaltyPercentage" xlink:to="GCTK_RoyaltyPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_RoyaltyPercentage_doc" xml:lang="en-US">Royalty percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_IntellectualPropertyPurchaseAgreementMember" xlink:to="GCTK_IntellectualPropertyPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_IntellectualPropertyPurchaseAgreementMember_doc" xml:lang="en-US">Intellectual Property Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_AggregateSalesPriceOfUnitsPercentage" xlink:to="GCTK_AggregateSalesPriceOfUnitsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_AggregateSalesPriceOfUnitsPercentage_doc" xml:lang="en-US">Aggregate sales price of units percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_TrueupSharesMember" xlink:to="GCTK_TrueupSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_TrueupSharesMember_doc" xml:lang="en-US">Trueup Shares [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_MarketabilityDiscountRate" xlink:to="GCTK_MarketabilityDiscountRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_MarketabilityDiscountRate_doc" xml:lang="en-US">Marketability discount rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ModificationOfEquityClassifiedContractsPolicyTextBlock" xlink:to="GCTK_ModificationOfEquityClassifiedContractsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_ModificationOfEquityClassifiedContractsPolicyTextBlock_doc" xml:lang="en-US">Modification Of Equity Classified Contracts [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_SignificantTransactionsTextBlock" xlink:to="GCTK_SignificantTransactionsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_SignificantTransactionsTextBlock_doc" xml:lang="en-US">Significant Transactions [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_PerformanceMilestoneMember" xlink:to="GCTK_PerformanceMilestoneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_PerformanceMilestoneMember_doc" xml:lang="en-US">Performance Milestone [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_LessThanOneYearMember" xlink:to="GCTK_LessThanOneYearMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_LessThanOneYearMember_doc" xml:lang="en-US">Less Than One Year [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_BetweenOneYearToTwoYearsMember" xlink:to="GCTK_BetweenOneYearToTwoYearsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_BetweenOneYearToTwoYearsMember_doc" xml:lang="en-US">Between 1 - 2 Years [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_MoreThanTwoYearsMember" xlink:to="GCTK_MoreThanTwoYearsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_MoreThanTwoYearsMember_doc" xml:lang="en-US">More Than 2 Years [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_PromissoryNotesCurrent" xlink:to="GCTK_PromissoryNotesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_PromissoryNotesCurrent_doc" xml:lang="en-US">Promissory notes current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions" xlink:to="GCTK_StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions_doc" xml:lang="en-US">Stock issued during period value issuance of detachable warrants through private placement transactions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" xlink:to="GCTK_StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_doc" xml:lang="en-US">Stock issued during period value issuance of shares and warrants as settlement of financial liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" xlink:to="GCTK_StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_doc" xml:lang="en-US">Stock issued during period shares issuance of shares and warrants as settlement of financial liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" xlink:to="GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities_doc" xml:lang="en-US">Revaluation expenses incurred from settlement of financial liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities" xlink:to="GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities_doc" xml:lang="en-US">Revaluation expenses related to derivative financial liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ProceedsFromConvertibleDebtPrivatePlacementTransaction" xlink:to="GCTK_ProceedsFromConvertibleDebtPrivatePlacementTransaction_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_ProceedsFromConvertibleDebtPrivatePlacementTransaction_doc" xml:lang="en-US">Proceeds from convertible debt private placement transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ConvertiblePromissoryNotesPolicyTextBlock" xlink:to="GCTK_ConvertiblePromissoryNotesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_ConvertiblePromissoryNotesPolicyTextBlock_doc" xml:lang="en-US">Convertible Promissory Notes [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock" xlink:to="GCTK_AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock_doc" xml:lang="en-US">Allocation Of Proceeds And Related Issuance Costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock" xlink:to="GCTK_ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_doc" xml:lang="en-US">Schedule Of Reconciliation Of Carrying Amount Of Notes [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_JuneTwentySevenWarrantsMember" xlink:to="GCTK_JuneTwentySevenWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_JuneTwentySevenWarrantsMember_doc" xml:lang="en-US">June Twenty Seven Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ProceedsFromAllocatedWarrantsAtInitialRecognition" xlink:to="GCTK_ProceedsFromAllocatedWarrantsAtInitialRecognition_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_ProceedsFromAllocatedWarrantsAtInitialRecognition_doc" xml:lang="en-US">Proceeds from allocated warrants at initial recognition.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_DiscountAmortizationAndInterestExpenses" xlink:to="GCTK_DiscountAmortizationAndInterestExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_DiscountAmortizationAndInterestExpenses_doc" xml:lang="en-US">Discount amortization and interest expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_PartialConversionNotesAndAccruedInterest" xlink:to="GCTK_PartialConversionNotesAndAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_PartialConversionNotesAndAccruedInterest_doc" xml:lang="en-US">Partial conversion notes and accrued interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_JulyEighteenNotesMember" xlink:to="GCTK_JulyEighteenNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_JulyEighteenNotesMember_doc" xml:lang="en-US">July Eighteen Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_PartialConversionAndAccruedInterest" xlink:to="GCTK_PartialConversionAndAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_PartialConversionAndAccruedInterest_doc" xml:lang="en-US">Partial conversion and accrued interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_EmbeddedConversionFeaturePercentage" xlink:to="GCTK_EmbeddedConversionFeaturePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_EmbeddedConversionFeaturePercentage_doc" xml:lang="en-US">Embedded conversion feature percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" xlink:to="GCTK_IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_doc" xml:lang="en-US">Issuance of shares and warrants as settlement of financial liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_JulyThirteenNotesMember" xlink:to="GCTK_JulyThirteenNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_JulyThirteenNotesMember_doc" xml:lang="en-US">July Thirteen Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock" xlink:to="GCTK_ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock_doc" xml:lang="en-US">Schedule Of Reconciliation Of Fair Value Of Embedded Conversion Feature [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_RevaluationExpensesRelatedToEmbeddedRedemptionFeature" xlink:to="GCTK_RevaluationExpensesRelatedToEmbeddedRedemptionFeature_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_RevaluationExpensesRelatedToEmbeddedRedemptionFeature_doc" xml:lang="en-US">Revaluation expenses related to embedded redemption feature.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_AugustTwentyThreeWarrantMember" xlink:to="GCTK_AugustTwentyThreeWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_AugustTwentyThreeWarrantMember_doc" xml:lang="en-US">August Twenty Three Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_AugustTwentyThreeWarrantOneMember" xlink:to="GCTK_AugustTwentyThreeWarrantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_AugustTwentyThreeWarrantOneMember_doc" xml:lang="en-US">August Twenty Three Warrant One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_AugustTwentyThreeWarrantTwoMember" xlink:to="GCTK_AugustTwentyThreeWarrantTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_AugustTwentyThreeWarrantTwoMember_doc" xml:lang="en-US">August Twenty Three Warrant Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_AugustTwentyThreeWarrantThreeMember" xlink:to="GCTK_AugustTwentyThreeWarrantThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_AugustTwentyThreeWarrantThreeMember_doc" xml:lang="en-US">August Twenty Three Warrant Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_JuneTwentySevenNotesMember" xlink:to="GCTK_JuneTwentySevenNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_JuneTwentySevenNotesMember_doc" xml:lang="en-US">June Twenty Seven Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeptemberFiveTwoThousandTwentyFourWarrantOneMember" xlink:label="GCTK_SeptemberFiveTwoThousandTwentyFourWarrantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_SeptemberFiveTwoThousandTwentyFourWarrantOneMember" xlink:to="GCTK_SeptemberFiveTwoThousandTwentyFourWarrantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_SeptemberFiveTwoThousandTwentyFourWarrantOneMember_doc" xml:lang="en-US">September Five Two Thousand Twenty Four Warrant One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_SeptemberFiveWarrantsOneMember" xlink:to="GCTK_SeptemberFiveWarrantsOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_SeptemberFiveWarrantsOneMember_doc" xml:lang="en-US">September Five Warrants One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_SeptemberFiveWarrantsMember" xlink:to="GCTK_SeptemberFiveWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_SeptemberFiveWarrantsMember_doc" xml:lang="en-US">September Five Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_SeptemberFiveWarrantsTwoMember" xlink:to="GCTK_SeptemberFiveWarrantsTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_SeptemberFiveWarrantsTwoMember_doc" xml:lang="en-US">September Five Warrants Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_SeptemberFiveWarrantsThreeMember" xlink:to="GCTK_SeptemberFiveWarrantsThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_SeptemberFiveWarrantsThreeMember_doc" xml:lang="en-US">September Five Warrants Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_DiscountAmortizationAndInterestExpensesOne" xlink:to="GCTK_DiscountAmortizationAndInterestExpensesOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_DiscountAmortizationAndInterestExpensesOne_doc" xml:lang="en-US">Discount amortization and interest expenses one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_DiscountAmortizationAndInterestExpensesTwo" xlink:to="GCTK_DiscountAmortizationAndInterestExpensesTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_DiscountAmortizationAndInterestExpensesTwo_doc" xml:lang="en-US">Discount amortization and interest expenses two.</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeriesAWarrantSharesMember" xlink:label="GCTK_SeriesAWarrantSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_SeriesAWarrantSharesMember" xlink:to="GCTK_SeriesAWarrantSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_SeriesAWarrantSharesMember_doc" xml:lang="en-US">Series A Warrant Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeriesBWarrantSharesMember" xlink:label="GCTK_SeriesBWarrantSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_SeriesBWarrantSharesMember" xlink:to="GCTK_SeriesBWarrantSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_SeriesBWarrantSharesMember_doc" xml:lang="en-US">Series B Warrant Shares [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_SeriesACommonWarrantMember" xlink:to="GCTK_SeriesACommonWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_SeriesACommonWarrantMember_doc" xml:lang="en-US">Series A Common Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_SeriesBCommonWarrantMember" xlink:to="GCTK_SeriesBCommonWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_SeriesBCommonWarrantMember_doc" xml:lang="en-US">Series B Common Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_JulyThirtyNotesMember" xlink:to="GCTK_JulyThirtyNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GCTK_JulyThirtyNotesMember_doc" xml:lang="en-US">July Thirty Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_FinanceIncomeNet" xlink:to="GCTK_FinanceIncomeNet_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_FinanceIncomeNet_4_lbl" xml:lang="en-US">FinanceIncomeNet</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_2_lbl" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" xlink:to="GCTK_StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity" xlink:to="GCTK_StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant" xlink:to="GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodValueIssuanceOfWarrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" xlink:to="GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors_3_lbl" xml:lang="en-US">IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_2_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" xlink:to="GCTK_IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities_3_lbl" xml:lang="en-US">IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature" xlink:to="GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature_3_lbl" xml:lang="en-US">DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones" xlink:to="GCTK_EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_3_lbl" xml:lang="en-US">EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GCTK_LesseeOperatingLeaseLiabilityImputedInterest" xlink:to="GCTK_LesseeOperatingLeaseLiabilityImputedInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GCTK_LesseeOperatingLeaseLiabilityImputedInterest_3_lbl" xml:lang="en-US">LesseeOperatingLeaseLiabilityImputedInterest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_3_lbl" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_3_lbl" xml:lang="en-US">Convertible Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Other Research and Development Expense</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>gctk-20240930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://glucotrack.com/role/Cover" xlink:href="gctk-20240930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/BalanceSheets" xlink:href="gctk-20240930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/BalanceSheetsParenthetical" xlink:href="gctk-20240930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="gctk-20240930.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" xlink:href="gctk-20240930.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/StatementsOfCashFlows" xlink:href="gctk-20240930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/General" xlink:href="gctk-20240930.xsd#General" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="gctk-20240930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SignificantTransactions" xlink:href="gctk-20240930.xsd#SignificantTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/CommitmentsAndContingentLiabilities" xlink:href="gctk-20240930.xsd#CommitmentsAndContingentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/FinanceIncomeExpensesNet" xlink:href="gctk-20240930.xsd#FinanceIncomeExpensesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SubsequentEvents" xlink:href="gctk-20240930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gctk-20240930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="gctk-20240930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SignificantTransactionsTables" xlink:href="gctk-20240930.xsd#SignificantTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/FinanceIncomeExpensesNetTables" xlink:href="gctk-20240930.xsd#FinanceIncomeExpensesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/GeneralDetailsNarrative" xlink:href="gctk-20240930.xsd#GeneralDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails" xlink:href="gctk-20240930.xsd#ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails" xlink:href="gctk-20240930.xsd#ScheduleOfOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails" xlink:href="gctk-20240930.xsd#ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails" xlink:href="gctk-20240930.xsd#ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails" xlink:href="gctk-20240930.xsd#ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails" xlink:href="gctk-20240930.xsd#ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureDetails" xlink:href="gctk-20240930.xsd#ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" xlink:href="gctk-20240930.xsd#SignificantTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:href="gctk-20240930.xsd#CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails" xlink:href="gctk-20240930.xsd#ScheduleOfFinanceExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://glucotrack.com/role/SubsequentEventsDetailsNarrative" xlink:href="gctk-20240930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingParValuePerShare" xlink:label="loc_deiEntityListingParValuePerShare" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityListingParValuePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaapRestrictedCashNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapRestrictedCashNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PromissoryNotesCurrent" xlink:label="loc_GCTKPromissoryNotesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_GCTKPromissoryNotesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ReceiptsOnAccountOfShares" xlink:label="loc_GCTKReceiptsOnAccountOfShares" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_GCTKReceiptsOnAccountOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaapMarketingExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapMarketingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_FinanceIncomeNet" xlink:label="loc_GCTKFinanceIncomeNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_GCTKFinanceIncomeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ReceiptsOnAccountOfSharesMember" xlink:label="loc_GCTKReceiptsOnAccountOfSharesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_GCTKReceiptsOnAccountOfSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted" xlink:label="loc_GCTKAdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKAdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_GCTKStockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockToBeIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares" xlink:label="loc_GCTKStockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares" xlink:label="loc_GCTKStockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions" xlink:label="loc_GCTKStockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" xlink:label="loc_GCTKStockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" xlink:label="loc_GCTKStockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" xlink:label="loc_GCTKStockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" xlink:label="loc_GCTKStockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity" xlink:label="loc_GCTKStockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity" xlink:label="loc_GCTKStockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant" xlink:label="loc_GCTKStockIssuedDuringPeriodValueIssuanceOfWarrant" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKStockIssuedDuringPeriodValueIssuanceOfWarrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" xlink:label="loc_GCTKIssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GCTKIssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_LinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:label="loc_GCTKLinkageDifferenceOnPrincipalOfLoansFromStockholders" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GCTKLinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" xlink:label="loc_GCTKRevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GCTKRevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities" xlink:label="loc_GCTKRevaluationExpensesRelatedToDerivativeFinancialLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GCTKRevaluationExpensesRelatedToDerivativeFinancialLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ProceedsFromConvertibleDebtPrivatePlacementTransaction" xlink:label="loc_GCTKProceedsFromConvertibleDebtPrivatePlacementTransaction" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_GCTKProceedsFromConvertibleDebtPrivatePlacementTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ProceedsReceivedFromUnderwrittenPublicOffering" xlink:label="loc_GCTKProceedsReceivedFromUnderwrittenPublicOffering" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_GCTKProceedsReceivedFromUnderwrittenPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidAbstract" xlink:label="loc_us-gaapInterestPaidAbstract" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapInterestPaidAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterestPaidAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DeemedDividendUponTriggerOfDownRoundProtection" xlink:label="loc_GCTKDeemedDividendUponTriggerOfDownRoundProtection" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_GCTKDeemedDividendUponTriggerOfDownRoundProtection" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" xlink:label="loc_GCTKIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_GCTKIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/General" xlink:title="00000007 - Disclosure - GENERAL">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SignificantTransactions" xlink:title="00000009 - Disclosure - SIGNIFICANT TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DisclosureSignificantTransactionsAbstract" xlink:label="loc_GCTKDisclosureSignificantTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SignificantTransactionsTextBlock" xlink:label="loc_GCTKSignificantTransactionsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GCTKDisclosureSignificantTransactionsAbstract" xlink:to="loc_GCTKSignificantTransactionsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/CommitmentsAndContingentLiabilities" xlink:title="00000010 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/FinanceIncomeExpensesNet" xlink:title="00000011 - Disclosure - FINANCE (INCOME) EXPENSES, NET">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaapFinancialInstrumentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapFinancialInstrumentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SubsequentEvents" xlink:title="00000012 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ModificationOfEquityClassifiedContractsPolicyTextBlock" xlink:label="loc_GCTKModificationOfEquityClassifiedContractsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_GCTKModificationOfEquityClassifiedContractsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ConvertiblePromissoryNotesPolicyTextBlock" xlink:label="loc_GCTKConvertiblePromissoryNotesPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_GCTKConvertiblePromissoryNotesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock" xlink:label="loc_GCTKAllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_GCTKAllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SignificantTransactionsTables" xlink:title="00000015 - Disclosure - SIGNIFICANT TRANSACTIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DisclosureSignificantTransactionsAbstract" xlink:label="loc_GCTKDisclosureSignificantTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GCTKDisclosureSignificantTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JuneTwentySevenWarrantsMember" xlink:label="loc_GCTKJuneTwentySevenWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKJuneTwentySevenWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JulyEighteenNotesMember" xlink:label="loc_GCTKJulyEighteenNotesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKJulyEighteenNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JulyThirteenNotesMember" xlink:label="loc_GCTKJulyThirteenNotesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKJulyThirteenNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock" xlink:label="loc_GCTKScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock" xlink:label="loc_GCTKScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock" xlink:label="loc_GCTKScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/FinanceIncomeExpensesNetTables" xlink:title="00000016 - Disclosure - FINANCE (INCOME) EXPENSES, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="loc_srtScheduleOfCondensedFinancialStatementsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_srtScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/GeneralDetailsNarrative" xlink:title="00000017 - Disclosure - GENERAL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromUnsecuredNotesPayable" xlink:label="loc_us-gaapProceedsFromUnsecuredNotesPayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromUnsecuredNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSecuredNotesPayable" xlink:label="loc_us-gaapProceedsFromSecuredNotesPayable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromSecuredNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecurities" xlink:label="loc_us-gaapDebtSecurities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtSecurities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails" xlink:title="00000018 - Disclosure - SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PrefundedWarrantsMember" xlink:label="loc_GCTKPrefundedWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKPrefundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PerformanceMilestoneMember" xlink:label="loc_GCTKPerformanceMilestoneMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKPerformanceMilestoneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature" xlink:label="loc_GCTKDeemedDividendRelatedToTriggerOfDownRoundProtectionFeature" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKDeemedDividendRelatedToTriggerOfDownRoundProtectionFeature" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones" xlink:label="loc_GCTKEarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKEarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails" xlink:title="00000019 - Disclosure - SCHEDULE OF OPERATING LEASE (Details)">
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DisclosureSignificantTransactionsAbstract" xlink:label="loc_GCTKDisclosureSignificantTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GCTKDisclosureSignificantTransactionsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GCTKDisclosureSignificantTransactionsAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GCTKDisclosureSignificantTransactionsAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails" xlink:title="00000020 - Disclosure - SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DisclosureSignificantTransactionsAbstract" xlink:label="loc_GCTKDisclosureSignificantTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GCTKDisclosureSignificantTransactionsAbstract" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaapLesseeLeaseDescriptionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLesseeLeaseDescriptionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_LessThanOneYearMember" xlink:label="loc_GCTKLessThanOneYearMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_GCTKLessThanOneYearMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_BetweenOneYearToTwoYearsMember" xlink:label="loc_GCTKBetweenOneYearToTwoYearsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_GCTKBetweenOneYearToTwoYearsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_MoreThanTwoYearsMember" xlink:label="loc_GCTKMoreThanTwoYearsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_GCTKMoreThanTwoYearsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_LesseeOperatingLeaseLiabilityImputedInterest" xlink:label="loc_GCTKLesseeOperatingLeaseLiabilityImputedInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_GCTKLesseeOperatingLeaseLiabilityImputedInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails" xlink:title="00000021 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DisclosureSignificantTransactionsAbstract" xlink:label="loc_GCTKDisclosureSignificantTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GCTKDisclosureSignificantTransactionsAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GCTKDisclosureSignificantTransactionsAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails" xlink:title="00000022 - Disclosure - SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES (Details)">
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DisclosureSignificantTransactionsAbstract" xlink:label="loc_GCTKDisclosureSignificantTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GCTKDisclosureSignificantTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JuneTwentySevenWarrantsMember" xlink:label="loc_GCTKJuneTwentySevenWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKJuneTwentySevenWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JulyEighteenNotesMember" xlink:label="loc_GCTKJulyEighteenNotesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKJulyEighteenNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ProceedsFromAllocatedWarrantsAtInitialRecognition" xlink:label="loc_GCTKProceedsFromAllocatedWarrantsAtInitialRecognition" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKProceedsFromAllocatedWarrantsAtInitialRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DiscountAmortizationAndInterestExpenses" xlink:label="loc_GCTKDiscountAmortizationAndInterestExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKDiscountAmortizationAndInterestExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PartialConversionNotesAndAccruedInterest" xlink:label="loc_GCTKPartialConversionNotesAndAccruedInterest" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKPartialConversionNotesAndAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PartialConversionAndAccruedInterest" xlink:label="loc_GCTKPartialConversionAndAccruedInterest" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKPartialConversionAndAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleDebt_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails" xlink:title="00000023 - Disclosure - SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES (Details)">
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DisclosureSignificantTransactionsAbstract" xlink:label="loc_GCTKDisclosureSignificantTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GCTKDisclosureSignificantTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JulyThirtyNotesMember" xlink:label="loc_GCTKJulyThirtyNotesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKJulyThirtyNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaapEmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DiscountAmortizationAndInterestExpenses" xlink:label="loc_GCTKDiscountAmortizationAndInterestExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GCTKDiscountAmortizationAndInterestExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleDebt_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureDetails" xlink:title="00000024 - Disclosure - SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE (Details)">
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DisclosureSignificantTransactionsAbstract" xlink:label="loc_GCTKDisclosureSignificantTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GCTKDisclosureSignificantTransactionsAbstract" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaapEmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GCTKDisclosureSignificantTransactionsAbstract" xlink:to="loc_us-gaapEmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_RevaluationExpensesRelatedToEmbeddedRedemptionFeature" xlink:label="loc_GCTKRevaluationExpensesRelatedToEmbeddedRedemptionFeature" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GCTKDisclosureSignificantTransactionsAbstract" xlink:to="loc_GCTKRevaluationExpensesRelatedToEmbeddedRedemptionFeature" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GCTKDisclosureSignificantTransactionsAbstract" xlink:to="loc_us-gaapDerivativeLiabilities_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" xlink:title="00000025 - Disclosure - SIGNIFICANT TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DisclosureSignificantTransactionsAbstract" xlink:label="loc_GCTKDisclosureSignificantTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GCTKDisclosureSignificantTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PrefundedWarrantsMember" xlink:label="loc_GCTKPrefundedWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKPrefundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_FirstWarrantMember" xlink:label="loc_GCTKFirstWarrantMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKFirstWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SecondWarrantMember" xlink:label="loc_GCTKSecondWarrantMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKSecondWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ThirdWarrantMember" xlink:label="loc_GCTKThirdWarrantMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKThirdWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JuneTwentySevenNotesMember" xlink:label="loc_GCTKJuneTwentySevenNotesMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKJuneTwentySevenNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_AugustTwentyThreeWarrantMember" xlink:label="loc_GCTKAugustTwentyThreeWarrantMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKAugustTwentyThreeWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_AugustTwentyThreeWarrantOneMember" xlink:label="loc_GCTKAugustTwentyThreeWarrantOneMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKAugustTwentyThreeWarrantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_AugustTwentyThreeWarrantTwoMember" xlink:label="loc_GCTKAugustTwentyThreeWarrantTwoMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKAugustTwentyThreeWarrantTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_AugustTwentyThreeWarrantThreeMember" xlink:label="loc_GCTKAugustTwentyThreeWarrantThreeMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKAugustTwentyThreeWarrantThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JulyEighteenNotesMember" xlink:label="loc_GCTKJulyEighteenNotesMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKJulyEighteenNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JulyTwentySevenNotesMember" xlink:label="loc_GCTKJulyTwentySevenNotesMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKJulyTwentySevenNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeptemberFiveWarrantsMember" xlink:label="loc_GCTKSeptemberFiveWarrantsMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKSeptemberFiveWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeptemberFiveWarrantsOneMember" xlink:label="loc_GCTKSeptemberFiveWarrantsOneMember" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKSeptemberFiveWarrantsOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeptemberFiveWarrantsTwoMember" xlink:label="loc_GCTKSeptemberFiveWarrantsTwoMember" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKSeptemberFiveWarrantsTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeptemberFiveWarrantsThreeMember" xlink:label="loc_GCTKSeptemberFiveWarrantsThreeMember" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKSeptemberFiveWarrantsThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ExchangeAgreementMember" xlink:label="loc_GCTKExchangeAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GCTKExchangeAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaapLeaseAgreementsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapLeaseAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_WarrantsAgreementMember" xlink:label="loc_GCTKWarrantsAgreementMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GCTKWarrantsAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_UnsecuredPromissoryNotesMember" xlink:label="loc_GCTKUnsecuredPromissoryNotesMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GCTKUnsecuredPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_ConvertiblePromissoryNotesMember" xlink:label="loc_GCTKConvertiblePromissoryNotesMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_GCTKConvertiblePromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_LockUpPeriodDescription" xlink:label="loc_GCTKLockUpPeriodDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_GCTKLockUpPeriodDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtDescription" xlink:label="loc_us-gaapShortTermDebtDescription" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShortTermDebtDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaapSaleOfStockDescriptionOfTransaction" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSaleOfStockDescriptionOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault" xlink:label="loc_us-gaapDebtDefaultLongtermDebtDescriptionOfNoticeOfDefault" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtDefaultLongtermDebtDescriptionOfNoticeOfDefault" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDefaultLongtermDebtAmount" xlink:label="loc_us-gaapDebtDefaultLongtermDebtAmount" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtDefaultLongtermDebtAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_EmbeddedConversionFeaturePercentage" xlink:label="loc_GCTKEmbeddedConversionFeaturePercentage" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_GCTKEmbeddedConversionFeaturePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="loc_us-gaapEmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapEmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaapEquityFairValueDisclosure" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapEquityFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:title="00000026 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="loc_us-gaapLegalEntityTypeOfCounterpartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="loc_us-gaapLegalEntityTypeOfCounterpartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_IsraeliInnovationAuthorityMember" xlink:label="loc_GCTKIsraeliInnovationAuthorityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLegalEntityTypeOfCounterpartyDomain" xlink:to="loc_GCTKIsraeliInnovationAuthorityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_IsraeliInnovationAuthorityMember" xlink:label="loc_GCTKIsraeliInnovationAuthorityMember_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_GCTKIsraeliInnovationAuthorityMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_IntellectualPropertyPurchaseAgreementMember" xlink:label="loc_GCTKIntellectualPropertyPurchaseAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GCTKIntellectualPropertyPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_TrueupSharesMember" xlink:label="loc_GCTKTrueupSharesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GCTKTrueupSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_RoyaltyPercentage" xlink:label="loc_GCTKRoyaltyPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GCTKRoyaltyPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_AggregateSalesPriceOfUnitsPercentage" xlink:label="loc_GCTKAggregateSalesPriceOfUnitsPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GCTKAggregateSalesPriceOfUnitsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesRestrictedStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesRestrictedStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_MarketabilityDiscountRate" xlink:label="loc_GCTKMarketabilityDiscountRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GCTKMarketabilityDiscountRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails" xlink:title="00000027 - Disclosure - SCHEDULE OF FINANCE EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DiscountAmortizationAndInterestExpensesOne" xlink:label="loc_GCTKDiscountAmortizationAndInterestExpensesOne" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_GCTKDiscountAmortizationAndInterestExpensesOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_DiscountAmortizationAndInterestExpensesTwo" xlink:label="loc_GCTKDiscountAmortizationAndInterestExpensesTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_GCTKDiscountAmortizationAndInterestExpensesTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities" xlink:label="loc_GCTKRevaluationExpensesRelatedToDerivativeFinancialLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_GCTKRevaluationExpensesRelatedToDerivativeFinancialLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" xlink:label="loc_GCTKRevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_GCTKRevaluationExpensesIncurredFromSettlementOfFinancialLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDeposits" xlink:label="loc_us-gaapInterestExpenseDeposits" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapInterestExpenseDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_FinanceIncomeNet" xlink:label="loc_GCTKFinanceIncomeNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_GCTKFinanceIncomeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://glucotrack.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000028 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PrefundedWarrantsMember" xlink:label="loc_GCTKPrefundedWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKPrefundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeriesACommonWarrantMember" xlink:label="loc_GCTKSeriesACommonWarrantMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKSeriesACommonWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeriesCommonWarrantMember" xlink:label="loc_GCTKSeriesCommonWarrantMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GCTKSeriesCommonWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeriesACommonWarrantMember" xlink:label="loc_GCTKSeriesACommonWarrantMember_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GCTKSeriesACommonWarrantMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_SeriesBCommonWarrantMember" xlink:label="loc_GCTKSeriesBCommonWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GCTKSeriesBCommonWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_PrefundedWarrantsMember" xlink:label="loc_GCTKPrefundedWarrantsMember_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GCTKPrefundedWarrantsMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="gctk-20240930.xsd#GCTK_JulyThirtyNotesMember" xlink:label="loc_GCTKJulyThirtyNotesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GCTKJulyThirtyNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233095659936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Nov. 03, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GLUCOTRACK,
INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001506983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0668934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">301
    Route 17 North<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rutherford<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">842-7715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GCTK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,772,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingParValuePerShare', window );">Entity Listing, Par Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233095349488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 346<span></span>
</td>
<td class="nump">$ 4,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">642<span></span>
</td>
<td class="nump">4,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset, net (Note 3C)</a></td>
<td class="nump">65<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">826<span></span>
</td>
<td class="nump">4,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,857<span></span>
</td>
<td class="nump">839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current (Note 3C)</a></td>
<td class="nump">25<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_PromissoryNotesCurrent', window );">Promissory notes (Note 3G and Note 3H)</a></td>
<td class="nump">1,988<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory notes (Note 3F)</a></td>
<td class="nump">5<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative financial liabilities (Note 3G and Note 3H)</a></td>
<td class="nump">37<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">699<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,611<span></span>
</td>
<td class="nump">1,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Loans from stockholders</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current (Note 3C)</a></td>
<td class="nump">40<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">4,848<span></span>
</td>
<td class="nump">1,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingent liabilities (Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock of $ 0.001 par value (&#8220;Common Stock&#8221;):100,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 5,772,190 and 4,178,274 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">118,223<span></span>
</td>
<td class="nump">112,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_ReceiptsOnAccountOfShares', window );">Receipts on account of shares</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(122,356)<span></span>
</td>
<td class="num">(109,853)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; (deficit) equity</a></td>
<td class="num">(4,022)<span></span>
</td>
<td class="nump">3,197<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY</a></td>
<td class="nump">$ 826<span></span>
</td>
<td class="nump">$ 4,905<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_PromissoryNotesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Promissory notes current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_PromissoryNotesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_ReceiptsOnAccountOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receipts on account of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_ReceiptsOnAccountOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233097814368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">5,772,026<span></span>
</td>
<td class="nump">4,178,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">5,772,026<span></span>
</td>
<td class="nump">4,178,274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233096323568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 2,063<span></span>
</td>
<td class="nump">$ 1,693<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="nump">$ 2,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingExpense', window );">Marketing expenses</a></td>
<td class="nump">125<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,063<span></span>
</td>
<td class="nump">531<span></span>
</td>
<td class="nump">2,598<span></span>
</td>
<td class="nump">1,725<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,251<span></span>
</td>
<td class="nump">2,224<span></span>
</td>
<td class="nump">10,693<span></span>
</td>
<td class="nump">4,687<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="nump">3,251<span></span>
</td>
<td class="nump">2,224<span></span>
</td>
<td class="nump">10,693<span></span>
</td>
<td class="nump">4,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_FinanceIncomeNet', window );">Finance (income) expenses, net (Note 5)</a></td>
<td class="nump">1,848<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">1,822<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="nump">5,087<span></span>
</td>
<td class="nump">2,223<span></span>
</td>
<td class="nump">12,503<span></span>
</td>
<td class="nump">4,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (income) loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">17<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss for the period</a></td>
<td class="nump">$ 5,104<span></span>
</td>
<td class="nump">$ 2,217<span></span>
</td>
<td class="nump">$ 12,514<span></span>
</td>
<td class="nump">$ 4,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common stock</a></td>
<td class="num">$ (0.91)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (2.39)<span></span>
</td>
<td class="num">$ (1.38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common stock</a></td>
<td class="num">$ (0.91)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (2.39)<span></span>
</td>
<td class="num">$ (1.38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common stock outstanding used in computing basic net loss per share</a></td>
<td class="nump">5,594,880<span></span>
</td>
<td class="nump">4,593,733<span></span>
</td>
<td class="nump">5,355,806<span></span>
</td>
<td class="nump">4,006,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common stock outstanding used in computing diluted net loss per share</a></td>
<td class="nump">5,594,880<span></span>
</td>
<td class="nump">4,593,733<span></span>
</td>
<td class="nump">5,355,806<span></span>
</td>
<td class="nump">4,006,527<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_FinanceIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance income net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_FinanceIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233099347360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Receipts on Account of Shares [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 103,107,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="num">$ (101,901,000)<span></span>
</td>
<td class="nump">$ 1,230,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">3,099,982<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,685,000)<span></span>
</td>
<td class="num">(4,685,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Other comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">260,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted', window );">Deemed dividend resulted from trigger of down round protection feature of certain warrants granted</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">855,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(855,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock upon private placement transaction (Note 3D)</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,729,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,730,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock upon private placement transaction (Note 3D), shares</a></td>
<td class="nump">1,075,294<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted shares as compensation towards directors</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9,000<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of shares as compensation to the board of directors, shares</a></td>
<td class="nump">2,998<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">112,960,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">34,000<span></span>
</td>
<td class="num">(107,441,000)<span></span>
</td>
<td class="nump">5,557,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="nump">4,178,274<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">112,929,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="num">(105,218,000)<span></span>
</td>
<td class="nump">7,743,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2023</a></td>
<td class="nump">4,178,274<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,223,000)<span></span>
</td>
<td class="num">(2,223,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Other comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">31,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">31,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">112,960,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">34,000<span></span>
</td>
<td class="num">(107,441,000)<span></span>
</td>
<td class="nump">5,557,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="nump">4,178,274<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">112,982,000<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="num">(109,853,000)<span></span>
</td>
<td class="nump">3,197,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">4,178,274<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,503,000)<span></span>
</td>
<td class="num">(12,503,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Other comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">239,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">239,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock upon private placement transaction (Note 3D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock upon private placement transaction (Note 3D), shares</a></td>
<td class="nump">79,366<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted shares as compensation towards directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">126,000<span></span>
</td>
<td class="num">(48,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">78,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted shares as compensation towards directors, shares</a></td>
<td class="nump">86,861<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted shares to be issued as compensation towards directors</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares', window );">Exercise of prefunded warrants into shares (Note 3A)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares', window );">Exercise of prefunded warrants into shares (Note 3A), shares</a></td>
<td class="nump">395,294<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Exchange of warrants into shares (Note 3B)</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exchange of warrants into shares (Note 3B), shares</a></td>
<td class="nump">718,641<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions', window );">Issuance of detachable warrants through private placement transactions (Note 3F and Note 3H)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,635,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,635,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities', window );">Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J)</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,742,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,743,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities', window );">Issuance of Common Stock upon private placement transaction (Note 3D), shares</a></td>
<td class="nump">293,590<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b', window );">Issuance of restricted shares as payment for a previous achievement of milestone pursuant to purchase agreement (Note 4B)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b', window );">Issuance of restricted shares as payment for a previous achievement of milestone pursuant to purchase agreement (Note 4B), shares</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">118,223,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="num">(122,356,000)<span></span>
</td>
<td class="num">(4,022,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2024</a></td>
<td class="nump">5,772,026<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">113,903,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
<td class="num">(117,269,000)<span></span>
</td>
<td class="num">(3,289,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="nump">5,478,436<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,087,000)<span></span>
</td>
<td class="num">(5,087,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Other comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(17,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(17,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted shares to be issued as compensation towards directors</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity', window );">Issuance of detachable warrants through private placement transactions (Note 3F and Note 3H)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,567,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,567,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity', window );">Settlement of liabilities with equity, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant', window );">Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J)</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,742,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,743,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 118,223,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="num">$ (122,356,000)<span></span>
</td>
<td class="num">$ (4,022,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2024</a></td>
<td class="nump">5,772,026<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents
    amount lower than $1.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital deemed dividend resulted from trigger of down round protection feature of certain warrants granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of prefunded warrants into shares ,shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement ,shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issuance of shares and warrants as settlement of financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares settlement of liabilities with equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of prefunded warrants into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance of detachable warrants through private placement transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance of shares and warrants as settlement of financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance of warrant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value settlement of liabilities with equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock to be issued during period value restricted stock award gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233095450528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period</a></td>
<td class="num">$ (12,503)<span></span>
</td>
<td class="num">$ (4,685)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors', window );">Issuance of restricted shares as compensation towards directors</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_LinkageDifferenceOnPrincipalOfLoansFromStockholders', window );">Linkage difference on principal of loans from stockholders</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities', window );">Revaluation expenses incurred from settlement of financial liabilities (Note 3I and Note 3J)</a></td>
<td class="nump">1,505<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities', window );">Revaluation expenses related to derivative financial liabilities (Note 3H)</a></td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Discount amortization and interest expenses related to promissory notes (Note 3F, Note 3G and Note 3H)</a></td>
<td class="nump">330<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">80<span></span>
</td>
<td class="num">(216)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,129<span></span>
</td>
<td class="nump">598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">26<span></span>
</td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(8,991)<span></span>
</td>
<td class="num">(4,147)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(104)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(104)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds received from private placement transaction (Note 3D)</a></td>
<td class="nump">500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Issuance of promissory notes and detachable warrants through private placement transaction (Note 3F)</a></td>
<td class="nump">100<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Issuance of convertible promissory notes and bifurcated conversion feature through private placement transaction (Note 3G)</a></td>
<td class="nump">360<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_ProceedsFromConvertibleDebtPrivatePlacementTransaction', window );">Issuance of convertible promissory note, bifurcated conversion and redemption features and detachable warrants through private placement transaction (Note 3H)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_ProceedsReceivedFromUnderwrittenPublicOffering', window );">Net proceeds received from underwritten U.S. public offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,730<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,960<span></span>
</td>
<td class="nump">8,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and cash equivalents, and restricted cash</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash and cash equivalents, and restricted cash</a></td>
<td class="num">(4,146)<span></span>
</td>
<td class="nump">4,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, and restricted cash at beginning of the period</a></td>
<td class="nump">4,502<span></span>
</td>
<td class="nump">2,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">356<span></span>
</td>
<td class="nump">6,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidAbstract', window );"><strong>(a) Net cash (received) paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="num">(37)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>(b) Non-cash investment and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_DeemedDividendUponTriggerOfDownRoundProtection', window );">Deemed dividend upon trigger of down round protection</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Recognition of right for use asset against a lease liability (Note 3C)</a></td>
<td class="nump">79<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities', window );">Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J)</a></td>
<td class="nump">$ 238<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_DeemedDividendUponTriggerOfDownRoundProtection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend upon trigger of down round protection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_DeemedDividendUponTriggerOfDownRoundProtection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of restricted shares as compensation to the board of directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares and warrants as settlement of financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_LinkageDifferenceOnPrincipalOfLoansFromStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Linkage difference on principal of loans from stockholders .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_LinkageDifferenceOnPrincipalOfLoansFromStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_ProceedsFromConvertibleDebtPrivatePlacementTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from convertible debt private placement transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_ProceedsFromConvertibleDebtPrivatePlacementTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_ProceedsReceivedFromUnderwrittenPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds received from underwritten public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_ProceedsReceivedFromUnderwrittenPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revaluation expenses incurred from settlement of financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revaluation expenses related to derivative financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233094129152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL</a></td>
<td class="text"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zn0fJ1kBrjhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 - <span id="xdx_825_zxsgLp8ybfod">GENERAL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glucotrack
    Inc. (the &#8220;Company&#8221;) was incorporated on May 18, 2010 under the laws of the State of Delaware. The Company is a medical
    device company, focused on development of an Implantable Continuous Glucose Monitor (CGM) for persons with Type 1 diabetes and insulin-dependent
    Type 2 diabetes (the &#8220;Glucotrack CBGM Product&#8221;).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
    and capital resources</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    date, the Company has not yet commercialized the Glucotrack CBGM Product. Further development and commercialization efforts are
    expected to require substantial additional expenditure. Therefore, the Company is dependent upon external sources for financing its
    operations. As of September 30, 2024, the Company has incurred an accumulated deficit of $<span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20240930_z6Z3fzOakOh">122,356</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
    in addition, the Company has generated operating losses and negative operating cash flow for all reported periods. As of September
    30, 2024, the balance of cash and cash equivalents amounted to $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20240930_zkcgNVTj1v9i" title="Cash and cash equivalents">346</span>,
    together with the net proceeds in total amount of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20240101__20240930_z0zWkCuuh5g" title="Net proceeds from public offering">8,873</span> which expected to be received upon closing of a public offering through
    registration statements on Form S-1 (see also Note 6 below) on November 14, 2024.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company raised net proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_pn3n3_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zpKbIUIvAMZf">8,730
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">through completion of underwritten public offering.
Moreover, during the period of nine months ended September 30, 2024, the Company entered into (i) exchange agreement with certain shareholders
under which warrants with down round protection feature have been exchanged into shares of common stock in order to facilitate its equity
structure (see also Note 3B below), (ii) private placement agreement under which the Company raised proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_pn3n3_c20240101__20240930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zg1RZcGu6XNk">500
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(see also Note 3D below), (iii) <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unsecured promissory notes
and warrant agreements under which the Company raised proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromUnsecuredNotesPayable_pn3n3_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQfhEVgk4yZf" title="Unsecured promissory notes">100</span> (see also Note 3F below), (iv) unsecured promissory notes under
which the Company raised proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromUnsecuredNotesPayable_pn3n3_c20240101__20240930_zM3dYnOomgo2" title="Unsecured promissory notes">360</span> (see also Note 3G below), (v) secured promissory note and warrant agreements under which the
Company raised proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromSecuredNotesPayable_pn3n3_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGVIM3egHdR1" title="Secured promissory notes">4,000</span> (see also Note 3H below) and (vi) conversion agreements under which certain financial liabilities have
been settled for issuance of shares of common stock and warrants of the Company (see also Note 3I and Note 3J below</span>).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company plans to finance its operations through the sale of equity securities (including shelf registration statement on Form S-3 was declared effective on October 3, 2023 by the Securities
and Exchange Commission (SEC) which allows the Company to register up to $<span id="xdx_90E_eus-gaap--DebtSecurities_iI_c20240930_zXydevKeSl6d">30,000</span> of certain equity and/or debt securities of
the Company through prospectus supplement) and/or debt securities. There can be no assurance that the Company
    will succeed in obtaining the necessary financing or generating sufficient revenue from sale of its Glucotrack CBGM Product in
    order to continue its operations as a going concern.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
    has considered the significance of such conditions in relation to the Company&#8217;s ability to meet its current obligations and
    to achieve its business targets and determined that these conditions raise substantial doubt about the Company&#8217;s ability to
    continue as a going concern.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    condensed interim consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233186107344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zdjNiMPZU7ck" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 - <span id="xdx_821_zeS9LwxMHg55">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p id="xdx_847_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zBk6y2rc9TH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zE5VrcHnpgzg">Basis
    of Presentation</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    accompanying unaudited condensed interim consolidated financial statements and related notes should be read in conjunction with the
    Company&#8217;s consolidated financial statements and related notes included in the Company&#8217;s annual report on Form 10-K for
    the fiscal year ended December 31, 2023, as was filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 28,
    2024. The unaudited condensed interim consolidated financial statements have been prepared in accordance with the rules and regulations
    of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures
    normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial
    information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary
    to present fairly the results of the Company&#8217;s financial position and operating results for the interim periods. All such adjustments
    are of a normal recurring nature.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    results for the period of three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected
    for the year ending December 31, 2024 or for any other interim period or for any future period.</span></td></tr>
</table>

<p id="xdx_84B_eus-gaap--UseOfEstimates_zRBBoArUAa42" style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z7LpEpyqQxfl">Use
    of Estimates in the Preparation of Financial Statements</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates
    and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities
    at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could
    differ from those estimates. As applicable to these interim financial statements, the most significant estimates and assumptions include identification and measurement of financial instruments.</span></td></tr>
</table>

<p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zmLrlRp17BSa" style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zttyu0kFfb0a">Principles
    of Consolidation</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    condensed interim consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany
    balances and transactions have been eliminated in consolidation.</span></td></tr>
</table>

<p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zdGHStKilDFl" style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_ztmSw1zOzLMh">Cash
    and Cash Equivalents</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    equivalents are short-term highly liquid investments which include short-term bank deposits (up to three months from date of deposit),
    that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as
    of the date acquired.</span></td></tr>
</table>

<p id="xdx_84D_ecustom--ModificationOfEquityClassifiedContractsPolicyTextBlock_z8qXmJM3USR6" style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_z1Av9IYetR81">Modification
    of equity-classified contracts</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    modification or exchange of equity-classified contracts, such as warrants that were classified as equity before the modification
    or exchange and remained eligible for equity classification after the modification, is accounted for in a similar manner to a modification
    of stock-based compensation. Accordingly, the incremental fair value from the modification or exchange (the change in the fair value
    of the instrument before and after the modification or exchange) is recognized as a reduction of retained earnings of increase of
    accumulated deficit as a deemed dividend. Modifications or exchanges that result in a decrease in the fair value of an equity-classified
    share-based payment awards are not recognized. In addition, the amount of the deemed dividend is also recognized as an adjustment
    to earnings available to common shareholders for purposes of calculating earnings per share.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></p>

<p id="xdx_84A_ecustom--ConvertiblePromissoryNotesPolicyTextBlock_zkZ8o3MQtn6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zLDCavFUdVDf">Convertible Promissory Notes</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    initial recognition of convertible promissory notes and similar instruments, the Company considers the provisions of ASC 815-40,
    &#8220;Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity&#8221; (&#8220;ASC 815-40&#8221;) in order to determine whether
    the conversion features embedded within the convertible instrument should be separated from the host instrument.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
    it is determined that an embedded derivative required to be bifurcated (such as embedded conversion feature that does not qualify
    for equity classification), the Company recognized the embedded derivative bifurcated as a separate derivative liability upon
    initial recognition and on subsequent periods at fair value. The remaining consideration amount received or allocated to the entire
    convertible instrument is allocated to the host debt instrument. The difference between the face value of the host and such an
    allocated amount represents a discount which is amortized as finance expense to profit or loss using an effective interest method
    over the term of the note until its stated maturity.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
    it is determined that the embedded conversion feature qualifies for equity classification (such when the embedded conversion option,
    if it were freestanding, is not qualified as a derivative in accordance with the provisions of ASC 815-10, &#8220;Derivatives and
    Hedging&#8221; since its terms did not require or permit net settlement or when the embedded conversion option is indexed to the
    entity&#8217;s own stock), the conversion option is not bifurcated. When bifurcation is not required, the Company considers whether
    the debt instrument involves a significant premium (i.e. when the proceeds received or allocated upon issuance exceed the principal
    amount that will be paid at maturity). When it is determined that a substantial premium exists, the entire premium is allocated to
    paid-in capital and when it is determined, otherwise no additional accounting is required and the convertible promissory note is
    accounted for at amortized cost using effective interest method over the term of the note until its stated maturity.</span></p></td></tr>
  </table>
<p id="xdx_847_ecustom--AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock_zskbeHi3THyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zwlQGZrpQPe7">Allocation
    of proceeds and related issuance costs</span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
    multiple instruments are issued in a single transaction (package issuance), the total net proceeds from the transaction are allocated
    among the individual freestanding instruments identified. The allocation occurs after identifying all freestanding instruments and
    the subsequent measurement basis for those instruments.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    instruments that are required to be subsequently measured at fair value (such as derivative liabilities) are measured at fair value
    and the remaining consideration is allocated to other financial instruments that are not required to be subsequently measured at
    fair value (such as liabilities measured at amortized cost, common shares and warrants eligible for equity classification), based
    on the relative fair value basis for such instruments.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    costs allocated to financial instruments that are required to be subsequently measured at fair value immediately expensed. Issuance
    costs allocated to shares and warrants classified as equity components and are recorded as a reduction of additional paid-in capital.
    Issuance costs allocated to financial liabilities measured at amortized cost are recorded as a discount and accreted over the contractual
    term of the financial instrument using the effective interest method.</span></p></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>



<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p id="xdx_840_eus-gaap--DerivativesPolicyTextBlock_zTw3FWwKVhEd" style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zjqH5CCt7BB">Warrants</span></b></span></td></tr>
  </table>
<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    warrants that were issued to several holders are classified as a component of permanent equity since they are freestanding financial
    instruments that are legally detachable and separately exercisable, do not embody an obligation for the Company to repurchase its
    own shares, and permit the holders to receive a fixed number of Ordinary Shares upon exercise for a fixed exercise price and thus,
    are considered as indexed to the Company&#8217;s own shares. As such warrants were issued together with financial instruments that
    are not subsequently measured at fair value and the warrants were measured based on allocation of the proceeds received by the Company
    in accordance with the relative fair value basis. When applicable, direct issuance expenses that were allocated to certain warrants
    were deducted from additional paid-in capital.</span></td></tr>
</table>

<p id="xdx_840_eus-gaap--LesseeLeasesPolicyTextBlock_zHAYzcA7DY9f" style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zRB01wOYGo4b">Leases</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company applies ASC Topic 842, &#8220;Leases&#8221; (&#8220;ASC 842&#8221;) under which the Company determines if an arrangement
    is a lease at inception.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
    are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following
    criteria are met: (i) the lease transfers ownership of the asset by the end of the lease term, (ii) the lease contains an option
    to purchase the asset that is reasonably certain to be exercised, (iii) the lease term is for a major part of the remaining useful
    life of the asset, (iv) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset,
    or (v) the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end
    of lease term. A lease is classified as an operating lease if it does not meet any one of these criteria. Since all the Company&#8217;s
    lease contracts for premises do not meet any of the criteria above, the Company concluded that all its lease contracts should be
    classified as operating leases.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    of Use (&#8220;ROU&#8221;) assets and liabilities are recognized on the commencement date based on the present value of remaining
    lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the
    time of commencement. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its Incremental Borrowing
    Rate (&#8220;IBR&#8221;) based on the information available on the commencement date in determining the present value of lease payments.
    The Company&#8217;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments
    and in economic environments where the leased asset is located. The ROU asset also includes any lease payments made prior to commencement
    and is recorded net of any lease incentives received. Moreover, the ROU asset may also include initial direct costs, which are incremental
    costs of a lease that would not have been incurred if the lease had not been obtained. The Company uses the long-lived assets impairment
    guidance in ASC 360-10, &#8220;Property, Plant, and Equipment - Overall&#8221;, to determine whether a ROU asset is impaired, and
    if so, the amount of the impairment loss to recognize. Certain leases include options to extend or terminate the lease. An option
    to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain
    that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company
    will not exercise the option.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></p>

<p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zYpF2IOulXnk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zajuTRwUQnY8">Basic
    and diluted loss per share</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
                                                         loss per share is computed by dividing the loss for the period applicable (after considering the effect of deemed dividend related
                                                         to trigger of down round protection feature) for Common Stockholders by the weighted average number of shares of Common Stock
                                                         outstanding and shares of Common Stock to be issued upon achievement of certain performance milestones during the period <span style="background-color: white">and
                                                         upon </span>exercise of pre-funded warrants. In computing, diluted loss per share, basic earnings per share are adjusted to reflect
                                                         the potential dilution that could occur upon the exercise of options or warrants issued or granted using the &#8220;treasury stock
                                                         method&#8221; and using the if-converted method with respect to certain convertible promissory notes and bifurcated redemption
feature accounted for as derivative financial liability, if the effect of each of such financial instruments is dilutive. In computing diluted loss per share, the average
                                                         stock price for the period is used in determining the number of Common Stock assumed to be purchased from the proceeds to be
                                                         received from the exercise of stock options or stock warrants.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    to be issued upon exercise of all options and warrants, convertible promissory notes and bifurcated redemption feature, have been excluded from the calculation of the diluted net loss
    per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as result
    of the exercise or conversion of these instruments was anti-dilutive.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    net loss and the weighted average number of shares of Common Stock used in computing basic and diluted net loss per Common Stock
    for the period of three and nine months ended September 30, 2024 and 2023, is as follows:</span></td></tr>
  </table>
<p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zECRBfAsXP8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zlH3UMgBCy09" style="display: none">SCHEDULE
OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240701__20240930_zY1fwQEntJ1j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230701__20230930_zyh7Jwyw3RX4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20240930_zk8T6rrK77Zk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230930_zGuY6kLIwKf7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">US dollars (except share data)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">US dollars (except share data)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three-month period ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine-month
period ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_iN_pn3n3_di_maNILATzfsR_z3h5F4HaMWLd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 44%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">5,087</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,223</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">12,503</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,685</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature_iN_pn3n3_di_maNILATzfsR_zLtm2Uj52lz3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Deemed dividend related to trigger of down round protection feature</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0684">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0685">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0686">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">855</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iNT_pn3n3_di_mtNILATzfsR_zzJULLVnGMdh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Net loss attributable to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,087</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,223</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,503</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,540</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Shares of Common Stock used in computing basic and diluted net loss per common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zVmjIIryPAmh" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zoZOdvODAwxd" title="Ordinary shares used in computing diluted net loss per common stock">5,564,880</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zKGeyIxhq1n7" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zNtDgyEEgYN" title="Ordinary shares used in computing diluted net loss per common stock">4,593,733</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_z7D7t5EV2Tld" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zZ2dQIclzRx7" title="Ordinary shares used in computing diluted net loss per common stock">5,340,532</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_ztUZlocG5Z42" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zSgMwvqxjys" title="Ordinary shares used in computing diluted net loss per common stock">3,758,590</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Shares of Common Stock to be issued upon exercise of pre-funded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zefuTJYCqzc" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zWheIw9VGqE6" title="Ordinary shares used in computing basic net loss per common stock"><span style="-sec-ix-hidden: xdx2ixbrl0710"><span style="-sec-ix-hidden: xdx2ixbrl0712">-</span></span></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zkBxULuZabwb" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zHNW06k4Cbta" title="Ordinary shares used in computing diluted net loss per common stock"><span style="-sec-ix-hidden: xdx2ixbrl0714"><span style="-sec-ix-hidden: xdx2ixbrl0716">-</span></span></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zDyS5M8xO2Og" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zGjWmtb2Havc" title="Ordinary shares used in computing diluted net loss per common stock"><span style="-sec-ix-hidden: xdx2ixbrl0718"><span style="-sec-ix-hidden: xdx2ixbrl0720">-</span></span></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zZoCHb218dwf" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_z18oaHPtHo4j" title="Ordinary shares used in computing diluted net loss per common stock">241,246</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Shares of Common Stock to be issued upon achievement of performance milestones</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_z1RWeBPjSvWl" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zg9ykkrfTP58" title="Ordinary shares used in computing diluted net loss per common stock">30,000</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zD7rw58jVuB2" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zRDWvYLlWlO7" title="Ordinary shares used in computing diluted net loss per common stock"><span style="-sec-ix-hidden: xdx2ixbrl0730"><span style="-sec-ix-hidden: xdx2ixbrl0732">-</span></span></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_ziP4Gvys9mb8" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_z0W0wTgEHEx4" title="Ordinary shares used in computing diluted net loss per common stock">15,275</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zr59VvXkLhbe" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zR2GCY4Jyrhj" title="Ordinary shares used in computing diluted net loss per common stock">6,691</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average number of Common Stock outstanding used in computing basic and diluted net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930_zyw8P5D5hxPe" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930_z30ArI9toSR8" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share">5,594,880</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930_zQs2xS3Sy7lg" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930_znjWzcAjwsXd" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share">4,593,733</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930_zn2Qx0dJPtVh" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930_zNEM4narGaFe" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share">5,355,806</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930_zOjdbevyrhHb" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930_zOQXvVfVxnR5" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share">4,006,527</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per common stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240701__20240930_z91DnSu7T2Ka" title="Diluted net loss per common stock"><span id="xdx_906_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240701__20240930_zuRoixSV9Nua" title="Diluted net loss per common stock">(0.91</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230701__20230930_zchev55s3gn" title="Diluted net loss per common stock"><span id="xdx_90D_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230701__20230930_z5Pvp7a8vFg4" title="Diluted net loss per common stock">(0.49</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240101__20240930_zNUAReKKbO7" title="Diluted net loss per common stock"><span id="xdx_90D_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240101__20240930_zxIeGyO6KKO3" title="Diluted net loss per common stock">(2.39</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230101__20230930_zowndlo5mvYd" title="Diluted net loss per common stock"><span id="xdx_909_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230101__20230930_zXz74f5ovqRg" title="Diluted net loss per common stock">(1.38</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A1_zEuqK0oVDPO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p id="xdx_858_zdCThtqixkGb" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233097589296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_DisclosureSignificantTransactionsAbstract', window );"><strong>Significant Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_SignificantTransactionsTextBlock', window );">SIGNIFICANT TRANSACTIONS</a></td>
<td class="text"><p id="xdx_802_ecustom--SignificantTransactionsTextBlock_z7r92uxTpit6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 - <span id="xdx_822_zqACE4jkYJr9">SIGNIFICANT TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
    of pre-funded warrants</b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    January 3, 2024, <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20240103__20240103__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zvUMykTLeWlc" title="Pre-funded warrants">395,294</span> pre-funded warrants granted through underwritten public offering in April 2023 have been fully
    exercised into the same number of shares of Common Stock of the Company. </span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exchange
    Agreement</b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    February 13, 2024, the Company entered into an Exchange Agreement with certain warrant holders (the &#8220;Holders&#8221;), pursuant
    to which the Company and the Holders agreed to exchange (the &#8220;Exchange&#8221;) warrants with down round protection feature
    exercisable to common shares (the &#8220;Warrants&#8221;) owned by the Holders for shares of Common Stock to be issued by the
    Company. On February 15, 2024, <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pid_c20240213_z7xBRoTYBUcl" title="Shares of Common Stock">718,641</span> shares of Common Stock have been issued in exchange for <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20240213__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zI5RNUfzJWu1" title="Shares of Common Stock">876,391</span> Warrants (the &#8220;Shares&#8221;).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
    was also agreed that the Holders will not, during the period (&#8220;Lock-Up Period&#8221;) (i) offer, pledge, announce the intention
    to sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option,
    right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Shares, (ii) enter into any swap or
    other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Shares of, whether any
    such transaction described in clause (i) or (ii) above is to be settled by delivery of Shares or such other securities, in cash or
    otherwise, (iii) make any demand for or exercise any right with respect to, the registration of any Shares or any security convertible
    into or exercisable or exchangeable for shares of common stock, or (iv) publicly announce an intention to effect any transaction
    specific in clause (i), (ii) or (iii) above, provided that the Holder, during the Lock-Up Period, may<span id="xdx_900_ecustom--LockUpPeriodDescription_c20240213__20240213__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zWEYX8w2NVEh" title="Lock-up period conditions"> (a) sell or contract
    to sell Shares at a price higher than $0.50 per Share on any trading day up to 10% of the daily volume of Shares or (b) sell or contract
    to sell Shares at a price higher than $0.80 per Share on any trading day with no volume limitation.</span></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Lock-Up Period shall expire at the earliest of (i) 365 days after the date hereof or (ii) until the Shares traded above $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20240213__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zFDzbdvxhtne" title="Share price">1.00</span> per
    Share for five consecutive trading days.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company accounted for the Exchange of the aforesaid warrants with shares as deemed dividend which was calculated at the closing date
    by the management using the assistance of external appraiser as the excess of fair value of the share to be issued after taking into
    consideration a discount for lack of marketability at a rate of 16.81% over the Lock-Up Period over the fair value of the original
    equity instrument (i.e. warrants which included down round protection feature). However, since the fair value of the new equity
    instrument (common shares) was estimated as lesser than the fair value of the replaced equity instrument, deemed dividend was not
    recorded.</span></p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lease
    Agreement</b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    February 19, 2024, the Company entered into Lease Agreement (the &#8220;Agreement&#8221;) with Tapsak Enterprises LLC dba Virginia
    Analytical (the &#8220;Landlord&#8221;) under which it was agreed that the Company will lease from the Landlord a premises located
    in Front Royal, Virginia area for a monthly rental fee of $<span id="xdx_904_eus-gaap--OperatingLeasePayments_pn2n3_c20240219__20240219__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zWEPgI704uA4" title="Monthly rental fee">2.5</span> over a period of <span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20240219__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zwseJGRqKbB" title="Lessee term of contract">3</span>-years commencing March 1, 2024 through February
    28, 2027 (the &#8220;Initial Lease Period&#8221;). Security deposit of $<span id="xdx_908_eus-gaap--SecurityDeposit_iI_pn2n3_c20240219__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zYKYu0ivesP3" title="Security deposit">2.5</span> which represents payment of one month is held by the
    Landlord which will be return to the Company at the end of the Initial Lease Period.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Company has an option to renew the Initial Lease Period for another two additional periods of 3-years each following the
Initial Lease Period (the &#8220;Option Term&#8221;), following advanced notice as defined in the Agreement. The monthly rental fee over
the Option Term shall be the fair market rate determined as what is a comparable cost for similar property in Front Royal, Virginia area.</span></p>
                                                                              <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                              <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance
                                                                              with the provision of ASC 842, Leases, at the commencement date of the Agreement, the Company recognized the right to use asset
                                                                              equals to lease liability in total amount of $<span id="xdx_90D_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20240219_zUEtACXcKmf5" title="Lease liability">79</span>. The lease liability was measured at the present value of the future lease
                                                                              payments, which are discounted based on an estimate of the incremental interest rate that the Company would be required to pay to
                                                                              borrow a similar amount for a similar period in order to obtain a similar amount on the initial recognition date of the lease.</span></p>
                                                                              <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
                                                                              <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the leasing period, the Company considered only the Initial Lease Period as the realization of the option
to extend the period was not considered as reasonably certain.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 - SIGNIFICANT TRANSACTIONS (CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lease
    Agreement (Cont.)</b></span></td></tr>
</table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--LeaseCostTableTextBlock_zIzel0VXWKy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_z3vDuEBqrYq6" style="display: none">SCHEDULE
OF OPERATING
LEASE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240930_zZZP4RDv7wKg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zsaPUwH9wOCa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left; padding-bottom: 2.5pt">Operating right-of-use asset</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 18%; text-align: right">65</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zyV0tTXRkczh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Current operating lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zsi5QhiaesRb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Non-Current operating lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">40</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zsWg4xTRsw31" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zjcYrVnemZJ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturity
analysis of the Company&#8217;s lease liability:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_ztlO01gzXIGk" style="display: none">SCHEDULE
OF MATURITY
ANALYSIS OF LEASE LIABILITY</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240930_zhZxTL7nJvg3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_hus-gaap--LeaseContractualTermAxis__custom--LessThanOneYearMember_zXc3Tv74rw9c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Less than one year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">30</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_hus-gaap--LeaseContractualTermAxis__custom--BetweenOneYearToTwoYearsMember_zC0BaIt2ItC1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Between 1-2 years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_hus-gaap--LeaseContractualTermAxis__custom--MoreThanTwoYearsMember_zUYBx9ixmCL2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">More than 2 years</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">13</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zR8mOjemPfEj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total operating lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">73</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--LesseeOperatingLeaseLiabilityImputedInterest_iNI_di_zDVgdFWJRpO7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">8</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_zrTAHbTQkpxb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">65</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zIP5L8OLIHc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Additional
information on lease</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock_zZMEFboNQckj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the weighted average remaining lease terms and discount rate for the lease:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zg2FCIS7FFqb" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Lease term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240930_zE2X8TvuDZW1" title="Lease term (years)">2.42</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20240930_zxtunKEZIuh9" title="Weighted average discount rate">9.03</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8AB_zhcJ7QICHX1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Private
    Placement Agreement</b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    April 22, 2024, the Company entered into a private placement agreement under which the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240422__20240422__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z02OXS5tWxCl" title="Number of shares issued">79,366</span> shares of its common
    stock at a price of $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240422__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zGVygKaVHZY" title="Common stock share price">6.30</span> per share for aggregate gross proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20240422__20240422__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zo4ISivbb5A6" title="Aggregate gross proceeds offering">500 </span>(the &#8220;Offering&#8221;). The Offering included participation
    of certain members of the Company&#8217;s executive management, Board of Directors and existing shareholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Adoption
    of 2024 Equity Incentive Plan and Reverse Share Split</b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    April 26, 2024, the Company held its Annual Meeting of Shareholders (the &#8220;Annual Meeting&#8221;) under which the Company&#8217;s
    stockholders approved, inter alia, the following proposals: (i) adoption of the Company&#8217;s 2024 Equity Incentive Plan and (ii)
    an amendment to Article IV of the Company&#8217;s Certificate of Incorporation, to effect a reverse stock split of the Company&#8217;s
    Common Stock at a ratio of between one-for-five and one-for-thirty, with such ratio to be determined at the sole discretion of the
    Board of Directors. Following the Annual Meeting, on April 30, 2024, the Company&#8217;s Board of Directors approved a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20240430__20240430_zI4eRcuuZfv3" title="Reverse stock split">one-for-five</span>
    reverse stock split of the Company&#8217;s issued and outstanding shares of common stock (the &#8220;Reverse Stock Split&#8221;).
    On May 17, 2024, the Company filed a Certificate of Amendment to the Company&#8217;s Certificate of Incorporation with the Secretary
    of State of the State of Delaware which effected the Reverse Stock Split.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    accounting purposes, all shares, options and warrants to purchase shares of common stock and loss per share amounts have been adjusted
    to give retroactive effect to the Reverse Share Split for all periods presented in these interim consolidated financial statements.
    Any fractional shares resulting from the Reverse Share Split were rounded up to the nearest whole share.</span></p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 - SIGNIFICANT TRANSACTIONS (CONT.)</b></span></p>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
    and Warrant Purchase Agreements</b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                                         June 27, 2024, the Company entered into note and warrant purchase agreements (the &#8220;Purchase Agreement&#8221;) with certain
                                                         investors (the &#8220;June 27 Investors&#8221;), providing for the private placement of unsecured promissory notes in the aggregate
                                                         principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240627__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNotesMember_zOhRbwCA6P52" title="Aggregate principal amount">100</span>
                                                         (the &#8220;June 27 Notes&#8221; and each a &#8220;June 27 Note&#8221;) and warrants to purchase up to an aggregate of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240627_zKAYWNYv4bP1" title="Aggregate of shares">300,000</span>
                                                         shares of the Company&#8217;s Common Stock (the &#8220;June 27 Warrants&#8221;).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShortTermDebtDescription_c20240627__20240627_zsH3tYKPYR06" title="Notes payable description">The
    June 27 Notes bear simple interest at a rate of 3% per annum and are due and payable in cash on the earlier of: (a) 12 months
    from the date of the June 27 Note; or (b) the date the Company raises third-party equity capital in an amount equal to or in excess
    of $1,000 (the &#8220;Maturity Date&#8221;). The Company may prepay the June 27 Notes at any time prior to the Maturity Date without
    penalty. If an event of default occurs, the then-outstanding principal amount of the June 27 Notes plus any unpaid accrued interest
    will accelerate and become immediately payable in cash.</span></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    of June 27 Warrants has an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240627_zriHWWg9YRhk" title="Warrants exercise price">4.95</span>
    per share. The June 27 Warrants are immediately exercisable and have a <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20240627_zGREZ9zlCaZ4" title="Warrants term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0838">5-year</span></span>
    term.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon initial recognition, the management allocated the gross cash proceeds received based on the relative fair value
of the June 27 Notes and the detachable June 27 Warrants in total amount of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfDebt_pn3n3_c20240627__20240627_zJngEYUKS1ga" title="Proceeds from notes">15</span> and $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20240627__20240627_zz49PcCQcMLh" title="Fair value of warrants">85</span>, respectively. The fair value of the June 27 Note
was determined based on a rating model using a debt discount rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20240627_zBw0S6KB0Nog" title="Debt discount rate">28.65</span>% which represented the Company&#8217;s applicable rate of risk.
The fair value of the June 27 Warrants was determined by using Black-Scholes pricing model taking into account, inter alia, expected stock
price volatility of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240627__20240627_zwAzZcOMetV8" title="Price volatility">245</span>% and risk-free interest rate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240627__20240627_zhS0SwSVZhVa" title="Risk free interest rate">4.52</span>%. The amount allocated to June 27 Warrants was classified as a component
of permanent equity (as their terms permit the holders to receive a fixed number of shares of common stock upon exercise for a fixed exercise
price).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    June 27 Notes are accounted for as a financial liability measured at amortized cost. In subsequent periods, the Company recognized a
    discount and interest expense over the economic life of the June 27 Notes based on the effective interest rate method.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tabular presentation reflects the reconciliation of the carrying amount of the June 27 Notes during
the period of nine months ended September 30, 2024:&#160;</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_ecustom--ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenWarrantsMember_ztHe4s0Y6vC" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zmhwp7QEQiti" style="display: none">SCHEDULE
OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenWarrantsMember_zq6138sou90d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine-month period ended<br/>
 September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>(Unaudited)</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_zqYDDjqLHFkl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Open balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0852">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfWarrants_pn3n3_zyhzU0eZMena" style="vertical-align: bottom; background-color: White">
    <td>Total proceeds received</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ProceedsFromAllocatedWarrantsAtInitialRecognition_pn3n3_zX9355DzW9V4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
proceeds allocated to June 27 Warrants at initial recognition</span></td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 18%">(85</td><td style="text-align: left; width: 1%">)</td></tr>
  <tr id="xdx_409_ecustom--DiscountAmortizationAndInterestExpenses_pn3n3_zE75HDXl0Vsd" style="vertical-align: bottom; background-color: White">
    <td>Discount amortization and interest expenses related to <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
27 Notes (Note 5 below)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--PartialConversionNotesAndAccruedInterest_pn3n3_zT1rqNwyyTs5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Partial conversion <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 27 Notes and accrued
Interest (Note 3I and Note 3J below)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(26</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--WarrantsAndRightsOutstanding_iE_pn3n3_zhz6ftz91vk2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_z0tPSidYjd83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the period commencing the issuance date through September 30, 2024,
none of the June 27 Warrants have been exercised.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 - SIGNIFICANT TRANSACTIONS (CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-size: 10pt"><b>G.</b></span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><b>Convertible Promissory Notes</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                                         July 18, 2024, the Company entered into a series of convertible promissory notes with three directors, and one member of the
                                                         Company&#8217;s executive management (the &#8220;July 18 Investors&#8221;), providing for the private placement of unsecured
                                                         convertible promissory notes in the aggregate principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240718__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z7fJNvPujgik" title="Debt instrument face amount">360</span>
                                                         (the &#8220;July 18 Notes&#8221; and each a &#8220;July 18 Note&#8221;).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    July 18 Notes bear simple interest at a rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240718__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z1HHp0TCjWbj" title="Debt instrument interest rate">8</span>%
    per annum. Interest on the outstanding principal will accrue and, unless converted earlier as set forth below, be due and payable on
    (i) the 12-month anniversary of the date hereof, or (ii) the closing date of a Qualified Financing, as defined herein (the
    &#8220;Maturity Date&#8221;).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
    regarding the conversion of the July 18 Notes as discussed below, the Company may not prepay the July 18 Notes without the written
    consent of the July 18 Investors. If not sooner repaid, all outstanding principal and accrued but unpaid interest on the July 18
    Notes (the &#8220;July 18 Note Balance&#8221;), as of the close of business on the day immediately preceding the date of the closing
    of the next issuance and sale of capital stock of the Company, in a single transaction or series of related transactions, to
    investors resulting in gross proceeds to the Company of at least $<span id="xdx_902_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20240718__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zsXQiQu4rIZ8" title="Gross proceeds from notes conversion">500</span>
    (excluding indebtedness converted in such financing) (a &#8220;Qualified Financing&#8221;), will automatically be converted into
    that number of shares of equity securities of the Company sold in the Qualified Financing equal to the number of shares calculated
    by dividing (X) the July 18 Note Balance by (Y) an amount equal to the price per share or other unit of equity securities issued in
    such Qualified Financing, and otherwise on the same terms as the security issued in the Qualified Financing, provided that the
    conversion price per share shall not be lower than $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240718__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z4eUBxeoaARb" title="Conversion price per share">1.56</span>.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    the occurrence of an Event of Default (as defined below), each July 18 Investors may, by written notice to the Company, declare the
    July 18 Note to be due immediately and payable with respect to the July 18 Note Balance. An &#8220;Event of Default&#8221; means (i)
    failure by the Company to pay the July 18 Note Balance on the Maturity Date, (ii) voluntary bankruptcy, or (iii) involuntary
    bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii) above, the July 18 Note Balance shall automatically
    and immediately become due and payable, in all cases without any action on the part of any July 18 Investors.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon initial date, the management measured the fair value of the embedded
conversion feature which is accounted for as embedded derivative liability. The difference between the total gross cash proceeds received
and the fair value of the embedded conversion feature is allocated to July 18 Notes that are measured at amortized cost under which in
subsequent periods the Company recognizes a discount expense over the economic life of the July 18 Notes based on the effective interest
rate method. However, the fair value of the embedded derivative liability related to the conversion feature was determined by the management
at an insignificant amount since upon closing of a Qualified Financing the conversion will be done based on market conditions (i.e. conversion
price will be equal to the fair value of the share upon conversion) and thus all proceeds received of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_pid_c20240718__20240718__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zpDthaLemiE2" title="Conversion price">360</span> were allocated to the July
18 Notes.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tabular presentation reflects the reconciliation of the carrying
amount of the July 18 Notes during the period of nine months ended September 30, 2024:&#160;</span></p></td></tr>
</table>

<p id="xdx_89F_ecustom--ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--JulyEighteenNotesMember_z1cKGNZR7vUa" style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zwhuunhzDGij" style="display: none">SCHEDULE
OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--JulyEighteenNotesMember_z5oURXRylszg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine-month period ended <br/>
September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ConvertibleDebt_iS_pn3n3_z2iF2SE7fnzd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Open balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfDebt_pn3n3_zF7GWCyQYXw" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Total proceeds allocated to July 18 Notes at initial recognition</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">360</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestExpense_pn3n3_zpZevaxptRE3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expenses related to July 18 Notes (Note 5 below)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PartialConversionAndAccruedInterest_pn3n3_zv1dVDK0cmVl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Partial conversion July 18 Notes and accrued Interest (Note 3J below)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(101</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--ConvertibleDebt_iE_z4h2ISWrdvL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">264</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A8_zvjwyH7nOxb" style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>



<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 - SIGNIFICANT TRANSACTIONS (CONT.)</b></span></p>


<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-size: 10pt"><b>H.</b></span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><b>Convertible Promissory Note and Warrant Agreements</b></span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    July 30, 2024, the Company entered into a convertible promissory note and three warrant agreements (the &#8220;July 30
    Warrants&#8221;) with an existing investor (the &#8220;July 30 Holder&#8221;), providing for the private placement of a secured
    convertible promissory note in the aggregate principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240730__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--WarrantsAgreementMember_z38Rua6Xufea" title="Debt instrument face amount">4,000</span>
    (the &#8220;July 30 Note&#8221;). The July 30 Note is not convertible until and unless approved at a meeting of the Company&#8217;s
    stockholders (the &#8220;Stockholder Approval&#8221;). </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
July 30 Note bears simple interest at a rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240730__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--WarrantsAgreementMember_zVKre55BlA8i" title="Debt instrument interest rate">8</span>%
per annum and is due and payable in cash on earlier of: <span id="xdx_909_eus-gaap--DebtInstrumentDescription_c20240730__20240730__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--WarrantsAgreementMember_z3mjP06wK9Mj" title="Debt instrument description">(i)
12 months anniversary of July 30 Note, or (ii) closing date of a Sale Transaction (defined below) (the &#8220;Maturity
Date&#8221;)</span>. The July 30 Note is secured by a first-priority security interest on all Company&#8217;s assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
regarding the conversion of the July 30 Note or a Sale Transaction as discussed below, the Company may not prepay the July 30 Note
without the written consent of the July 30 Holder. If Stockholder Approval is obtained, the July 30 Note <span id="xdx_90F_eus-gaap--DebtInstrumentDescription_c20240730__20240730__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zGGr5AJGdj7l" title="Debt instrument description">(i)
is convertible at the discretion of the July 30 Holder at a price equal to the closing price of the Common Stock on the date of
conversion and, (ii) if the Closing Price of the Common stock exceeds $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20240730__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_ztZiSbU2C6Xj" title="Sale of stock issued price per share">5.00</span>
per share for a period of 5 consecutive trading days, will automatically convert at a price equal to the 5 daily Volume Weighted
Average Price (&#8220;VWAP&#8221;) of the Common Stock (subject to adjustment for any stock split, stock dividend, reverse stock
split, combination or similar transaction).</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
Sale Transaction on or prior to the Maturity Date, the Company will repay the July 30 Holder, at the July 30 Holder&#8217;s
election, as follows: <span id="xdx_907_eus-gaap--SaleOfStockDescriptionOfTransaction_c20240730__20240730__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zjf1zIUFekU7" title="Sale of stock description of transaction">(i)
cash equal to 200% of the Note balance, or (ii) transaction consideration in the amount to be received by the Holder in such Sale
Transaction if the July 30 Note was converted pursuant to an optional conversion. &#8220;Sale Transaction&#8221; means a merger or
consolidation of the Company with or into any other entity, or a sale of all or substantially all of the Company&#8217;s assets, or any other transaction or series of related transactions in which the Company&#8217;s stockholders immediately prior
to such transaction(s) receive cash, securities or other property in exchange for their shares and, immediately after such
transaction(s), own less than 50% of the equity securities of the surviving corporation or its parent.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the occurrence of an Event of Default (defined below), the July 30 Holder may, by written notice to the Company, declare the Note to
be due immediately and payable with respect to the July 30 Note balance. An &#8220;Event of Default&#8221; means <span id="xdx_906_eus-gaap--DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault_c20240730__20240730_zfJPzROqFKAj" title="Debt description of notice of default">(i)
failure by the Company to pay the July 30 Note balance on the Maturity Date, (ii) the Company becomes subject to a judgement of more
than $<span id="xdx_904_eus-gaap--DebtDefaultLongtermDebtAmount_iI_pn3n3_c20240730_zP2KMCyVHcE6" title="Debt default long term debt amount">50,000</span>,
(iii) voluntary bankruptcy, or (iv) involuntary bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii)
above, the July 30 Note balance shall automatically and immediately become due and payable, in all cases without any action on the
part of the July 30 Holder.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
July 30 Warrant becomes exercisable 12 months after its issuance and has term of <span id="xdx_901_eus-gaap--DebtInstrumentTerm_dtY_c20240730__20240730_zJduixxhgpdk">10
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years. The July 30 Warrants are exercisable for
cash only and have no price-based antidilution. The first July 30 Warrant is for <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240730__20240730__us-gaap--StatementEquityComponentsAxis__custom--FirstWarrantMember_zqTbmwV8W7kc">2,133,334
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240730__us-gaap--StatementEquityComponentsAxis__custom--FirstWarrantMember_z8ZsNrZqH5Zd" title="Exercise price">1.875
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The second July 30 Warrant is for
<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240730__20240730__us-gaap--StatementEquityComponentsAxis__custom--SecondWarrantMember_zhP7ZBPUM3z">1,523,810
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares at $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240730__us-gaap--StatementEquityComponentsAxis__custom--SecondWarrantMember_zdDCUegw3YBe" title="Exercise price">2.625
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The third July 30 Warrant is for <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240730__20240730__us-gaap--StatementEquityComponentsAxis__custom--ThirdWarrantMember_zYV4mNMoM6M2">1,185,186
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares at $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240730__us-gaap--StatementEquityComponentsAxis__custom--ThirdWarrantMember_zbLOxZG0Utj" title="Exercise price">3.375
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the initial date, the Company has issued two instruments that include (i) a financial instrument that is considered as &#8220;host&#8221;
which comprised of July 30 Note and two embedded derivative financial instruments (i.e. an embedded conversion feature and an embedded
redemption feature to receive cash equals to <span id="xdx_90F_ecustom--EmbeddedConversionFeaturePercentage_iI_pid_dp_c20240730_zHpOGMbkvSf2" title="Embedded conversion feature percentage">200</span>% of July 30 Note balance upon Sale Transaction) and (ii) three series of detachable
warrants. At the initial date, the Company is required to estimate the fair value of both two instruments and allocate the total gross
proceeds received between them based on that relative fair value identified. The fair value of the embedded derivative financial instruments
(i.e. the conversion right and the redemption right) should be bifurcated from the host instrument and remeasured on recurring basis
at each reporting period under marked to market approach, the July 30 Note is accounted for under carrying amount whereby discount and
interest expenses are recorded over the economic life of the July 30 Note based on the effective interest rate method and the July 30
Warrants are classified into equity without any further subsequent measurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 - SIGNIFICANT TRANSACTIONS (CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible
    Promissory Note and Warrant Agreements (Cont.)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
                                                         initial recognition, the management by using the assistance of an external appraiser allocated the gross cash proceeds received
                                                         based on the relative fair value of the July 30 Note and the detachable July 30 Warrants in total amount of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfDebt_c20240730__20240730_zcvcskdIz6L" title="Proceeds from notes">1,450</span>
                                                         and $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20240730__20240730_zBb7XG2JF2rc" title="Fair value of warrants">2,550</span>,
                                                         respectively. The fair value of the convertible note was determined by using hybrid method that includes conversion
                                                         scenario and liquidation scenario taking into account, inter alia, a debt discount rate of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20240730_zr46TEhAsdIk" title="Debt discount rate">28.65</span>%.
                                                         The fair value of the July 30 Warrants was determined by using Black-Scholes pricing model taking into account, inter alia, expected
                                                         stock price volatility of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240730__20240730_z7P6OiQpLtof" title="Volatility">122.8</span>%
                                                         and risk-free interest rate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240730__20240730_za4oQLVx6iI5" title="Risk- free interest rate">4.78</span>%.
                                                         The amount allocated to July 30 Warrants was classified as a component of permanent equity (as their terms permit the holders to
                                                         receive a fixed number of shares of common stock upon exercise for a fixed exercise price).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
it was determined that the embedded conversion feature and embedded redemption feature are required to be bifurcated from the host loan
instrument. The fair value of the bifurcated derivatives was determined by the management using the assistance of an external appraiser
in a total amount of $<span id="xdx_903_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_pn3n3_c20240730_zhLPZmjp7eU3" title="Fair value of embedded derivative liability">35
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon initial recognition and in subsequent periods
as derivative liability at fair value through profit and loss. The remaining amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240730_z41X6Q5ys25k">1,415
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">was allocated to the host loan instrument which
in subsequent periods is accounted for using the effective interest method over the term of the loan, until its stated maturity.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    following tabular presentation reflects the reconciliation of the carrying amount of the July 30 Note during the period of nine months
    ended September 30, 2024:</span></p></td></tr>
  </table>
<p id="xdx_898_ecustom--ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--JulyThirteenNotesMember_zYc0P3ckmT7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="display: none"><span id="xdx_8B2_z3vRAylczGji">SCHEDULE
OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY  30 NOTES</span></span></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--JulyThirtyNotesMember_zdScknDfgcK7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine-month period ended <br/>
September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ConvertibleDebt_iS_pn3n3_z52nzxn0zku7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Open balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromIssuanceOfDebt_pn3n3_zL8inGKJRWpb" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Total proceeds received</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">4,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_zqFwYLU1yITe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total proceeds allocated to July 30 Warrants at initial recognition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,550</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_pn3n3_zv82Po9flfcg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total proceeds allocated to embedded redemption feature at initial recognition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(35</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--DiscountAmortizationAndInterestExpenses_pn3n3_zW1ptRHkBZxf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Amortization of discount and interest expenses related to July 30 Note (Note 5 below)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">309</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ConvertibleDebt_iE_pn3n3_zC5jJ7G5R526" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,724</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zESJf0AQXKE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89E_ecustom--ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock_zXF9TfCc680g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tabular presentation reflects the reconciliation of the fair value of the embedded conversion feature and embedded redemption
feature during the period of nine months ended September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zuF3YLAqrakf" style="display: none">SCHEDULE
OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20240930_zt5zN59dkSx8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine-month period ended <br/>
September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DerivativeLiabilities_iS_zozdHaCn3yp4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Open balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0943">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_pn3n3_zP200s6qmuRd" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Proceeds allocated to embedded redemption feature at initial recognition</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">35</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--RevaluationExpensesRelatedToEmbeddedRedemptionFeature_pn3n3_zihVxNPa8Od1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Revaluation expenses related to embedded redemption feature (Note 5 below)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DerivativeLiabilities_iE_zkchSUvzHfM1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zapTcKaPmV92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 24, 2024, the Company held a special meeting of its stockholders under which shares of common stock issuable by the Company
upon conversion of the July 30 Note and exercise of the July 30 Warrants has been approved. However, through September 30, 2024, July
30 Holder has not elected to trigger the conversion of July 30 Note or the exercise of the July 30 Warrants into shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 - SIGNIFICANT TRANSACTIONS (CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>August 23
    Conversion</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    August 23, 2024 (the &#8220;Commitment Date&#8221;), the Company and two of June 27 Investors entered into conversion agreement,
    under which the Company agreed to convert the principal nominal amount plus any accrued but unpaid interest pursuant to each of June
    27 Notes, totalling approximately $<span id="xdx_90F_eus-gaap--InterestExpense_pn3n3_c20240823__20240823__us-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenNotesMember_zWxpyAz6cV45" title="Interest expense">20</span> each (the &#8220;Debt&#8221;), held by the Investors to Common Stock at a conversion price
    of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240823__us-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenNotesMember_zVdF1YSkjFs9" title="Conversion price">1.02</span> per share. On October 15, 2024, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20241015__20241015__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIHLNVy4FjEb" title="Stock issued during period shares issued for services">19,682</span> shares of common stock for each of the two of the June 27 Investors
    in respect of each respective Debt converted.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    satisfaction of the Debt, the Company also issued to each of the two June 27 Investors three warrants (each an &#8220;August 23 Warrant&#8221;).
    Each August 23 Warrant becomes exercisable on <span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240823__20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantMember_zOolTvNjVPF8" title="Warrants exercisable">August 16, 2025</span> and has term of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantMember_zPIvgDc6Wy7a" title="Warrants and rights outstanding term::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0959">10</span></span> years. The August 23 Warrants are exercisable for
    cash only and have no price-based antidilution. The first August 23 Warrant is for <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantOneMember_zgKCXWgB51w2" title="Class of warrant or right number of securities called by warrants or rights">10,707</span> shares of Common Stock and is exercisable
    at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantOneMember_zqHZ1Vlj9dPb" title="Exercise price">1.875</span> per share. The second August 23 Warrant is for <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantTwoMember_zT1svfPEATIc" title="Class of warrant or right number of securities called by warrants or rights">7,648</span> shares of Common Stock, exercisable at $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantTwoMember_zMDZF2QlRRbe" title="Exercise price">2.625</span> per share. The third
    August 23 Warrant is for <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantThreeMember_zcJiiOjJZ0Ja" title="Class of warrant or right number of securities called by warrants or rights">5,948</span> shares of Common Stock, exercisable at $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantThreeMember_zBHRahYCFjc2" title="Exercise price">3.375</span> per share.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    above transaction was accounted for as settlements of financial liabilities under which the instruments issued or to be issued to
    the June 27 Investors (i.e. shares of common stock and August 23 Warrants) are eligible for equity classification and thus both have
    been recorded as part of the permanent equity based on the total fair value of $<span id="xdx_904_eus-gaap--EquityFairValueDisclosure_iI_pn3n3_c20240823_zZiLMCIoNcoh" title="Equity fair value disclosure">238</span> at the Commitment Date. The difference between
    the fair value of these equity instruments and the carrying amount of each of the respective Debt at the Commitment Date amounted
    to $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240823_zsJluKmFvjaa" title="Debt instrument face amount">11</span> was charged immediately to the finance expenses (see also Note 5 below).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the period commencing the issuance date through September 30, 2024, none of the August 23 Warrants have been exercised.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sep 5 Conversion</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    September 5, 2024 (the &#8220;Commitment Date&#8221;), the Company and one of June 27 Investors and July 18 Investors entered into
    a conversion agreement, under which the Company agreed to convert outstanding board fees amounted $<span id="xdx_90F_eus-gaap--InterestExpense_pn3n3_c20240905__20240905__us-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenNotesMember_zhbP7e0kpav1" title="Interest expense">113</span> and the principal nominal
    amount plus any accrued but unpaid interest pursuant to June 27 Note and July 18 Note, totalling $<span id="xdx_909_eus-gaap--InterestExpense_pn3n3_c20240905__20240905__us-gaap--StatementEquityComponentsAxis__custom--JulyEighteenNotesMember_zooXaIH17PN7" title="Interest expense">146</span> (referring together as a &#8220;Debt&#8221;),
    held by the Investor to Common Stock at a conversion price of $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240823__us-gaap--StatementEquityComponentsAxis__custom--JulyTwentySevenNotesMember_zsDO7fWyYe1g" title="Conversion price">1.02</span> per share. On October 15, 2024, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20241015__20241015__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenNotesMember_zeUrn5PRxDO9" title="Stock issued during period shares issued for services">254,226</span> shares
    of common stock for the June 27 Investor in respect of the Debt converted.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    satisfaction of the Debt, the Company also issued to June 27 Investor and July 18 Investor three warrants (each an &#8220;September
    5 Warrant&#8221;). Each September 5 Warrant becomes exercisable on <span id="xdx_904_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240905__20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsMember_zkAfYk20Ghab" title="Warrants exercisable">August 16, 2025</span> and has term of <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsMember_zV8yWD4JRDWh" title="Warrants and rights outstanding term::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0987">10</span></span> years. The September 5 Warrants
    are exercisable for cash only and have no price-based antidilution. The first September 5 Warrant is for <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsOneMember_zMPLfHDDzBx4" title="Class of warrant or right number of securities called by warrants or rights">138,299</span> shares of Common
    Stock and is exercisable at $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsOneMember_z77WflL0Wfy8" title="Exercise price">1.875</span> per share. The second September 5 Warrant is for <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsTwoMember_z2GIl1yqeUb2" title="Class of warrant or right number of securities called by warrants or rights">98,785</span> shares of Common Stock, exercisable at
    $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsTwoMember_zz1Ym84sgTie" title="Exercise price">2.625</span> per share. The third September 5 Warrant is for <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsThreeMember_zaKm6gzzUXv5" title="Class of warrant or right number of securities called by warrants or rights">76,833</span> shares of Common Stock, exercisable at $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsThreeMember_zShYVelRWV1e" title="Exercise price">3.375</span> per share.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    above transaction was accounted for as settlements of financial liabilities under which the instruments issued or to be issued to
    the July 18 Investor (i.e. shares of common stock and September 5 Warrants) are eligible for equity classification and thus both
    have been recorded as part of permanent equity based on the total fair value of $<span id="xdx_901_eus-gaap--EquityFairValueDisclosure_iI_pn3n3_c20240905_zIQnmVLV7pRd" title="Equity fair value disclosure">1,505</span> at the Commitment Date. The difference between
    the fair value of these equity instruments and the carrying amount of the Debt at the Commitment Date amounted to $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240905_znjTytI72ePi" title="Debt instrument face amount">227</span> was charged
    immediately to the finance expenses (see also Note 5 below).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the period commencing the issuance date through September 30, 2024, none of the September 5 Warrants have been exercised.</span></p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_DisclosureSignificantTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_DisclosureSignificantTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_SignificantTransactionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Transactions [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_SignificantTransactionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233097826784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENT LIABILITIES</a></td>
<td class="text"><p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zCOc37QMoXDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 - <span id="xdx_822_zdDaUGCzfqad">COMMITMENTS AND CONTINGENT LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    2004, the Israeli Innovation Authority (IIA) provided Integrity Israel with a grant of approximately $<span id="xdx_908_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember_zaHViVdRghJ1">93</span>
    (NIS <span id="xdx_90E_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pp0p0_uIsrael_c20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember_zhBK2jlcIrLh">420,000</span>),
    for develop a non-invasive blood glucose monitor (the &#8220;Development Plan&#8221;). Integrity Israel is required to pay royalties
    to IIA at a rate ranging between <span id="xdx_90B_ecustom--RoyaltyPercentage_pid_dp_uPure_c20040303__20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember__srt--RangeAxis__srt--MinimumMember_zunJ0lR75WF5" title="Royalty percentage minimum">3</span>-<span id="xdx_903_ecustom--RoyaltyPercentage_pid_dp_uPure_c20040303__20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember__srt--RangeAxis__srt--MaximumMember_zxphyp4Enfx8" title="Royalty percentage maximum">5</span>%
    of the proceeds from sale of the Company&#8217;s products arising from the Development Plan up to an amount equal to $<span id="xdx_906_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pp0p0_c20040304__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember_zPm8IVWj1hOj" title="Business combination contingent consideration liability">93</span>,
    plus interest at LIBOR from the grant date. As to replacement of the LIBOR benchmark rate, even though the IIA has not
    declared the alternative benchmark rate to replace the LIBOR, the Company does not believe it will have a significant impact. As of
    September 30, 2024, the remaining contingent liability with respect to royalty payment on future sales equals approximately $<span id="xdx_90D_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pp0p0_c20240930__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember_zGM71gfi1iJ4" title="Contingent consideration liability">73</span>,
    excluding interest. Such contingent obligation has no expiration date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    October 7, 2022 (&#8220;the Closing Date&#8221;), the Company entered into Intellectual Property Purchase Agreement (the &#8220;Agreement&#8221;)
    with Paul Goode, which is the Company&#8217;s Chief Executive Officer (the &#8220;Seller&#8221;), under which it was agreed that
    on and subject to the terms and conditions of the Agreement, at the Closing Date, Seller sold and assigned to the Company, all of Seller&#8217;s right, title and interest in and to the following assets, properties and rights (collectively,
    the &#8220;Purchased Assets&#8221;): (i) all rights, title, interests in all current and future intellectual
property, including, but not limited to patents, trademarks, trade secrets, industry know-how and other IP rights relating to an implantable
continuous glucose sensor (collectively, the &#8220;Conveyed Intellectual Property&#8221;); and (ii) all the goodwill relating to the
Purchased Assets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    consideration for the sale of the Purchased Assets to the Company, at the Closing Date, the Company paid to Seller cash
    in the amount of one dollar and obligated to issue up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221007__20221007__us-gaap--TypeOfArrangementAxis__custom--IntellectualPropertyPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXEZOIwXqj5i" title="Number of common shares issued">200,000</span> shares of Common Stock to be issued based upon specified performance
    milestones as set forth in the Agreement (the &#8220;Purchase Price&#8221;). In addition, if upon the final issuance, the aggregate
    <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221007__20221007__us-gaap--TypeOfArrangementAxis__custom--IntellectualPropertyPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zrtE6UgOrJne" title="Number of common shares issued">200,000</span> shares represent less than <span id="xdx_905_ecustom--AggregateSalesPriceOfUnitsPercentage_iI_pid_dp_uPure_c20221007__us-gaap--TypeOfArrangementAxis__custom--IntellectualPropertyPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zCCi3QJaefZ3" title="Commission as a percentage of aggregate sales price">1.5</span>% of the then outstanding Common Stock of the Company, the final issuance will include such
    number of additional shares so that the total aggregate issuance equals <span id="xdx_900_ecustom--AggregateSalesPriceOfUnitsPercentage_iI_pid_dp_uPure_c20221007__us-gaap--TypeOfArrangementAxis__custom--IntellectualPropertyPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__custom--TrueupSharesMember_z9Vfinwd0cze" title="Commission as a percentage of aggregate sales price">1.5</span>% of the outstanding shares (the &#8220;True-Up Shares&#8221;).
    All shares of Common Stock of the Company that will be issued under the agreement shall be (i) restricted over a limited period
    as defined in the Agreement and (ii) subject to the lockup provisions.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
    the Company acquires net assets that do not constitute a business, as defined under ASU 2017-01 Business Combinations (Topic 805)
    Clarifying the Definition of a Business (such when there is no substantive process in the acquired entity) the transaction is accounted
    for as asset acquisition and no goodwill is recognized. The acquired In-Process Research and Development intangible asset (&#8220;IPR&amp;D&#8221;)
    to be used in research and development projects which have been determined not to have alternative future use at the acquisition
    date, is expensed immediately.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    the Closing Date, it was determined that the asset acquisition represents the purchase of IPR&amp;D with no alternative future use.
    However, the achievement of each of the performance milestones is considered as a contingent event outside the Company&#8217;s
    control and thus the contingent consideration which is equal to the fair value of the Purchase Price as measured at the Closing Date
    will be recognized when it becomes probable that each target will be achieved within the reasonable period. Such additional
    contingent consideration will be recognized in subsequent periods if and when the contingency (the achievement of targets) is
    resolved.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    June 2023, the Company achieved the first performance milestone out of the five performance milestones outlined in the Agreement
    executed between the Company and the Seller as of the Closing Date. As a result, upon the date of the fulfilment of the first performance
    milestone the Company was committed to issue <span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesRestrictedStock_pid_c20230601__20230620_z25ocrgRy8S8" title="Restricted shares to the seller">20,000</span> restricted shares to the Seller. Accordingly, the Company recorded an amount
    of $<span id="xdx_906_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_c20240101__20240930_zSuklHwUuhGb" title="Research and development expenses">131</span> as research and development expenses with a similar amount as an increase to additional paid-in capital. The first performance
    milestone shares were issued on February 6, 2024.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    May 2024, the Company achieved the second performance milestone out of the five performance milestones outlined in the Agreement
    executed between the Company and the Seller as of the Closing Date. As result, the Company is committed to issue <span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesRestrictedStock_pid_c20240501__20240531_z0lpNVaxB1S6" title="Restricted shares">30,000</span> restricted
    shares to the Seller. Accordingly, the Company recorded stock-based compensation expenses amounted to $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZzAsjd0Z9tl" title="Stock based compensation">192</span> which represents the
    quoted price of its Common Stock at the Closing Date, after taking into consideration a discount for lack of marketability in a rate
    of <span id="xdx_906_ecustom--MarketabilityDiscountRate_pid_dp_uPure_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSM3uI0t0A02" title="Discount rate">30</span> % over the applicable restriction period. As of September 30, 2024, the second performance milestone shares were not yet issued.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of September 30, 2024, the achievement of all other remaining performance milestones was not considered probable and thus no
    stock-based compensation expenses were recorded with respect to thereof.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233097837168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCE (INCOME) EXPENSES, NET<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FINANCE (INCOME) EXPENSES, NET</a></td>
<td class="text"><p id="xdx_809_eus-gaap--FinancialInstrumentsDisclosureTextBlock_zwBry1e2Aijg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 - <span id="xdx_82D_z1HgvlIKamTb">FINANCE (INCOME) EXPENSES, NET</span></b></span></p>

<p id="xdx_893_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zauJhdSM0g7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zDk8QpTWxw05" style="display: none">SCHEDULE
OF FINANCE EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20240701__20240930_zFF3zx8ch3R" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20230701__20230930_zuGbgWYkprh8" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20240101__20240930_zGqfKKbestH2" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20230101__20230930_z6aWwu5CAgM5" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three-month period ended<br/>
 September
    30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine-month period ended<br/>
 September
    30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_ecustom--DiscountAmortizationAndInterestExpensesOne_msFINztjv_zhyhrts5GOFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; width: 40%; text-align: left">Discount amortization and interest expenses related to June 27 Notes</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">16</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1040">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">16</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1042">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InterestExpense_msFINztjv_zlTcp83Lkpjj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expenses related to July 18 Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1045">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DiscountAmortizationAndInterestExpensesTwo_msFINztjv_z9b63atu2dth" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; text-indent: -10pt">Discount amortization and interest expenses related to July 30 Note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--RevaluationExpensesRelatedToDerivativeFinancialLiabilities_pn3n3_msFINztjv_zezxB21JZ20i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; text-indent: -10pt">Revaluation expenses related to derivative financial liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1055">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1057">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities_pn3n3_msFINztjv_zmxtjfjUkxt3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; text-indent: -10pt">Revaluation expenses incurred from settlement of financial liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,505</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,505</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InterestExpenseDeposits_pn3n3_msFINztjv_zXVl7imz3jTk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest on bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(38</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherExpenses_pn3n3_msFINztjv_zd1FJnu5PiL" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; text-indent: -10pt">Exchange rate differentials, bank commissions and miscellaneous</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1070">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--FinanceIncomeNet_iNT_pn3n3_di_mtFINztjv_zV1QX83jCJJ6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance (income) expenses,
    net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,848</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,822</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233185747312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zFTwVRbQnGqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 - <span id="xdx_82B_zqoEpMyZAPt">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed interim consolidated financial statements were available to be issued. Based upon this review, the Company did not identify any other significant subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below.</span></p>



<p style="margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Completion
of underwritten U.S. public offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2024, the Company completed a public offering (the &#8220;Offering&#8221;) under which the Company received gross proceeds
of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20241112__20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpSI7AiY6Yh3" title="Gross proceeds from public offering">10,000</span> in exchange for issuance of an aggregate of (i) <span id="xdx_90A_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1tP9c9SG7M" title="Shares issued">2,437,340</span> shares (the &#8220;Shares&#8221;) of its Common Stock, (ii) <span id="xdx_90B_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zXoTQPrrcpu5" title="Shares issued">4,756,900</span>
pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to an aggregate of <span id="xdx_90B_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z1bGPQv2CdIa" title="Shares issued">4,756,900</span> shares of Common Stock (the &#8220;Pre-Funded
Warrant Shares&#8221;) in lieu of Shares, (iii) Series A Warrants (the &#8220;Series A Warrants&#8221;) to purchase up to <span id="xdx_909_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesACommonWarrantMember_zSc1j3V7lBt4" title="Shares issued">7,194,240</span> shares
of Common Stock (the &#8220;Series A Warrant Shares&#8221;) and (iv) Series B Warrants (the &#8220;Series B Warrants&#8221; and, together
with the Series A Warrants, the &#8220;Common Warrants&#8221;) to purchase up to <span id="xdx_90C_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBCommonWarrantMember_zCY3WAecN04a" title="Shares issued">7,194,240</span> shares of Common Stock (&#8220;the &#8220;Series
B Warrant Shares&#8221; together with the Series A Warrant Shares, the &#8220;Warrant Shares&#8221;). Each Share or Pre-Funded Warrant,
as applicable, was sold together with one Series A Warrant to purchase one share of Common Stock and one Series B Warrant to purchase
one Common Share. The public offering price for each Share and accompanying Common Warrants was $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--PrefundedWarrantsMember_zzpcZaXFd25" title="Shares issued, per share">1.39</span>, and the public offering price
for each Pre-Funded Warrant and accompanying Common Warrants was $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z668fmof9Om7" title="Shares issued, per share">1.389</span> (the &#8220;Offering Price&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Pre-Funded Warrants have an exercise price of $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zsVYEpqkpIf7" title="Share price">0.001</span> per share, are exercisable immediately and expire when exercised in full. Each Series
A Common Warrant will have an exercise price per share of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesACommonWarrantMember_zXzfJApE7vL4" title="Warrant, exercise price">1.81</span> and will be exercisable beginning on the date on which Stockholder
Approval (as defined below) is received and deemed effective (the &#8220;Initial Exercise Date&#8221; or the &#8220;Stockholder Approval
Date&#8221;). The Series A Warrants will expire on the five-year anniversary of the Initial Exercise Date. The Series B Warrants will
have an exercise price per share of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBCommonWarrantMember_z4d9LMCKojVg" title="Warrant, exercise price">1.81</span> and will be exercisable beginning on the Initial Exercise Date. The Series B Warrants
will expire on the two and one-half year anniversary of the Initial Exercise Date. The issuance of Common Warrant Shares upon exercise
of the Common Warrants is subject to stockholder approval under applicable rules and regulations of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;)
(&#8220;Stockholder Approval&#8221; and the date on which Stockholder Approval is received and deemed effective, the &#8220;Stockholder
Approval Date&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price of Series A Warrants and Series B Warrants is subject to certain adjustments. If at the time of exercise there is no effective
registration statement registering, or the prospectus contained therein is not available for the issuance of the Series A Warrants Shares
and Series B Warrant Shares to the holders, then the Series A Warrants and Series B Warrants may also be exercised, in whole or in part,
at such time by means of a &#8220;cashless exercise&#8221;. In addition, the holders are entitled to an option to require the Company
to purchase the Series A Warrants and Series B Warrants for cash in an amount equal to their Black-Scholes Option Pricing Model value,
in the event that certain fundamental transactions (which some of them are not considered solely within the control of the Company) as
defined in the Series B Warrants agreement, occur. Additionally, holders of Series B Warrants may also effect an &#8220;alternative cashless
exercise&#8221; at any time while the Series B Warrants are outstanding following the Initial Exercise Date. Under the alternate cashless
exercise option, the holder of the Series B Warrant has the right to receive an aggregate number of shares equal to the product of (i)
the aggregate number of shares of Common Stock that would be issuable upon a cashless exercise of the Series B Warrant and (ii) 3.0.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
incremental and direct issuance costs are estimated at the total amount of $<span id="xdx_90A_eus-gaap--PaymentsOfDebtIssuanceCosts_pn3n3_c20241112__20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPu6cLA8K3w9" title="Incremental and direct issuance costs">1,127</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
closing of the public offering occurred on November 14, 2024 (the &#8220;Closing Date&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a private placement offering completed&#160; concurrently with the completion of the public offering, the July 30 Investor voluntarily
converted &#160;approximately $<span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn3n3_c20241112__20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--JulyThirtyNotesMember_z9NM5WmfsPJ4" title="Debt conversion converted instrument amount">4,089</span> of Debt, which represents the outstanding minimal amount of principal and accrued interest under
the July 30 Note as of November 12, 2024, on substantially the same terms as the public offering, resulting in the issuance of <span id="xdx_906_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--JulyThirtyNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zILd82iiKKig" title="Stock issuance">2,640,717</span>
shares of Common Stock (plus <span id="xdx_908_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--JulyThirtyNotesMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesACommonWarrantMember_zJv0FEwEYMm3" title="Stock issuance">2,640,717</span> accompanying Series A Warrants and <span id="xdx_90C_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--JulyThirtyNotesMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCommonWarrantMember_zhrDrbg04nW7" title="Stock issuance">2,640,717</span> accompanying Series B Common Warrants), based on
a conversion price of $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--JulyThirtyNotesMember_zoxmTKBDtus" title="Conversion price, per share">1.55</span> per share.</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233098000048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_847_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zBk6y2rc9TH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zE5VrcHnpgzg">Basis
    of Presentation</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    accompanying unaudited condensed interim consolidated financial statements and related notes should be read in conjunction with the
    Company&#8217;s consolidated financial statements and related notes included in the Company&#8217;s annual report on Form 10-K for
    the fiscal year ended December 31, 2023, as was filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 28,
    2024. The unaudited condensed interim consolidated financial statements have been prepared in accordance with the rules and regulations
    of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures
    normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial
    information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary
    to present fairly the results of the Company&#8217;s financial position and operating results for the interim periods. All such adjustments
    are of a normal recurring nature.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    results for the period of three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected
    for the year ending December 31, 2024 or for any other interim period or for any future period.</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates in the Preparation of Financial Statements</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--UseOfEstimates_zRBBoArUAa42" style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z7LpEpyqQxfl">Use
    of Estimates in the Preparation of Financial Statements</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates
    and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities
    at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could
    differ from those estimates. As applicable to these interim financial statements, the most significant estimates and assumptions include identification and measurement of financial instruments.</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zmLrlRp17BSa" style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zttyu0kFfb0a">Principles
    of Consolidation</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    condensed interim consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany
    balances and transactions have been eliminated in consolidation.</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zdGHStKilDFl" style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_ztmSw1zOzLMh">Cash
    and Cash Equivalents</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    equivalents are short-term highly liquid investments which include short-term bank deposits (up to three months from date of deposit),
    that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as
    of the date acquired.</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_ModificationOfEquityClassifiedContractsPolicyTextBlock', window );">Modification of equity-classified contracts</a></td>
<td class="text"><p id="xdx_84D_ecustom--ModificationOfEquityClassifiedContractsPolicyTextBlock_z8qXmJM3USR6" style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_z1Av9IYetR81">Modification
    of equity-classified contracts</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    modification or exchange of equity-classified contracts, such as warrants that were classified as equity before the modification
    or exchange and remained eligible for equity classification after the modification, is accounted for in a similar manner to a modification
    of stock-based compensation. Accordingly, the incremental fair value from the modification or exchange (the change in the fair value
    of the instrument before and after the modification or exchange) is recognized as a reduction of retained earnings of increase of
    accumulated deficit as a deemed dividend. Modifications or exchanges that result in a decrease in the fair value of an equity-classified
    share-based payment awards are not recognized. In addition, the amount of the deemed dividend is also recognized as an adjustment
    to earnings available to common shareholders for purposes of calculating earnings per share.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_ConvertiblePromissoryNotesPolicyTextBlock', window );">Convertible Promissory Notes</a></td>
<td class="text"><p id="xdx_84A_ecustom--ConvertiblePromissoryNotesPolicyTextBlock_zkZ8o3MQtn6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zLDCavFUdVDf">Convertible Promissory Notes</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    initial recognition of convertible promissory notes and similar instruments, the Company considers the provisions of ASC 815-40,
    &#8220;Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity&#8221; (&#8220;ASC 815-40&#8221;) in order to determine whether
    the conversion features embedded within the convertible instrument should be separated from the host instrument.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
    it is determined that an embedded derivative required to be bifurcated (such as embedded conversion feature that does not qualify
    for equity classification), the Company recognized the embedded derivative bifurcated as a separate derivative liability upon
    initial recognition and on subsequent periods at fair value. The remaining consideration amount received or allocated to the entire
    convertible instrument is allocated to the host debt instrument. The difference between the face value of the host and such an
    allocated amount represents a discount which is amortized as finance expense to profit or loss using an effective interest method
    over the term of the note until its stated maturity.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
    it is determined that the embedded conversion feature qualifies for equity classification (such when the embedded conversion option,
    if it were freestanding, is not qualified as a derivative in accordance with the provisions of ASC 815-10, &#8220;Derivatives and
    Hedging&#8221; since its terms did not require or permit net settlement or when the embedded conversion option is indexed to the
    entity&#8217;s own stock), the conversion option is not bifurcated. When bifurcation is not required, the Company considers whether
    the debt instrument involves a significant premium (i.e. when the proceeds received or allocated upon issuance exceed the principal
    amount that will be paid at maturity). When it is determined that a substantial premium exists, the entire premium is allocated to
    paid-in capital and when it is determined, otherwise no additional accounting is required and the convertible promissory note is
    accounted for at amortized cost using effective interest method over the term of the note until its stated maturity.</span></p></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock', window );">Allocation of proceeds and related issuance costs</a></td>
<td class="text"><p id="xdx_847_ecustom--AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock_zskbeHi3THyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zwlQGZrpQPe7">Allocation
    of proceeds and related issuance costs</span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
    multiple instruments are issued in a single transaction (package issuance), the total net proceeds from the transaction are allocated
    among the individual freestanding instruments identified. The allocation occurs after identifying all freestanding instruments and
    the subsequent measurement basis for those instruments.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    instruments that are required to be subsequently measured at fair value (such as derivative liabilities) are measured at fair value
    and the remaining consideration is allocated to other financial instruments that are not required to be subsequently measured at
    fair value (such as liabilities measured at amortized cost, common shares and warrants eligible for equity classification), based
    on the relative fair value basis for such instruments.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    costs allocated to financial instruments that are required to be subsequently measured at fair value immediately expensed. Issuance
    costs allocated to shares and warrants classified as equity components and are recorded as a reduction of additional paid-in capital.
    Issuance costs allocated to financial liabilities measured at amortized cost are recorded as a discount and accreted over the contractual
    term of the financial instrument using the effective interest method.</span></p></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>



<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_840_eus-gaap--DerivativesPolicyTextBlock_zTw3FWwKVhEd" style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zjqH5CCt7BB">Warrants</span></b></span></td></tr>
  </table>
<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    warrants that were issued to several holders are classified as a component of permanent equity since they are freestanding financial
    instruments that are legally detachable and separately exercisable, do not embody an obligation for the Company to repurchase its
    own shares, and permit the holders to receive a fixed number of Ordinary Shares upon exercise for a fixed exercise price and thus,
    are considered as indexed to the Company&#8217;s own shares. As such warrants were issued together with financial instruments that
    are not subsequently measured at fair value and the warrants were measured based on allocation of the proceeds received by the Company
    in accordance with the relative fair value basis. When applicable, direct issuance expenses that were allocated to certain warrants
    were deducted from additional paid-in capital.</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_840_eus-gaap--LesseeLeasesPolicyTextBlock_zHAYzcA7DY9f" style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zRB01wOYGo4b">Leases</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company applies ASC Topic 842, &#8220;Leases&#8221; (&#8220;ASC 842&#8221;) under which the Company determines if an arrangement
    is a lease at inception.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
    are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following
    criteria are met: (i) the lease transfers ownership of the asset by the end of the lease term, (ii) the lease contains an option
    to purchase the asset that is reasonably certain to be exercised, (iii) the lease term is for a major part of the remaining useful
    life of the asset, (iv) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset,
    or (v) the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end
    of lease term. A lease is classified as an operating lease if it does not meet any one of these criteria. Since all the Company&#8217;s
    lease contracts for premises do not meet any of the criteria above, the Company concluded that all its lease contracts should be
    classified as operating leases.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    of Use (&#8220;ROU&#8221;) assets and liabilities are recognized on the commencement date based on the present value of remaining
    lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the
    time of commencement. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its Incremental Borrowing
    Rate (&#8220;IBR&#8221;) based on the information available on the commencement date in determining the present value of lease payments.
    The Company&#8217;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments
    and in economic environments where the leased asset is located. The ROU asset also includes any lease payments made prior to commencement
    and is recorded net of any lease incentives received. Moreover, the ROU asset may also include initial direct costs, which are incremental
    costs of a lease that would not have been incurred if the lease had not been obtained. The Company uses the long-lived assets impairment
    guidance in ASC 360-10, &#8220;Property, Plant, and Equipment - Overall&#8221;, to determine whether a ROU asset is impaired, and
    if so, the amount of the impairment loss to recognize. Certain leases include options to extend or terminate the lease. An option
    to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain
    that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company
    will not exercise the option.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands of US Dollars)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and diluted loss per share</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zYpF2IOulXnk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zajuTRwUQnY8">Basic
    and diluted loss per share</span></b></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
                                                         loss per share is computed by dividing the loss for the period applicable (after considering the effect of deemed dividend related
                                                         to trigger of down round protection feature) for Common Stockholders by the weighted average number of shares of Common Stock
                                                         outstanding and shares of Common Stock to be issued upon achievement of certain performance milestones during the period <span style="background-color: white">and
                                                         upon </span>exercise of pre-funded warrants. In computing, diluted loss per share, basic earnings per share are adjusted to reflect
                                                         the potential dilution that could occur upon the exercise of options or warrants issued or granted using the &#8220;treasury stock
                                                         method&#8221; and using the if-converted method with respect to certain convertible promissory notes and bifurcated redemption
feature accounted for as derivative financial liability, if the effect of each of such financial instruments is dilutive. In computing diluted loss per share, the average
                                                         stock price for the period is used in determining the number of Common Stock assumed to be purchased from the proceeds to be
                                                         received from the exercise of stock options or stock warrants.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    to be issued upon exercise of all options and warrants, convertible promissory notes and bifurcated redemption feature, have been excluded from the calculation of the diluted net loss
    per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as result
    of the exercise or conversion of these instruments was anti-dilutive.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    net loss and the weighted average number of shares of Common Stock used in computing basic and diluted net loss per Common Stock
    for the period of three and nine months ended September 30, 2024 and 2023, is as follows:</span></td></tr>
  </table>
<p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zECRBfAsXP8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zlH3UMgBCy09" style="display: none">SCHEDULE
OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240701__20240930_zY1fwQEntJ1j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230701__20230930_zyh7Jwyw3RX4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20240930_zk8T6rrK77Zk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230930_zGuY6kLIwKf7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">US dollars (except share data)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">US dollars (except share data)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three-month period ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine-month
period ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_iN_pn3n3_di_maNILATzfsR_z3h5F4HaMWLd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 44%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">5,087</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,223</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">12,503</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,685</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature_iN_pn3n3_di_maNILATzfsR_zLtm2Uj52lz3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Deemed dividend related to trigger of down round protection feature</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0684">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0685">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0686">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">855</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iNT_pn3n3_di_mtNILATzfsR_zzJULLVnGMdh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Net loss attributable to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,087</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,223</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,503</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,540</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Shares of Common Stock used in computing basic and diluted net loss per common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zVmjIIryPAmh" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zoZOdvODAwxd" title="Ordinary shares used in computing diluted net loss per common stock">5,564,880</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zKGeyIxhq1n7" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zNtDgyEEgYN" title="Ordinary shares used in computing diluted net loss per common stock">4,593,733</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_z7D7t5EV2Tld" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zZ2dQIclzRx7" title="Ordinary shares used in computing diluted net loss per common stock">5,340,532</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_ztUZlocG5Z42" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zSgMwvqxjys" title="Ordinary shares used in computing diluted net loss per common stock">3,758,590</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Shares of Common Stock to be issued upon exercise of pre-funded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zefuTJYCqzc" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zWheIw9VGqE6" title="Ordinary shares used in computing basic net loss per common stock"><span style="-sec-ix-hidden: xdx2ixbrl0710"><span style="-sec-ix-hidden: xdx2ixbrl0712">-</span></span></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zkBxULuZabwb" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zHNW06k4Cbta" title="Ordinary shares used in computing diluted net loss per common stock"><span style="-sec-ix-hidden: xdx2ixbrl0714"><span style="-sec-ix-hidden: xdx2ixbrl0716">-</span></span></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zDyS5M8xO2Og" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zGjWmtb2Havc" title="Ordinary shares used in computing diluted net loss per common stock"><span style="-sec-ix-hidden: xdx2ixbrl0718"><span style="-sec-ix-hidden: xdx2ixbrl0720">-</span></span></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zZoCHb218dwf" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_z18oaHPtHo4j" title="Ordinary shares used in computing diluted net loss per common stock">241,246</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Shares of Common Stock to be issued upon achievement of performance milestones</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_z1RWeBPjSvWl" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zg9ykkrfTP58" title="Ordinary shares used in computing diluted net loss per common stock">30,000</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zD7rw58jVuB2" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zRDWvYLlWlO7" title="Ordinary shares used in computing diluted net loss per common stock"><span style="-sec-ix-hidden: xdx2ixbrl0730"><span style="-sec-ix-hidden: xdx2ixbrl0732">-</span></span></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_ziP4Gvys9mb8" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_z0W0wTgEHEx4" title="Ordinary shares used in computing diluted net loss per common stock">15,275</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zr59VvXkLhbe" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zR2GCY4Jyrhj" title="Ordinary shares used in computing diluted net loss per common stock">6,691</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average number of Common Stock outstanding used in computing basic and diluted net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930_zyw8P5D5hxPe" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930_z30ArI9toSR8" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share">5,594,880</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930_zQs2xS3Sy7lg" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930_znjWzcAjwsXd" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share">4,593,733</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930_zn2Qx0dJPtVh" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930_zNEM4narGaFe" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share">5,355,806</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930_zOjdbevyrhHb" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930_zOQXvVfVxnR5" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share">4,006,527</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per common stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240701__20240930_z91DnSu7T2Ka" title="Diluted net loss per common stock"><span id="xdx_906_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240701__20240930_zuRoixSV9Nua" title="Diluted net loss per common stock">(0.91</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230701__20230930_zchev55s3gn" title="Diluted net loss per common stock"><span id="xdx_90D_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230701__20230930_z5Pvp7a8vFg4" title="Diluted net loss per common stock">(0.49</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240101__20240930_zNUAReKKbO7" title="Diluted net loss per common stock"><span id="xdx_90D_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240101__20240930_zxIeGyO6KKO3" title="Diluted net loss per common stock">(2.39</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230101__20230930_zowndlo5mvYd" title="Diluted net loss per common stock"><span id="xdx_909_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230101__20230930_zXz74f5ovqRg" title="Diluted net loss per common stock">(1.38</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A1_zEuqK0oVDPO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allocation Of Proceeds And Related Issuance Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_ConvertiblePromissoryNotesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Promissory Notes [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_ConvertiblePromissoryNotesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_ModificationOfEquityClassifiedContractsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Modification Of Equity Classified Contracts [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_ModificationOfEquityClassifiedContractsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233186217056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zECRBfAsXP8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zlH3UMgBCy09" style="display: none">SCHEDULE
OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240701__20240930_zY1fwQEntJ1j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230701__20230930_zyh7Jwyw3RX4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20240930_zk8T6rrK77Zk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230930_zGuY6kLIwKf7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">US dollars (except share data)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">US dollars (except share data)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three-month period ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine-month
period ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_iN_pn3n3_di_maNILATzfsR_z3h5F4HaMWLd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 44%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">5,087</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,223</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">12,503</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,685</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature_iN_pn3n3_di_maNILATzfsR_zLtm2Uj52lz3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Deemed dividend related to trigger of down round protection feature</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0684">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0685">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0686">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">855</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iNT_pn3n3_di_mtNILATzfsR_zzJULLVnGMdh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Net loss attributable to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,087</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,223</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,503</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,540</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Shares of Common Stock used in computing basic and diluted net loss per common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zVmjIIryPAmh" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zoZOdvODAwxd" title="Ordinary shares used in computing diluted net loss per common stock">5,564,880</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zKGeyIxhq1n7" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zNtDgyEEgYN" title="Ordinary shares used in computing diluted net loss per common stock">4,593,733</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_z7D7t5EV2Tld" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zZ2dQIclzRx7" title="Ordinary shares used in computing diluted net loss per common stock">5,340,532</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_ztUZlocG5Z42" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zSgMwvqxjys" title="Ordinary shares used in computing diluted net loss per common stock">3,758,590</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Shares of Common Stock to be issued upon exercise of pre-funded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zefuTJYCqzc" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zWheIw9VGqE6" title="Ordinary shares used in computing basic net loss per common stock"><span style="-sec-ix-hidden: xdx2ixbrl0710"><span style="-sec-ix-hidden: xdx2ixbrl0712">-</span></span></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zkBxULuZabwb" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zHNW06k4Cbta" title="Ordinary shares used in computing diluted net loss per common stock"><span style="-sec-ix-hidden: xdx2ixbrl0714"><span style="-sec-ix-hidden: xdx2ixbrl0716">-</span></span></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zDyS5M8xO2Og" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zGjWmtb2Havc" title="Ordinary shares used in computing diluted net loss per common stock"><span style="-sec-ix-hidden: xdx2ixbrl0718"><span style="-sec-ix-hidden: xdx2ixbrl0720">-</span></span></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zZoCHb218dwf" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_z18oaHPtHo4j" title="Ordinary shares used in computing diluted net loss per common stock">241,246</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Shares of Common Stock to be issued upon achievement of performance milestones</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_z1RWeBPjSvWl" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zg9ykkrfTP58" title="Ordinary shares used in computing diluted net loss per common stock">30,000</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zD7rw58jVuB2" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zRDWvYLlWlO7" title="Ordinary shares used in computing diluted net loss per common stock"><span style="-sec-ix-hidden: xdx2ixbrl0730"><span style="-sec-ix-hidden: xdx2ixbrl0732">-</span></span></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_ziP4Gvys9mb8" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_z0W0wTgEHEx4" title="Ordinary shares used in computing diluted net loss per common stock">15,275</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zr59VvXkLhbe" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zR2GCY4Jyrhj" title="Ordinary shares used in computing diluted net loss per common stock">6,691</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average number of Common Stock outstanding used in computing basic and diluted net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930_zyw8P5D5hxPe" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930_z30ArI9toSR8" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share">5,594,880</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930_zQs2xS3Sy7lg" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930_znjWzcAjwsXd" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share">4,593,733</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930_zn2Qx0dJPtVh" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930_zNEM4narGaFe" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share">5,355,806</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930_zOjdbevyrhHb" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930_zOQXvVfVxnR5" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share">4,006,527</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per common stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240701__20240930_z91DnSu7T2Ka" title="Diluted net loss per common stock"><span id="xdx_906_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240701__20240930_zuRoixSV9Nua" title="Diluted net loss per common stock">(0.91</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230701__20230930_zchev55s3gn" title="Diluted net loss per common stock"><span id="xdx_90D_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230701__20230930_z5Pvp7a8vFg4" title="Diluted net loss per common stock">(0.49</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240101__20240930_zNUAReKKbO7" title="Diluted net loss per common stock"><span id="xdx_90D_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240101__20240930_zxIeGyO6KKO3" title="Diluted net loss per common stock">(2.39</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230101__20230930_zowndlo5mvYd" title="Diluted net loss per common stock"><span id="xdx_909_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230101__20230930_zXz74f5ovqRg" title="Diluted net loss per common stock">(1.38</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233095103280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">SCHEDULE OF OPERATING LEASE</a></td>
<td class="text"><p id="xdx_897_eus-gaap--LeaseCostTableTextBlock_zIzel0VXWKy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_z3vDuEBqrYq6" style="display: none">SCHEDULE
OF OPERATING
LEASE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240930_zZZP4RDv7wKg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zsaPUwH9wOCa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left; padding-bottom: 2.5pt">Operating right-of-use asset</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 18%; text-align: right">65</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zyV0tTXRkczh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Current operating lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zsi5QhiaesRb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Non-Current operating lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">40</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zjcYrVnemZJ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturity
analysis of the Company&#8217;s lease liability:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_ztlO01gzXIGk" style="display: none">SCHEDULE
OF MATURITY
ANALYSIS OF LEASE LIABILITY</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240930_zhZxTL7nJvg3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_hus-gaap--LeaseContractualTermAxis__custom--LessThanOneYearMember_zXc3Tv74rw9c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Less than one year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">30</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_hus-gaap--LeaseContractualTermAxis__custom--BetweenOneYearToTwoYearsMember_zC0BaIt2ItC1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Between 1-2 years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_hus-gaap--LeaseContractualTermAxis__custom--MoreThanTwoYearsMember_zUYBx9ixmCL2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">More than 2 years</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">13</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zR8mOjemPfEj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total operating lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">73</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--LesseeOperatingLeaseLiabilityImputedInterest_iNI_di_zDVgdFWJRpO7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">8</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_zrTAHbTQkpxb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">65</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock', window );">SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE</a></td>
<td class="text"><p id="xdx_892_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock_zZMEFboNQckj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the weighted average remaining lease terms and discount rate for the lease:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zg2FCIS7FFqb" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Lease term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240930_zE2X8TvuDZW1" title="Lease term (years)">2.42</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20240930_zxtunKEZIuh9" title="Weighted average discount rate">9.03</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock', window );">SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE</a></td>
<td class="text"><p id="xdx_89E_ecustom--ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock_zXF9TfCc680g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tabular presentation reflects the reconciliation of the fair value of the embedded conversion feature and embedded redemption
feature during the period of nine months ended September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zuF3YLAqrakf" style="display: none">SCHEDULE
OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20240930_zt5zN59dkSx8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine-month period ended <br/>
September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DerivativeLiabilities_iS_zozdHaCn3yp4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Open balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0943">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_pn3n3_zP200s6qmuRd" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Proceeds allocated to embedded redemption feature at initial recognition</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">35</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--RevaluationExpensesRelatedToEmbeddedRedemptionFeature_pn3n3_zihVxNPa8Od1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Revaluation expenses related to embedded redemption feature (Note 5 below)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DerivativeLiabilities_iE_zkchSUvzHfM1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_JuneTwentySevenWarrantsMember', window );">June Twenty Seven Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock', window );">SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenWarrantsMember_ztHe4s0Y6vC" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zmhwp7QEQiti" style="display: none">SCHEDULE
OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenWarrantsMember_zq6138sou90d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine-month period ended<br/>
 September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>(Unaudited)</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_zqYDDjqLHFkl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Open balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0852">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfWarrants_pn3n3_zyhzU0eZMena" style="vertical-align: bottom; background-color: White">
    <td>Total proceeds received</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ProceedsFromAllocatedWarrantsAtInitialRecognition_pn3n3_zX9355DzW9V4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
proceeds allocated to June 27 Warrants at initial recognition</span></td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 18%">(85</td><td style="text-align: left; width: 1%">)</td></tr>
  <tr id="xdx_409_ecustom--DiscountAmortizationAndInterestExpenses_pn3n3_zE75HDXl0Vsd" style="vertical-align: bottom; background-color: White">
    <td>Discount amortization and interest expenses related to <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
27 Notes (Note 5 below)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--PartialConversionNotesAndAccruedInterest_pn3n3_zT1rqNwyyTs5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Partial conversion <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 27 Notes and accrued
Interest (Note 3I and Note 3J below)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(26</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--WarrantsAndRightsOutstanding_iE_pn3n3_zhz6ftz91vk2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_JulyEighteenNotesMember', window );">July Eighteen Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock', window );">SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES</a></td>
<td class="text"><p id="xdx_89F_ecustom--ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--JulyEighteenNotesMember_z1cKGNZR7vUa" style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zwhuunhzDGij" style="display: none">SCHEDULE
OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--JulyEighteenNotesMember_z5oURXRylszg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine-month period ended <br/>
September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ConvertibleDebt_iS_pn3n3_z2iF2SE7fnzd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Open balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfDebt_pn3n3_zF7GWCyQYXw" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Total proceeds allocated to July 18 Notes at initial recognition</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">360</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestExpense_pn3n3_zpZevaxptRE3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expenses related to July 18 Notes (Note 5 below)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PartialConversionAndAccruedInterest_pn3n3_zv1dVDK0cmVl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Partial conversion July 18 Notes and accrued Interest (Note 3J below)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(101</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--ConvertibleDebt_iE_z4h2ISWrdvL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">264</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_JulyThirteenNotesMember', window );">July Thirteen Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock', window );">SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES</a></td>
<td class="text"><p id="xdx_898_ecustom--ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--JulyThirteenNotesMember_zYc0P3ckmT7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="display: none"><span id="xdx_8B2_z3vRAylczGji">SCHEDULE
OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY  30 NOTES</span></span></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--JulyThirtyNotesMember_zdScknDfgcK7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine-month period ended <br/>
September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ConvertibleDebt_iS_pn3n3_z52nzxn0zku7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Open balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromIssuanceOfDebt_pn3n3_zL8inGKJRWpb" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Total proceeds received</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">4,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_zqFwYLU1yITe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total proceeds allocated to July 30 Warrants at initial recognition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,550</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_pn3n3_zv82Po9flfcg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total proceeds allocated to embedded redemption feature at initial recognition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(35</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--DiscountAmortizationAndInterestExpenses_pn3n3_zW1ptRHkBZxf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Amortization of discount and interest expenses related to July 30 Note (Note 5 below)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">309</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ConvertibleDebt_iE_pn3n3_zC5jJ7G5R526" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,724</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Reconciliation Of Carrying Amount Of Notes [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Reconciliation Of Fair Value Of Embedded Conversion Feature [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Weighted Average Remaining Lease Terms And Discount Rate [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_JuneTwentySevenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_JuneTwentySevenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_JulyEighteenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_JulyEighteenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_JulyThirteenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_JulyThirteenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233094134864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCE (INCOME) EXPENSES, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock', window );">SCHEDULE OF FINANCE EXPENSES</a></td>
<td class="text"><p id="xdx_893_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zauJhdSM0g7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zDk8QpTWxw05" style="display: none">SCHEDULE
OF FINANCE EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20240701__20240930_zFF3zx8ch3R" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20230701__20230930_zuGbgWYkprh8" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20240101__20240930_zGqfKKbestH2" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20230101__20230930_z6aWwu5CAgM5" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three-month period ended<br/>
 September
    30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine-month period ended<br/>
 September
    30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unaudited</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_ecustom--DiscountAmortizationAndInterestExpensesOne_msFINztjv_zhyhrts5GOFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; width: 40%; text-align: left">Discount amortization and interest expenses related to June 27 Notes</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">16</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1040">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">16</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1042">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InterestExpense_msFINztjv_zlTcp83Lkpjj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expenses related to July 18 Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1045">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DiscountAmortizationAndInterestExpensesTwo_msFINztjv_z9b63atu2dth" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; text-indent: -10pt">Discount amortization and interest expenses related to July 30 Note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--RevaluationExpensesRelatedToDerivativeFinancialLiabilities_pn3n3_msFINztjv_zezxB21JZ20i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; text-indent: -10pt">Revaluation expenses related to derivative financial liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1055">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1057">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities_pn3n3_msFINztjv_zmxtjfjUkxt3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; text-indent: -10pt">Revaluation expenses incurred from settlement of financial liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,505</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,505</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InterestExpenseDeposits_pn3n3_msFINztjv_zXVl7imz3jTk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest on bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(38</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherExpenses_pn3n3_msFINztjv_zd1FJnu5PiL" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; text-indent: -10pt">Exchange rate differentials, bank commissions and miscellaneous</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1070">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--FinanceIncomeNet_iNT_pn3n3_di_mtFINztjv_zV1QX83jCJJ6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance (income) expenses,
    net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,848</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,822</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedFinancialStatementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233095441648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 22, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,356<span></span>
</td>
<td class="nump">$ 109,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346<span></span>
</td>
<td class="nump">4,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromUnsecuredNotesPayable', window );">Unsecured promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromUnsecuredNotesPayable', window );">Unsecured promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSecuredNotesPayable', window );">Secured promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from Debt, Net of Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from public offering</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from Debt, Net of Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSecuredNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings supported by a written promise to pay an obligation that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSecuredNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromUnsecuredNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings supported by a written promise to pay an obligation that is uncollateralized (where debt is not backed by the pledge of collateral).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromUnsecuredNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233096668752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 5,087<span></span>
</td>
<td class="nump">$ 2,223<span></span>
</td>
<td class="nump">$ 12,503<span></span>
</td>
<td class="nump">$ 4,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature', window );">Deemed dividend related to trigger of down round protection feature</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="nump">$ 5,087<span></span>
</td>
<td class="nump">$ 2,223<span></span>
</td>
<td class="nump">$ 12,503<span></span>
</td>
<td class="nump">$ 5,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of Common Stock outstanding used in computing basic net loss per share</a></td>
<td class="nump">5,594,880<span></span>
</td>
<td class="nump">4,593,733<span></span>
</td>
<td class="nump">5,355,806<span></span>
</td>
<td class="nump">4,006,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of Common Stock outstanding used in computing diluted net loss per share</a></td>
<td class="nump">5,594,880<span></span>
</td>
<td class="nump">4,593,733<span></span>
</td>
<td class="nump">5,355,806<span></span>
</td>
<td class="nump">4,006,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones', window );">Diluted net loss per common stock</a></td>
<td class="num">$ (0.91)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (2.39)<span></span>
</td>
<td class="num">$ (1.38)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of Common Stock outstanding used in computing basic net loss per share</a></td>
<td class="nump">5,564,880<span></span>
</td>
<td class="nump">4,593,733<span></span>
</td>
<td class="nump">5,340,532<span></span>
</td>
<td class="nump">3,758,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of Common Stock outstanding used in computing diluted net loss per share</a></td>
<td class="nump">5,564,880<span></span>
</td>
<td class="nump">4,593,733<span></span>
</td>
<td class="nump">5,340,532<span></span>
</td>
<td class="nump">3,758,590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_PrefundedWarrantsMember', window );">Prefunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of Common Stock outstanding used in computing basic net loss per share</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">241,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of Common Stock outstanding used in computing diluted net loss per share</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">241,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_PerformanceMilestoneMember', window );">Performance Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of Common Stock outstanding used in computing basic net loss per share</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,275<span></span>
</td>
<td class="nump">6,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of Common Stock outstanding used in computing diluted net loss per share</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,275<span></span>
</td>
<td class="nump">6,691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend related to trigger of down round protection feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings per share diluted including warrants and performance milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_PerformanceMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_PerformanceMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233093172528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF OPERATING LEASE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_DisclosureSignificantTransactionsAbstract', window );"><strong>Significant Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use asset</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liability</a></td>
<td class="nump">25<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-Current operating lease liability</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_DisclosureSignificantTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_DisclosureSignificantTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233094976000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Feb. 19, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_LesseeOperatingLeaseLiabilityImputedInterest', window );">Less: imputed interest</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=GCTK_LessThanOneYearMember', window );">Less Than One Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=GCTK_BetweenOneYearToTwoYearsMember', window );">Between 1 - 2 Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=GCTK_MoreThanTwoYearsMember', window );">More Than 2 Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_LesseeOperatingLeaseLiabilityImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability imputed interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_LesseeOperatingLeaseLiabilityImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=GCTK_LessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=GCTK_LessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=GCTK_BetweenOneYearToTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=GCTK_BetweenOneYearToTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=GCTK_MoreThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=GCTK_MoreThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233094095968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_DisclosureSignificantTransactionsAbstract', window );"><strong>Significant Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Lease term (years)</a></td>
<td class="text">2 years 5 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">9.03%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_DisclosureSignificantTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_DisclosureSignificantTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233095041904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 05, 2024</div></th>
<th class="th"><div>Jul. 30, 2024</div></th>
<th class="th"><div>Jun. 27, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Total proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Total proceeds allocated to July 18 Notes at initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,450<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expenses related to July 18 Notes (Note 5 below)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_JuneTwentySevenWarrantsMember', window );">June Twenty Seven Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Open balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Total proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_ProceedsFromAllocatedWarrantsAtInitialRecognition', window );">Total proceeds allocated to June 27 Warrants at initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_DiscountAmortizationAndInterestExpenses', window );">Discount amortization and interest expenses related to June 27 Notes (Note 5 below)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_PartialConversionNotesAndAccruedInterest', window );">Partial conversion June 27 Notes and accrued Interest (Note 3I and Note 3J below)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_JulyEighteenNotesMember', window );">July Eighteen Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Open balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Total proceeds allocated to July 18 Notes at initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expenses related to July 18 Notes (Note 5 below)</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_PartialConversionAndAccruedInterest', window );">Partial conversion July 18 Notes and accrued Interest (Note 3J below)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_DiscountAmortizationAndInterestExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount amortization and interest expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_DiscountAmortizationAndInterestExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_PartialConversionAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Partial conversion and accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_PartialConversionAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_PartialConversionNotesAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Partial conversion notes and accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_PartialConversionNotesAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_ProceedsFromAllocatedWarrantsAtInitialRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from allocated warrants at initial recognition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_ProceedsFromAllocatedWarrantsAtInitialRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_JuneTwentySevenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_JuneTwentySevenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_JulyEighteenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_JulyEighteenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233096176720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 30, 2024</div></th>
<th class="th"><div>Jun. 27, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Total proceeds received</a></td>
<td class="nump">$ 1,450<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Total proceeds allocated to July 30 Warrants at initial recognition</a></td>
<td class="nump">$ 2,550<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Total proceeds allocated to embedded redemption feature at initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_JulyThirtyNotesMember', window );">July 30 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Open balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Total proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Total proceeds allocated to July 30 Warrants at initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Total proceeds allocated to embedded redemption feature at initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_DiscountAmortizationAndInterestExpenses', window );">Amortization of discount and interest expenses related to July 30 Note (Note 5 below)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,724<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_DiscountAmortizationAndInterestExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount amortization and interest expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_DiscountAmortizationAndInterestExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 15<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815-15/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_JulyThirtyNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_JulyThirtyNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233094279520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_DisclosureSignificantTransactionsAbstract', window );"><strong>Significant Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Open balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Proceeds allocated to embedded redemption feature at initial recognition</a></td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_RevaluationExpensesRelatedToEmbeddedRedemptionFeature', window );">Revaluation expenses related to embedded redemption feature (Note 5 below)</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Ending balance</a></td>
<td class="nump">$ 37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_DisclosureSignificantTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_DisclosureSignificantTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_RevaluationExpensesRelatedToEmbeddedRedemptionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revaluation expenses related to embedded redemption feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_RevaluationExpensesRelatedToEmbeddedRedemptionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 15<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815-15/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233082153936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 12, 2024</div></th>
<th class="th"><div>Oct. 15, 2024</div></th>
<th class="th"><div>Sep. 05, 2024</div></th>
<th class="th"><div>Aug. 23, 2024</div></th>
<th class="th"><div>Jul. 30, 2024</div></th>
<th class="th"><div>Jul. 18, 2024</div></th>
<th class="th"><div>Jun. 27, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Apr. 22, 2024</div></th>
<th class="th"><div>Feb. 19, 2024</div></th>
<th class="th"><div>Feb. 13, 2024</div></th>
<th class="th"><div>Jan. 03, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">718,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,772,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,772,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,178,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Aggregate gross proceeds offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,873,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-five<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227,000<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="nump">$ 1,415,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right number of securities called by warrants or rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtDescription', window );">Notes payable description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
    June 27 Notes bear simple interest at a rate of 3% per annum and are due and payable in cash on the earlier of: (a) 12 months
    from the date of the June 27 Note; or (b) the date the Company raises third-party equity capital in an amount equal to or in excess
    of $1,000 (the &#8220;Maturity Date&#8221;). The Company may prepay the June 27 Notes at any time prior to the Maturity Date without
    penalty. If an event of default occurs, the then-outstanding principal amount of the June 27 Notes plus any unpaid accrued interest
    will accelerate and become immediately payable in cash.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk- free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.78%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault', window );">Debt description of notice of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i)
failure by the Company to pay the July 30 Note balance on the Maturity Date, (ii) the Company becomes subject to a judgement of more
than $50,000,
(iii) voluntary bankruptcy, or (iv) involuntary bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii)
above, the July 30 Note balance shall automatically and immediately become due and payable, in all cases without any action on the
part of the July 30 Holder.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDefaultLongtermDebtAmount', window );">Debt default long term debt amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_EmbeddedConversionFeaturePercentage', window );">Embedded conversion feature percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Equity fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,505,000<span></span>
</td>
<td class="nump">$ 238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Aggregate gross proceeds offering</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued during period shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,682,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Gross proceeds from notes conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=GCTK_ConvertiblePromissoryNotesMember', window );">Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt instrument description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i)
is convertible at the discretion of the July 30 Holder at a price equal to the closing price of the Common Stock on the date of
conversion and, (ii) if the Closing Price of the Common stock exceeds $5.00
per share for a period of 5 consecutive trading days, will automatically convert at a price equal to the 5 daily Volume Weighted
Average Price (&#8220;VWAP&#8221;) of the Common Stock (subject to adjustment for any stock split, stock dividend, reverse stock
split, combination or similar transaction).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Sale of stock description of transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i)
cash equal to 200% of the Note balance, or (ii) transaction consideration in the amount to be received by the Holder in such Sale
Transaction if the July 30 Note was converted pursuant to an optional conversion. &#8220;Sale Transaction&#8221; means a merger or
consolidation of the Company with or into any other entity, or a sale of all or substantially all of the Company&#8217;s assets, or any other transaction or series of related transactions in which the Company&#8217;s stockholders immediately prior
to such transaction(s) receive cash, securities or other property in exchange for their shares and, immediately after such
transaction(s), own less than 50% of the equity securities of the surviving corporation or its parent.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=GCTK_UnsecuredPromissoryNotesMember', window );">Unsecured Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Aggregate gross proceeds offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GCTK_ExchangeAgreementMember', window );">Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_LockUpPeriodDescription', window );">Lock-up period conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(a) sell or contract
    to sell Shares at a price higher than $0.50 per Share on any trading day up to 10% of the daily volume of Shares or (b) sell or contract
    to sell Shares at a price higher than $0.80 per Share on any trading day with no volume limitation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Monthly rental fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GCTK_WarrantsAgreementMember', window );">Warrants Agreement [Member] | Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt instrument description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i)
12 months anniversary of July 30 Note, or (ii) closing date of a Sale Transaction (defined below) (the &#8220;Maturity
Date&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_PrefundedWarrantsMember', window );">Prefunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_PrefundedWarrantsMember', window );">Prefunded Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">876,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_FirstWarrantMember', window );">First Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,133,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_SecondWarrantMember', window );">Second Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,523,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_ThirdWarrantMember', window );">Third Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,185,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_JuneTwentySevenNotesMember', window );">June Twenty Seven Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_JuneTwentySevenNotesMember', window );">June Twenty Seven Notes [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued during period shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,226,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_AugustTwentyThreeWarrantMember', window );">August Twenty Three Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 16,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_AugustTwentyThreeWarrantOneMember', window );">August Twenty Three Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right number of securities called by warrants or rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,707,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_AugustTwentyThreeWarrantTwoMember', window );">August Twenty Three Warrant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right number of securities called by warrants or rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,648,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_AugustTwentyThreeWarrantThreeMember', window );">August Twenty Three Warrant Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right number of securities called by warrants or rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_JulyEighteenNotesMember', window );">July Eighteen Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_JulyTwentySevenNotesMember', window );">July Twenty Seven Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_SeptemberFiveWarrantsMember', window );">September Five Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 16,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_SeptemberFiveWarrantsOneMember', window );">September Five Warrants One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right number of securities called by warrants or rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,299,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_SeptemberFiveWarrantsTwoMember', window );">September Five Warrants Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right number of securities called by warrants or rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,785,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GCTK_SeptemberFiveWarrantsThreeMember', window );">September Five Warrants Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right number of securities called by warrants or rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,833,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_EmbeddedConversionFeaturePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Embedded conversion feature percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_EmbeddedConversionFeaturePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_LockUpPeriodDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lock up period description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_LockUpPeriodDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDefaultLongtermDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDefaultLongtermDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the facts pertaining to a notice received from a lender that an event of default has occurred with respect to the long-term debt instrument or borrowing, and a description of the expected financial consequences of receiving such notice, including the effects of a demand for immediate repayment of all amounts due, and the classification of the debt on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-23<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of borrowing classified as short-term upon issuance. Includes, but is not limited to, description of underlying arrangement, repayment terms, interest rate, collateral provided, restriction on use of asset and activity, and compliance with debt covenant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=GCTK_ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=GCTK_ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=GCTK_UnsecuredPromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=GCTK_UnsecuredPromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GCTK_ExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GCTK_ExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GCTK_WarrantsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GCTK_WarrantsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_FirstWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_FirstWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_SecondWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_SecondWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_ThirdWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_ThirdWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_JuneTwentySevenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_JuneTwentySevenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_AugustTwentyThreeWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_AugustTwentyThreeWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_AugustTwentyThreeWarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_AugustTwentyThreeWarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_AugustTwentyThreeWarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_AugustTwentyThreeWarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_AugustTwentyThreeWarrantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_AugustTwentyThreeWarrantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_JulyEighteenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_JulyEighteenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_JulyTwentySevenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_JulyTwentySevenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_SeptemberFiveWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_SeptemberFiveWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_SeptemberFiveWarrantsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_SeptemberFiveWarrantsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_SeptemberFiveWarrantsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_SeptemberFiveWarrantsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_SeptemberFiveWarrantsThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_SeptemberFiveWarrantsThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233095636384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 07, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 04, 2004 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 20, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 04, 2004 </div>
<div>ILS (&#8362;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesRestrictedStock', window );">Restricted shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239,000<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,366<span></span>
</td>
<td class="nump">1,075,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_MarketabilityDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GCTK_IntellectualPropertyPurchaseAgreementMember', window );">Intellectual Property Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares issued | shares</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=GCTK_IsraeliInnovationAuthorityMember', window );">Israeli Innovation Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Intellectual Property Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares issued | shares</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_AggregateSalesPriceOfUnitsPercentage', window );">Commission as a percentage of aggregate sales price</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Intellectual Property Purchase Agreement [Member] | Common Stock [Member] | Trueup Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_AggregateSalesPriceOfUnitsPercentage', window );">Commission as a percentage of aggregate sales price</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=GCTK_IsraeliInnovationAuthorityMember', window );">Israeli Innovation Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 420,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=GCTK_IsraeliInnovationAuthorityMember', window );">Israeli Innovation Authority [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_RoyaltyPercentage', window );">Royalty percentage maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=GCTK_IsraeliInnovationAuthorityMember', window );">Israeli Innovation Authority [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_RoyaltyPercentage', window );">Royalty percentage maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_AggregateSalesPriceOfUnitsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate sales price of units percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_AggregateSalesPriceOfUnitsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_MarketabilityDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketability discount rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_MarketabilityDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GCTK_IntellectualPropertyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GCTK_IntellectualPropertyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=GCTK_IsraeliInnovationAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=GCTK_IsraeliInnovationAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GCTK_TrueupSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GCTK_TrueupSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=GCTK_IsraeliInnovationAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=GCTK_IsraeliInnovationAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233080295200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FINANCE EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_DiscountAmortizationAndInterestExpensesOne', window );">Discount amortization and interest expenses related to June 27 Notes</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expenses related to July 18 Notes</a></td>
<td class="nump">5<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_DiscountAmortizationAndInterestExpensesTwo', window );">Discount amortization and interest expenses related to July 30 Note</a></td>
<td class="nump">309<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities', window );">Revaluation expenses related to derivative financial liabilities</a></td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities', window );">Revaluation expenses incurred from settlement of financial liabilities</a></td>
<td class="nump">1,505<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,505<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDeposits', window );">Interest on bank deposits</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Exchange rate differentials, bank commissions and miscellaneous</a></td>
<td class="nump">18<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GCTK_FinanceIncomeNet', window );">Finance (income) expenses, net</a></td>
<td class="nump">$ 1,848<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 1,822<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_DiscountAmortizationAndInterestExpensesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount amortization and interest expenses one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_DiscountAmortizationAndInterestExpensesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_DiscountAmortizationAndInterestExpensesTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount amortization and interest expenses two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_DiscountAmortizationAndInterestExpensesTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_FinanceIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance income net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_FinanceIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revaluation expenses incurred from settlement of financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revaluation expenses related to derivative financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GCTK_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest expense on all deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233097945312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 12, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 27, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from public offering</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Incremental and direct issuance costs</a></td>
<td class="nump">1,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | July 30 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion converted instrument amount</a></td>
<td class="nump">$ 4,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price, per share</a></td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 1.389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Series A Common Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Stock issuance</a></td>
<td class="nump">7,194,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="nump">$ 1.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Series B Common Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Stock issuance</a></td>
<td class="nump">7,194,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="nump">$ 1.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Prefunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Stock issuance</a></td>
<td class="nump">2,437,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member] | July 30 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Stock issuance</a></td>
<td class="nump">2,640,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Prefunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Stock issuance</a></td>
<td class="nump">4,756,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Series A Common Warrant [Member] | July 30 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Stock issuance</a></td>
<td class="nump">2,640,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Series Common Warrant [Member] | July 30 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Stock issuance</a></td>
<td class="nump">2,640,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GCTK_JulyThirtyNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GCTK_JulyThirtyNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GCTK_SeriesACommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GCTK_SeriesACommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GCTK_SeriesBCommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GCTK_SeriesBCommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GCTK_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GCTK_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_SeriesACommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_SeriesACommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GCTK_SeriesCommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GCTK_SeriesCommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>40
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M00<MV8IFH;H1#U]92:BO_2U$*//_Z*&T=3IHD4DEHG(P((AX7'S27^6+V!B
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MMDAMODOXSF"O#\;$.EE+>6.#+^7<"ZP@X% 8RT#QL8,%<&Z)4,;OGM,;MK3
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M6#Q$V[3ZD#]QL3\@M^8M\K1L_B=/>UMK1!;;LLK7^\*R!>LDV_V-ONP[XJ@
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M30V:5A*CO36Q.[%Y36RKT7!L,!#ZJ%BW>ROE3$/9#%H0F-LV($D ZK3UIH6
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MXU@T-4A:)=(V*Y''*Y-85)$,F?J^_$.\5*LBWRY79O7B$$H!B;*8[%YS>-K
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M4^6;YD=3[O.JRM?-RY6(8E'4!O+[AUR>$_9OZ@H./S9T]3]02P,$%     @
M]8%N6=TPU<O[!P  B",  !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6RM
M6FUSVK@6_BL:[LY.,A.";?&:39A)2=)R9YMF0MO]+&P!NC665Y)#<W_]'LD.
M!EM6 \N78#O2\3G/>7LD^7K#Q0^YHE2AG^LXD3>ME5+I5:<CPQ5=$WG)4YK
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MU@/@_PL.<!4W^@7;CV_&_P!02P,$%     @ ]8%N6<.)W+31!@  60X  !@
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MPZN77/7H5OW1J%SY;<+R,U$K#YZ!%*:QF73)PB1@INP&I':0% !:&T];E&9
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M\@9\7QD4C?:%%>QODY?_!U!+ P04    " #U@6Y9<RZ]95D3  #F.   &
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M(J'PY4H6CZ3RNI!UIBN5B=3 0 J+3[JH5*F7],1B1S))KV>ZD$6J92XLQE*
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M[D]3Q(TCP_$%"BI:@6M21:*-)AWQ0DT@E"%E7+HPH.%P"D?Y?3LNV%-A<>N
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MMN%(C\]-7 [C]X\RBT:#S]E7L6Z-PI4)8OUK29?VNC9'N^]MC<[+R#I)+QL
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M5W:\<S#_8(<G*VQ.X]&K+OG^5!OK%]*UXR9FZHX+G:XZ)LH]3#'?SYE0>1R
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M/K]B2IN])55!-!^B'D[B*EJB$^;*DJ\H)Y6/(#&4L 8!+AZ2M;_^GNYY8$"
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M('-E.;;6$^<]>:F0 G?5>6<OUGG\N%?A^060NUK7663+M^&F"#\!48 ,'+Z
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MV9K_O%<A;)-NP/>K#,6!^4 +N-]??//_4$L#!!0    ( /6!;EF[%WC*U <
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M*WH\4;L ^E\H.@=;QTW0/L?C[U!+ P04    " #U@6Y9B*1Z9T4&  !@#@
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M&:3$1,V;FKRG8@U+'X4=G+DJMICP,G[#@X#?@01Y$*DLBZI% L^N?4+1!(I
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M58X#X'=\E\U_P07"*]?O_A]02P,$%     @ ]8%N6?Y2.L\+!   Z@@  !D
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ME6Q@&,P74@U4ST\3.H<1R+ODEN-;-9?B!Q'$(F QX3 [JSC6R85EJPUZQ;<
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M[123S)J.BVMS-AW37"0D@SE#/$]3S'[<0D)W$\NUWBX\D?5&J OV=+S%:UB
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M-$^PD%=#6)&(B(]M0+7&78&69H/"3,W@KW(D>'ZO/[9?#U&U-'-&PYY?-VM
MZ-40>EH(,\PW2(YW%*D#^):35_EH9:)M_-]JK;JF79KU#O+Q@^.<3]L$P<AK
MS[A?9]S79OPHW[-;1B. F*,5HRG:YLN$1'(XK8#)YZ M<ZUEU\S[)UD-AP/_
M*'5#$1N(!C6B@1;1<\8ARID<!!)42CBG[ ?*J(#6IT+KU97-X/2IZ#M': P%
M;* 9UFB&6C0A+ 5:*#I$D'8>6H.N/(:G/!SY=T3$4,@&D5%-9*0E\D75$IE
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MF[P\$71;;!POJ1 T+0XW@&-@JH'\?D5E;5B=J #UCQ73?P!02P,$%     @
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M(*_6,M6ZC85TW;[C>49-N";.<?MVSZYK)^&S7=<SNC7U)'S\A<>U>G(!>Y6
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ME*'/)$D($RGZZY;&3S3YNTX0+;2I() P!Q*&(6$N),R#A$V 8!4!^Z6 ?:V
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M9J*:A6HVJCFHYJ*:AVH^J@6H%E):-XZ;-O"EN WL;JH#X>W)0.VU>7J3&"T
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MUHWFIA)W?<7.$Z/U.%2344U!-175-%334<U -1/5+%2S4<U!-1?5/%3S42U
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M-DV+_1^J ;ZGV>_;N_/I_P%02P,$%     @ ]8%N6=WC!C3)!P  #U,  !D
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M\;Y4=+I4"6ZS@-NLA7M;CY!^1W[G;82Y[^9.7,T*P5KU(PB^JQ2=KE0"V"H
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ML<.0M# %50N@U$PO-7M@.WL<+W:5P/%B9Q^IM2^G( ZLB0/;B:--L?.?5.Q
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MJ'H/[KV/PLU[*FS_=S;^#5!+ P04    " #U@6Y9EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( /6!;EG'(PO:+@,
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M<' N>&UL4$L! A0#%     @ ]8%N6=1?I;?N    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ]8%N69E<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " #U@6Y9Q.,9E 0&  !_(   &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ]8%N6=;PVFY$
M!@  .AH  !@              ("!1PX  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( /6!;EE E..RE (  #,'   8              "
M@<$4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #U@6Y9
M 2Z7)F$%   U%P  &               @(&+%P  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ ]8%N6:1=4W :#   >&@  !@
M     ("!(AT  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M /6!;EG=,-7+^P<  (@C   8              " @7(I  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " #U@6Y9PXG<M-$&  !9#@  &
M            @(&C,0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ ]8%N67,NO659$P  YC@  !@              ("!JC@  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( /6!;EGZ3KB8O!@  (M1
M   8              " @3E,  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " #U@6Y9NQ=XRM0'  !5$@  &0              @($K90
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( /6!;EG!"PJ-
M4P,  )H'   9              " @39M  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ ]8%N68BD>F=%!@  8 X  !D
M ("!P'   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #U
M@6Y9A*%B' ,4  !^/0  &0              @($\=P  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( /6!;EG^4CK/"P0  .H(   9
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M970Q."YX;6Q02P$"% ,4    " #U@6Y9Q!Z\U70"  #,!@  &0
M    @(%OHP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M /6!;EGG.U>K:0,  $0/   9              " @1JF  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ ]8%N61Q)GY11 @  Y00  !D
M             ("!NJD  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " #U@6Y9&(KR<+$%  #3+   &0              @(%"K   >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( /6!;EDY*KX$UP,
M 'L0   9              " @2JR  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ ]8%N6;_S$AW. @  P08  !D              ("!
M.+8  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #U@6Y9
M<K,U&XPI  "+T@( &0              @($]N0  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( /6!;EG=XP8TR0<   ]3   9
M      " @0#C  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ ]8%N6>'UX48A!   X1   !D              ("! .L  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #U@6Y9G;W%]X@&  !Z-P
M&0              @(%8[P  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( /6!;EEZ# /"/0,  $@3   -              "  1?V  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ ]8%N69>*NQS     $P(   L
M         ( !?_D  %]R96QS+RYR96QS4$L! A0#%     @ ]8%N6<<C"]HN
M P  ?1,   \              ( !:/H  'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( /6!;EDO ()43 $  &L1   :              "  </]  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( /6!;EDBX&C7>P$
M #H2   3              "  4?_  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     D "0 LPD  /,  0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>155</ContextCount>
  <ElementCount>213</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/StatementOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - GENERAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/General</Role>
      <ShortName>GENERAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - SIGNIFICANT TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/SignificantTransactions</Role>
      <ShortName>SIGNIFICANT TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/CommitmentsAndContingentLiabilities</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - FINANCE (INCOME) EXPENSES, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/FinanceIncomeExpensesNet</Role>
      <ShortName>FINANCE (INCOME) EXPENSES, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - SIGNIFICANT TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/SignificantTransactionsTables</Role>
      <ShortName>SIGNIFICANT TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glucotrack.com/role/SignificantTransactions</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - FINANCE (INCOME) EXPENSES, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/FinanceIncomeExpensesNetTables</Role>
      <ShortName>FINANCE (INCOME) EXPENSES, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glucotrack.com/role/FinanceIncomeExpensesNet</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - GENERAL (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/GeneralDetailsNarrative</Role>
      <ShortName>GENERAL (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://glucotrack.com/role/General</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails</Role>
      <ShortName>SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - SCHEDULE OF OPERATING LEASE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails</Role>
      <ShortName>SCHEDULE OF OPERATING LEASE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails</Role>
      <ShortName>SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails</Role>
      <ShortName>SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails</Role>
      <ShortName>SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails</Role>
      <ShortName>SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureDetails</Role>
      <ShortName>SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - SIGNIFICANT TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/SignificantTransactionsDetailsNarrative</Role>
      <ShortName>SIGNIFICANT TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://glucotrack.com/role/SignificantTransactionsTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://glucotrack.com/role/CommitmentsAndContingentLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - SCHEDULE OF FINANCE EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails</Role>
      <ShortName>SCHEDULE OF FINANCE EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glucotrack.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://glucotrack.com/role/SubsequentEvents</ParentRole>
      <Position>28</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="form10-q.htm">form10-q.htm</File>
    <File>gctk-20240930.xsd</File>
    <File>gctk-20240930_cal.xml</File>
    <File>gctk-20240930_def.xml</File>
    <File>gctk-20240930_lab.xml</File>
    <File>gctk-20240930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="525">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>47
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-q.htm": {
   "nsprefix": "GCTK",
   "nsuri": "http://glucotrack.com/20240930",
   "dts": {
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "schema": {
     "local": [
      "gctk-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "gctk-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gctk-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "gctk-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gctk-20240930_pre.xml"
     ]
    }
   },
   "keyStandard": 168,
   "keyCustom": 45,
   "axisStandard": 11,
   "axisCustom": 0,
   "memberStandard": 12,
   "memberCustom": 33,
   "hidden": {
    "total": 162,
    "http://fasb.org/us-gaap/2024": 102,
    "http://glucotrack.com/20240930": 56,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 155,
   "entityCount": 1,
   "segmentCount": 49,
   "elementCount": 346,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 525,
    "http://xbrl.sec.gov/dei/2024": 31,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://glucotrack.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://glucotrack.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:OtherAssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://glucotrack.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity",
     "longName": "00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://glucotrack.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://glucotrack.com/role/General",
     "longName": "00000007 - Disclosure - GENERAL",
     "shortName": "GENERAL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://glucotrack.com/role/SignificantTransactions",
     "longName": "00000009 - Disclosure - SIGNIFICANT TRANSACTIONS",
     "shortName": "SIGNIFICANT TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "GCTK:SignificantTransactionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "GCTK:SignificantTransactionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://glucotrack.com/role/CommitmentsAndContingentLiabilities",
     "longName": "00000010 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES",
     "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://glucotrack.com/role/FinanceIncomeExpensesNet",
     "longName": "00000011 - Disclosure - FINANCE (INCOME) EXPENSES, NET",
     "shortName": "FINANCE (INCOME) EXPENSES, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://glucotrack.com/role/SubsequentEvents",
     "longName": "00000012 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "00000013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "00000014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://glucotrack.com/role/SignificantTransactionsTables",
     "longName": "00000015 - Disclosure - SIGNIFICANT TRANSACTIONS (Tables)",
     "shortName": "SIGNIFICANT TRANSACTIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "GCTK:SignificantTransactionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "GCTK:SignificantTransactionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://glucotrack.com/role/FinanceIncomeExpensesNetTables",
     "longName": "00000016 - Disclosure - FINANCE (INCOME) EXPENSES, NET (Tables)",
     "shortName": "FINANCE (INCOME) EXPENSES, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://glucotrack.com/role/GeneralDetailsNarrative",
     "longName": "00000017 - Disclosure - GENERAL (Details Narrative)",
     "shortName": "GENERAL (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "17",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:ProceedsFromUnsecuredNotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R18": {
     "role": "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails",
     "longName": "00000018 - Disclosure - SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details)",
     "shortName": "SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-09-30",
      "name": "GCTK:DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R19": {
     "role": "http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails",
     "longName": "00000019 - Disclosure - SCHEDULE OF OPERATING LEASE (Details)",
     "shortName": "SCHEDULE OF OPERATING LEASE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "19",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails",
     "longName": "00000020 - Disclosure - SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY (Details)",
     "shortName": "SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "20",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "GCTK:SignificantTransactionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "GCTK:SignificantTransactionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://glucotrack.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails",
     "longName": "00000021 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE (Details)",
     "shortName": "SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "GCTK:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock",
       "GCTK:SignificantTransactionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "GCTK:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock",
       "GCTK:SignificantTransactionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails",
     "longName": "00000022 - Disclosure - SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES (Details)",
     "shortName": "SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:ProceedsFromIssuanceOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-09-30_custom_JuneTwentySevenWarrantsMember",
      "name": "us-gaap:ProceedsFromIssuanceOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "GCTK:ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock",
       "GCTK:SignificantTransactionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R23": {
     "role": "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails",
     "longName": "00000023 - Disclosure - SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES (Details)",
     "shortName": "SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-07-302024-07-30",
      "name": "us-gaap:ProceedsFromIssuanceOfDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "GCTK:SignificantTransactionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-09-30_custom_JulyThirtyNotesMember",
      "name": "us-gaap:ProceedsFromIssuanceOfDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "GCTK:ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock",
       "GCTK:SignificantTransactionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R24": {
     "role": "http://glucotrack.com/role/ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureDetails",
     "longName": "00000024 - Disclosure - SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE (Details)",
     "shortName": "SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "GCTK:ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock",
       "GCTK:SignificantTransactionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "GCTK:RevaluationExpensesRelatedToEmbeddedRedemptionFeature",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "GCTK:ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock",
       "GCTK:SignificantTransactionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
     "longName": "00000025 - Disclosure - SIGNIFICANT TRANSACTIONS (Details Narrative)",
     "shortName": "SIGNIFICANT TRANSACTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "AsOf2024-02-13",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "GCTK:SignificantTransactionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-02-13",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "GCTK:SignificantTransactionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
     "longName": "00000026 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-05-012024-05-31",
      "name": "us-gaap:WeightedAverageNumberOfSharesRestrictedStock",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-05-012024-05-31",
      "name": "us-gaap:WeightedAverageNumberOfSharesRestrictedStock",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails",
     "longName": "00000027 - Disclosure - SCHEDULE OF FINANCE EXPENSES (Details)",
     "shortName": "SCHEDULE OF FINANCE EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "GCTK:DiscountAmortizationAndInterestExpensesOne",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "GCTK:DiscountAmortizationAndInterestExpensesOne",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://glucotrack.com/role/SubsequentEventsDetailsNarrative",
     "longName": "00000028 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-11-122024-11-12_us-gaap_SubsequentEventMember",
      "name": "us-gaap:PaymentsOfDebtIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity of Counterparty, Type [Axis]",
        "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r59"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r443"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r60",
      "r111",
      "r303",
      "r318",
      "r319"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8",
      "r15",
      "r245",
      "r248",
      "r286",
      "r314",
      "r315",
      "r483",
      "r484",
      "r485",
      "r494",
      "r495",
      "r496",
      "r497"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r494",
      "r495",
      "r496",
      "r497",
      "r526",
      "r553"
     ]
    },
    "GCTK_AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed dividend resulted from trigger of down round protection feature of certain warrants granted",
        "documentation": "Adjustments to additional paid in capital deemed dividend resulted from trigger of down round protection feature of certain warrants granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_AggregateSalesPriceOfUnitsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "AggregateSalesPriceOfUnitsPercentage",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commission as a percentage of aggregate sales price",
        "documentation": "Aggregate sales price of units percentage."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock",
     "presentation": [
      "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocation of proceeds and related issuance costs",
        "documentation": "Allocation Of Proceeds And Related Issuance Costs [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount amortization and interest expenses related to promissory notes (Note 3F, Note 3G and Note 3H)",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r433",
      "r434",
      "r488",
      "r536"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r88",
      "r107",
      "r136",
      "r165",
      "r169",
      "r172",
      "r173",
      "r176",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r240",
      "r242",
      "r260",
      "r300",
      "r370",
      "r426",
      "r427",
      "r443",
      "r457",
      "r521",
      "r522",
      "r541"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r113",
      "r136",
      "r176",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r240",
      "r242",
      "r260",
      "r443",
      "r521",
      "r522",
      "r541"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "GCTK_AugustTwentyThreeWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "AugustTwentyThreeWarrantMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "August Twenty Three Warrant [Member]",
        "documentation": "August Twenty Three Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_AugustTwentyThreeWarrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "AugustTwentyThreeWarrantOneMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "August Twenty Three Warrant One [Member]",
        "documentation": "August Twenty Three Warrant One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_AugustTwentyThreeWarrantThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "AugustTwentyThreeWarrantThreeMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "August Twenty Three Warrant Three [Member]",
        "documentation": "August Twenty Three Warrant Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_AugustTwentyThreeWarrantTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "AugustTwentyThreeWarrantTwoMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "August Twenty Three Warrant Two [Member]",
        "documentation": "August Twenty Three Warrant Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_BetweenOneYearToTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "BetweenOneYearToTwoYearsMember",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Between 1 - 2 Years [Member]",
        "documentation": "Between 1 - 2 Years [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r76",
      "r236",
      "r255",
      "r256",
      "r257"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets",
      "http://glucotrack.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r106",
      "r420"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, and restricted cash at beginning of the period",
        "periodEndLabel": "Cash and cash equivalents, and restricted cash, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r66",
      "r133"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Change in cash and cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r66"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r108",
      "r109",
      "r110",
      "r136",
      "r156",
      "r157",
      "r160",
      "r162",
      "r167",
      "r168",
      "r176",
      "r188",
      "r190",
      "r191",
      "r192",
      "r195",
      "r196",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r260",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r358",
      "r379",
      "r396",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r478",
      "r490",
      "r498"
     ]
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercisable",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "verboseLabel": "Warrant, exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of warrant or right number of securities called by warrants or rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingent liabilities (Note 4)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r83",
      "r301",
      "r357"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENT LIABILITIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r180",
      "r181",
      "r416",
      "r513",
      "r518"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails",
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity",
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r448",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r494",
      "r495",
      "r497",
      "r526",
      "r551",
      "r553"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://glucotrack.com/role/BalanceSheetsParenthetical",
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "verboseLabel": "Common stock share price",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://glucotrack.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r358"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://glucotrack.com/role/BalanceSheetsParenthetical",
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Shares of Common Stock",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://glucotrack.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r52",
      "r358",
      "r376",
      "r553",
      "r554"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock of $ 0.001 par value (\u201cCommon Stock\u201d):100,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 5,772,190 and 4,178,274 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r302",
      "r443"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Comprehensive loss for the period",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r118",
      "r120",
      "r125",
      "r295",
      "r309",
      "r310"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r422"
     ]
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails",
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Open balance",
        "periodEndLabel": "Ending balance",
        "label": "Convertible Debt",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r82",
      "r550"
     ]
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from notes conversion",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r82",
      "r550"
     ]
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible promissory notes (Note 3F)",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable [Member]",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r81"
     ]
    },
    "GCTK_ConvertiblePromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "ConvertiblePromissoryNotesMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Notes [Member]",
        "documentation": "Convertible Promissory Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_ConvertiblePromissoryNotesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "ConvertiblePromissoryNotesPolicyTextBlock",
     "presentation": [
      "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Notes",
        "documentation": "Convertible Promissory Notes [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt conversion converted instrument amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22"
     ]
    },
    "us-gaap_DebtDefaultLongtermDebtAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDefaultLongtermDebtAmount",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt default long term debt amount",
        "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt description of notice of default",
        "documentation": "Description of the facts pertaining to a notice received from a lender that an event of default has occurred with respect to the long-term debt instrument or borrowing, and a description of the expected financial consequences of receiving such notice, including the effects of a demand for immediate repayment of all amounts due, and the classification of the debt on the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r43",
      "r44",
      "r81",
      "r82",
      "r138",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r441",
      "r491",
      "r514",
      "r515",
      "r516",
      "r535",
      "r537"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price",
        "verboseLabel": "Conversion price, per share",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r199"
     ]
    },
    "us-gaap_DebtInstrumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentDescription",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument description",
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r30",
      "r40",
      "r43",
      "r81",
      "r82",
      "r270"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument face amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r270",
      "r271",
      "r431",
      "r432",
      "r441"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt discount rate",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r213",
      "r270",
      "r271",
      "r441"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r198"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r138",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r441",
      "r491",
      "r514",
      "r515",
      "r516",
      "r535",
      "r537"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://glucotrack.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities",
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading)."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r298",
      "r299",
      "r445",
      "r446"
     ]
    },
    "GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deemed dividend related to trigger of down round protection feature",
        "documentation": "Deemed dividend related to trigger of down round protection feature.",
        "label": "DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_DeemedDividendUponTriggerOfDownRoundProtection": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "DeemedDividendUponTriggerOfDownRoundProtection",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed dividend upon trigger of down round protection",
        "documentation": "Deemed dividend upon trigger of down round protection."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r29"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets",
      "http://glucotrack.com/role/ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial liabilities (Note 3G and Note 3H)",
        "periodStartLabel": "Open balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r253",
      "r254",
      "r258",
      "r259",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r371",
      "r373",
      "r374",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r421",
      "r529",
      "r530",
      "r531",
      "r552"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r36",
      "r37",
      "r38",
      "r39",
      "r137",
      "r152"
     ]
    },
    "GCTK_DisclosureSignificantTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "DisclosureSignificantTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Transactions",
        "verboseLabel": "Schedule Of Operating Lease",
        "terseLabel": "Schedule Of Weighted Average Remaining Lease Terms And Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_DiscountAmortizationAndInterestExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "DiscountAmortizationAndInterestExpenses",
     "crdr": "debit",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails",
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount amortization and interest expenses related to June 27 Notes (Note 5 below)",
        "verboseLabel": "Amortization of discount and interest expenses related to July 30 Note (Note 5 below)",
        "documentation": "Discount amortization and interest expenses."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_DiscountAmortizationAndInterestExpensesOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "DiscountAmortizationAndInterestExpensesOne",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails": {
       "parentTag": "GCTK_FinanceIncomeNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount amortization and interest expenses related to June 27 Notes",
        "documentation": "Discount amortization and interest expenses one."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_DiscountAmortizationAndInterestExpensesTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "DiscountAmortizationAndInterestExpensesTwo",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails": {
       "parentTag": "GCTK_FinanceIncomeNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount amortization and interest expenses related to July 30 Note",
        "documentation": "Discount amortization and interest expenses two."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r471",
      "r472"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic net loss per common stock",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r153",
      "r156",
      "r160",
      "r161",
      "r162",
      "r164",
      "r234",
      "r238",
      "r251",
      "r252",
      "r296",
      "r311",
      "r423"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted net loss per common stock",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r156",
      "r160",
      "r161",
      "r162",
      "r164",
      "r234",
      "r238",
      "r251",
      "r252",
      "r296",
      "r311",
      "r423"
     ]
    },
    "GCTK_EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted net loss per common stock",
        "documentation": "Earnings per share diluted including warrants and performance milestones.",
        "label": "EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted loss per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r163"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents, and restricted cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "GCTK_EmbeddedConversionFeaturePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "EmbeddedConversionFeaturePercentage",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Embedded conversion feature percentage",
        "documentation": "Embedded conversion feature percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of embedded derivative liability",
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r529",
      "r530",
      "r531"
     ]
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails",
      "http://glucotrack.com/role/ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total proceeds allocated to embedded redemption feature at initial recognition",
        "verboseLabel": "Proceeds allocated to embedded redemption feature at initial recognition",
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://glucotrack.com/role/GeneralDetailsNarrative",
      "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails",
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails",
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails",
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
      "http://glucotrack.com/role/SignificantTransactionsTables",
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity",
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r102",
      "r121",
      "r122",
      "r123",
      "r139",
      "r140",
      "r141",
      "r143",
      "r148",
      "r150",
      "r152",
      "r166",
      "r177",
      "r178",
      "r179",
      "r220",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r237",
      "r238",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r272",
      "r273",
      "r286",
      "r308",
      "r314",
      "r315",
      "r316",
      "r329",
      "r396"
     ]
    },
    "us-gaap_EquityFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity fair value disclosure",
        "documentation": "Fair value of the entity's equity."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r528",
      "r532"
     ]
    },
    "GCTK_ExchangeAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "ExchangeAgreementMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange Agreement [Member]",
        "documentation": "Exchange Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails",
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total proceeds allocated to July 30 Warrants at initial recognition",
        "verboseLabel": "Fair value of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r6"
     ]
    },
    "GCTK_FinanceIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "FinanceIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      },
      "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails",
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance (income) expenses, net (Note 5)",
        "negatedTotalLabel": "Finance (income) expenses, net",
        "documentation": "Finance income net.",
        "label": "FinanceIncomeNet"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://glucotrack.com/role/FinanceIncomeExpensesNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FINANCE (INCOME) EXPENSES, NET",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_FirstWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "FirstWarrantMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Warrant [Member]",
        "documentation": "First Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r381"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://glucotrack.com/role/GeneralDetailsNarrative",
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current liabilities",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "GCTK_IntellectualPropertyPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "IntellectualPropertyPurchaseAgreementMember",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intellectual Property Purchase Agreement [Member]",
        "documentation": "Intellectual Property Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails": {
       "parentTag": "GCTK_FinanceIncomeNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails",
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails",
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expenses related to July 18 Notes (Note 5 below)",
        "verboseLabel": "Interest expense",
        "terseLabel": "Interest expenses related to July 18 Notes",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r169",
      "r170",
      "r171",
      "r173",
      "r269",
      "r426",
      "r427"
     ]
    },
    "us-gaap_InterestExpenseDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDeposits",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails": {
       "parentTag": "GCTK_FinanceIncomeNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest on bank deposits",
        "documentation": "Aggregate amount of interest expense on all deposits."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_InterestPaidAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidAbstract",
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(a) Net cash (received) paid during the year for:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r131",
      "r132"
     ]
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_IsraeliInnovationAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "IsraeliInnovationAuthorityMember",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israeli Innovation Authority [Member]",
        "documentation": "Israeli Innovation Authority [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of restricted shares as compensation towards directors",
        "documentation": "Issuance of restricted shares as compensation to the board of directors.",
        "label": "IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J)",
        "documentation": "Issuance of shares and warrants as settlement of financial liabilities.",
        "label": "IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_JulyEighteenNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "JulyEighteenNotesMember",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails",
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
      "http://glucotrack.com/role/SignificantTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July Eighteen Notes [Member]",
        "documentation": "July Eighteen Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_JulyThirteenNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "JulyThirteenNotesMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July Thirteen Notes [Member]",
        "documentation": "July Thirteen Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_JulyThirtyNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "JulyThirtyNotesMember",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails",
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 30 Notes [Member]",
        "documentation": "July Thirty Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_JulyTwentySevenNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "JulyTwentySevenNotesMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July Twenty Seven Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_JuneTwentySevenNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "JuneTwentySevenNotesMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June Twenty Seven Notes [Member]",
        "documentation": "June Twenty Seven Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_JuneTwentySevenWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "JuneTwentySevenWarrantsMember",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails",
      "http://glucotrack.com/role/SignificantTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June Twenty Seven Warrants [Member]",
        "documentation": "June Twenty Seven Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseAgreementsMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Agreements [Member]",
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512"
     ]
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r479"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r479"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OPERATING LEASE",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalEntityTypeOfCounterpartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalEntityTypeOfCounterpartyDomain",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of the other party participating in a financial transaction."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_LessThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "LessThanOneYearMember",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less Than One Year [Member]",
        "documentation": "Less Than One Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r285"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r285"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "GCTK_LesseeOperatingLeaseLiabilityImputedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "LesseeOperatingLeaseLiabilityImputedInterest",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "documentation": "Lessee operating lease liability imputed interest",
        "label": "LesseeOperatingLeaseLiabilityImputedInterest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total operating lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee term of contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r43",
      "r44",
      "r45",
      "r47",
      "r48",
      "r49",
      "r50",
      "r136",
      "r176",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r241",
      "r242",
      "r243",
      "r260",
      "r356",
      "r424",
      "r457",
      "r521",
      "r541",
      "r542"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 (DEFICIT) EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r84",
      "r305",
      "r443",
      "r492",
      "r504",
      "r533"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 (DEFICIT) EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r105",
      "r136",
      "r176",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r241",
      "r242",
      "r243",
      "r260",
      "r443",
      "r521",
      "r541",
      "r542"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_LinkageDifferenceOnPrincipalOfLoansFromStockholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "LinkageDifferenceOnPrincipalOfLoansFromStockholders",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Linkage difference on principal of loans from stockholders",
        "documentation": "Linkage difference on principal of loans from stockholders ."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_LockUpPeriodDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "LockUpPeriodDescription",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lock-up period conditions",
        "documentation": "Lock up period description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r187",
      "r227",
      "r429",
      "r519",
      "r520"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r187",
      "r227",
      "r429",
      "r519",
      "r520"
     ]
    },
    "GCTK_MarketabilityDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "MarketabilityDiscountRate",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount rate",
        "documentation": "Marketability discount rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing expenses",
        "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r183",
      "r184",
      "r185",
      "r186",
      "r222",
      "r227",
      "r257",
      "r292",
      "r312",
      "r313",
      "r320",
      "r348",
      "r349",
      "r399",
      "r400",
      "r401",
      "r402",
      "r410",
      "r417",
      "r418",
      "r428",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r444",
      "r523",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r183",
      "r184",
      "r185",
      "r186",
      "r222",
      "r227",
      "r257",
      "r292",
      "r312",
      "r313",
      "r320",
      "r348",
      "r349",
      "r399",
      "r400",
      "r401",
      "r402",
      "r410",
      "r417",
      "r418",
      "r428",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r444",
      "r523",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548"
     ]
    },
    "GCTK_ModificationOfEquityClassifiedContractsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "ModificationOfEquityClassifiedContractsPolicyTextBlock",
     "presentation": [
      "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Modification of equity-classified contracts",
        "documentation": "Modification Of Equity Classified Contracts [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_MoreThanTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "MoreThanTwoYearsMember",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "More Than 2 Years [Member]",
        "documentation": "More Than 2 Years [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r68"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails",
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity",
      "http://glucotrack.com/role/StatementsOfCashFlows",
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net Loss",
        "label": "Loss for the period",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r68",
      "r85",
      "r103",
      "r116",
      "r119",
      "r123",
      "r136",
      "r142",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r151",
      "r152",
      "r158",
      "r176",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r234",
      "r238",
      "r252",
      "r260",
      "r307",
      "r378",
      "r394",
      "r395",
      "r455",
      "r521"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net loss attributable to common stockholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r144",
      "r145",
      "r146",
      "r147",
      "r153",
      "r154",
      "r159",
      "r162",
      "r238"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(b) Non-cash investment and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r425",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recognition of right for use asset against a lease liability (Note 3C)",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r442"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails",
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Present value of lease liabilities",
        "verboseLabel": "Lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets",
      "http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, current (Note 3C)",
        "verboseLabel": "Current operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets",
      "http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, non-current (Note 3C)",
        "verboseLabel": "Non-Current operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly rental fee",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r280"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets",
      "http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use asset, net (Note 3C)",
        "verboseLabel": "Operating right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r442"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease term (years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r442"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://glucotrack.com/role/General"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GENERAL",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r77",
      "r321",
      "r322"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r443"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r308"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r12",
      "r117",
      "r120",
      "r124",
      "r148",
      "r261",
      "r262",
      "r267",
      "r294",
      "r308",
      "r483",
      "r484"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive (income) loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails": {
       "parentTag": "GCTK_FinanceIncomeNet",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange rate differentials, bank commissions and miscellaneous",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r443"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans from stockholders",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other income",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development expenses",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "GCTK_PartialConversionAndAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "PartialConversionAndAccruedInterest",
     "crdr": "debit",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Partial conversion July 18 Notes and accrued Interest (Note 3J below)",
        "documentation": "Partial conversion and accrued interest."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_PartialConversionNotesAndAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "PartialConversionNotesAndAccruedInterest",
     "crdr": "debit",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Partial conversion June 27 Notes and accrued Interest (Note 3I and Note 3J below)",
        "documentation": "Partial conversion notes and accrued interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental and direct issuance costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "GCTK_PerformanceMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "PerformanceMilestoneMember",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Milestone [Member]",
        "documentation": "Performance Milestone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "GCTK_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails",
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prefunded Warrants [Member]",
        "documentation": "Prefunded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://glucotrack.com/role/GeneralDetailsNarrative",
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_ProceedsFromAllocatedWarrantsAtInitialRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "ProceedsFromAllocatedWarrantsAtInitialRecognition",
     "crdr": "debit",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total proceeds allocated to June 27 Warrants at initial recognition",
        "documentation": "Proceeds from allocated warrants at initial recognition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of convertible promissory notes and bifurcated conversion feature through private placement transaction (Note 3G)",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "GCTK_ProceedsFromConvertibleDebtPrivatePlacementTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "ProceedsFromConvertibleDebtPrivatePlacementTransaction",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of convertible promissory note, bifurcated conversion and redemption features and detachable warrants through private placement transaction (Note 3H)",
        "documentation": "Proceeds from convertible debt private placement transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://glucotrack.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://glucotrack.com/role/GeneralDetailsNarrative",
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from public offering",
        "verboseLabel": "Aggregate gross proceeds offering",
        "terseLabel": "Gross proceeds from public offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails",
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails",
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total proceeds allocated to July 18 Notes at initial recognition",
        "verboseLabel": "Total proceeds received",
        "terseLabel": "Proceeds from notes",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds received from private placement transaction (Note 3D)",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails",
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of promissory notes and detachable warrants through private placement transaction (Note 3F)",
        "verboseLabel": "Total proceeds received",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromSecuredNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSecuredNotesPayable",
     "crdr": "debit",
     "presentation": [
      "http://glucotrack.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured promissory notes",
        "documentation": "The cash inflow from borrowings supported by a written promise to pay an obligation that is collateralized (backed by pledge, mortgage or other lien in the entity's assets)."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ProceedsFromUnsecuredNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromUnsecuredNotesPayable",
     "crdr": "debit",
     "presentation": [
      "http://glucotrack.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured promissory notes",
        "documentation": "The cash inflow from borrowings supported by a written promise to pay an obligation that is uncollateralized (where debt is not backed by the pledge of collateral)."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "GCTK_ProceedsReceivedFromUnderwrittenPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "ProceedsReceivedFromUnderwrittenPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds received from underwritten U.S. public offering",
        "documentation": "Proceeds received from underwritten public offering."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_PromissoryNotesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "PromissoryNotesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory notes (Note 3G and Note 3H)",
        "documentation": "Promissory notes current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r284",
      "r297",
      "r306",
      "r443"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r183",
      "r184",
      "r185",
      "r186",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r257",
      "r290",
      "r291",
      "r292",
      "r312",
      "r313",
      "r320",
      "r348",
      "r349",
      "r399",
      "r400",
      "r401",
      "r402",
      "r410",
      "r417",
      "r418",
      "r428",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r444",
      "r449",
      "r517",
      "r523",
      "r530",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r183",
      "r184",
      "r185",
      "r186",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r257",
      "r290",
      "r291",
      "r292",
      "r312",
      "r313",
      "r320",
      "r348",
      "r349",
      "r399",
      "r400",
      "r401",
      "r402",
      "r410",
      "r417",
      "r418",
      "r428",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r444",
      "r449",
      "r517",
      "r523",
      "r530",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548"
     ]
    },
    "GCTK_ReceiptsOnAccountOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "ReceiptsOnAccountOfShares",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receipts on account of shares",
        "documentation": "Receipts on account of shares."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_ReceiptsOnAccountOfSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "ReceiptsOnAccountOfSharesMember",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receipts on Account of Shares [Member]",
        "documentation": "Receipts on Account of Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r419",
      "r426",
      "r549"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r481",
      "r489"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets",
      "http://glucotrack.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r74",
      "r304",
      "r317",
      "r319",
      "r328",
      "r359",
      "r443"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r139",
      "r140",
      "r141",
      "r143",
      "r148",
      "r150",
      "r152",
      "r177",
      "r178",
      "r179",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r237",
      "r238",
      "r244",
      "r246",
      "r247",
      "r249",
      "r250",
      "r272",
      "r273",
      "r314",
      "r316",
      "r329",
      "r553"
     ]
    },
    "GCTK_RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails": {
       "parentTag": "GCTK_FinanceIncomeNet",
       "weight": -1.0,
       "order": 5.0
      },
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails",
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revaluation expenses incurred from settlement of financial liabilities (Note 3I and Note 3J)",
        "verboseLabel": "Revaluation expenses incurred from settlement of financial liabilities",
        "documentation": "Revaluation expenses incurred from settlement of financial liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "RevaluationExpensesRelatedToDerivativeFinancialLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails": {
       "parentTag": "GCTK_FinanceIncomeNet",
       "weight": -1.0,
       "order": 4.0
      },
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails",
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revaluation expenses related to derivative financial liabilities (Note 3H)",
        "verboseLabel": "Revaluation expenses related to derivative financial liabilities",
        "documentation": "Revaluation expenses related to derivative financial liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_RevaluationExpensesRelatedToEmbeddedRedemptionFeature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "RevaluationExpensesRelatedToEmbeddedRedemptionFeature",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revaluation expenses related to embedded redemption feature (Note 5 below)",
        "documentation": "Revaluation expenses related to embedded redemption feature."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_RoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "RoyaltyPercentage",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty percentage maximum",
        "documentation": "Royalty percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockDescriptionOfTransaction": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockDescriptionOfTransaction",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock description of transaction",
        "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r35",
      "r78"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://glucotrack.com/role/GeneralDetailsNarrative",
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock issued price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "srt_ScheduleOfCondensedFinancialStatementsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfCondensedFinancialStatementsTableTextBlock",
     "presentation": [
      "http://glucotrack.com/role/FinanceIncomeExpensesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FINANCE EXPENSES",
        "documentation": "Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r493"
     ]
    },
    "GCTK_ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES",
        "documentation": "Schedule Of Reconciliation Of Carrying Amount Of Notes [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE",
        "documentation": "Schedule Of Reconciliation Of Fair Value Of Embedded Conversion Feature [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "GCTK_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE",
        "documentation": "Schedule Of Weighted Average Remaining Lease Terms And Discount Rate [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_SecondWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "SecondWarrantMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Warrant [Member]",
        "documentation": "Second Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "GCTK_SeptemberFiveWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "SeptemberFiveWarrantsMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September Five Warrants [Member]",
        "documentation": "September Five Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_SeptemberFiveWarrantsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "SeptemberFiveWarrantsOneMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September Five Warrants One [Member]",
        "documentation": "September Five Warrants One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_SeptemberFiveWarrantsThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "SeptemberFiveWarrantsThreeMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September Five Warrants Three [Member]",
        "documentation": "September Five Warrants Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_SeptemberFiveWarrantsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "SeptemberFiveWarrantsTwoMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September Five Warrants Two [Member]",
        "documentation": "September Five Warrants Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_SeriesACommonWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "SeriesACommonWarrantMember",
     "presentation": [
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Common Warrant [Member]",
        "documentation": "Series A Common Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_SeriesBCommonWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "SeriesBCommonWarrantMember",
     "presentation": [
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Common Warrant [Member]",
        "documentation": "Series B Common Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_SeriesCommonWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "SeriesCommonWarrantMember",
     "presentation": [
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Common Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://glucotrack.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Stock based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk- free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issuance",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtDescription",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable description",
        "documentation": "Description of borrowing classified as short-term upon issuance. Includes, but is not limited to, description of underlying arrangement, repayment terms, interest rate, collateral provided, restriction on use of asset and activity, and compliance with debt covenant."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r514",
      "r515",
      "r516"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r514",
      "r515",
      "r516"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r134"
     ]
    },
    "GCTK_SignificantTransactionsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "SignificantTransactionsTextBlock",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT TRANSACTIONS",
        "documentation": "Significant Transactions [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r108",
      "r109",
      "r110",
      "r136",
      "r156",
      "r157",
      "r160",
      "r162",
      "r167",
      "r168",
      "r176",
      "r188",
      "r190",
      "r191",
      "r192",
      "r195",
      "r196",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r260",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r358",
      "r379",
      "r396",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r478",
      "r490",
      "r498"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://glucotrack.com/role/GeneralDetailsNarrative",
      "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails",
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails",
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails",
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
      "http://glucotrack.com/role/SignificantTransactionsTables",
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity",
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r52",
      "r56",
      "r57",
      "r102",
      "r121",
      "r122",
      "r123",
      "r139",
      "r140",
      "r141",
      "r143",
      "r148",
      "r150",
      "r152",
      "r166",
      "r177",
      "r178",
      "r179",
      "r220",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r237",
      "r238",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r272",
      "r273",
      "r286",
      "r308",
      "r314",
      "r315",
      "r316",
      "r329",
      "r396"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails",
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails",
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails",
      "http://glucotrack.com/role/SignificantTransactionsTables",
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r166",
      "r273",
      "r293",
      "r323",
      "r340",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r358",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r450"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails",
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails",
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails",
      "http://glucotrack.com/role/SignificantTransactionsTables",
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r166",
      "r174",
      "r273",
      "r293",
      "r323",
      "r340",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r358",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r450"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange of warrants into shares (Note 3B), shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r30",
      "r52",
      "r56",
      "r74",
      "r207"
     ]
    },
    "GCTK_StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of prefunded warrants into shares (Note 3A), shares",
        "documentation": "Exercise of prefunded warrants into shares ,shares."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted shares as payment for a previous achievement of milestone pursuant to purchase agreement (Note 4B), shares",
        "documentation": "Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement ,shares"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of Common Stock upon private placement transaction (Note 3D), shares",
        "documentation": "Stock issued during period shares issuance of shares and warrants as settlement of financial liabilities.",
        "label": "StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued during period shares issued for services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock upon private placement transaction (Note 3D), shares",
        "verboseLabel": "Number of shares issued",
        "terseLabel": "Number of common shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r51",
      "r52",
      "r74",
      "r324",
      "r396",
      "r412"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted shares as compensation towards directors, shares",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r74"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares as compensation to the board of directors, shares",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r51",
      "r52",
      "r74"
     ]
    },
    "GCTK_StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement of liabilities with equity, shares",
        "documentation": "Stock issued during period shares settlement of liabilities with equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded warrants",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r51",
      "r52",
      "r74",
      "r223"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange of warrants into shares (Note 3B)",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r52",
      "r56",
      "r57",
      "r74"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Conversion price",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r52",
      "r56",
      "r57",
      "r74"
     ]
    },
    "GCTK_StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of prefunded warrants into shares (Note 3A)",
        "documentation": "Exercise of prefunded warrants into shares."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of detachable warrants through private placement transactions (Note 3F and Note 3H)",
        "documentation": "Stock issued during period value issuance of detachable warrants through private placement transactions."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted shares as payment for a previous achievement of milestone pursuant to purchase agreement (Note 4B)",
        "documentation": "Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement ."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J)",
        "documentation": "Stock issued during period value issuance of shares and warrants as settlement of financial liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfWarrant",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J)",
        "documentation": "Stock issued during period value issuance of warrant",
        "label": "StockIssuedDuringPeriodValueIssuanceOfWarrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock upon private placement transaction (Note 3D)",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r51",
      "r52",
      "r74",
      "r329",
      "r396",
      "r412",
      "r456"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted shares as compensation towards directors",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r74"
     ]
    },
    "GCTK_StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of detachable warrants through private placement transactions (Note 3F and Note 3H)",
        "documentation": "Stock issued during period value settlement of liabilities with equity.",
        "label": "StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r51",
      "r52",
      "r74"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of restricted shares as compensation towards directors",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture",
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted shares to be issued as compensation towards directors",
        "documentation": "Stock to be issued during period value restricted stock award gross."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://glucotrack.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets",
      "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 (deficit) equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r56",
      "r57",
      "r71",
      "r360",
      "r376",
      "r397",
      "r398",
      "r443",
      "r457",
      "r492",
      "r504",
      "r533",
      "r553"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://glucotrack.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r288"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r288"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r288"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r288"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r288"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://glucotrack.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r289"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://glucotrack.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://glucotrack.com/role/GeneralDetailsNarrative",
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://glucotrack.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://glucotrack.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow activities:"
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_ThirdWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "ThirdWarrantMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third Warrant [Member]",
        "documentation": "Third Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "GCTK_TrueupSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "TrueupSharesMember",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trueup Shares [Member]",
        "documentation": "Trueup Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
      "http://glucotrack.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "GCTK_UnsecuredPromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "UnsecuredPromissoryNotesMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured Promissory Notes [Member]",
        "documentation": "Unsecured Promissory Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates in the Preparation of Financial Statements",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r90",
      "r91",
      "r92",
      "r93"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://glucotrack.com/role/GeneralDetailsNarrative",
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r448",
      "r451",
      "r452",
      "r453",
      "r454"
     ]
    },
    "GCTK_WarrantsAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glucotrack.com/20240930",
     "localname": "WarrantsAgreementMember",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Agreement [Member]",
        "documentation": "Warrants Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Open balance",
        "periodEndLabel": "Ending balance",
        "label": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r530",
      "r531"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and rights outstanding term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r530",
      "r531"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails",
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of common stock outstanding used in computing diluted net loss per share",
        "verboseLabel": "Weighted average number of Common Stock outstanding used in computing diluted net loss per share",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r162"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails",
      "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of common stock outstanding used in computing basic net loss per share",
        "verboseLabel": "Weighted average number of Common Stock outstanding used in computing basic net loss per share",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r162"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesRestrictedStock",
     "presentation": [
      "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted shares",
        "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://glucotrack.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "15",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815-15/tableOfContent"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>48
<FILENAME>0001493152-24-045894-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-045894-xbrl.zip
M4$L#!!0    ( /6!;ED0Z7"+H <  %$K   *    97@S,2TQ+FAT;>U:;6_B
M1A#^7JG_88O4*B>9 'EI5:!()) [I#2DP%6]CXN]AFULK\]K0^BO[S/K%YS
M):0E24]-/@1LS^[,SCXS\\SB]H?)KY>=;[]I?^AW>_AD]->>#":7_4Z[EG[B
M:2U[W#X;]CZQ\>339?^7BJN"N,D:]3!F$^D+S:[$DHV4SP,KO6&QL8BD6\%
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MON1ESL'/O\%NWYZ=%U'MK-(S58OUR%IE:HJ-)W"WK6:B,(VCH8AU9 JZ9&]
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M.'#%_#10WQL(B'8EQS>H8UX6E_CO;\DH\:F5-"Z0OFF\Z[SKOL/@U:<S25E
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MFB_?R9HXU/QN0'MYU=Q<?=?BY>&8Q8U%\12<KNDD(%!V' 6/5@'XWNNY)LI
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M_KCD;$UR1-R14J$4L3TYU)N(;Q 6*V <+7C-[@H:Y7CR^ [P&NB@-[5&]QK
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M>L<3YZ%'O% @$2_D.>\A5BD'#]!"CZ6.1,3!9O)E[[.O*1</T,-]44N!2(N
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MLPT<3:1E&\HV'+WRTA=Y_87\''VT@[>G$XI0<3<TYR0.L'H7^AR?RL2"WT+
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M8<MH4TE"::.0? N1H*+QR>](Z:.9NM=BOF)LD0X1![]VQPD)]R<YG[RN;4[
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M8F0=RWO$>N_ MY5.2U?=!,>F;0JF@XOV*6(0%@\3NF3+.S+A[%"S:1M(=]9
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M+3-+9PC^,]2'DT$L!78P(W%"(:<(#4JF1Z_B*SX1&D'<5Q?!$W6@0,=K(!H
M70ALFN;)L.$)/\Z.B:\B(2FNCS& !P^L%^TN8!M$#V0@$*+:Q=0NK>^.XO3(
M"<_-2;Q<<%LJ T_WE8')50:>[BL#]Y6!NUE0MJ\,_"LK W=E87],R5S\DCCA
MB!!M^^0#RCF+)9\[J.JZO&X-CF1& <GF>H JK@<H]A!/TY=?93UW_=W2BL\[
M7="YM_0W[) ZIYTE=MDKE7^:7M6JXNOYO?10ZQU^\5P3P;TG"#NW=T'M!F%N
M$43\QBGZ?L0<-@IM8<'-=N[=\,9*9K!<P87"O4&>)#<_GC>O^*'(=V2,5\6D
MOHV>4&E5A7*F<)Q/T]@.*RBKR8C7K+RR=US*4A\L_6/!"32 RZ.N68KE%@,U
MQYI  Q.L&LTI4'-?X]2I>?&[':@K83S %B9._9P'UY(!A9L"U!!($BN58XX7
M[RYY/$UNT:!)4T;!C<9]6@-(.G0?3AKR:C>!KC8^ZQ\#F=&[19M>^5'.P&?&
MSU=RJ- MU:.E)AVE9QM=/,XC[L-UOC9+,W1H29=ID[#?-EE>;^+4J83Z9#\%
M6C&XSC3X<]@</9-"SR(G.>\S/*EW@EU>(N\]UM!IF%*$_@^+9^9"%K#K9*3U
MA-31S,#;\*8SIS+U$CI]96B3)[W+RRYQ'>0&&TY^5-@50F]BX%MX<Q#)T7-]
M<"XT/1@=-AW9&D,J$_6+DC\X?E%G"&1?>'QT*]P7.7-G)8GHJ55,=(7SL#:V
ME2(39@Y.#E?*,IQI/:/>@V9F!G;"$FSLJ"-J'FQ13,Z2R52&A._HU#L+S11P
MCA@J9_/%2E) IE!ILI>%TV3QZLF>=VP#[_!=S! N0.\])!=$1V(H.R%B2(L<
M3L=,="HO%4 ,I0&CGB'+@,0(VA]&;EQ6HW"6X.$$$;73X>(YDTY%B&:<!1//
M7.H2,F>PO; _9)\4B<44:)M"VBAXJ%C8688"/M.D>2/.RF%MD(3UYC $FJ'B
M5P:@V0<&H!@C#1T&9N6RS1,!#MCY@^<9SOZC%)N@VA#@39 4HZNX8[XJ \)<
MAHH]%(Z4$\)+G:4[4.GAK!/[<SG0V/(;0M'2[V%J,ROL9BR,1A0!M9;(K9%(
MC@(P&!G?^,26'"$+?>">?++RFV)R%8^R;^>C *^FQ3+DE<>00\KZS2)@=]@[
M4[0$<PR@HH##Z_:O%!U0'AJ+8Z*8EYG,T5 %!D'B#V+"TAS.W05!0#ES)%M>
MER5'A*$V[@(Z];F *O1H,'^'H]-7-.F. B'XNJLLS)[E/J'5QWR:FB\=^5+)
MM2\G:Z)^[5U#?YP%#L&,W7<-U9ZF8_7[Q2]C]/U6+AU^<6\+STQP6+T7 <;A
M[<";YON,MH$*MM/SLF_/O75'LOW.,$?!']JJ!45B7J\6YL; W60@/*#G]B%C
MQ2VA$8Z(+'B!N#>_PTS[I)UOM9G6L_B9Y_OP"D>%XFH<*Y,%_(M718*Z6*^N
M[YLBKTKE6#^BPW$$O=NUB:I*,Y[8<XB4!<@]D0,ZB/$#V>L.\):Z=@#IC0%N
MZ*9OR_9VZ;O,^CR Z.0>GR?UW>? <H]2G?##E/S.'=>S%>(_(D;L)QPW_+M.
MA8HUQS\4].Q0!);0JNE@SG^LM5#_6LAZO!7QWOG[C8*4+P_-]'<:6IQ322X^
M)MA12:^QG5#I-GIFY=X>G-[^\KSWK+F1PIR0IA4@RP4$N<+%4H9#65+(^.01
MYBV$+,L%\P@CP] DX:[3[8RFN.(DP=,3FKWJL;,#ICK5OQL^931J:^)=J9"Y
M.$Y5G&JW:\@PMF-O\UQIF_$VK_T==C#,DD??1)0UO]@RCQ& #7O 13N.D[29
M2>^S-I/+VLRD]VF;[Y2V&79^WFU*SY!FY.79\H2U?4KE/J5RNQ>V3ZD<)=I1
M.[0*8]-^^M(,*I,GR#;?%9_V-8>,^M+3M#W.G?\8?WL8U*7##?#Q625H[Q[?
ML'O\<O?=XV=/T^??EX5JU2J=G1U^83V.%SJ\9\NX]EF2NYTEN7D8"XK1CO,+
MJ;5E3ETPL@'@G%B4O.Q0G*G$%5W[&@,XQ" 5\1?>@UBAO6/E"7[9YU@-(J^'
MN!-4N2\"-KPD6V)W@/2+64HLEPL]!K+154SX*,4;+LK#CBX!%)2GVZ<#@>SK
M-3RR#3*LB>D9U#4UYAXN"MS(,C-HCA3=!/PB9B*0U?<4R+O0; 12)AO0A#I>
MZ'C;HOX)S$Y@<Z3N,?X=YX\C(C9EYAZTS92#MNZ!AA>#*1XSR._NO!'WD:;-
M\*/UGVH?DS-HCDNT-\>9!FQH'#<.]V_ZW^H\3,MKP:?O\<'W(A(\6$-I;Z?A
MJ.8&43Y$ELKA F 2ZE ,  GUY(HP\$V7]'W^'-[*@*^(WA=X3$*7$<]>G>,S
M^E (E-(,.-B5;)JR? 4UTDMH4G.^]32]K#Q.NY52[?&TMP<T^6@MJ/'7 ('E
M *P]G1DW'R_T?.?P"Z7.?4')3E#J%L70/Z"3M(-4":*)C !9I6U]1%A^.9]U
M$DLI08=6;N2S3MD&;<!#,["]RHV31VA"3BR 38 (\S1>AV@CT:Y ]1&Q0[4\
M\J-9[ERC[EUO-$X/W-7^_+$LQ1,-ENG!(1J*V]J'_HUH?^Q8E6 \3/1_G1+&
MA*AD3A5 CS @?4P&HT$W0P%@5I$%MLGF'2F?\#GZ?4S4Z(%&3)1/\I^!,N(#
M(6XZU^( !(7]G7V1D&:*#.8;C35;0F04FI',45$<'=T=&14V3'X53:)W=0#$
MCBEKO/D)5:XE?(]_VA S8S%FD9SU,^1?BX:#W^+&YVU3[MG4.%&5GNQ;'(S[
M^HFIK[1-DZ^@@KZ+H<E@+)(A\-$$9=.;2TQF#TDG_!!\H#7N"SFJT1%[+5Y]
ME::LX*8HZ,>E47W!',F@UF.L4?-4W= T8]X;!G8+46XAPU@E.Z-19=HV.5X\
MHOS1)&%VECQ7S]W->32G!2F4Y>@[U3]#6;8"= C4P&@/L'N!8F%_0LP>>C8.
M_=!*.,3&@11LQ-77 V^A6^K2=D=_E6?RV%GS,6J&JC2A.?@:IYB-7A;?LF=N
MY>ZRI5UGJW=*?V!QFKTG)\A%Z5WSWA&C4?TA6'R>59KIO+AQ.(1@*@;8$?'2
ML6U#V8'#4#S4ZC &)[3OO4[GZ*H@EXE!/$756>@:81W.4([3A/H78#%<#:".
M$\LI#K'(GM%J5G<IZ#? S@\1S>68T&$W"BMC)##[!64(-C:YU."2\<_5AF_
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M3A=3A6P8HMT?GC&4/2F ?_AL>?25* \-&W%9CS-^39!TNZ/*L7"IEQPENB"
M.SN#S8P9@38T:'Y,/N ):Q5-"O.@F=%^@M-,36O9I7;VFYO(7HL;E_558V]^
MKO:=KKRU'DYO[*7F>C0'>G7=R:YBY1>6TOI#T>INY[.W#UM:<2GU;/[2TB?)
MNVCQ#H9=X86-OG:+=50V<!UG7 [=@?Q:*)BYOK8.YZB]QU0+MZ^CDEA^/>_G
MMYIS+/ 7%)>R';:+<RQ:VE)JWB+.D3_=<X[5.,?I1@1YT'EQ7[F3OWWK>++%
MMH1SS$SUK2%?3)K%;]^:N:WF' O]#L6E[)#MXAV+%Y>@2I4]R>VYQXK<([,1
M81YP@^AC35+UPO#U45J'?6R"T\W,]>>TE.\5]-??=_VM9A\+G!BE!/7Z;5M:
M@CI5YB17?F_6P3TW_\7F$5\.#OC[L!.FTH4^XYSHRY7,T[1N__Z6UA]JM\V"
MT^]BS7;=+G\:+9A H?PTE:KM@?5;>7NYZ*PP 4DQ1ZHX^2R0-\B1\TFN53A?
MF=,<_("LD"Q0?@.BE+_\^W^.CX5S15:ES\*MV"=3:LF_;9G0)1DA^X_P(*HV
M^3$K'!\SUBTIKW$3$^GJG,^+V+N<=@GIRJK*:.5_#PE-P^]DCEW^N_\-75U5
MQ9%))L)_<KI&9M+0/FVV17JT*]#21V$$&>%LI/UV?:\[].T:WZ]_A/9D1-Y?
M,<2.TOU'N"&,@>[IC0Z[E\EZO_5?_C7XR+T*_![\^U^RS2$;;LCBRW%')C>>
MC#W"\V*;3%:U0SOLV\V@)S=L$[Q;!WM*M\U#R(2L1XGQ@XW>O\3F&=X8.KFY
M_]OY<G%U7VVV[RK5;P>-F^K)O__M?-G9M=PTV_760;LI5)LWM?I-JUZ#GUK-
MJT:MTB:_G#=N*C?51N5*:+7)'Z[K-^V6<'1_4[FO-<CGGX[(T^V33SN]!T>*
M=F -=-L4-0D+F>];0@TNO&'N\,+"+EE0BOM^C6VER697'(%$,&PYH'CE#[VZ
M7XLL3>D1)JA9;:+DF519,MOD)6<J5> ]>H0W.++HFT_3DG&:M=_:(\4J)J7R
M^$_DF4Q%Z4TV<-\.<L*QX#==RMGLT_1WI5K//[\\?C5.#[^T&A<WC?-&M7+3
M%@BON6E5JNT&N9G.@;X/76Y@%\((TY7.7FD<E-9++] GK".%^F$@3!I__! 9
M/QLI77JZZ9."HB5,=Q6_F KQ.<2?YN9O29V!&N(<HX -_<NA1I/'9'+N@T/E
M 9-F3W.;I+G +=]F@FMJ.+6OHF9#&5$N)8"T2PGS:J0P Z>!Z"8UVR#$<DL&
MUUEZ"7[8'*'(XJ0L^?S1.>:/QI^2PBB:OMY?3U[:5_(/U<7KNIV].HLR:)9?
MVQP/;\[]:2E,GM)Z.3:YTT(J>YJ/<M2$<12A#_^!!M(#0[?[ P$^-L:&8EFR
M)HSLCDIT)+W7DV%+(->J,C(4%6@E)PS$5UGHR.2YGJVJ$Z0GCLP*>5G0DWH@
M"R;99T\VEQD.G4-^AX?A^$5M<B+LV=SVLCDBK,YV3+1V!Z+6IZ*UTC=D9#A[
M:;K=9+9[TO1<[A@H3C..//4P-0'-7<X:R9LY6;HD2?;2&A ",BR1\%K&I 76
M7U0X@L'^W_\E=E/ZGTOZ-_PM\\^G%.'5AFF3IW$B9/SQ0.D.?*^'U$/XG7U5
M$.&M$CPK\XEXW\!GQU_AR@R<I*2/-0'S)XE<X>V\A1[MY^V5!<%>T)3_>]_$
M1:+S)C(TF5AGXILN$8Q1PL.'NT:_AC-PI$E3\YQ-(4K7\?9 \B"Y4_%*=8,G
MI>'1:;*9'#'*W\[N]/;CV7W711,+QX=;I(-$O-.O:%3,9H^J%]GC3"Z@/ZQ7
MAU/*E%/%?%BR&M4?(G;?U0/8"2B:2U%P:O/P6&+O\_(=%1A9<46Q4;B[N>]-
MO_ZP,^]_3DZ' -^D_*=77J\FI%PJIG*AJ8;T]/@M\UT]^F5^\4YFQ>$VB)B_
M5*C,3G5_) MGM3,>P0:5U&.1"&+5U!UI/! MG]@;*ZHJ:+J5$B2T2_'#$1JG
MPA&[Q5>$$QW?CP1JLSIB]$CY1&TWHAVHLM274T0'T(C([LHX"M%#"-LD/(+K
M#";17%/(Q8!YN'^!?PN@0NAH PNZX7N(J!Z$VYMRROEISL-T1#0[/4^E< J8
MC0-?X)J/;W#R=YU,VQA#YP\+/.0],"D-#*7KV V$;))B$%5$G<#?%8W_EL)7
M46:7(OM"-@:5,:Z*301S+([(=ZCS#=Y"#P25,GHF[(7D^Z":$9U,IN\01J)A
MT1<P(U8FZ]6'-+A@LN@N"AG0:PQSH(SXDX[\29$19?I:C5K2I@WJFQL'(/S?
M[!I*AY4\J:)-5HPG;- %B1W]%90@I@V9LD5$'*I#DJPJY/;C_/@;#?H"NE13
M[A+:LA29+JXKF@/?7L".X[:1UPS%%WJ\DCP$C1($//F?TY(%/J+GB&HB>=E(
MQI.GNK A]Q63+(N21L]S+C *G@2=S 1V#WD6T1]Q*GA6[JM0K\1?J:J!O_N5
M1&\R4HINU.LGYM50)^YE .V$WP74A\FEZ5+R])P /1:R&@C2^ ^!T10]"GX6
M*5",7Q5I]E;[[K+_\J;(!D]"NG1Q/Q@\?3^BS]:0(O#^>!6E$)4)$A*:O0I<
MJC[2M-^YQE5]QP[A.M./^N//\CA[\U!WRXYQOO:(\R!R2I*"GK'#+T*LX!KH
M0Q[-B#G((N804)&ROEA;Q&8<?CD2/U&FY6$^7B;'28Z<BDA.22$T," T2ZX"
M.2E-^!]BRZ8QG0V?$P#(F=("UAU*XD0@&T#&RJ3_PZ^R)!(Q(+SJ*EF[_Z(=
M==:=3'G!9/"F:3I_NZH,%0MOV,E,]#.0LS5BLG9GQ.9L(&VWYM]FIJG_U@//
M(H0@OXV(P!(8KY!%0R4L&8'#@='GB@4X;4(H/0N) XC.(L0B&S((%R8';,+&
M5*]T 4J!PEJ4#_\S#XP(OW +%#C/_EJ5F9S7IAWI]6U@:;+? *-$O]!#[TQN
MKJ&U%#M9K2;7GRH9"I#,'.XR%:)TE2";>D004[6@:UOPL^<:FR>[2]9_RK5T
M?&7=+E$-(# "IP:7R7'6,7XO0NJ=*2I2P"_&M ^BUDM >%#M"SH T92H1PX4
M?F*%=6U5Q')W>M>[JFY2,K#H1)CSB\Q=I)=,L$VN,8BFJ4 I=Q<G0S9&-C21
M*.BCD2$2%<R ER,#>2-Z)RI"/5$QA%?(X.33QVGZ'6>,K8@O--1CZ3@1(%8R
M?Z:QB:!LX];@QF">)QF1'-J+;(D=107%#069 :R)?)0IGI0S1$J^,I858'S.
MWV>GJ!,U4B$+H\Y$]/60:1'ET<;].%).Y!//YN/N*IAB#;L^SSWYZ80H8F/Y
M%30QLJO,')J=@4;HA[Z8*:#NRWW>S$]XJH15$W:!AVH**MEY+L'#!S?D$=D^
M\O3,TE*SI$-&)#8@-9*(>6&0)7JYQ3Y^L87QBW\[7ZJ)A<D2GMB5+)K[<-A&
MR"E$4NUC9&$QLM.%,3*D4D]TS.NY=O[JQJ= _+8)+8@O0AV&(6JE2:9X=545
MI(XH/"A MHI(R9X(E@D>NV_4*Q%JL@S7AX;Y$%RX6-1=%_#4\:FCIT[%*?>(
ML4NE'1L/+3MYB/-1]2Y("292!&(8DZ7=Z1-133ES%(A8$5'$B@*1,]: V)8&
M62R9;D]&$3*CR'NC*LT1"FRMCSMX*TY@H\RGD9;5<HY.?^JX"DX7:_?.YSBB
ML_FFZRFX[3=*Z;Q=<2O3KV<FODC'#Y]W5*8-T?=/W9^<$$OH# .*?]Q$F^,L
M85B$2,@<<WX+  HLPU#(J>:/:HW(?23DN(*G5?"<UA7H"K)_[6W9&#9[5>8N
M '-,LAZ]1[?N@8U-^>O%W>]OG3/7LX/S('S &%+O&7WYX;R<:9_UM? ,/'L.
MC2T^2[8Q(69NX'#*AP&R6+Q!AU]R$:Z.8WB!B:Y 60.A)%R+!KG,&<I]G,0G
MSI?P6F;+^&G)QQL:Y/050L>4*_E][2>$[3&WI22/B"YOA=Y1;TM8_H4:?1XM
M[N#]7/>0'[\]VFEB9IJW;M5W<*(+[6[_/.<8WTM=P=.XT<Y5KR#EV43+)@HZ
M3$(847:"CGA-IFP5_.4#6?5E#3@\FQELP-8[H*\3TP'=P[ZD"N:KT22NUX>1
MR98&5C\@A+D-^N\V!U9WZ$BBIAJP$VA!8GJF"#31ZKJ&=@ F!H82??=S  J;
MQF.1Y/(2982,&G51J<JET;"8-=8%/BIYC@IS]*?DF%211<(@>L0"T<?,.7,0
M.JI7C- \8@'DEYN]Y8XA2J_@V9' WH=0 #J2>HI&XWXPCL-73X3V0 Y5#PE)
M'L"CGG<Q%W/'X^N@7AOJJ9%D$/OX&A&<*82O$=8H(K:B:%##3C>IU\=4R"&)
M!CA6R)Z@ZV*.%COCU4SNGR5(S6.H?M@<DB1W]% :$I!*P@M",PJ3#"!Z:;(X
M;:55%<KY;(K2-9D:=UQ2O8K:9Q+S^?FHU'\?P7O5U\A2:"XBC123:PF!5)%H
M>5;"JY%_VT2+@#=0RTQ5N)<2;I,.-T8<HC\S3%^K1=I45WP<JK?E?'K;]+YN
M5:H_N]^&O8)'N_:]?SE3R'G=//4KH&#%!80XSD4K6*4P"!F\SI3Y!#<5[.,A
M^9MMN+YMIH#YO9\]&QRQ]/L)'SG3\\P44^# T<V]UI 0(4)Y D91'9<MGY6B
M=0TD6D(6"GHB3,8?9ZU]W0:U$?3"W[9BT$1:\FJ!^<V3^Z>C&X8^)KR8\UU&
ML-0[X#!C*FD42+@!EP7D2G0PC7CFB[K&%DLE%;N2-,G$LQEX-MO!O3<=J-KQ
M155,3$+R'ARH$B.64>(E6Q[.P2N@3J(5(19#(@)<5:9.N@[&95"I.,"\<4MF
M2>6,_%B@POL:\A<RB$E4J YY'\MMCPA>>/!?$HL=@LOU(^I[XZ.KY/;H*@FB
MJ^3VZ"I_'[K*OQUG>;N*7;$'6=F#K.S$PMX/R6C#<"11<"/"QFGOHW22?8A^
MG_'AC:=#^"Q YW$S/S9+ITF#-)WF9V.*9#^JNFFU8941\$RG)5^8-O0;3]/&
M5%;3#S]_?)ODDH)E>A<&X;B8#M#4__SNO,Z7/;3"^^)@:+XGJ_7#6YUEGZ:Y
MUYI=/_MM//YV$;M\LS[\TJI>UFOW5_6#YKG0O*W?5=J-FXN#JWJE50_)UC]8
MSNR(OY>+#90R,'=F!M$..(R!QFFXX[+KB!Y;N*=C[&,$WU&EV48ZD6W6R51A
MA_[W,'OH;'^>W%T7_OS7K]O\7>VU-/[6#YIDD69UR(S"%*N6/+(POBWDTC2G
M(%:#Y9G15VMD%+FO"S<JT@B?UT'-.R]GIZ%K3H2;_ [6U^S=FW(%G/O@+)^:
MXNW]^/)TW*R*A_,7MUJ7)D:NI?)_ENC.Y$R;AB2.]=ZQ$Y((GB=[0?8_D:.M
M!W/.M:F0^:^&>,X'#.X(1S]?(A 1.-"H<,0L/O5I[)2K.>&(8EBZ1^CA9*(.
M9XG6YBZ!EQ?'@:JV 1%8I/#)0]IJ_[Q[Z4X'*U!XS ;ID<3'9B+H#DD'HC0[
MCM6_2MB,[<D2Y!H72F,>N687DVMR-)I;3*,WNM;UD*FI%+X/%%$V[SH;8<2Q
M*9;,ZWA/M?/.*S;AEM.Q\^KF$&X^K*8M0<*-!_)?)"3ZHY]_:]^9XUQF9Q!O
MW\&>+:>S<7)D'4*ZAK(G\M^YMFY]04KR@M&>IL_=1^-!DX>_ON9WR@[FZSD0
MH2C 5,P &B&D:65*_YA!CK0A@_E#"'1#UO?F_;D;MN'/GJ:6VDQG^M.?C8N7
M.#;\=:5]?]=H/QY4;BI7CZU&2R!_1'->N&I4SAI7Y+.@8;^W[U>P[^L>^W[P
MZZU]5=*^OO9S>_L^<?N^$E<R\(J=FHT( H.@[Y06:]BB"AFI?M@ &+<]$+6F
M)C_*HL$K&'YV<^W74MX8GW;?W5EP^ 4F16MXH6( <GXC?0%S-<_E+/JUS/6X
MYS-/H^0@"J%G$E!$XD(HS%,W<XO5S;D[N!4$?"9;8UGF>]76VV,=?G!J<:KI
M,[%A91M6-;,YI\#A%S8-(7.<18(UYS*,R&'"F?B'4N/\#0Z091+>IAADN0(M
MYM^!%J]U0X:+&Z3!^\>SMU/E;5B]RGZ0Q8\R'J9'V6J 1N=(U.4M>X^HCTO?
MRXSS[O0??J@!ND_";97)+6W]9Y9R6JW+_>*H0NMSML4/KN"96^;&3^_*P^:S
M/+SMU9\_UD'7QD*)H&N.)]K_R9ZY)"ZP_XIFDG#0E9:_HLMZEO^R2UKP8"S.
M._/&<$1[N=+JD"?EIO$D*4_3VD-?.O_Q]6X$S< _3K3"W#\+"IVD4\/R_O(U
MWN5<1;12Y,<ECFB)J[E:R51H,]W#+V$M=/=2=.4+&IUDX*O%FQKMRF6G_?UE
M]+:9J%:$=+L-5KGYG<6*_$>+R26K%4.N7A)^A!CI >\0MBH\31NWA:MR\ZIQ
MV=V=1HV;3.M^ES".;R1\EP10>5B[]ID".:D*>.LK3DW_@:)1HL/R-HW>V5"O
M_$X'=Y*./F:*_I:GW8$LV:K<[/U ?[<L50C#%?ORG3P4%<V+V ,M[VNL%O=.
MM.2Y 4EO;]2D7O$T_75=/^_H-]^[+\\[%:4$B%(7)@+!&4Q[.!0-!W=^S+9&
M$.G>" ;?'":, .+!Q#Y #HHG%C=SC-,/2@/>.AZV;EXQ%+7N:D U/ R:>YKV
ML^?51JMT?OZ[$R<,^J/>N+B$0J_*0_VN<E$7[NK7E<9-X^:"!4/;];OKEE"Y
MJ0FU1JO:O+]I"W>5]C[G>868:$P3:PSZ_S'LF PG-C;$T8Y$03<3V^,L43A"
M)_2G#<3VPL]]48!O#FJ<7]%>* PS?N1 C)77LS_+[5>[]NM')@!.XMV,F*A_
M5%6(@^M7SLS@^BV[& !\RV<C>QJL'S%<VZ3^$13!/D&[Z5!<@&[.X]*-5UVZ
ME8TN2Q"%!@#2R$LZ;Y:M?:O_:MB#4X=TYB]Y.<-Q\;SB6Y39I=JI,9,2P 8=
MF_+6-LC\3T_28<[64)J;/;S_K&)!GCU-!]VOI>^-ZN7/3&^G+<A]P>F&"TYK
MVUIP>FLHK[R;P2T@W6/)Z1YN?'=(*P118P< QEF'\NSB#KS0=P9(5!@YY.DV
M??,"?WN'8,TR@K(VXT7VG==+GJP'/S(]_77RV2S#XL:?W('LCJE("C'Q6R+X
M/G#@ /(ONV;.#>.I'NEL\V>K8/UXJ[IM:6^"7=CI8A8B ,=:3Q1*=_XXFW5_
M<B""P^<=$.%QXS$1_6Q/4[EB,48[6\4R6:\XVN,-V]IZVG$M@G+V-(2]%8VF
M@1UJ)<1T(EN%T_$W5$KNF"\>)OUOXL/EKT?GE*N>KG>LSTNL!DLQ5A&E?2U_
MLNMW7BJ>A.9G.9V7V-(1):]/KG4?;CK1WDT3D"V[LDPA6>8>["U[$*@9J!S@
M-AE:VBUV$6Q">TUR(WP0D)NXSGJ^T5)>.YU"I>@<="5Z6716BTX\]O(V<;>3
MR- KA#3?$A@-^#!WV3I<N'8 K^1_=;L& 8J>TE5&HM/O$7#P63OV(:XBLCA$
M?N,]O=RF32GA3!<-A :O82M2W:#^5YF<.F;2()&R!N_A*.&) ^+MBA?V@PI*
M]N;+>^J8]<3,E_> CJI(#/R2L0;L($';T L-#?P3</\)W]/PEM]!BS&3-6(4
M6B-5V9L]6TZ2?V<S<K_I5 PSG;!+!BC*%4VS156XEF448+S5+9-A_AY-OD=#
M>RJ%2%)7!^=C0F=#_5664C2A32 ;(=+9N0%1 */73:(Q?,9FJ:+$VX^'2^L%
M-Q<ZJ>(\X'<BR27:"%P7*D#%Y/XU'J)&K@*A]Y0N0U(F@^O&B*4AI+S=I06#
ML0>FJ0-[B!B4]Z8$O;[E6B<X*'REPXH^=$T^)DK5,;89A77P/U@#Q; F*=:B
M$CI_T^_2!I!>\'^*<FU">W-PY!JR9Q=Q&K,:S8EP[FV!$*"0%"164,KBH:-4
MZ,:%J4KLX,E:Y[6[:GF(A9XIX[SX ?)=KIKGTEPU!W]V(R_?=6W[5^_5[8]S
M-WLJ<V,A7FTXEW9_"JB[,\&/&),^_.(]T(BX!VL*&9>4G&Z?0!VV!7U$)4<1
MG>F:[KO.CCC#3W"&CD*-LVAJPK4X$3*E, ;24U0\R,#]J'AOU[+WR6U6T)*!
M5'G_)F!*E@?*W/FE)JOB&(0QY3[T*K)>!"'+VW?D_;#YG^NT=S+KQ(LLWB8'
M3YM/J"HCV!2#(Z=FE=,-%K#X;:,[@*AF!&7#\RJ:S8ZO@.+CF\) ).RS PQ5
ME&!IK%D?&;0/C)40FJ&#M4E^9LR<T6Z(PD<=$*K;/H:U0W#ZN9@RE6K*$%'3
M(52/361[BD;L<<!E-X%ZL=#@A/4N)+>)F;LBWP@R*]-6<9^<[H-ATQG+Y$>,
M89)WT"[VM-6MB,T.Q@/@_#CDH@:SNT-+$3EQL<#9\WMP]@3!V?-[</:_#YS]
M_?Q!>U3V/2K[PCW8H[)OG8!.")5][S+[("_N^4YY<6]TEI8")L /:C((M]Q<
M<-O6[GVUR1!>R(GN';@;<>"N],]76Y.%;*C/QI<OHY%KX[6R70O;R9KQNW]G
MKY3C D:_#0NLKCYS17LE-JL>\#JS]0@-_JG;9A5;6J*[BY>\S*8 $87 UDQH
M>@T!86)**Z:I&Q-<OLE[L#H9!:M/GKQ9@U#SW :4WC;Q-;EC-333,FR8YSF9
M;P6_&.Q 6<R6/ D%_F_Y86+N^3IOG64";W3@8IJ#N\ZX6BG>%K(A20?!!2S*
M-HB:?U122?&8+(1AG\R?J=_5FDL"8"$3DEG@=;BN]$\8E>(R&(72U #H*2R&
M/>;<GDA7%_7G0,S".25"54&B.O.F+JFB27:<2<&F@?C>-$^LV6.MWQ79K(JJ
M*DMG$_:<R1XT@?9<JIM^JSS^N'E\S7=N,R$$X^2=+<Q$6F]2\P@J0"IK]DCE
MN4BY=#J5W@3%N+[+4->X-R(41EQ\9QPW_>[Z@W?=GQV\A%5O_&J@&Q94N "+
MK,EFUU#0J>UEZ.XE,R]SUN.WV\>[M)L*AEP$ 'E0X93<(6*&KN!J1%Z2F=XY
M4?.E1:IP+C[N)G1D$;N&CU39;:O+(YC(%W+_03>\J)$;B.P-F_;:5-_@RR*R
MMRN: ]Z_E@RJ*IC.^EDX$C\)F2SMA4ZCI8X3W-O2UCNM?P2B AQU/KD/^?I4
MBXHI _:C8DC'D!8V@5;2$"WNBB.%]@>FP6&4W=AF&GON&O"!_-:539.'HOXG
M \S!=T$YY+!0$UV^3K/2^ R&X@1B!=A2.#!U$S>//&,1F@,YK!O<C^\;&-4L
MW:8]M4>R)JK6Y$1H]+#U\2M3=B2Y)]HJ^;%+^*I)]3_R?^W8&QT,4U9F9S52
M;1/G96LC49$@=F/8'A@:G,=8457X1%9E/'TXX8[<U<E*E.%0EA3R1W42//23
MR*JOS3"$;.8D%P2&V'.UF?G7B;+"R3PH= 2BDB"EO<E&5S'E.<G4"S62.AOC
M%H9P/G0D?L:?7HULTE N?_SHGS[>#5[<6C4^-?^<5M)'%DUI"2TD;BIL=#)T
M_N0T#/O$U3Z<("=E,C-G!?S6>_W8!N$5A!N*(='9+ PO9CP?JZ))= N:+@,!
M88&EJ&]7WC.ZN*O_.IVJ5?%7?O:,("?E\^>?M9^?/]\6'@-4"V6FQ\K;\4"1
M))G0-IE.5GGK&"K9SO+AE\(Q!>OU\@@:PR6#[K6@#YO__8A<KI#&\U3LN(G3
M$#'7NR)/S:#Y[2C\G21W\FU9@=R@#K%\)*X4&+(J8F"^)RH&!6,Z")55(FM<
M+LD6X6%(YS.7 HQ]1#Z<8Z$O*A=H]D!)FC70W4OP5>O7'^^_M3)]T;D$?"2J
MQJ#K895D?OKRJ.S]>4I?/A$C.I(GX?;/[*47IOF<G!\&WBN8@@%$X3+9>=LY
MS9_>=JO?N]=7 V<[SQUB@#/DIO.B'9T[A94V=4USD\+*16YJ"G) 1C(FIJ@3
MRNA[OI4'K\'!F(AH3_:?<Y5H;B%1_(:Z)*N";<+/(GFT8P6P8T+\"]E(IQ6'
MY(."[CIFSI"ILLIN<O-GBL[Q0,_&Z5;QVUGZ1N\[!UJ;F<ARWJ<%$XDON_-+
M%3)%5YEGRR>AZ&5XL/]AZ6K$&G"2A\+\ >)HI"I=Y&7\; S%?#DYF$\)#K\+
M4L.$'3PFM0 &DZZ"ED\4'I<T+/&%EM" XXGF:OG3=.6W$<VQP[2K ZH$ONK
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MDU,Z)HOAK7?F3C7@#$PB;R!7W#A.#J7:A3@Y[F-[M),/G[^;G^\YO1@X(/.
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ML97.>$7Z3\(3EGTW/UAFL>"M/TU?NH/6_>OTLG>]"IGO_6 ?XP<+/<]YWK
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MT':TJ:OMUYOGA]OSLL.WG+B19[D.6YJ?5!^NF<R?A)^?0"\\S""5Q,E$)DQ
M"_ ?!VQF7N/3^#M]R W@3!$%4&$F9,PX$JC8$*KCT$WS8.'X^RJ:1%_8M"T
MGP/O2IM\'U0/Z>UJ'=5CT<'>-E[[M6[QQZ0DSAXL!3"%B0FZ.S-<VN?//VL_
M/W^^S:0?XT,#%$X)0T_[D[4%.#V&>#9SHVAW.>]U@O[N< ,1NE[7U G;\%>
MM*;:TC&%H2=?5R1%M8%Q,+Q Q2"CSU[;B-;/V44M@&\0U;+9:T&?0,R/J!(S
M1);.)D%"@H/<P"$V-9F?8_];]>>/_EDA,W8;<N*D/9#I$ BF/1,]>)S.W,F6
MPN1!YW;8(O_"0G5CS?V)HY<NW 0_ RBN:;XX"D@Z54J'Y:$$%1"_70+%I3[.
MB%0;UFFZE&RGZ4T1V._+7YD']?E4NOW_[+WI5^+JT@?Z/7]%[E[GO:O[-BJC
MP-[G[+5P;)P5I_9+KT "1$."&43\ZV]5/4.>0$"TL46;=[WG'%LA>8::ZU=5
MS468//TKE#$/QZ62,H@ZQ7-!L1-@J9$YN]QY=O3XN\N=\X$GR.(\%SRT3[9K
MY_76'R9WY"&,4-><')]R9KTXL:OT!+&32:C*-&%36V!AHU#5X=;-3O[4.3MK
M6A]%V$PBAUD1O9.%37YU/3^SL F[MF\F@\7/R9NMQ9<W^+.@C=:>;1_?[MUD
M]XP_3>+$QS!"9+\(MA645LI4WT#F/$M?[RES5,K:^'YF=']L[MRV\A]&ZDPB
MB?*LYN]DN5-8+<QDY'RTP-+'#(>)QL-&TP-?-X3+#S@)4J/J1(]I^$5@A4"_
M;/(C<&S;=@V7T-).C.8?2^7%/:UES!FQP]2:7P;7:!6ID53]B[T*:FA"3-9(
MLX&#K\S#AV.SN7LO1E2(@18M0[9:#[M1@*4B77+X:2$$K,9R.M]DDR_ZAB][
M*8^-O4@,J&,=_),E_V/"JZB6)])#9%<%;)?C>#C!?K3!.HJHIQO[X'"S[AVU
MO&XL3=@RE'>:\B'/EN!->OLT^3$B%%[7!VTDI5>8K"+X5(B17#2S3$R[W;9\
M@N@VK7  ]R8I::SM LA;?F,J28I)@2F=L]6 [VC@/GU1_,M\(!30^-0!#K.V
MUJ>;#_:<:+^W\W!K&,DA84K/^#8\@B]AWNWW4^Y]+NWW<Q.OG>;/ -=W$#W0
MZUFFS?+OO&D^$SY67%SX); L%K)/E \N-<EO637+!TKFXZE&E-7 G*)AB<V;
M@>H8:)]:IH+%=8+U4@*X%)HE*2WJ3Q()M F-Z1?\")=XR7? 2^Y]*+PDL H(
MMB5.<F'O:(F3_+0XR5A-E7X%*<D5V[B?@W^DZLE<90)^DKEJZ2C*%R HU:QK
MTS-\<.\L.!!ANKX>X(C3)G_&/\T3T-9MGI2M[%W?>,B]-<"QNI(MQ3^]%,!6
MGD>SA5RN,-D;XO[*& :64<<K<;""'&4!LJ!$_(6*A1TCCNKO(@YGN(VAK=&1
M.)YW;=2_Y\HG1^7WHHS4E8V0Q5Q:=1;7)Y+%%]\"1YBU!O0Z%LY99",[TW"P
M1"II6-C9H+#/3B;\O3!89SA):@1;Q^7VU?"'E>LL"@QVTF*3Y%+Y]4#K6\-@
M*XL&@YVKOK$N?+=T<O:X=5S];)#:EVJTRB_&]V3&L53,Y/.3)1@[0P&S'T/>
MI@6'1Q"V L6Y1-5^(%3MV)VFV<'/(6NE;4[K*(WA:QFV5K'@7XJN+;X!NO87
M+2*YFQW[063NI/RZJ[5_W.6SNUVC.0]H;;KE,V4%+\/55DH+BJO-OAI7._\K
MO:P,K[:*>V=;5]VW!]56RM-!M2FLQ$1W"K3V%V"U:1P[ 7!2?0O R?QN40$]
M'IX<M+]O;3UM/!8_$=;D6<$P 3A9F1/,)(<=*ZMIXSK2@28LIC,!5_L[8&YO
M0EOE\E7;.<A>M8>514";O)8HJO/P?UZ.IGV!N'D68/V^XD:!/>9WZTYN>&]=
M-#\3B/]9RIH G:S.R9NI5C+ERF3ZF@W61C+HK:%M;T)43[D?O4HQZ)S;"X&E
M?34US(IAF">0]B5B9GO!Q8R*=#3V>^N=IZ>+ZX?2'R5H)J$EJ[^8"I"@_?5,
MI3 Y(?!:!.VS%2'O)F94HFIT?UQ:SMG59>Z#")J)U#"KG;O$SGZ,52\B=G8D
M:O8L=#;-C7\=>):EE"0L*PT\.P?@;.XUP%F43$_U4[=W>7!9[N,PC_< SJ+D
M4"5"#OY_+N/[2MG),N'=H+,R%/\,3C85(UMZ!4:6+MF]/1^&]7+>.K'? R.;
M<L5SP4;G)U<**R!9UG)D"91=\%6_(5 V39J_#BH[O_;^"]N$^0W7.38/=*8^
M[M5E'_<Y]G&O+ONX+V@?]P\J(#YT7_;?OY>CA>O$_OO/X&6]UT=3U/.=(PW,
M/YYDET8Y)K4WX0T@KM *L8+8GYDP+'ID7/U+'O3S:?.X52B?'GK76W?SF@?]
M <>__,;%BS[S17UE),1<R>=_/IE;QL7NYE/[WC#_^G?S^/"P?LX8LG9$;'M>
M/]J%?^L']=I&_:!^7M]NR(-X*_Y<5E9]\,JJVL>IK.+XM7PVR[&O]< W+,?6
MZZ[K/;!H5RT"4>YC".1+O5[[JN/4+1LC7 @>[] ?V+?@3,.N;N@=EN]H/]<^
M6@72;D2![5I!  *U"6X[OEA*4\0>!_!&GWXMYN<-$X&0;#%;R!:5.'R-A2$#
M0G<>>(:+ GJ'Q1[=SIG5LNP'9(1@8WA@=0QG&UX6#H_;FQ2>\3%T-XP1N")L
MSX\G/AUY.#(7]/W2OC3/.MV]W'-1EE?L.2T DP456%B!S?/H_'-K'%&.ZW,(
MU%0G)FF(O+X<U1M3$WROO?U^MI_]&;$-+Q05=#?V\[=.J^X?=#\&%<R:L<M*
M(L@J1,!>]M>_Q7PVD\U.;%+.ZR\PL&Y:#Y;C]4%:P.=6;/?!"+##0-/Q/%/O
M.%'+"RR]Y\$+,)J?:&M.7Z2(YHECN#'2=4P<V3AW]SZR?19M[1M#W?>&AH,)
M!]&F "0:*_7P,=X$@JM#Q6$L+#Q&L^JH8GK2\,3RT8(&5Y$R@F;_9W2"D7A!
MC-1&=E'(\F?@A[!RV"3_)OW[T';M7M03I!NY>UGGK%RZVHF3V7RS&+/CN]5[
M[%O31_V.GE$:BI\3;N'E)(S+_YE8_0A1ORCQR,EZ):_0]0GE0R8*MY644J!/
M2!_&HTH?C_WNL%_<=MN/E:GTP;[U_O2AKCY)'[D78>TFT\?$+-3_B9H.5K;(
M)]RW85MZ8#@R>LWK U"2Y<K_!/A),VI1MUX[0'%$WV")I:3PTZ,^"C'X@2>@
M0-P93FIJ:7U>ZE91LZ9EKZPH!/A2+7G2J]0OKVYSW>-;24IB;9@8$(LCJF"K
MPQ_CY<D4\G!!M6R^6JUDR]G"".'-FAQ+U[;/F%Q,R5(AK*QX!15W4-\X/HM)
MB1GI)B5%:S0)Q+?ZCM&B1+V@3/:=IN6VNN"JWI&2S.A8-*5C>*?#<O6H0_DX
M77HUK-\Q2.EV,=T&2\ #IV2,^B#EG?'+DA4SIF>Q*;U-.&1XK6Z'X&0X#LOM
M&'H ?A&EY1%'!E]IA;09KSU2MQYGC5A'HYX!6@,82Z$K24G,BQ'%5;A&(=R,
M(3L;5V]'.)2>F#A@/!<\Y^QLS9'_,.M;R/XZ_^T>EG.=MIVS]XIJE>ABL)J(
M[+W.H,W-BF^<PF+E9UB,Y020C@2?K>J-J-55R<IK@N_.#I"Q"&:C;7ZDQ'W+
MEAD+% _Y4[J8_+?Y[\;'B5+Q/B2B6KM,PCRO?^$N(6D,QR-3:7(+$K6?"/F*
M#DY^1W/IQ/? < 4)#^9<"[C4TFNBNTC"]92_%2^@59&Z.#$B1]\%WQ74(P.Q
MV4&J;;?9M:VVOOT(?@*IQ.,VJ"\KZ>(V<&E^O L5&X<*$$%VO+=)ET/I.2@M
MB)JW7&L1LLSR>PRLA$4>-LJ<0/86BQNH"*22<H1X%[@(3+&;] 0$P'5<YDDK
M&X-O@SJ&9\:+IGT2<CG#E HK,Q*FB,WQ<QRCXSF.-R (51!8(1!!G]T&@@*5
MVKXO&$!F;0B=84:"2/B)B8LS0?OC4\39_:U_L;_2"MEC^((R<C4!+0?^WHI\
M'^\;7\FUNZW0B,97-<2O<JF?H=XB:)TX=L\.19 AQ&10!F&1IH6VCO@9T=X^
M[=!V3> 1?ZC?N=Y@I>L-6'L<ZEQ1/Q$[]BW'"%E7"S3PP;P!@Y]B]QK3+Y$'
M%IX(E026&V"D)'%,ZA%1TX8AC]J.D;XXL']H*5]L?FID* )5D\VE+@C^H(T>
M>KHFFU,/NF5ZY'.D1Q:H?=9OS$+R-$O2H!:]'=10P"A/C4O;-%FMJCGJ= 3?
MXO(;*Y#%2#9RQR10%>%S)N7DF?AAABJ38H2PYL&%:>UNIO;P@..A/P6R5B*/
M@6:J_.<_R0=AL.JX74/D7H>TTH@KH\@L(;+$44E%]M)N*(DDON?27H1G=+U]
M<UP?7-_?EF(\[9&LVQ%H<K7WR2^U.Y%'E=KF)(_-3;+E^"?I$KW@6$1GE+'-
MCOA-KQNP(&O"LE,3 )/F^R1P_0P<'_7QA,$'!_\>_@E[HV6Y?!XI\"$B_5VT
M$JC$ %<-AA@G\W0#3MIW5/RB9@YT%.VX4M#.;?9N@2!V)":5,9K1@6<CIS#!
M-07!_5FY8Z8T@A]NKU]TCOT]U_KL'/1<'B+WN@*H%_*4;_7A?RB4A>%3< W&
M\U>E.#]1$V3<P" 6KP:[@'<'2LJ"U[FI68M/09R;FW;A=,^PVC<%)?#5ZP$A
M4GT/MH]3<AD(91#'Q8-^4POP*+DQRP&GQKW>@T3S<TJ%Y%8G)T/D!-&NY29Z
MM21403(GDDD1PRP"S-PPN(ZHQ0R<N*Q6R'+X#N>-P"-762FWBN]3/I;'<5,Z
MX2QY)O4]O+Z4GI3<P+D?65&?"3#!<]5+N,:!F6T]67\JSXG'CQ_/"#>^:*3>
MKW&CRHB<6U23"9>Z<M'7V6*38WMKCC/)H$MR,6,^8MO8S&-1+691"6,-GL8^
M@V$;C,_ #:)+XCU@4T\99V&E0ZP&-8#C ,*BP-Z(Z2=#&2-A,83B@F]#.#:D
MO6#>!6#O"L[]6.N_ZBK5E[)17HM0.X'N@EUO<$<82<CT*-Z&?C1(D C+*?4F
M3S=E5%I@Q%5K7.AY<&E6LCE=YI65M!20^KG7MUMZ)5MBP5P0:;#.H:A&V\+'
MV:*KGQ$_Y NJ'7W0I42HA<%"RNT H2$S4627\OU!(!WO%D<B692J^\ITD5([
M;2NETQ(FA5(1]\^^'MBR_!A>)@-SA'-J>1T7SM5D):[R;75WY80OY RL0\.G
M[H%F DE@@UQT6<TS>YD(K-=/SOY?H]?_9RL1\&;.6A0PEO/5IYK*4V'_R'0!
M#US'U7BFA7%INB:\3'@<R^8JB6(>@85WB("'LG^68Z; !_6NHN+.Q*24)3^_
MV_IK8<S-B1@53UPHER\MLG$*E[X,2Z+TA=\.3"AIDB5>@ _2"8>IJ._> $C2
MYYY[JXL@ @%P4(<<*>$%-;1@!S)FQRKZ#36WBS@(UE0>/I"6[1%!O]#WG+AI
M !6.3\JRR^211/*DEJ7KR5 &+JUG&5AL8J:%"'FBBNG66%8P 6;'O4"!9YL4
M_J:[H0,*L<0Z5M[\#$TZ?2[:?'@S6-OX/::9>1H\ML/E0:3O>7QA\.1 MO#E
M3PTP-(.G*,1N_,36D!DM(S?,UAY\A?.D%0!-><[#_)OC+N7#2R/AK/<M&+HC
M'7(%=86R$68J9R+3"4YHD[)-YU_XF)-J&W+\!F9A,>+(X;ZC$RM8:3G%T0V9
M.%7YBM!&!M)5Y. D"A$WI.)UL;[(:=N.BJH:VU@RHIE8!K4YH"*S1&A^6BG%
ME44]^<T:"#XL"Q:-H,A2/Y-&-1GJ,OA8R*YG<Q1\A)_RV9]/^9+7\CMGPTI#
M@7G&%CFW^[E\"NB0G@O@O61AJ6&\PDIV'6PY\5,^.^(VO:ZG61QGFQIF\R=M
MGE$(D$(+.[\ :8C,J[C#N"6,P&D*7.A4E.8Q6I;":*NYIF*RI8V9R/'[8]BP
MIT9TYWP?7$3=W:9Z?^FVFNB0\=P-/K^D21,DQNLU$S<WE]DAA<DC]8Q@LJ$J
MVX/P\J4 O$S*BK%4&6I]%\--J.8(M*C$ES#;M@+"I67T[=!PU Z^D_F;D\^
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M%OLL_"'[7-[GAV7ON0O,"]>(3"RW64":6.S-_C)AS,H0S]I"R^>F/%>Y'FF
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M-I;HIV!5K[?%&.405H(/EZ^C<:3X#->+Z4L#CK"#D ]3EO HG?V:'-&,T+1
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MAL"\17UZ$LMG.*P+W.2#QPP-*_G%FF NVG%)+FA!VV7A )+Z_+C8NC60EG1
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M,C\N(YB_:XBEK@ZQY+WU!9R;Y!#*+![75>EO-,V.4B%"*Q;OG+L (]>D]G?
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M@_<!%18B(UW6RY2UX%.\;\$Y4_D^:6T"$71LWI,LB)H]$"T&=N)W4]7:*G6
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M?"NZ=O$$@3)1M[0PF\@0+/&0\Y N$EG]^6 Y2DZ16 9:=XI$M.X:3=ULK6*
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M9BYX;6SM7>N3XCB2_WX1]S_XZB(N9B*NNI[]W.G;< '5PQX%+% ].Y\(ERW
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MAH][<$P3G'$@Q=4[<55]Y,8EUAE:+VVM?'49&M_'RNT0'B8+V^?7=$EKI8O
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ML49#F$+._$51,PV/75%5FJ[$P:+RU+0W=$>-0SRZ 3(C'UE#+(<=!)[/4=>
M3C2]DI019+X+7C41P#55[;R@V*-J)!;&6$^5-V_2A$.5N"3JH PR3 <<(I"T
M8J+JF8&)NG..*%A4GG$$0*?HZB=7""4>G8?&B@P5K$40E6QZ)>M(/>.M 6O
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MCCRY433F 1P>=HX3K5$EY[?*6O]3K$N.?14U9+E55A]J7C:=++" *\YW0P-
M<\4'<SKS$"C2\N$UKV\N">56[4A.&(^.B[>?2.K%YF3!J^3\=7@3..Z$A\5V
M'&2&D>$,?0\/9.%J&/GF(G^A/7WNX^]A^EY.?$[ ]?)5I83P>R_Q2@DCC+E,
M\OKD?+#GQAJA7WQ$)VO&1,HENT+EH[?89.4_@.:2KCWBTG795A- 7I6F0A'
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MX=SDQ^USD^/6KYWV8Z^C#>ZU^VY?[[<Z6N<?PTY_G#LM^7-.2/&"%*]]YSP
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MC$8?+E=__^T!ASC>E<4BG85AMD_+Q7KY%)!W(F61G8H+$HT!3SED(^^=0B-
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M&RIP-2>&OX/@@@*4<)T[#VNG<H@+>JGY>I<@+>^"K:R'D(NY98 <9)\%?1E
M3) "4["AE454V LC+C'-E9/,TPA_^3M^499+D'/+"07,/BD&0H!8(4>FH$4E
MC)@T(N)>B'&?Q]L@?UG&H6&H$ 7=4D,%M,^-H10@<BB@*=A12:/E_-+G2+(*
MOLPC0M1X'8=LT]G $J6\6[(88/<YHQ &1!T]0@6#B!+J:_DDTCP-LWR7=<(=
M6%*(_.4RB]0>BD'++:FLBM"GEE8%$,%L<"IHUE,]XS$I*,M190!1"UX8-XLB
M\J**ZI_;.,5OE>67RKIEEP9NGU,204!,4J-3\*>2/*L_(*I#L_D!(<V[$45]
MYY\T[VQ)\PXT:=Y-(<WJ<P:$-.]'%/6]?]*\MR7->]"D>3^)-#2MN4_:7-+L
M6ODJ^RP+SE9*>J&,"%5*F%8,'ET$;":R7+(<9CFB*CYIPARK17Z?9\]Q&JI=
M9I6X%\(H0$M9,Y"%1QTY0!-_&H>XUO/:UW"GW-A(:C$_O4P?I+R+X3+P2-('
M9NQ<N+1/2MQG11DD_T^\TT[$Y<)>Z"$%+"5)3Q(>563P3(3A.H@H^9A85W2E
M&QK2HV2#W]T= 9; :H\ =WX$00(9(O$(,%\]X4*NJYER-,>!HD?H_^RLDB6@
MFCKN_ :CBD5 0@VS=DUD?#3DVXS&2#UEJ3I 0!1QEOI. :[)?3?X'42-*T )
MV>\R%FM&Y3RMQG\I<5K(N^_.;\Y&]B&<9B"O?P!1NT,TPC!=_^ZX-G_.XY(\
MF28(V:?5+H\L;E AYZJ6M3#K&I<*@:A]';(A$RI9U!=V3(MEEL1A7,;IYB.9
M?.9Q("N53,@5(=0 :S:($B"HH(0EI.YI!%$MZ9@$]SFF),2D(M@A0)Q&.%^L
MU]+17B?LBA1FP#4YU)(@2&*$-R0+43@/.QJ(JR"FXY<V\Z+8XWP4>20JGBBD
M!*\@DB /D4XJD$92<46?W%KB<$^O;7C[[G$5EXEL<BF*.!N3%.":$6GP.PAN
M*$ )N4KI;S0][=MW7S]^@VHMQ]5_EZWR(")#XO)E^Y@EBNQ34BE7)-! K'D@
M$0%!!36N(1ON,E2)(B[K(SM5#ZRD.(/?71% "JNN^MZ/("I=ADA,5-RM:T]=
M_O67\(E>_*(XD" 7<]WURT .N_^N# @*:(")^42Y**IE?1Q(:(>LC=D)V'AS
M C8&)V #T0G8V#H!&V].0/U8GB*$]$N+QR3>!(KDA%IIUZ300![R0R(*BBIJ
M?,H^HU%!K8[KC)8LQ=D\76?YECW_AGR0E%(AYRRGI0YFD]12)@2"(SID0EI+
MGG2N(XRHM&M>[*.XQ!$'4UUE&21->D39BKA9Q1E;+,$WQ#'(P^"0'4B!3ERM
MSF78*+:I+ETOI?, C)]QDOP]S3ZG2QP468HCOI8BVRG2R[N-F#' [@?-*(1!
MT,D&H2)TABJ=_TZU4*U6K81Y8=)/6;)/RR!G9\ES6<^DD'/+' 7,/F,&0H"8
M(D>F8$@CC+BTGP/:/'M$XV31#D^: D8O[OBXMA;TX-2V5!809[0 56>XJYP?
MK6_,M3P=L2PQO2\B?L9701E4V)3E58F[/E2I ST\32F3!40A+4#E^<E&AZ:*
M"6I.>4L9DU\25VN3::+$!U+N$\<($,7<,8T(('K(<&DRR.2HEO7"A>4V2)*+
M?1&GN% /1 ,IMUR00NQSH2<"B LR7 HN,%%4RWKAPO46YQLRO'W(L\_E4Y6?
M55DVA;1;;F@A]SDB%07$%1T^!6=J%<1UZI2Z?LCSI4THSK,LJDLJ$75,&R78
M 6<$.4B$48$3V$*O1B83XKNL1*L,?2HP*I\P8N&L$?F^DPF>V_%UTT@8T@,1
MW"M/HR"744@G[/S6$25@X>X101($D8SPU/>0-!JH5G',F@7A<-Z=QS$0\Q)O
ME:<=S"JN&&0+ON:121X$FRQ!#CG%U/J3:Z:(J*;/;$;=Y/9J%Z\GY-@SE@ <
M.,8="1 <4<)2N<7=NP+\Y,[;/R9Q>)-D@7J5I2?C.&.>"&^0+*\5 ,0 $94J
M11X31$S22_U?!.GO^7Y7AB_W>19B3*.LBJ:W,JV_66J[Y<RH(O799*4*B&=C
M\"H8V)I '1MGG1'+YV(>OS9Z66;A[\NG@+S Q;XLZ A*@*E7P;5*CK<7+ HP
MV&30: "BG@5,U88#OPJ<J9XAKHPZVI[F9T6;!1!'%R\/>(US>NY@A;^4%^1!
MOVMF&!:ZKF=OUL493N:,BB!(.!:M:JI7H*X!]$ACQ"H3Z%=J!#$KKN\OYTWE
M-BYH#WP?Y#\%R1[?XYRU%F6;5,J[[?,,L/O=G4(8!,EL$"HZN4KI#!$UQ/3H
MZA/O[8[*I750/++B[(OS31#L.*%P4A;U-RVSJB]^:R*1%NLF/.D^XXMDLT>:
MYST<^GSC5%WP;4IA*/7&Z'EGX02P0O!KK4K#IMMHM%H;_5KK'[>/F\++65'@
MLC P<"CDDFMR@%U6]27 \$<*2XA<7"ZO5TL@+*AF'59D$&3=<T(!5Z3&0! 8
M0^3H5-<$!4S'.V$N@^)IED;TG^M_[./G(*&.W:R\#/+\A0S";/A5%-M2UR6A
M1A6G2S K13"$&X-6("!10F2VB$+Z ;?JWKG(EOM[;4E1?)F@2Y:I@78I)4J!
MX8\2FGP')H359]E0Q",[C,3PQXDR*X/DUG8D4YTCI$:@<6*QP_0*BG1SBX,"
M/\2;)^+N?RHP*Y"J%>AUG/8H-O![G8M. 4X_8X%2Z')J'910)913K?-L?;XG
M?S"VG:$4E^CKNZS$Z/WE-]ZY=Y]G!'/Y<D_*49)AF0[).SIKO%-23Z_BDGDV
MX+O$T\F#X9T%2#%=#E=AKA&NY1G5O!/L 9,I14PCM:CS=D<J53OVJ<5=$LL$
MNDLJE2P80AD #LG4BC,OVSN!^+"N'?-]^$AJYPBB5Z1RAQ:KV2T"LOYS&P>/
M<1*7,2Y(M\>V"9^R),)Y0;O \L6P)&2O[I(L8PO5I9.M+IB>9B1@(<'P?'8Q
MOYVOYM=+-+N[0LO5XO+O?UW<7ET_+/^O?_N/=V__]&?T]=7US?QROOH&7?_7
MI_GJ%TBLM5NZU"EX8J;%(J9:&B+[QBUG)JVB=SI5$<C%?? 2/";8L%"@$'8Z
M&FH!]T9'J208^FCA"5LFE3#:<6GOO.G/5NNF\&)8BS0H^5M%4!5 O8PPU ##
M*RN8IH6$NHMZ.6L6KXZVAK )R]\9H=[\\/X-(]6'R]7?Z3QT&Q=%EK_0!RF6
M++62+NAC 95R1B/FG2AF;)+Y?B6,4BI=<^$#6P#@G__J?VWI,DN?<5[&I']D
MA;(:TTQ*3G?DK K0VXK3:GBGVBB8XKT^C1+:*1AXXY]U5SB/GP.:DZ#C$"K>
M@T+6)<>T<+O4D@J"890.G1"#V<BB=1.7U''"@79G;#]1G&3HMBEETLXW>]60
MA1U?410,P?3X]'N_D"9XU@3RS1T[VGAFC''YTYHQ_9UAH(QI%^_M%YED.IYX
MI(:OH)2H *8_LD$I)J]/SR$R;-BW&G?I= H^QS?]3IU:&@RKC!#%2_F"M$#T
MK:"BL][NGU+R50\SL\QZ %:E##PS*<&AFR72$<M3::>/@Q/F8IX*>IL &J9]
MOB9[8SPKK4L%::"C1U#CDIW_HR'(&4OU@LD$5$D+K8;;M2@C]/Y"E%(<3.]C
MQB@N034:/ R\UBDEZP??^^]V1@<Q0 E;&!>H\ I"$T8'(W05ZN #S!2]LZIS
M!%][Q$40<]U?R4 ..ZFN#!BV*(#)NJ,ZHP$]9?E_HC??OGGS%NV"'#VSL[]?
M4^J\>_/GKB3[ZNV?O_GQ[9LW9V_X_U'!TR$$^_(IR^-_X@@%!36Y)*\9TUQ1
MZ/V;,T2IP#J^*QQ6W[YEW[[_,_KWLS_]Z=W9VQ_>,('OS][^Z3_.WOWI^]IR
M3//&1^RWK,VY,/(I9XB8VF&6\3?QWQ!F4<3.L@;)?1!'\_0RV,7$Y>C4GFJO
MWT+1:1"%=4%Z 15&+3 -RAJJ$&C1*))6%4?G<8I"KGNB;>\'POEX5Q:+M(KQ
M6*QYJA+9KJU&V-GFMQ%PL_^ME/1.$RMX8J RET>D8PVX!NW+>'_GOV\*P_UV
MG]#L(FQ1AR9[R_$33@O2=]+<(UM\FQ7%'2;%7 5?U$%)XZPX#OV:4L1!3-@8
M$]Z)>AAN2119;05E?,>J:P?%S)!W*C_@,HA3'%T'>4J3A'5@7^$UO2I>\99L
M%-T>Z[ M2/^ ATD+#"VMH>J8&'%)[[03IVS6<SO?DV6[23*L]3PE/OFR7B&9
M'W]=4><;*#-ETX$$\]*F0@W2$1+#JK%4!Q;U+-'*3R^]RE,CG8G/?9 O<I:L
M*=)E>QNEZ6FAQU04Q=J/2@W,L&J/5;%"5/"<E\VZ$"3^\3G6K%EX,K\#4<,3
MWU30%3P;BD/DEP*CGE?"XB$\?K%K*ZVY54M[Y54?LI937!0NGWKXK+C$EXOA
M\4B=!]I.Q2NC%#F@;>3A<LN<_UE*L.Q$B9^GL(POV#0),PU[M$IIE]PR0.[2
M2B$*AE%Z?$,R<>GV4FU(>4P?<(')2Z3I[:[P,TXREH?E^LL.IX7*GS?H.,YZ
M8H8_2'VB5@##+QN4DB0H3(=M@T:M%L)<S?_^PL<@_QW3X!<]O40QEXQ2@>R2
M:"@#AC<*8$.J-&)PN/$!IS@/$D+X6;2-TYCVCW3+7D\5HY9+YE@6H4LD@PH8
M7MGA'-*LTF(=4M#3@\.[)BRX*HHJJ%(BYR6H>PA3&L1="\%:,E7!DR_69TV\
M-CRNM+NEIJ)V);WP180J94PKYH8S/W#.I'A#ER57UM01<&K"_+,CW]X\^9C2
M799F_0+H1S63DO/C2L8""$>6E!H^Z*5EE@U:^5'=XX0Z*&*Z^.T755R&F-A4
M(>,L@DL%KPG<&@I J7<=N&$U5V+H:U[3WS0C43<C[K_[#]DG)3".2 ,9EUV(
M%%ZWQ^@)@!Q_9 B%D[*$$K=@QAQ#=!>_7IQ\G]/#<%>8_VM813R&8>=CUU%>
MA#"^'605S+3N:$51Y++H108VO2AUS'X$W4INLAS'FY1G7PA?5GF0%J2P] *K
M-&)_)0'[*_KO?5%6B:YU,;&G>AB4UG3X"[-M8=.?!,4#<5)*P97A!JMD(>$+
M*ELC*&BL>&^5DO=A:%I:#<=;IR;H@YU3E3A(%\B,5[*'VNG^::^/UEF.".W1
MC@TJWME6QQS7$5$701&'BO(K9%TR3 NWRRVI(!BO0X=NR"'V&YMM,?[LN%?1
M;,V#8]!5G.Q+9="04MHGBP:0=3RJ1,$RJ8]/R.''?P7,II\QO7P'1[-GG <;
M?+>G)UGK(V6=H!5=/S72ADOF32I>EX^C#(!AZ1340^[6-E# C:"46:&'![L,
M[IV3WA=$GAX^)>/PGBV)/XJ]:0'BEF?%*ZI:K&T8W6@K ,AO*J(%_54FH#<
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MK/JF_X178.+_").@&\#X<ARC!;R*F?!EEI)I5$'&K\6:?R[CQP0O<4@D-1<
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MNI<^\I;\'6SP517+3]X*W3I-PW@7),29R(*4!0^R=ON4)1&6$&."#5B,F%X
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M4%SV,D892NU/PBR<<1IAQ%.'WR'; [U2R!2IJI,'4'>C8 ZKJTG]Q29F3 U
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M[_3L'!%WF$DM["'O7A(FML]+HDV<HQ1"4Y:L9KRXBPF74S*'Y-70P@77WZ=
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MU 7.DBI>%-6P7X!4X0B$Q+D]1H4\2+TM-6EH_RDIA :01*;,&K5GI'(&P9O
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M\)G*GF.>/IX'4P:KCIXJ0)L['5A:,O??ABX_1V36H2RU5]>WXYC^EO";/!,
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M<!I>>\5>!=N_L/^YMV-"?_,_4$L! A0#%     @ ]8%N61#I<(N@!P  42L
M  H              ( !     &5X,S$M,2YH=&U02P$"% ,4    " #U@6Y9
MV 70VIT'  !/*P  "@              @ '(!P  97@S,2TR+FAT;5!+ 0(4
M Q0    ( /6!;ED!L+0>AP0  %X@   *              "  8T/  !E>#,R
M+3$N:'1M4$L! A0#%     @ ]8%N6=!7FOD[!   >A(   H
M ( !/!0  &5X,S(M,BYH=&U02P$"% ,4    " #U@6Y9YQZZ0*P_ 0#Z*@P
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7;%!+!08     "@ * &4"   C&@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:GCTK="http://glucotrack.com/20240930"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gctk-20240930.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <instant>2024-11-03</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ReceiptsOnAccountOfSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ReceiptsOnAccountOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_ReceiptsOnAccountOfSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ReceiptsOnAccountOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ReceiptsOnAccountOfSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ReceiptsOnAccountOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_ReceiptsOnAccountOfSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ReceiptsOnAccountOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ReceiptsOnAccountOfSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ReceiptsOnAccountOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_ReceiptsOnAccountOfSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ReceiptsOnAccountOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ReceiptsOnAccountOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_ReceiptsOnAccountOfSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ReceiptsOnAccountOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ReceiptsOnAccountOfSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ReceiptsOnAccountOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_ReceiptsOnAccountOfSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ReceiptsOnAccountOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_PerformanceMilestoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:PerformanceMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_PerformanceMilestoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:PerformanceMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_PerformanceMilestoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:PerformanceMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_PerformanceMilestoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:PerformanceMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-032024-01-03_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-03</startDate>
            <endDate>2024-01-03</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <instant>2024-02-13</instant>
        </period>
    </context>
    <context id="AsOf2024-02-13_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-13</instant>
        </period>
    </context>
    <context id="From2024-02-132024-02-13_custom_ExchangeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-13</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-13_custom_ExchangeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-13</instant>
        </period>
    </context>
    <context id="From2024-02-192024-02-19_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-19</startDate>
            <endDate>2024-02-19</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-19_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-19</instant>
        </period>
    </context>
    <context id="AsOf2024-02-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <instant>2024-02-19</instant>
        </period>
    </context>
    <context id="From2024-04-222024-04-22_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-22</startDate>
            <endDate>2024-04-22</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-22_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-22</instant>
        </period>
    </context>
    <context id="From2024-04-302024-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <startDate>2024-04-30</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-27_custom_UnsecuredPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GCTK:UnsecuredPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-27</instant>
        </period>
    </context>
    <context id="AsOf2024-06-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <instant>2024-06-27</instant>
        </period>
    </context>
    <context id="From2024-06-272024-06-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <startDate>2024-06-27</startDate>
            <endDate>2024-06-27</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-18_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-18</instant>
        </period>
    </context>
    <context id="From2024-07-182024-07-18_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-18</startDate>
            <endDate>2024-07-18</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-30_custom_ConvertiblePromissoryNotesMember_custom_WarrantsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">GCTK:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:WarrantsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-30</instant>
        </period>
    </context>
    <context id="From2024-07-302024-07-30_custom_ConvertiblePromissoryNotesMember_custom_WarrantsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">GCTK:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:WarrantsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-30</startDate>
            <endDate>2024-07-30</endDate>
        </period>
    </context>
    <context id="From2024-07-302024-07-30_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">GCTK:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-30</startDate>
            <endDate>2024-07-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-30_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-30</instant>
        </period>
    </context>
    <context id="From2024-07-302024-07-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <startDate>2024-07-30</startDate>
            <endDate>2024-07-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <instant>2024-07-30</instant>
        </period>
    </context>
    <context id="From2024-07-302024-07-30_custom_FirstWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:FirstWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-30</startDate>
            <endDate>2024-07-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-30_custom_FirstWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:FirstWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-30</instant>
        </period>
    </context>
    <context id="From2024-07-302024-07-30_custom_SecondWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:SecondWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-30</startDate>
            <endDate>2024-07-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-30_custom_SecondWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:SecondWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-30</instant>
        </period>
    </context>
    <context id="From2024-07-302024-07-30_custom_ThirdWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ThirdWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-30</startDate>
            <endDate>2024-07-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-30_custom_ThirdWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:ThirdWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-30</instant>
        </period>
    </context>
    <context id="From2024-08-232024-08-23_custom_JuneTwentySevenNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JuneTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-23</startDate>
            <endDate>2024-08-23</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-23_custom_JuneTwentySevenNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JuneTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-23</instant>
        </period>
    </context>
    <context id="From2024-10-152024-10-15_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-15</startDate>
            <endDate>2024-10-15</endDate>
        </period>
    </context>
    <context id="From2024-08-232024-08-23_custom_AugustTwentyThreeWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:AugustTwentyThreeWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-23</startDate>
            <endDate>2024-08-23</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-23_custom_AugustTwentyThreeWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:AugustTwentyThreeWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-23</instant>
        </period>
    </context>
    <context id="AsOf2024-08-23_custom_AugustTwentyThreeWarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:AugustTwentyThreeWarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-23</instant>
        </period>
    </context>
    <context id="AsOf2024-08-23_custom_AugustTwentyThreeWarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:AugustTwentyThreeWarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-23</instant>
        </period>
    </context>
    <context id="AsOf2024-08-23_custom_AugustTwentyThreeWarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:AugustTwentyThreeWarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-23</instant>
        </period>
    </context>
    <context id="AsOf2024-08-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <instant>2024-08-23</instant>
        </period>
    </context>
    <context id="From2024-09-052024-09-05_custom_JuneTwentySevenNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JuneTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-05</startDate>
            <endDate>2024-09-05</endDate>
        </period>
    </context>
    <context id="From2024-09-052024-09-05_custom_JulyEighteenNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JulyEighteenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-05</startDate>
            <endDate>2024-09-05</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-23_custom_JulyTwentySevenNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JulyTwentySevenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-23</instant>
        </period>
    </context>
    <context id="From2024-10-152024-10-15_us-gaap_SubsequentEventMember_custom_JuneTwentySevenNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JuneTwentySevenNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-15</startDate>
            <endDate>2024-10-15</endDate>
        </period>
    </context>
    <context id="From2024-09-052024-09-05_custom_SeptemberFiveWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:SeptemberFiveWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-05</startDate>
            <endDate>2024-09-05</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-05_custom_SeptemberFiveWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:SeptemberFiveWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-05</instant>
        </period>
    </context>
    <context id="AsOf2024-09-05_custom_SeptemberFiveWarrantsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:SeptemberFiveWarrantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-05</instant>
        </period>
    </context>
    <context id="AsOf2024-09-05_custom_SeptemberFiveWarrantsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:SeptemberFiveWarrantsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-05</instant>
        </period>
    </context>
    <context id="AsOf2024-09-05_custom_SeptemberFiveWarrantsThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:SeptemberFiveWarrantsThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-05</instant>
        </period>
    </context>
    <context id="AsOf2024-09-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <instant>2024-09-05</instant>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_JuneTwentySevenWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JuneTwentySevenWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_JulyEighteenNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JulyEighteenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_JulyThirteenNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JulyThirteenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_LessThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">GCTK:LessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_BetweenOneYearToTwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">GCTK:BetweenOneYearToTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_MoreThanTwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">GCTK:MoreThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_JuneTwentySevenWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JuneTwentySevenWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_JuneTwentySevenWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JuneTwentySevenWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_JulyEighteenNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JulyEighteenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_JulyEighteenNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JulyEighteenNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_JulyThirtyNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JulyThirtyNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_JulyThirtyNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JulyThirtyNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_JulyThirtyNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:JulyThirtyNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2004-03-04_custom_IsraeliInnovationAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">GCTK:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2004-03-04</instant>
        </period>
    </context>
    <context id="From2004-03-032004-03-04_custom_IsraeliInnovationAuthorityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">GCTK:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2004-03-03</startDate>
            <endDate>2004-03-04</endDate>
        </period>
    </context>
    <context id="From2004-03-032004-03-04_custom_IsraeliInnovationAuthorityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">GCTK:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2004-03-03</startDate>
            <endDate>2004-03-04</endDate>
        </period>
    </context>
    <context id="AsOf2004-03-04_custom_IsraeliInnovationAuthorityMember29980703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">GCTK:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2004-03-04</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_IsraeliInnovationAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">GCTK:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-072022-10-07_custom_IntellectualPropertyPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:IntellectualPropertyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-07</startDate>
            <endDate>2022-10-07</endDate>
        </period>
    </context>
    <context id="From2022-10-072022-10-07_custom_IntellectualPropertyPurchaseAgreementMember_us-gaap_CommonStockMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:IntellectualPropertyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-07</startDate>
            <endDate>2022-10-07</endDate>
        </period>
    </context>
    <context id="AsOf2022-10-07_custom_IntellectualPropertyPurchaseAgreementMember_us-gaap_CommonStockMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:IntellectualPropertyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-07</instant>
        </period>
    </context>
    <context id="AsOf2022-10-07_custom_IntellectualPropertyPurchaseAgreementMember_us-gaap_CommonStockMember_srt_MinimumMember_custom_TrueupSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GCTK:TrueupSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:IntellectualPropertyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-07</instant>
        </period>
    </context>
    <context id="From2023-06-012023-06-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="From2024-11-122024-11-12_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-11-12</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_SeriesACommonWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GCTK:SeriesACommonWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_SeriesBCommonWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GCTK:SeriesBCommonWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_PrefundedWarrantsMember29981921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GCTK:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <context id="From2024-11-122024-11-12_us-gaap_SubsequentEventMember_custom_JulyThirtyNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:JulyThirtyNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-11-12</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_JulyThirtyNotesMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:JulyThirtyNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_JulyThirtyNotesMember_custom_SeriesACommonWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:SeriesACommonWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:JulyThirtyNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_JulyThirtyNotesMember_custom_SeriesCommonWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GCTK:SeriesCommonWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:JulyThirtyNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_JulyThirtyNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GCTK:JulyThirtyNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Israel">
        <measure>iso4217:ILS</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-09-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-09-30" id="Fact000004">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-09-30" id="Fact000005">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-09-30" id="Fact000006">0001506983</dei:EntityCentralIndexKey>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0057"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0078"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:PromissoryNotesCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0081"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0084"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0087"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0102"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0107"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketingExpense
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl0159"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketingExpense
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0161"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl0179"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0181"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0249"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0250"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0251"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0258"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted
      contextRef="From2023-01-012023-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted
      contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-07-012023-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-012023-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares
      contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares
      contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions
      contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions
      contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities
      contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities
      contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0426"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b
      contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b
      contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0470"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0475"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-07-012024-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0477"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2024-07-012024-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity
      contextRef="From2024-07-012024-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0498"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfWarrant
      contextRef="From2024-07-012024-09-30_custom_ReceiptsOnAccountOfSharesMember"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfWarrant
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfWarrant
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:RevaluationExpensesRelatedToDerivativeFinancialLiabilities
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0556"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0559"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0580"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0583"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0589"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0592"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0595"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:ProceedsFromConvertibleDebtPrivatePlacementTransaction
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0598"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:ProceedsReceivedFromUnderwrittenPublicOffering
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl0600"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0625"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:DeemedDividendUponTriggerOfDownRoundProtection
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl0630"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0634"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0637"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0684"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl0685"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl0686"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012024-09-30_custom_PrefundedWarrantsMember"
      id="xdx2ixbrl0710"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012024-09-30_custom_PrefundedWarrantsMember"
      id="xdx2ixbrl0712"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012023-09-30_custom_PrefundedWarrantsMember"
      id="xdx2ixbrl0714"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012023-09-30_custom_PrefundedWarrantsMember"
      id="xdx2ixbrl0716"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-09-30_custom_PrefundedWarrantsMember"
      id="xdx2ixbrl0718"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-09-30_custom_PrefundedWarrantsMember"
      id="xdx2ixbrl0720"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012023-09-30_custom_PerformanceMilestoneMember"
      id="xdx2ixbrl0730"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012023-09-30_custom_PerformanceMilestoneMember"
      id="xdx2ixbrl0732"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2024-06-27" id="xdx2ixbrl0838">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2023-12-31_custom_JuneTwentySevenWarrantsMember"
      id="xdx2ixbrl0852"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2023-12-31_custom_JulyEighteenNotesMember"
      id="xdx2ixbrl0876"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2023-12-31_custom_JulyThirtyNotesMember"
      id="xdx2ixbrl0929"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0943"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-08-23_custom_AugustTwentyThreeWarrantMember"
      id="xdx2ixbrl0959">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-09-05_custom_SeptemberFiveWarrantsMember"
      id="xdx2ixbrl0987">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <GCTK:DiscountAmortizationAndInterestExpensesOne
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl1040"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:DiscountAmortizationAndInterestExpensesOne
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl1042"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl1045"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl1047"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:DiscountAmortizationAndInterestExpensesTwo
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl1050"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:DiscountAmortizationAndInterestExpensesTwo
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl1052"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:RevaluationExpensesRelatedToDerivativeFinancialLiabilities
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl1055"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:RevaluationExpensesRelatedToDerivativeFinancialLiabilities
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl1057"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl1060"
      unitRef="USD"
      xsi:nil="true"/>
    <GCTK:RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl1062"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherExpenses
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl1070"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherExpenses
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl1072"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-09-30" id="Fact000013">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2024-01-01to2024-09-30" id="Fact000014">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-09-30" id="Fact000015">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-09-30" id="Fact000016">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-09-30" id="Fact000017">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-09-30" id="Fact000018">001-41141</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-09-30" id="Fact000019">GLUCOTRACK, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-09-30" id="Fact000020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-09-30" id="Fact000021">98-0668934</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-09-30" id="Fact000022">301     Route 17 North</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-01-01to2024-09-30" id="Fact000023">Suite 800</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-09-30" id="Fact000024">Rutherford</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-09-30" id="Fact000025">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-09-30" id="Fact000026">07070</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-09-30" id="Fact000027">(201)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-09-30" id="Fact000028">842-7715</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-01-01to2024-09-30" id="Fact000029">Common     Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-01-01to2024-09-30" id="Fact000030">GCTK</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-01-01to2024-09-30" id="Fact000031">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-09-30" id="Fact000032">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-09-30" id="Fact000033">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-09-30" id="Fact000034">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-09-30" id="Fact000035">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-09-30" id="Fact000036">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-09-30" id="Fact000037">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-11-03"
      decimals="INF"
      id="Fact000038"
      unitRef="Shares">5772026</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityListingParValuePerShare
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact000039"
      unitRef="USDPShares">0.001</dei:EntityListingParValuePerShare>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000047"
      unitRef="USD">346000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000048"
      unitRef="USD">4492000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000050"
      unitRef="USD">296000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000051"
      unitRef="USD">376000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000053"
      unitRef="USD">642000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000054"
      unitRef="USD">4868000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000056"
      unitRef="USD">65000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000059"
      unitRef="USD">109000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000060"
      unitRef="USD">27000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000062"
      unitRef="USD">10000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000063"
      unitRef="USD">10000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000065"
      unitRef="USD">826000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000066"
      unitRef="USD">4905000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000074"
      unitRef="USD">1857000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000075"
      unitRef="USD">839000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000077"
      unitRef="USD">25000</us-gaap:OperatingLeaseLiabilityCurrent>
    <GCTK:PromissoryNotesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000080"
      unitRef="USD">1988000</GCTK:PromissoryNotesCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000083"
      unitRef="USD">5000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000086"
      unitRef="USD">37000</us-gaap:DerivativeLiabilities>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000089"
      unitRef="USD">699000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000090"
      unitRef="USD">673000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000092"
      unitRef="USD">4611000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000093"
      unitRef="USD">1512000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000098"
      unitRef="USD">197000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000099"
      unitRef="USD">196000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000101"
      unitRef="USD">40000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000104"
      unitRef="USD">4848000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000105"
      unitRef="USD">1708000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000113"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000115"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000120"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000122"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000124"
      unitRef="Shares">5772026</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000126"
      unitRef="Shares">5772026</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000128"
      unitRef="Shares">4178274</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000130"
      unitRef="Shares">4178274</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000117"
      unitRef="USD">6000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000118"
      unitRef="USD">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000132"
      unitRef="USD">6000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000133"
      unitRef="USD">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000135"
      unitRef="USD">118223000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000136"
      unitRef="USD">112982000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <GCTK:ReceiptsOnAccountOfShares
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000138"
      unitRef="USD">100000</GCTK:ReceiptsOnAccountOfShares>
    <GCTK:ReceiptsOnAccountOfShares
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000139"
      unitRef="USD">48000</GCTK:ReceiptsOnAccountOfShares>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000141"
      unitRef="USD">5000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000142"
      unitRef="USD">16000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000144"
      unitRef="USD">-122356000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000145"
      unitRef="USD">-109853000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000147"
      unitRef="USD">-4022000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000148"
      unitRef="USD">3197000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000150"
      unitRef="USD">826000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000151"
      unitRef="USD">4905000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000153"
      unitRef="USD">2063000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000154"
      unitRef="USD">1693000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000155"
      unitRef="USD">7800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000156"
      unitRef="USD">2962000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:MarketingExpense
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000158"
      unitRef="USD">125000</us-gaap:MarketingExpense>
    <us-gaap:MarketingExpense
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000160"
      unitRef="USD">295000</us-gaap:MarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000163"
      unitRef="USD">1063000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000164"
      unitRef="USD">531000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000165"
      unitRef="USD">2598000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000166"
      unitRef="USD">1725000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000168"
      unitRef="USD">3251000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000169"
      unitRef="USD">2224000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000170"
      unitRef="USD">10693000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000171"
      unitRef="USD">4687000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000173"
      unitRef="USD">-3251000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000174"
      unitRef="USD">-2224000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000175"
      unitRef="USD">-10693000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000176"
      unitRef="USD">-4687000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000178"
      unitRef="USD">12000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000180"
      unitRef="USD">12000</us-gaap:OtherNonoperatingIncomeExpense>
    <GCTK:FinanceIncomeNet
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000183"
      unitRef="USD">-1848000</GCTK:FinanceIncomeNet>
    <GCTK:FinanceIncomeNet
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000184"
      unitRef="USD">1000</GCTK:FinanceIncomeNet>
    <GCTK:FinanceIncomeNet
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000185"
      unitRef="USD">-1822000</GCTK:FinanceIncomeNet>
    <GCTK:FinanceIncomeNet
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000186"
      unitRef="USD">2000</GCTK:FinanceIncomeNet>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000188"
      unitRef="USD">-5087000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000189"
      unitRef="USD">-2223000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000190"
      unitRef="USD">-12503000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000191"
      unitRef="USD">-4685000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000198"
      unitRef="USD">-17000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000199"
      unitRef="USD">6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000200"
      unitRef="USD">-11000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000201"
      unitRef="USD">17000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000203"
      unitRef="USD">-5104000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000204"
      unitRef="USD">-2217000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000205"
      unitRef="USD">-12514000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000206"
      unitRef="USD">-4668000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000208"
      unitRef="USDPShares">-0.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000210"
      unitRef="USDPShares">-0.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact000212"
      unitRef="USDPShares">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact000214"
      unitRef="USDPShares">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact000216"
      unitRef="USDPShares">-2.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact000218"
      unitRef="USDPShares">-2.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-09-30"
      decimals="INF"
      id="Fact000220"
      unitRef="USDPShares">-1.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-09-30"
      decimals="INF"
      id="Fact000222"
      unitRef="USDPShares">-1.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000224"
      unitRef="Shares">5594880</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000226"
      unitRef="Shares">5594880</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact000228"
      unitRef="Shares">4593733</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact000230"
      unitRef="Shares">4593733</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact000232"
      unitRef="Shares">5355806</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact000234"
      unitRef="Shares">5355806</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-09-30"
      decimals="INF"
      id="Fact000236"
      unitRef="Shares">4006527</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-09-30"
      decimals="INF"
      id="Fact000238"
      unitRef="Shares">4006527</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000247"
      unitRef="Shares">3099982</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000240"
      unitRef="USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000241"
      unitRef="USD">103107000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_ReceiptsOnAccountOfSharesMember"
      decimals="-3"
      id="Fact000242"
      unitRef="USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000243"
      unitRef="USD">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000244"
      unitRef="USD">-101901000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000245"
      unitRef="USD">1230000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000253"
      unitRef="USD">-4685000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000254"
      unitRef="USD">-4685000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000259"
      unitRef="USD">17000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000261"
      unitRef="USD">17000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000264"
      unitRef="USD">260000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000268"
      unitRef="USD">260000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <GCTK:AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted
      contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000271"
      unitRef="USD">855000</GCTK:AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted>
    <GCTK:AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted
      contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000274"
      unitRef="USD">-855000</GCTK:AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000284"
      unitRef="Shares">1075294</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000277"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000278"
      unitRef="USD">8729000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000282"
      unitRef="USD">8730000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000293"
      unitRef="Shares">2998</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000287"
      unitRef="USD">9000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-09-30_custom_ReceiptsOnAccountOfSharesMember"
      decimals="-3"
      id="Fact000288"
      unitRef="USD">-4000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000291"
      unitRef="USD">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000302"
      unitRef="Shares">4178274</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000295"
      unitRef="USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000296"
      unitRef="USD">112960000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000298"
      unitRef="USD">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000299"
      unitRef="USD">-107441000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000300"
      unitRef="USD">5557000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000311"
      unitRef="Shares">4178274</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000304"
      unitRef="USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000305"
      unitRef="USD">112929000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000307"
      unitRef="USD">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000308"
      unitRef="USD">-105218000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="Fact000309"
      unitRef="USD">7743000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000317"
      unitRef="USD">-2223000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000318"
      unitRef="USD">-2223000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000323"
      unitRef="USD">6000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000325"
      unitRef="USD">6000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000328"
      unitRef="USD">31000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000332"
      unitRef="USD">31000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000341"
      unitRef="Shares">4178274</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000334"
      unitRef="USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000335"
      unitRef="USD">112960000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000337"
      unitRef="USD">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000338"
      unitRef="USD">-107441000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000339"
      unitRef="USD">5557000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000350"
      unitRef="Shares">4178274</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000343"
      unitRef="USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000344"
      unitRef="USD">112982000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_ReceiptsOnAccountOfSharesMember"
      decimals="-3"
      id="Fact000345"
      unitRef="USD">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000346"
      unitRef="USD">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000347"
      unitRef="USD">-109853000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000348"
      unitRef="USD">3197000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000356"
      unitRef="USD">-12503000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000357"
      unitRef="USD">-12503000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000362"
      unitRef="USD">-11000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000364"
      unitRef="USD">-11000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000367"
      unitRef="USD">239000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000371"
      unitRef="USD">239000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000380"
      unitRef="Shares">86861</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000374"
      unitRef="USD">126000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember"
      decimals="-3"
      id="Fact000375"
      unitRef="USD">-48000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000378"
      unitRef="USD">78000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-09-30_custom_ReceiptsOnAccountOfSharesMember"
      decimals="-3"
      id="Fact000384"
      unitRef="USD">100000</GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross>
    <GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000387"
      unitRef="USD">100000</GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross>
    <GCTK:StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000396"
      unitRef="USD">395294</GCTK:StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000405"
      unitRef="Shares">718641</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000398"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000399"
      unitRef="USD">-1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000414"
      unitRef="Shares">79366</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000408"
      unitRef="USD">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000412"
      unitRef="USD">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000417"
      unitRef="USD">2635000</GCTK:StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000421"
      unitRef="USD">2635000</GCTK:StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions>
    <GCTK:StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000430"
      unitRef="Shares">293590</GCTK:StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000423"
      unitRef="USD">1000</GCTK:StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000424"
      unitRef="USD">1742000</GCTK:StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000428"
      unitRef="USD">1743000</GCTK:StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities>
    <GCTK:StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000439"
      unitRef="USD">20000</GCTK:StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000448"
      unitRef="Shares">5772026</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000441"
      unitRef="USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000442"
      unitRef="USD">118223000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_custom_ReceiptsOnAccountOfSharesMember"
      decimals="-3"
      id="Fact000443"
      unitRef="USD">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000444"
      unitRef="USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000445"
      unitRef="USD">-122356000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000446"
      unitRef="USD">-4022000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000457"
      unitRef="Shares">5478436</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000450"
      unitRef="USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000451"
      unitRef="USD">113903000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_ReceiptsOnAccountOfSharesMember"
      decimals="-3"
      id="Fact000452"
      unitRef="USD">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000453"
      unitRef="USD">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000454"
      unitRef="USD">-117269000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="-3"
      id="Fact000455"
      unitRef="USD">-3289000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000466"
      unitRef="Shares">5478436</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000459"
      unitRef="USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000460"
      unitRef="USD">113903000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_ReceiptsOnAccountOfSharesMember"
      decimals="-3"
      id="Fact000461"
      unitRef="USD">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000462"
      unitRef="USD">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000463"
      unitRef="USD">-117269000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="-3"
      id="Fact000464"
      unitRef="USD">-3289000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000472"
      unitRef="USD">-5087000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000473"
      unitRef="USD">-5087000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000478"
      unitRef="USD">-17000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000480"
      unitRef="USD">-17000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000483"
      unitRef="USD">11000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000487"
      unitRef="USD">11000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-07-012024-09-30_custom_ReceiptsOnAccountOfSharesMember"
      decimals="-3"
      id="Fact000491"
      unitRef="USD">50000</GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross>
    <GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000494"
      unitRef="USD">50000</GCTK:StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross>
    <GCTK:StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000497"
      unitRef="USD">2567000</GCTK:StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity>
    <GCTK:StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000501"
      unitRef="USD">2567000</GCTK:StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfWarrant
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000505"
      unitRef="USD">1000</GCTK:StockIssuedDuringPeriodValueIssuanceOfWarrant>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfWarrant
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000506"
      unitRef="USD">1742000</GCTK:StockIssuedDuringPeriodValueIssuanceOfWarrant>
    <GCTK:StockIssuedDuringPeriodValueIssuanceOfWarrant
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000510"
      unitRef="USD">1743000</GCTK:StockIssuedDuringPeriodValueIssuanceOfWarrant>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000519"
      unitRef="Shares">5772026</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000512"
      unitRef="USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000513"
      unitRef="USD">118223000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_custom_ReceiptsOnAccountOfSharesMember"
      decimals="-3"
      id="Fact000514"
      unitRef="USD">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000515"
      unitRef="USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000516"
      unitRef="USD">-122356000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000517"
      unitRef="USD">-4022000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000528"
      unitRef="Shares">5772026</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000521"
      unitRef="USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000522"
      unitRef="USD">118223000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_custom_ReceiptsOnAccountOfSharesMember"
      decimals="-3"
      id="Fact000523"
      unitRef="USD">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000524"
      unitRef="USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000525"
      unitRef="USD">-122356000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000526"
      unitRef="USD">-4022000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000534"
      unitRef="USD">-12503000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000535"
      unitRef="USD">-4685000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000540"
      unitRef="USD">22000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000541"
      unitRef="USD">21000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000543"
      unitRef="USD">239000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000544"
      unitRef="USD">260000</us-gaap:ShareBasedCompensation>
    <GCTK:IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000546"
      unitRef="USD">178000</GCTK:IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors>
    <GCTK:IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000547"
      unitRef="USD">5000</GCTK:IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors>
    <GCTK:LinkageDifferenceOnPrincipalOfLoansFromStockholders
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000549"
      unitRef="USD">1000</GCTK:LinkageDifferenceOnPrincipalOfLoansFromStockholders>
    <GCTK:LinkageDifferenceOnPrincipalOfLoansFromStockholders
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000550"
      unitRef="USD">4000</GCTK:LinkageDifferenceOnPrincipalOfLoansFromStockholders>
    <GCTK:RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000552"
      unitRef="USD">1505000</GCTK:RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities>
    <GCTK:RevaluationExpensesRelatedToDerivativeFinancialLiabilities
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000555"
      unitRef="USD">2000</GCTK:RevaluationExpensesRelatedToDerivativeFinancialLiabilities>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000558"
      unitRef="USD">330000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000564"
      unitRef="USD">-80000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000565"
      unitRef="USD">216000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000567"
      unitRef="USD">1129000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000568"
      unitRef="USD">598000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000570"
      unitRef="USD">26000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000571"
      unitRef="USD">-134000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000573"
      unitRef="USD">-8991000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000574"
      unitRef="USD">-4147000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000579"
      unitRef="USD">104000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000582"
      unitRef="USD">-104000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000588"
      unitRef="USD">500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000591"
      unitRef="USD">100000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000594"
      unitRef="USD">360000</us-gaap:ProceedsFromConvertibleDebt>
    <GCTK:ProceedsFromConvertibleDebtPrivatePlacementTransaction
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000597"
      unitRef="USD">4000000</GCTK:ProceedsFromConvertibleDebtPrivatePlacementTransaction>
    <GCTK:ProceedsReceivedFromUnderwrittenPublicOffering
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000601"
      unitRef="USD">8730000</GCTK:ProceedsReceivedFromUnderwrittenPublicOffering>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000603"
      unitRef="USD">4960000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000604"
      unitRef="USD">8730000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000606"
      unitRef="USD">-11000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000607"
      unitRef="USD">-17000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000609"
      unitRef="USD">-4146000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000610"
      unitRef="USD">4566000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000612"
      unitRef="USD">4502000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000613"
      unitRef="USD">2331000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000615"
      unitRef="USD">356000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000616"
      unitRef="USD">6897000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000624"
      unitRef="USD">37000</us-gaap:InterestPaidNet>
    <GCTK:DeemedDividendUponTriggerOfDownRoundProtection
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000631"
      unitRef="USD">855000</GCTK:DeemedDividendUponTriggerOfDownRoundProtection>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000633"
      unitRef="USD">79000</us-gaap:OperatingLeaseCost>
    <GCTK:IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000636"
      unitRef="USD">238000</GCTK:IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000639">&lt;p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zn0fJ1kBrjhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1 - &lt;span id="xdx_825_zxsgLp8ybfod"&gt;GENERAL&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Glucotrack
    Inc. (the &#x201c;Company&#x201d;) was incorporated on May 18, 2010 under the laws of the State of Delaware. The Company is a medical
    device company, focused on development of an Implantable Continuous Glucose Monitor (CGM) for persons with Type 1 diabetes and insulin-dependent
    Type 2 diabetes (the &#x201c;Glucotrack CBGM Product&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Liquidity
    and capital resources&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
    date, the Company has not yet commercialized the Glucotrack CBGM Product. Further development and commercialization efforts are
    expected to require substantial additional expenditure. Therefore, the Company is dependent upon external sources for financing its
    operations. As of September 30, 2024, the Company has incurred an accumulated deficit of $&lt;span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20240930_z6Z3fzOakOh"&gt;122,356&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
    in addition, the Company has generated operating losses and negative operating cash flow for all reported periods. As of September
    30, 2024, the balance of cash and cash equivalents amounted to $&lt;span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20240930_zkcgNVTj1v9i" title="Cash and cash equivalents"&gt;346&lt;/span&gt;,
    together with the net proceeds in total amount of $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20240101__20240930_z0zWkCuuh5g" title="Net proceeds from public offering"&gt;8,873&lt;/span&gt; which expected to be received upon closing of a public offering through
    registration statements on Form S-1 (see also Note 6 below) on November 14, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company raised net proceeds of $&lt;span id="xdx_90F_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_pn3n3_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zpKbIUIvAMZf"&gt;8,730
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;through completion of underwritten public offering.
Moreover, during the period of nine months ended September 30, 2024, the Company entered into (i) exchange agreement with certain shareholders
under which warrants with down round protection feature have been exchanged into shares of common stock in order to facilitate its equity
structure (see also Note 3B below), (ii) private placement agreement under which the Company raised proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_pn3n3_c20240101__20240930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zg1RZcGu6XNk"&gt;500
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(see also Note 3D below), (iii) &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;unsecured promissory notes
and warrant agreements under which the Company raised proceeds of $&lt;span id="xdx_900_eus-gaap--ProceedsFromUnsecuredNotesPayable_pn3n3_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQfhEVgk4yZf" title="Unsecured promissory notes"&gt;100&lt;/span&gt; (see also Note 3F below), (iv) unsecured promissory notes under
which the Company raised proceeds of $&lt;span id="xdx_904_eus-gaap--ProceedsFromUnsecuredNotesPayable_pn3n3_c20240101__20240930_zM3dYnOomgo2" title="Unsecured promissory notes"&gt;360&lt;/span&gt; (see also Note 3G below), (v) secured promissory note and warrant agreements under which the
Company raised proceeds of $&lt;span id="xdx_90E_eus-gaap--ProceedsFromSecuredNotesPayable_pn3n3_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGVIM3egHdR1" title="Secured promissory notes"&gt;4,000&lt;/span&gt; (see also Note 3H below) and (vi) conversion agreements under which certain financial liabilities have
been settled for issuance of shares of common stock and warrants of the Company (see also Note 3I and Note 3J below&lt;/span&gt;).&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company plans to finance its operations through the sale of equity securities (including shelf registration statement on Form S-3 was declared effective on October 3, 2023 by the Securities
and Exchange Commission (SEC) which allows the Company to register up to $&lt;span id="xdx_90E_eus-gaap--DebtSecurities_iI_c20240930_zXydevKeSl6d"&gt;30,000&lt;/span&gt; of certain equity and/or debt securities of
the Company through prospectus supplement) and/or debt securities. There can be no assurance that the Company
    will succeed in obtaining the necessary financing or generating sufficient revenue from sale of its Glucotrack CBGM Product in
    order to continue its operations as a going concern.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
    has considered the significance of such conditions in relation to the Company&#x2019;s ability to meet its current obligations and
    to achieve its business targets and determined that these conditions raise substantial doubt about the Company&#x2019;s ability to
    continue as a going concern.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    condensed interim consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
thousands of US Dollars)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000640"
      unitRef="USD">-122356000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000642"
      unitRef="USD">346000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000644"
      unitRef="USD">8873000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_IPOMember"
      decimals="-3"
      id="Fact000645"
      unitRef="USD">8730000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="From2024-01-012024-09-30_us-gaap_PrivatePlacementMember"
      decimals="-3"
      id="Fact000646"
      unitRef="USD">500000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromUnsecuredNotesPayable
      contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000648"
      unitRef="USD">100000</us-gaap:ProceedsFromUnsecuredNotesPayable>
    <us-gaap:ProceedsFromUnsecuredNotesPayable
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000650"
      unitRef="USD">360000</us-gaap:ProceedsFromUnsecuredNotesPayable>
    <us-gaap:ProceedsFromSecuredNotesPayable
      contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000652"
      unitRef="USD">4000000</us-gaap:ProceedsFromSecuredNotesPayable>
    <us-gaap:DebtSecurities
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000653"
      unitRef="USD">30000000</us-gaap:DebtSecurities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000655">&lt;p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zdjNiMPZU7ck" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 - &lt;span id="xdx_821_zeS9LwxMHg55"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zBk6y2rc9TH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zE5VrcHnpgzg"&gt;Basis
    of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    accompanying unaudited condensed interim consolidated financial statements and related notes should be read in conjunction with the
    Company&#x2019;s consolidated financial statements and related notes included in the Company&#x2019;s annual report on Form 10-K for
    the fiscal year ended December 31, 2023, as was filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 28,
    2024. The unaudited condensed interim consolidated financial statements have been prepared in accordance with the rules and regulations
    of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures
    normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial
    information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary
    to present fairly the results of the Company&#x2019;s financial position and operating results for the interim periods. All such adjustments
    are of a normal recurring nature.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    results for the period of three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected
    for the year ending December 31, 2024 or for any other interim period or for any future period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_84B_eus-gaap--UseOfEstimates_zRBBoArUAa42" style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_z7LpEpyqQxfl"&gt;Use
    of Estimates in the Preparation of Financial Statements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates
    and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities
    at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could
    differ from those estimates. As applicable to these interim financial statements, the most significant estimates and assumptions include identification and measurement of financial instruments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zmLrlRp17BSa" style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zttyu0kFfb0a"&gt;Principles
    of Consolidation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    condensed interim consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany
    balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zdGHStKilDFl" style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_ztmSw1zOzLMh"&gt;Cash
    and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
    equivalents are short-term highly liquid investments which include short-term bank deposits (up to three months from date of deposit),
    that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as
    of the date acquired.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_84D_ecustom--ModificationOfEquityClassifiedContractsPolicyTextBlock_z8qXmJM3USR6" style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;E.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_z1Av9IYetR81"&gt;Modification
    of equity-classified contracts&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    modification or exchange of equity-classified contracts, such as warrants that were classified as equity before the modification
    or exchange and remained eligible for equity classification after the modification, is accounted for in a similar manner to a modification
    of stock-based compensation. Accordingly, the incremental fair value from the modification or exchange (the change in the fair value
    of the instrument before and after the modification or exchange) is recognized as a reduction of retained earnings of increase of
    accumulated deficit as a deemed dividend. Modifications or exchanges that result in a decrease in the fair value of an equity-classified
    share-based payment awards are not recognized. In addition, the amount of the deemed dividend is also recognized as an adjustment
    to earnings available to common shareholders for purposes of calculating earnings per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
thousands of US Dollars)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--ConvertiblePromissoryNotesPolicyTextBlock_zkZ8o3MQtn6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;F.
    &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zLDCavFUdVDf"&gt;Convertible Promissory Notes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
    initial recognition of convertible promissory notes and similar instruments, the Company considers the provisions of ASC 815-40,
    &#x201c;Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity&#x201d; (&#x201c;ASC 815-40&#x201d;) in order to determine whether
    the conversion features embedded within the convertible instrument should be separated from the host instrument.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
    it is determined that an embedded derivative required to be bifurcated (such as embedded conversion feature that does not qualify
    for equity classification), the Company recognized the embedded derivative bifurcated as a separate derivative liability upon
    initial recognition and on subsequent periods at fair value. The remaining consideration amount received or allocated to the entire
    convertible instrument is allocated to the host debt instrument. The difference between the face value of the host and such an
    allocated amount represents a discount which is amortized as finance expense to profit or loss using an effective interest method
    over the term of the note until its stated maturity.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
    it is determined that the embedded conversion feature qualifies for equity classification (such when the embedded conversion option,
    if it were freestanding, is not qualified as a derivative in accordance with the provisions of ASC 815-10, &#x201c;Derivatives and
    Hedging&#x201d; since its terms did not require or permit net settlement or when the embedded conversion option is indexed to the
    entity&#x2019;s own stock), the conversion option is not bifurcated. When bifurcation is not required, the Company considers whether
    the debt instrument involves a significant premium (i.e. when the proceeds received or allocated upon issuance exceed the principal
    amount that will be paid at maturity). When it is determined that a substantial premium exists, the entire premium is allocated to
    paid-in capital and when it is determined, otherwise no additional accounting is required and the convertible promissory note is
    accounted for at amortized cost using effective interest method over the term of the note until its stated maturity.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_847_ecustom--AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock_zskbeHi3THyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;G.
    &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zwlQGZrpQPe7"&gt;Allocation
    of proceeds and related issuance costs&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
    multiple instruments are issued in a single transaction (package issuance), the total net proceeds from the transaction are allocated
    among the individual freestanding instruments identified. The allocation occurs after identifying all freestanding instruments and
    the subsequent measurement basis for those instruments.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
    instruments that are required to be subsequently measured at fair value (such as derivative liabilities) are measured at fair value
    and the remaining consideration is allocated to other financial instruments that are not required to be subsequently measured at
    fair value (such as liabilities measured at amortized cost, common shares and warrants eligible for equity classification), based
    on the relative fair value basis for such instruments.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance
    costs allocated to financial instruments that are required to be subsequently measured at fair value immediately expensed. Issuance
    costs allocated to shares and warrants classified as equity components and are recorded as a reduction of additional paid-in capital.
    Issuance costs allocated to financial liabilities measured at amortized cost are recorded as a discount and accreted over the contractual
    term of the financial instrument using the effective interest method.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0"&gt;&lt;/p&gt;



&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
thousands of US Dollars)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)&lt;/b&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_840_eus-gaap--DerivativesPolicyTextBlock_zTw3FWwKVhEd" style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;H.
    &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zjqH5CCt7BB"&gt;Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
    warrants that were issued to several holders are classified as a component of permanent equity since they are freestanding financial
    instruments that are legally detachable and separately exercisable, do not embody an obligation for the Company to repurchase its
    own shares, and permit the holders to receive a fixed number of Ordinary Shares upon exercise for a fixed exercise price and thus,
    are considered as indexed to the Company&#x2019;s own shares. As such warrants were issued together with financial instruments that
    are not subsequently measured at fair value and the warrants were measured based on allocation of the proceeds received by the Company
    in accordance with the relative fair value basis. When applicable, direct issuance expenses that were allocated to certain warrants
    were deducted from additional paid-in capital.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_840_eus-gaap--LesseeLeasesPolicyTextBlock_zHAYzcA7DY9f" style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;I.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zRB01wOYGo4b"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company applies ASC Topic 842, &#x201c;Leases&#x201d; (&#x201c;ASC 842&#x201d;) under which the Company determines if an arrangement
    is a lease at inception.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases
    are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following
    criteria are met: (i) the lease transfers ownership of the asset by the end of the lease term, (ii) the lease contains an option
    to purchase the asset that is reasonably certain to be exercised, (iii) the lease term is for a major part of the remaining useful
    life of the asset, (iv) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset,
    or (v) the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end
    of lease term. A lease is classified as an operating lease if it does not meet any one of these criteria. Since all the Company&#x2019;s
    lease contracts for premises do not meet any of the criteria above, the Company concluded that all its lease contracts should be
    classified as operating leases.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Right
    of Use (&#x201c;ROU&#x201d;) assets and liabilities are recognized on the commencement date based on the present value of remaining
    lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the
    time of commencement. As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its Incremental Borrowing
    Rate (&#x201c;IBR&#x201d;) based on the information available on the commencement date in determining the present value of lease payments.
    The Company&#x2019;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments
    and in economic environments where the leased asset is located. The ROU asset also includes any lease payments made prior to commencement
    and is recorded net of any lease incentives received. Moreover, the ROU asset may also include initial direct costs, which are incremental
    costs of a lease that would not have been incurred if the lease had not been obtained. The Company uses the long-lived assets impairment
    guidance in ASC 360-10, &#x201c;Property, Plant, and Equipment - Overall&#x201d;, to determine whether a ROU asset is impaired, and
    if so, the amount of the impairment loss to recognize. Certain leases include options to extend or terminate the lease. An option
    to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain
    that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company
    will not exercise the option.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
thousands of US Dollars)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zYpF2IOulXnk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;J.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zajuTRwUQnY8"&gt;Basic
    and diluted loss per share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
                                                         loss per share is computed by dividing the loss for the period applicable (after considering the effect of deemed dividend related
                                                         to trigger of down round protection feature) for Common Stockholders by the weighted average number of shares of Common Stock
                                                         outstanding and shares of Common Stock to be issued upon achievement of certain performance milestones during the period &lt;span style="background-color: white"&gt;and
                                                         upon &lt;/span&gt;exercise of pre-funded warrants. In computing, diluted loss per share, basic earnings per share are adjusted to reflect
                                                         the potential dilution that could occur upon the exercise of options or warrants issued or granted using the &#x201c;treasury stock
                                                         method&#x201d; and using the if-converted method with respect to certain convertible promissory notes and bifurcated redemption
feature accounted for as derivative financial liability, if the effect of each of such financial instruments is dilutive. In computing diluted loss per share, the average
                                                         stock price for the period is used in determining the number of Common Stock assumed to be purchased from the proceeds to be
                                                         received from the exercise of stock options or stock warrants.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shares
    to be issued upon exercise of all options and warrants, convertible promissory notes and bifurcated redemption feature, have been excluded from the calculation of the diluted net loss
    per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as result
    of the exercise or conversion of these instruments was anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    net loss and the weighted average number of shares of Common Stock used in computing basic and diluted net loss per Common Stock
    for the period of three and nine months ended September 30, 2024 and 2023, is as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zECRBfAsXP8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zlH3UMgBCy09" style="display: none"&gt;SCHEDULE
OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240701__20240930_zY1fwQEntJ1j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230701__20230930_zyh7Jwyw3RX4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20240930_zk8T6rrK77Zk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20230930_zGuY6kLIwKf7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;US dollars (except share data)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;US dollars (except share data)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three-month period ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nine-month
period ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLoss_iN_pn3n3_di_maNILATzfsR_z3h5F4HaMWLd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 44%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;5,087&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,223&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;12,503&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;4,685&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature_iN_pn3n3_di_maNILATzfsR_zLtm2Uj52lz3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Deemed dividend related to trigger of down round protection feature&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0684"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0685"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0686"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;855&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iNT_pn3n3_di_mtNILATzfsR_zzJULLVnGMdh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Net loss attributable to common stockholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,087&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,223&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,540&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Shares of Common Stock used in computing basic and diluted net loss per common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zVmjIIryPAmh" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zoZOdvODAwxd" title="Ordinary shares used in computing diluted net loss per common stock"&gt;5,564,880&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zKGeyIxhq1n7" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zNtDgyEEgYN" title="Ordinary shares used in computing diluted net loss per common stock"&gt;4,593,733&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_z7D7t5EV2Tld" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zZ2dQIclzRx7" title="Ordinary shares used in computing diluted net loss per common stock"&gt;5,340,532&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_ztUZlocG5Z42" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zSgMwvqxjys" title="Ordinary shares used in computing diluted net loss per common stock"&gt;3,758,590&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Shares of Common Stock to be issued upon exercise of pre-funded warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zefuTJYCqzc" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zWheIw9VGqE6" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0710"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0712"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zkBxULuZabwb" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zHNW06k4Cbta" title="Ordinary shares used in computing diluted net loss per common stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0714"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0716"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zDyS5M8xO2Og" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zGjWmtb2Havc" title="Ordinary shares used in computing diluted net loss per common stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0718"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0720"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zZoCHb218dwf" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_z18oaHPtHo4j" title="Ordinary shares used in computing diluted net loss per common stock"&gt;241,246&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Shares of Common Stock to be issued upon achievement of performance milestones&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_z1RWeBPjSvWl" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zg9ykkrfTP58" title="Ordinary shares used in computing diluted net loss per common stock"&gt;30,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zD7rw58jVuB2" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zRDWvYLlWlO7" title="Ordinary shares used in computing diluted net loss per common stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0730"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0732"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_ziP4Gvys9mb8" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_z0W0wTgEHEx4" title="Ordinary shares used in computing diluted net loss per common stock"&gt;15,275&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zr59VvXkLhbe" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zR2GCY4Jyrhj" title="Ordinary shares used in computing diluted net loss per common stock"&gt;6,691&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted average number of Common Stock outstanding used in computing basic and diluted net loss per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930_zyw8P5D5hxPe" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930_z30ArI9toSR8" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share"&gt;5,594,880&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930_zQs2xS3Sy7lg" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930_znjWzcAjwsXd" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share"&gt;4,593,733&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930_zn2Qx0dJPtVh" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930_zNEM4narGaFe" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share"&gt;5,355,806&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930_zOjdbevyrhHb" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930_zOQXvVfVxnR5" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share"&gt;4,006,527&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted net loss per common stock&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240701__20240930_z91DnSu7T2Ka" title="Diluted net loss per common stock"&gt;&lt;span id="xdx_906_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240701__20240930_zuRoixSV9Nua" title="Diluted net loss per common stock"&gt;(0.91&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230701__20230930_zchev55s3gn" title="Diluted net loss per common stock"&gt;&lt;span id="xdx_90D_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230701__20230930_z5Pvp7a8vFg4" title="Diluted net loss per common stock"&gt;(0.49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240101__20240930_zNUAReKKbO7" title="Diluted net loss per common stock"&gt;&lt;span id="xdx_90D_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240101__20240930_zxIeGyO6KKO3" title="Diluted net loss per common stock"&gt;(2.39&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230101__20230930_zowndlo5mvYd" title="Diluted net loss per common stock"&gt;&lt;span id="xdx_909_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230101__20230930_zXz74f5ovqRg" title="Diluted net loss per common stock"&gt;(1.38&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zEuqK0oVDPO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_858_zdCThtqixkGb" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
thousands of US Dollars)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000657">&lt;p id="xdx_847_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zBk6y2rc9TH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zE5VrcHnpgzg"&gt;Basis
    of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    accompanying unaudited condensed interim consolidated financial statements and related notes should be read in conjunction with the
    Company&#x2019;s consolidated financial statements and related notes included in the Company&#x2019;s annual report on Form 10-K for
    the fiscal year ended December 31, 2023, as was filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 28,
    2024. The unaudited condensed interim consolidated financial statements have been prepared in accordance with the rules and regulations
    of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures
    normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial
    information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary
    to present fairly the results of the Company&#x2019;s financial position and operating results for the interim periods. All such adjustments
    are of a normal recurring nature.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    results for the period of three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected
    for the year ending December 31, 2024 or for any other interim period or for any future period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-09-30" id="Fact000659">&lt;p id="xdx_84B_eus-gaap--UseOfEstimates_zRBBoArUAa42" style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_z7LpEpyqQxfl"&gt;Use
    of Estimates in the Preparation of Financial Statements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates
    and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities
    at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could
    differ from those estimates. As applicable to these interim financial statements, the most significant estimates and assumptions include identification and measurement of financial instruments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000661">&lt;p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zmLrlRp17BSa" style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zttyu0kFfb0a"&gt;Principles
    of Consolidation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    condensed interim consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany
    balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000663">&lt;p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zdGHStKilDFl" style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_ztmSw1zOzLMh"&gt;Cash
    and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
    equivalents are short-term highly liquid investments which include short-term bank deposits (up to three months from date of deposit),
    that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as
    of the date acquired.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <GCTK:ModificationOfEquityClassifiedContractsPolicyTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000665">&lt;p id="xdx_84D_ecustom--ModificationOfEquityClassifiedContractsPolicyTextBlock_z8qXmJM3USR6" style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;E.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_z1Av9IYetR81"&gt;Modification
    of equity-classified contracts&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    modification or exchange of equity-classified contracts, such as warrants that were classified as equity before the modification
    or exchange and remained eligible for equity classification after the modification, is accounted for in a similar manner to a modification
    of stock-based compensation. Accordingly, the incremental fair value from the modification or exchange (the change in the fair value
    of the instrument before and after the modification or exchange) is recognized as a reduction of retained earnings of increase of
    accumulated deficit as a deemed dividend. Modifications or exchanges that result in a decrease in the fair value of an equity-classified
    share-based payment awards are not recognized. In addition, the amount of the deemed dividend is also recognized as an adjustment
    to earnings available to common shareholders for purposes of calculating earnings per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
thousands of US Dollars)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</GCTK:ModificationOfEquityClassifiedContractsPolicyTextBlock>
    <GCTK:ConvertiblePromissoryNotesPolicyTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000667">&lt;p id="xdx_84A_ecustom--ConvertiblePromissoryNotesPolicyTextBlock_zkZ8o3MQtn6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;F.
    &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zLDCavFUdVDf"&gt;Convertible Promissory Notes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
    initial recognition of convertible promissory notes and similar instruments, the Company considers the provisions of ASC 815-40,
    &#x201c;Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity&#x201d; (&#x201c;ASC 815-40&#x201d;) in order to determine whether
    the conversion features embedded within the convertible instrument should be separated from the host instrument.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
    it is determined that an embedded derivative required to be bifurcated (such as embedded conversion feature that does not qualify
    for equity classification), the Company recognized the embedded derivative bifurcated as a separate derivative liability upon
    initial recognition and on subsequent periods at fair value. The remaining consideration amount received or allocated to the entire
    convertible instrument is allocated to the host debt instrument. The difference between the face value of the host and such an
    allocated amount represents a discount which is amortized as finance expense to profit or loss using an effective interest method
    over the term of the note until its stated maturity.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
    it is determined that the embedded conversion feature qualifies for equity classification (such when the embedded conversion option,
    if it were freestanding, is not qualified as a derivative in accordance with the provisions of ASC 815-10, &#x201c;Derivatives and
    Hedging&#x201d; since its terms did not require or permit net settlement or when the embedded conversion option is indexed to the
    entity&#x2019;s own stock), the conversion option is not bifurcated. When bifurcation is not required, the Company considers whether
    the debt instrument involves a significant premium (i.e. when the proceeds received or allocated upon issuance exceed the principal
    amount that will be paid at maturity). When it is determined that a substantial premium exists, the entire premium is allocated to
    paid-in capital and when it is determined, otherwise no additional accounting is required and the convertible promissory note is
    accounted for at amortized cost using effective interest method over the term of the note until its stated maturity.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</GCTK:ConvertiblePromissoryNotesPolicyTextBlock>
    <GCTK:AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000669">&lt;p id="xdx_847_ecustom--AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock_zskbeHi3THyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;G.
    &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zwlQGZrpQPe7"&gt;Allocation
    of proceeds and related issuance costs&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
    multiple instruments are issued in a single transaction (package issuance), the total net proceeds from the transaction are allocated
    among the individual freestanding instruments identified. The allocation occurs after identifying all freestanding instruments and
    the subsequent measurement basis for those instruments.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
    instruments that are required to be subsequently measured at fair value (such as derivative liabilities) are measured at fair value
    and the remaining consideration is allocated to other financial instruments that are not required to be subsequently measured at
    fair value (such as liabilities measured at amortized cost, common shares and warrants eligible for equity classification), based
    on the relative fair value basis for such instruments.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance
    costs allocated to financial instruments that are required to be subsequently measured at fair value immediately expensed. Issuance
    costs allocated to shares and warrants classified as equity components and are recorded as a reduction of additional paid-in capital.
    Issuance costs allocated to financial liabilities measured at amortized cost are recorded as a discount and accreted over the contractual
    term of the financial instrument using the effective interest method.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0"&gt;&lt;/p&gt;



&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
thousands of US Dollars)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)&lt;/b&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</GCTK:AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000671">&lt;p id="xdx_840_eus-gaap--DerivativesPolicyTextBlock_zTw3FWwKVhEd" style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;H.
    &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zjqH5CCt7BB"&gt;Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
    warrants that were issued to several holders are classified as a component of permanent equity since they are freestanding financial
    instruments that are legally detachable and separately exercisable, do not embody an obligation for the Company to repurchase its
    own shares, and permit the holders to receive a fixed number of Ordinary Shares upon exercise for a fixed exercise price and thus,
    are considered as indexed to the Company&#x2019;s own shares. As such warrants were issued together with financial instruments that
    are not subsequently measured at fair value and the warrants were measured based on allocation of the proceeds received by the Company
    in accordance with the relative fair value basis. When applicable, direct issuance expenses that were allocated to certain warrants
    were deducted from additional paid-in capital.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000673">&lt;p id="xdx_840_eus-gaap--LesseeLeasesPolicyTextBlock_zHAYzcA7DY9f" style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;I.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zRB01wOYGo4b"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company applies ASC Topic 842, &#x201c;Leases&#x201d; (&#x201c;ASC 842&#x201d;) under which the Company determines if an arrangement
    is a lease at inception.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases
    are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following
    criteria are met: (i) the lease transfers ownership of the asset by the end of the lease term, (ii) the lease contains an option
    to purchase the asset that is reasonably certain to be exercised, (iii) the lease term is for a major part of the remaining useful
    life of the asset, (iv) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset,
    or (v) the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end
    of lease term. A lease is classified as an operating lease if it does not meet any one of these criteria. Since all the Company&#x2019;s
    lease contracts for premises do not meet any of the criteria above, the Company concluded that all its lease contracts should be
    classified as operating leases.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Right
    of Use (&#x201c;ROU&#x201d;) assets and liabilities are recognized on the commencement date based on the present value of remaining
    lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the
    time of commencement. As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its Incremental Borrowing
    Rate (&#x201c;IBR&#x201d;) based on the information available on the commencement date in determining the present value of lease payments.
    The Company&#x2019;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments
    and in economic environments where the leased asset is located. The ROU asset also includes any lease payments made prior to commencement
    and is recorded net of any lease incentives received. Moreover, the ROU asset may also include initial direct costs, which are incremental
    costs of a lease that would not have been incurred if the lease had not been obtained. The Company uses the long-lived assets impairment
    guidance in ASC 360-10, &#x201c;Property, Plant, and Equipment - Overall&#x201d;, to determine whether a ROU asset is impaired, and
    if so, the amount of the impairment loss to recognize. Certain leases include options to extend or terminate the lease. An option
    to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain
    that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company
    will not exercise the option.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
thousands of US Dollars)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000675">&lt;p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zYpF2IOulXnk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;J.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zajuTRwUQnY8"&gt;Basic
    and diluted loss per share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
                                                         loss per share is computed by dividing the loss for the period applicable (after considering the effect of deemed dividend related
                                                         to trigger of down round protection feature) for Common Stockholders by the weighted average number of shares of Common Stock
                                                         outstanding and shares of Common Stock to be issued upon achievement of certain performance milestones during the period &lt;span style="background-color: white"&gt;and
                                                         upon &lt;/span&gt;exercise of pre-funded warrants. In computing, diluted loss per share, basic earnings per share are adjusted to reflect
                                                         the potential dilution that could occur upon the exercise of options or warrants issued or granted using the &#x201c;treasury stock
                                                         method&#x201d; and using the if-converted method with respect to certain convertible promissory notes and bifurcated redemption
feature accounted for as derivative financial liability, if the effect of each of such financial instruments is dilutive. In computing diluted loss per share, the average
                                                         stock price for the period is used in determining the number of Common Stock assumed to be purchased from the proceeds to be
                                                         received from the exercise of stock options or stock warrants.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shares
    to be issued upon exercise of all options and warrants, convertible promissory notes and bifurcated redemption feature, have been excluded from the calculation of the diluted net loss
    per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as result
    of the exercise or conversion of these instruments was anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    net loss and the weighted average number of shares of Common Stock used in computing basic and diluted net loss per Common Stock
    for the period of three and nine months ended September 30, 2024 and 2023, is as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zECRBfAsXP8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zlH3UMgBCy09" style="display: none"&gt;SCHEDULE
OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240701__20240930_zY1fwQEntJ1j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230701__20230930_zyh7Jwyw3RX4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20240930_zk8T6rrK77Zk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20230930_zGuY6kLIwKf7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;US dollars (except share data)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;US dollars (except share data)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three-month period ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nine-month
period ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLoss_iN_pn3n3_di_maNILATzfsR_z3h5F4HaMWLd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 44%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;5,087&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,223&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;12,503&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;4,685&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature_iN_pn3n3_di_maNILATzfsR_zLtm2Uj52lz3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Deemed dividend related to trigger of down round protection feature&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0684"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0685"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0686"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;855&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iNT_pn3n3_di_mtNILATzfsR_zzJULLVnGMdh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Net loss attributable to common stockholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,087&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,223&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,540&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Shares of Common Stock used in computing basic and diluted net loss per common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zVmjIIryPAmh" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zoZOdvODAwxd" title="Ordinary shares used in computing diluted net loss per common stock"&gt;5,564,880&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zKGeyIxhq1n7" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zNtDgyEEgYN" title="Ordinary shares used in computing diluted net loss per common stock"&gt;4,593,733&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_z7D7t5EV2Tld" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zZ2dQIclzRx7" title="Ordinary shares used in computing diluted net loss per common stock"&gt;5,340,532&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_ztUZlocG5Z42" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zSgMwvqxjys" title="Ordinary shares used in computing diluted net loss per common stock"&gt;3,758,590&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Shares of Common Stock to be issued upon exercise of pre-funded warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zefuTJYCqzc" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zWheIw9VGqE6" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0710"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0712"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zkBxULuZabwb" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zHNW06k4Cbta" title="Ordinary shares used in computing diluted net loss per common stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0714"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0716"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zDyS5M8xO2Og" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zGjWmtb2Havc" title="Ordinary shares used in computing diluted net loss per common stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0718"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0720"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zZoCHb218dwf" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_z18oaHPtHo4j" title="Ordinary shares used in computing diluted net loss per common stock"&gt;241,246&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Shares of Common Stock to be issued upon achievement of performance milestones&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_z1RWeBPjSvWl" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zg9ykkrfTP58" title="Ordinary shares used in computing diluted net loss per common stock"&gt;30,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zD7rw58jVuB2" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zRDWvYLlWlO7" title="Ordinary shares used in computing diluted net loss per common stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0730"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0732"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_ziP4Gvys9mb8" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_z0W0wTgEHEx4" title="Ordinary shares used in computing diluted net loss per common stock"&gt;15,275&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zr59VvXkLhbe" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zR2GCY4Jyrhj" title="Ordinary shares used in computing diluted net loss per common stock"&gt;6,691&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted average number of Common Stock outstanding used in computing basic and diluted net loss per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930_zyw8P5D5hxPe" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930_z30ArI9toSR8" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share"&gt;5,594,880&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930_zQs2xS3Sy7lg" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930_znjWzcAjwsXd" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share"&gt;4,593,733&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930_zn2Qx0dJPtVh" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930_zNEM4narGaFe" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share"&gt;5,355,806&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930_zOjdbevyrhHb" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930_zOQXvVfVxnR5" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share"&gt;4,006,527&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted net loss per common stock&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240701__20240930_z91DnSu7T2Ka" title="Diluted net loss per common stock"&gt;&lt;span id="xdx_906_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240701__20240930_zuRoixSV9Nua" title="Diluted net loss per common stock"&gt;(0.91&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230701__20230930_zchev55s3gn" title="Diluted net loss per common stock"&gt;&lt;span id="xdx_90D_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230701__20230930_z5Pvp7a8vFg4" title="Diluted net loss per common stock"&gt;(0.49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240101__20240930_zNUAReKKbO7" title="Diluted net loss per common stock"&gt;&lt;span id="xdx_90D_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240101__20240930_zxIeGyO6KKO3" title="Diluted net loss per common stock"&gt;(2.39&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230101__20230930_zowndlo5mvYd" title="Diluted net loss per common stock"&gt;&lt;span id="xdx_909_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230101__20230930_zXz74f5ovqRg" title="Diluted net loss per common stock"&gt;(1.38&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zEuqK0oVDPO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000677">&lt;p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zECRBfAsXP8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zlH3UMgBCy09" style="display: none"&gt;SCHEDULE
OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240701__20240930_zY1fwQEntJ1j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230701__20230930_zyh7Jwyw3RX4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20240930_zk8T6rrK77Zk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20230930_zGuY6kLIwKf7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;US dollars (except share data)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;US dollars (except share data)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three-month period ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nine-month
period ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLoss_iN_pn3n3_di_maNILATzfsR_z3h5F4HaMWLd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 44%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;5,087&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,223&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;12,503&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;4,685&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature_iN_pn3n3_di_maNILATzfsR_zLtm2Uj52lz3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Deemed dividend related to trigger of down round protection feature&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0684"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0685"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0686"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;855&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iNT_pn3n3_di_mtNILATzfsR_zzJULLVnGMdh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Net loss attributable to common stockholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,087&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,223&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,540&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Shares of Common Stock used in computing basic and diluted net loss per common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zVmjIIryPAmh" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zoZOdvODAwxd" title="Ordinary shares used in computing diluted net loss per common stock"&gt;5,564,880&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zKGeyIxhq1n7" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zNtDgyEEgYN" title="Ordinary shares used in computing diluted net loss per common stock"&gt;4,593,733&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_z7D7t5EV2Tld" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zZ2dQIclzRx7" title="Ordinary shares used in computing diluted net loss per common stock"&gt;5,340,532&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_ztUZlocG5Z42" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCop_zSgMwvqxjys" title="Ordinary shares used in computing diluted net loss per common stock"&gt;3,758,590&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Shares of Common Stock to be issued upon exercise of pre-funded warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zefuTJYCqzc" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zWheIw9VGqE6" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0710"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0712"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zkBxULuZabwb" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zHNW06k4Cbta" title="Ordinary shares used in computing diluted net loss per common stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0714"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0716"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zDyS5M8xO2Og" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zGjWmtb2Havc" title="Ordinary shares used in computing diluted net loss per common stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0718"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0720"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zZoCHb218dwf" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_z18oaHPtHo4j" title="Ordinary shares used in computing diluted net loss per common stock"&gt;241,246&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Shares of Common Stock to be issued upon achievement of performance milestones&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_z1RWeBPjSvWl" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zg9ykkrfTP58" title="Ordinary shares used in computing diluted net loss per common stock"&gt;30,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zD7rw58jVuB2" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zRDWvYLlWlO7" title="Ordinary shares used in computing diluted net loss per common stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0730"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0732"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_ziP4Gvys9mb8" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_z0W0wTgEHEx4" title="Ordinary shares used in computing diluted net loss per common stock"&gt;15,275&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zr59VvXkLhbe" title="Ordinary shares used in computing basic net loss per common stock"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PerformanceMilestoneMember_fKCop_zR2GCY4Jyrhj" title="Ordinary shares used in computing diluted net loss per common stock"&gt;6,691&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted average number of Common Stock outstanding used in computing basic and diluted net loss per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930_zyw8P5D5hxPe" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930_z30ArI9toSR8" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share"&gt;5,594,880&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930_zQs2xS3Sy7lg" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930_znjWzcAjwsXd" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share"&gt;4,593,733&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930_zn2Qx0dJPtVh" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930_zNEM4narGaFe" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share"&gt;5,355,806&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930_zOjdbevyrhHb" title="Weighted average number of Common Stock outstanding used in computing basic net loss per share"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930_zOQXvVfVxnR5" title="Weighted average number of Common Stock outstanding used in computing diluted net loss per share"&gt;4,006,527&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted net loss per common stock&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240701__20240930_z91DnSu7T2Ka" title="Diluted net loss per common stock"&gt;&lt;span id="xdx_906_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240701__20240930_zuRoixSV9Nua" title="Diluted net loss per common stock"&gt;(0.91&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230701__20230930_zchev55s3gn" title="Diluted net loss per common stock"&gt;&lt;span id="xdx_90D_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230701__20230930_z5Pvp7a8vFg4" title="Diluted net loss per common stock"&gt;(0.49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240101__20240930_zNUAReKKbO7" title="Diluted net loss per common stock"&gt;&lt;span id="xdx_90D_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20240101__20240930_zxIeGyO6KKO3" title="Diluted net loss per common stock"&gt;(2.39&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230101__20230930_zowndlo5mvYd" title="Diluted net loss per common stock"&gt;&lt;span id="xdx_909_ecustom--EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones_pid_c20230101__20230930_zXz74f5ovqRg" title="Diluted net loss per common stock"&gt;(1.38&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000679"
      unitRef="USD">-5087000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000680"
      unitRef="USD">-2223000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000681"
      unitRef="USD">-12503000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000682"
      unitRef="USD">-4685000</us-gaap:NetIncomeLoss>
    <GCTK:DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000687"
      unitRef="USD">-855000</GCTK:DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000689"
      unitRef="USD">-5087000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000690"
      unitRef="USD">-2223000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000691"
      unitRef="USD">-12503000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000692"
      unitRef="USD">-5540000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000694"
      unitRef="Shares">5564880</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000696"
      unitRef="Shares">5564880</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000698"
      unitRef="Shares">4593733</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000700"
      unitRef="Shares">4593733</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000702"
      unitRef="Shares">5340532</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000704"
      unitRef="Shares">5340532</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000706"
      unitRef="Shares">3758590</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000708"
      unitRef="Shares">3758590</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-09-30_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact000722"
      unitRef="Shares">241246</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-09-30_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact000724"
      unitRef="Shares">241246</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012024-09-30_custom_PerformanceMilestoneMember"
      decimals="INF"
      id="Fact000726"
      unitRef="Shares">30000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012024-09-30_custom_PerformanceMilestoneMember"
      decimals="INF"
      id="Fact000728"
      unitRef="Shares">30000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-09-30_custom_PerformanceMilestoneMember"
      decimals="INF"
      id="Fact000734"
      unitRef="Shares">15275</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-09-30_custom_PerformanceMilestoneMember"
      decimals="INF"
      id="Fact000736"
      unitRef="Shares">15275</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-09-30_custom_PerformanceMilestoneMember"
      decimals="INF"
      id="Fact000738"
      unitRef="Shares">6691</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-09-30_custom_PerformanceMilestoneMember"
      decimals="INF"
      id="Fact000740"
      unitRef="Shares">6691</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000742"
      unitRef="Shares">5594880</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000744"
      unitRef="Shares">5594880</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact000746"
      unitRef="Shares">4593733</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact000748"
      unitRef="Shares">4593733</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact000750"
      unitRef="Shares">5355806</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact000752"
      unitRef="Shares">5355806</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-09-30"
      decimals="INF"
      id="Fact000754"
      unitRef="Shares">4006527</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-09-30"
      decimals="INF"
      id="Fact000756"
      unitRef="Shares">4006527</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000758"
      unitRef="USDPShares">-0.91</GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones>
    <GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000760"
      unitRef="USDPShares">-0.91</GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones>
    <GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact000762"
      unitRef="USDPShares">-0.49</GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones>
    <GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact000764"
      unitRef="USDPShares">-0.49</GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones>
    <GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact000766"
      unitRef="USDPShares">-2.39</GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones>
    <GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact000768"
      unitRef="USDPShares">-2.39</GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones>
    <GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones
      contextRef="From2023-01-012023-09-30"
      decimals="INF"
      id="Fact000770"
      unitRef="USDPShares">-1.38</GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones>
    <GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones
      contextRef="From2023-01-012023-09-30"
      decimals="INF"
      id="Fact000772"
      unitRef="USDPShares">-1.38</GCTK:EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones>
    <GCTK:SignificantTransactionsTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000774">&lt;p id="xdx_802_ecustom--SignificantTransactionsTextBlock_z7r92uxTpit6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 - &lt;span id="xdx_822_zqACE4jkYJr9"&gt;SIGNIFICANT TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
    of pre-funded warrants&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    January 3, 2024, &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20240103__20240103__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zvUMykTLeWlc" title="Pre-funded warrants"&gt;395,294&lt;/span&gt; pre-funded warrants granted through underwritten public offering in April 2023 have been fully
    exercised into the same number of shares of Common Stock of the Company. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exchange
    Agreement&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    February 13, 2024, the Company entered into an Exchange Agreement with certain warrant holders (the &#x201c;Holders&#x201d;), pursuant
    to which the Company and the Holders agreed to exchange (the &#x201c;Exchange&#x201d;) warrants with down round protection feature
    exercisable to common shares (the &#x201c;Warrants&#x201d;) owned by the Holders for shares of Common Stock to be issued by the
    Company. On February 15, 2024, &lt;span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pid_c20240213_z7xBRoTYBUcl" title="Shares of Common Stock"&gt;718,641&lt;/span&gt; shares of Common Stock have been issued in exchange for &lt;span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20240213__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zI5RNUfzJWu1" title="Shares of Common Stock"&gt;876,391&lt;/span&gt; Warrants (the &#x201c;Shares&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;It
    was also agreed that the Holders will not, during the period (&#x201c;Lock-Up Period&#x201d;) (i) offer, pledge, announce the intention
    to sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option,
    right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Shares, (ii) enter into any swap or
    other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Shares of, whether any
    such transaction described in clause (i) or (ii) above is to be settled by delivery of Shares or such other securities, in cash or
    otherwise, (iii) make any demand for or exercise any right with respect to, the registration of any Shares or any security convertible
    into or exercisable or exchangeable for shares of common stock, or (iv) publicly announce an intention to effect any transaction
    specific in clause (i), (ii) or (iii) above, provided that the Holder, during the Lock-Up Period, may&lt;span id="xdx_900_ecustom--LockUpPeriodDescription_c20240213__20240213__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zWEYX8w2NVEh" title="Lock-up period conditions"&gt; (a) sell or contract
    to sell Shares at a price higher than $0.50 per Share on any trading day up to 10% of the daily volume of Shares or (b) sell or contract
    to sell Shares at a price higher than $0.80 per Share on any trading day with no volume limitation.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Lock-Up Period shall expire at the earliest of (i) 365 days after the date hereof or (ii) until the Shares traded above $&lt;span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20240213__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zFDzbdvxhtne" title="Share price"&gt;1.00&lt;/span&gt; per
    Share for five consecutive trading days.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company accounted for the Exchange of the aforesaid warrants with shares as deemed dividend which was calculated at the closing date
    by the management using the assistance of external appraiser as the excess of fair value of the share to be issued after taking into
    consideration a discount for lack of marketability at a rate of 16.81% over the Lock-Up Period over the fair value of the original
    equity instrument (i.e. warrants which included down round protection feature). However, since the fair value of the new equity
    instrument (common shares) was estimated as lesser than the fair value of the replaced equity instrument, deemed dividend was not
    recorded.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Lease
    Agreement&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    February 19, 2024, the Company entered into Lease Agreement (the &#x201c;Agreement&#x201d;) with Tapsak Enterprises LLC dba Virginia
    Analytical (the &#x201c;Landlord&#x201d;) under which it was agreed that the Company will lease from the Landlord a premises located
    in Front Royal, Virginia area for a monthly rental fee of $&lt;span id="xdx_904_eus-gaap--OperatingLeasePayments_pn2n3_c20240219__20240219__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zWEPgI704uA4" title="Monthly rental fee"&gt;2.5&lt;/span&gt; over a period of &lt;span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20240219__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zwseJGRqKbB" title="Lessee term of contract"&gt;3&lt;/span&gt;-years commencing March 1, 2024 through February
    28, 2027 (the &#x201c;Initial Lease Period&#x201d;). Security deposit of $&lt;span id="xdx_908_eus-gaap--SecurityDeposit_iI_pn2n3_c20240219__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zYKYu0ivesP3" title="Security deposit"&gt;2.5&lt;/span&gt; which represents payment of one month is held by the
    Landlord which will be return to the Company at the end of the Initial Lease Period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, the Company has an option to renew the Initial Lease Period for another two additional periods of 3-years each following the
Initial Lease Period (the &#x201c;Option Term&#x201d;), following advanced notice as defined in the Agreement. The monthly rental fee over
the Option Term shall be the fair market rate determined as what is a comparable cost for similar property in Front Royal, Virginia area.&lt;/span&gt;&lt;/p&gt;
                                                                              &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
                                                                              &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In accordance
                                                                              with the provision of ASC 842, Leases, at the commencement date of the Agreement, the Company recognized the right to use asset
                                                                              equals to lease liability in total amount of $&lt;span id="xdx_90D_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20240219_zUEtACXcKmf5" title="Lease liability"&gt;79&lt;/span&gt;. The lease liability was measured at the present value of the future lease
                                                                              payments, which are discounted based on an estimate of the incremental interest rate that the Company would be required to pay to
                                                                              borrow a similar amount for a similar period in order to obtain a similar amount on the initial recognition date of the lease.&lt;/span&gt;&lt;/p&gt;
                                                                              &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
                                                                              &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As part of the leasing period, the Company considered only the Initial Lease Period as the realization of the option
to extend the period was not considered as reasonably certain.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
thousands of US Dollars)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 - SIGNIFICANT TRANSACTIONS (CONT.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Lease
    Agreement (Cont.)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--LeaseCostTableTextBlock_zIzel0VXWKy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_z3vDuEBqrYq6" style="display: none"&gt;SCHEDULE
OF OPERATING
LEASE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240930_zZZP4RDv7wKg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zsaPUwH9wOCa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left; padding-bottom: 2.5pt"&gt;Operating right-of-use asset&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 18%; text-align: right"&gt;65&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zyV0tTXRkczh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Current operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zsi5QhiaesRb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Non-Current operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;40&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zsWg4xTRsw31" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zjcYrVnemZJ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Maturity
analysis of the Company&#x2019;s lease liability:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_ztlO01gzXIGk" style="display: none"&gt;SCHEDULE
OF MATURITY
ANALYSIS OF LEASE LIABILITY&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240930_zhZxTL7nJvg3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_hus-gaap--LeaseContractualTermAxis__custom--LessThanOneYearMember_zXc3Tv74rw9c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Less than one year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;30&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_hus-gaap--LeaseContractualTermAxis__custom--BetweenOneYearToTwoYearsMember_zC0BaIt2ItC1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Between 1-2 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_hus-gaap--LeaseContractualTermAxis__custom--MoreThanTwoYearsMember_zUYBx9ixmCL2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;More than 2 years&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zR8mOjemPfEj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total operating lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;73&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--LesseeOperatingLeaseLiabilityImputedInterest_iNI_di_zDVgdFWJRpO7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_zrTAHbTQkpxb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;65&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zIP5L8OLIHc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Additional
information on lease&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock_zZMEFboNQckj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of the weighted average remaining lease terms and discount rate for the lease:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zg2FCIS7FFqb" style="display: none"&gt;SCHEDULE
OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Lease term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240930_zE2X8TvuDZW1" title="Lease term (years)"&gt;2.42&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20240930_zxtunKEZIuh9" title="Weighted average discount rate"&gt;9.03&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zhcJ7QICHX1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Private
    Placement Agreement&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    April 22, 2024, the Company entered into a private placement agreement under which the Company issued &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240422__20240422__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z02OXS5tWxCl" title="Number of shares issued"&gt;79,366&lt;/span&gt; shares of its common
    stock at a price of $&lt;span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240422__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zGVygKaVHZY" title="Common stock share price"&gt;6.30&lt;/span&gt; per share for aggregate gross proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20240422__20240422__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zo4ISivbb5A6" title="Aggregate gross proceeds offering"&gt;500 &lt;/span&gt;(the &#x201c;Offering&#x201d;). The Offering included participation
    of certain members of the Company&#x2019;s executive management, Board of Directors and existing shareholders.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;E.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Adoption
    of 2024 Equity Incentive Plan and Reverse Share Split&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    April 26, 2024, the Company held its Annual Meeting of Shareholders (the &#x201c;Annual Meeting&#x201d;) under which the Company&#x2019;s
    stockholders approved, inter alia, the following proposals: (i) adoption of the Company&#x2019;s 2024 Equity Incentive Plan and (ii)
    an amendment to Article IV of the Company&#x2019;s Certificate of Incorporation, to effect a reverse stock split of the Company&#x2019;s
    Common Stock at a ratio of between one-for-five and one-for-thirty, with such ratio to be determined at the sole discretion of the
    Board of Directors. Following the Annual Meeting, on April 30, 2024, the Company&#x2019;s Board of Directors approved a &lt;span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20240430__20240430_zI4eRcuuZfv3" title="Reverse stock split"&gt;one-for-five&lt;/span&gt;
    reverse stock split of the Company&#x2019;s issued and outstanding shares of common stock (the &#x201c;Reverse Stock Split&#x201d;).
    On May 17, 2024, the Company filed a Certificate of Amendment to the Company&#x2019;s Certificate of Incorporation with the Secretary
    of State of the State of Delaware which effected the Reverse Stock Split.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
    accounting purposes, all shares, options and warrants to purchase shares of common stock and loss per share amounts have been adjusted
    to give retroactive effect to the Reverse Share Split for all periods presented in these interim consolidated financial statements.
    Any fractional shares resulting from the Reverse Share Split were rounded up to the nearest whole share.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
thousands of US Dollars)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 - SIGNIFICANT TRANSACTIONS (CONT.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;F.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
    and Warrant Purchase Agreements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
                                                         June 27, 2024, the Company entered into note and warrant purchase agreements (the &#x201c;Purchase Agreement&#x201d;) with certain
                                                         investors (the &#x201c;June 27 Investors&#x201d;), providing for the private placement of unsecured promissory notes in the aggregate
                                                         principal amount of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240627__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNotesMember_zOhRbwCA6P52" title="Aggregate principal amount"&gt;100&lt;/span&gt;
                                                         (the &#x201c;June 27 Notes&#x201d; and each a &#x201c;June 27 Note&#x201d;) and warrants to purchase up to an aggregate of &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240627_zKAYWNYv4bP1" title="Aggregate of shares"&gt;300,000&lt;/span&gt;
                                                         shares of the Company&#x2019;s Common Stock (the &#x201c;June 27 Warrants&#x201d;).&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShortTermDebtDescription_c20240627__20240627_zsH3tYKPYR06" title="Notes payable description"&gt;The
    June 27 Notes bear simple interest at a rate of 3% per annum and are due and payable in cash on the earlier of: (a) 12 months
    from the date of the June 27 Note; or (b) the date the Company raises third-party equity capital in an amount equal to or in excess
    of $1,000 (the &#x201c;Maturity Date&#x201d;). The Company may prepay the June 27 Notes at any time prior to the Maturity Date without
    penalty. If an event of default occurs, the then-outstanding principal amount of the June 27 Notes plus any unpaid accrued interest
    will accelerate and become immediately payable in cash.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
    of June 27 Warrants has an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240627_zriHWWg9YRhk" title="Warrants exercise price"&gt;4.95&lt;/span&gt;
    per share. The June 27 Warrants are immediately exercisable and have a &lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20240627_zGREZ9zlCaZ4" title="Warrants term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0838"&gt;5-year&lt;/span&gt;&lt;/span&gt;
    term.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon initial recognition, the management allocated the gross cash proceeds received based on the relative fair value
of the June 27 Notes and the detachable June 27 Warrants in total amount of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfDebt_pn3n3_c20240627__20240627_zJngEYUKS1ga" title="Proceeds from notes"&gt;15&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20240627__20240627_zz49PcCQcMLh" title="Fair value of warrants"&gt;85&lt;/span&gt;, respectively. The fair value of the June 27 Note
was determined based on a rating model using a debt discount rate of &lt;span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20240627_zBw0S6KB0Nog" title="Debt discount rate"&gt;28.65&lt;/span&gt;% which represented the Company&#x2019;s applicable rate of risk.
The fair value of the June 27 Warrants was determined by using Black-Scholes pricing model taking into account, inter alia, expected stock
price volatility of &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240627__20240627_zwAzZcOMetV8" title="Price volatility"&gt;245&lt;/span&gt;% and risk-free interest rate of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240627__20240627_zhS0SwSVZhVa" title="Risk free interest rate"&gt;4.52&lt;/span&gt;%. The amount allocated to June 27 Warrants was classified as a component
of permanent equity (as their terms permit the holders to receive a fixed number of shares of common stock upon exercise for a fixed exercise
price).&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    June 27 Notes are accounted for as a financial liability measured at amortized cost. In subsequent periods, the Company recognized a
    discount and interest expense over the economic life of the June 27 Notes based on the effective interest rate method.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following tabular presentation reflects the reconciliation of the carrying amount of the June 27 Notes during
the period of nine months ended September 30, 2024:&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenWarrantsMember_ztHe4s0Y6vC" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zmhwp7QEQiti" style="display: none"&gt;SCHEDULE
OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenWarrantsMember_zq6138sou90d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine-month period ended&lt;br/&gt;
 September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_zqYDDjqLHFkl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Open balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0852"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfWarrants_pn3n3_zyhzU0eZMena" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Total proceeds received&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ProceedsFromAllocatedWarrantsAtInitialRecognition_pn3n3_zX9355DzW9V4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
proceeds allocated to June 27 Warrants at initial recognition&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 18%"&gt;(85&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DiscountAmortizationAndInterestExpenses_pn3n3_zE75HDXl0Vsd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Discount amortization and interest expenses related to &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;June
27 Notes (Note 5 below)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--PartialConversionNotesAndAccruedInterest_pn3n3_zT1rqNwyyTs5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Partial conversion &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;June 27 Notes and accrued
Interest (Note 3I and Note 3J below)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(26&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--WarrantsAndRightsOutstanding_iE_pn3n3_zhz6ftz91vk2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_z0tPSidYjd83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the period commencing the issuance date through September 30, 2024,
none of the June 27 Warrants have been exercised.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
thousands of US Dollars)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 - SIGNIFICANT TRANSACTIONS (CONT.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;G.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Convertible Promissory Notes&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
                                                         July 18, 2024, the Company entered into a series of convertible promissory notes with three directors, and one member of the
                                                         Company&#x2019;s executive management (the &#x201c;July 18 Investors&#x201d;), providing for the private placement of unsecured
                                                         convertible promissory notes in the aggregate principal amount of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240718__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z7fJNvPujgik" title="Debt instrument face amount"&gt;360&lt;/span&gt;
                                                         (the &#x201c;July 18 Notes&#x201d; and each a &#x201c;July 18 Note&#x201d;).&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    July 18 Notes bear simple interest at a rate of &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240718__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z1HHp0TCjWbj" title="Debt instrument interest rate"&gt;8&lt;/span&gt;%
    per annum. Interest on the outstanding principal will accrue and, unless converted earlier as set forth below, be due and payable on
    (i) the 12-month anniversary of the date hereof, or (ii) the closing date of a Qualified Financing, as defined herein (the
    &#x201c;Maturity Date&#x201d;).&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Except
    regarding the conversion of the July 18 Notes as discussed below, the Company may not prepay the July 18 Notes without the written
    consent of the July 18 Investors. If not sooner repaid, all outstanding principal and accrued but unpaid interest on the July 18
    Notes (the &#x201c;July 18 Note Balance&#x201d;), as of the close of business on the day immediately preceding the date of the closing
    of the next issuance and sale of capital stock of the Company, in a single transaction or series of related transactions, to
    investors resulting in gross proceeds to the Company of at least $&lt;span id="xdx_902_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20240718__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zsXQiQu4rIZ8" title="Gross proceeds from notes conversion"&gt;500&lt;/span&gt;
    (excluding indebtedness converted in such financing) (a &#x201c;Qualified Financing&#x201d;), will automatically be converted into
    that number of shares of equity securities of the Company sold in the Qualified Financing equal to the number of shares calculated
    by dividing (X) the July 18 Note Balance by (Y) an amount equal to the price per share or other unit of equity securities issued in
    such Qualified Financing, and otherwise on the same terms as the security issued in the Qualified Financing, provided that the
    conversion price per share shall not be lower than $&lt;span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240718__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z4eUBxeoaARb" title="Conversion price per share"&gt;1.56&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
    the occurrence of an Event of Default (as defined below), each July 18 Investors may, by written notice to the Company, declare the
    July 18 Note to be due immediately and payable with respect to the July 18 Note Balance. An &#x201c;Event of Default&#x201d; means (i)
    failure by the Company to pay the July 18 Note Balance on the Maturity Date, (ii) voluntary bankruptcy, or (iii) involuntary
    bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii) above, the July 18 Note Balance shall automatically
    and immediately become due and payable, in all cases without any action on the part of any July 18 Investors.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon initial date, the management measured the fair value of the embedded
conversion feature which is accounted for as embedded derivative liability. The difference between the total gross cash proceeds received
and the fair value of the embedded conversion feature is allocated to July 18 Notes that are measured at amortized cost under which in
subsequent periods the Company recognizes a discount expense over the economic life of the July 18 Notes based on the effective interest
rate method. However, the fair value of the embedded derivative liability related to the conversion feature was determined by the management
at an insignificant amount since upon closing of a Qualified Financing the conversion will be done based on market conditions (i.e. conversion
price will be equal to the fair value of the share upon conversion) and thus all proceeds received of $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_pid_c20240718__20240718__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zpDthaLemiE2" title="Conversion price"&gt;360&lt;/span&gt; were allocated to the July
18 Notes.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following tabular presentation reflects the reconciliation of the carrying
amount of the July 18 Notes during the period of nine months ended September 30, 2024:&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_89F_ecustom--ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--JulyEighteenNotesMember_z1cKGNZR7vUa" style="margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zwhuunhzDGij" style="display: none"&gt;SCHEDULE
OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--JulyEighteenNotesMember_z5oURXRylszg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine-month period ended &lt;br/&gt;
September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ConvertibleDebt_iS_pn3n3_z2iF2SE7fnzd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Open balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0876"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfDebt_pn3n3_zF7GWCyQYXw" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Total proceeds allocated to July 18 Notes at initial recognition&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;360&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestExpense_pn3n3_zpZevaxptRE3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest expenses related to July 18 Notes (Note 5 below)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--PartialConversionAndAccruedInterest_pn3n3_zv1dVDK0cmVl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Partial conversion July 18 Notes and accrued Interest (Note 3J below)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(101&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ConvertibleDebt_iE_z4h2ISWrdvL4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;264&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A8_zvjwyH7nOxb" style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0"&gt;&lt;/p&gt;



&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
thousands of US Dollars)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 - SIGNIFICANT TRANSACTIONS (CONT.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;H.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Convertible Promissory Note and Warrant Agreements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    July 30, 2024, the Company entered into a convertible promissory note and three warrant agreements (the &#x201c;July 30
    Warrants&#x201d;) with an existing investor (the &#x201c;July 30 Holder&#x201d;), providing for the private placement of a secured
    convertible promissory note in the aggregate principal amount of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240730__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--WarrantsAgreementMember_z38Rua6Xufea" title="Debt instrument face amount"&gt;4,000&lt;/span&gt;
    (the &#x201c;July 30 Note&#x201d;). The July 30 Note is not convertible until and unless approved at a meeting of the Company&#x2019;s
    stockholders (the &#x201c;Stockholder Approval&#x201d;). &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
July 30 Note bears simple interest at a rate of &lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240730__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--WarrantsAgreementMember_zVKre55BlA8i" title="Debt instrument interest rate"&gt;8&lt;/span&gt;%
per annum and is due and payable in cash on earlier of: &lt;span id="xdx_909_eus-gaap--DebtInstrumentDescription_c20240730__20240730__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--WarrantsAgreementMember_z3mjP06wK9Mj" title="Debt instrument description"&gt;(i)
12 months anniversary of July 30 Note, or (ii) closing date of a Sale Transaction (defined below) (the &#x201c;Maturity
Date&#x201d;)&lt;/span&gt;. The July 30 Note is secured by a first-priority security interest on all Company&#x2019;s assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Except
regarding the conversion of the July 30 Note or a Sale Transaction as discussed below, the Company may not prepay the July 30 Note
without the written consent of the July 30 Holder. If Stockholder Approval is obtained, the July 30 Note &lt;span id="xdx_90F_eus-gaap--DebtInstrumentDescription_c20240730__20240730__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zGGr5AJGdj7l" title="Debt instrument description"&gt;(i)
is convertible at the discretion of the July 30 Holder at a price equal to the closing price of the Common Stock on the date of
conversion and, (ii) if the Closing Price of the Common stock exceeds $&lt;span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20240730__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_ztZiSbU2C6Xj" title="Sale of stock issued price per share"&gt;5.00&lt;/span&gt;
per share for a period of 5 consecutive trading days, will automatically convert at a price equal to the 5 daily Volume Weighted
Average Price (&#x201c;VWAP&#x201d;) of the Common Stock (subject to adjustment for any stock split, stock dividend, reverse stock
split, combination or similar transaction).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
Sale Transaction on or prior to the Maturity Date, the Company will repay the July 30 Holder, at the July 30 Holder&#x2019;s
election, as follows: &lt;span id="xdx_907_eus-gaap--SaleOfStockDescriptionOfTransaction_c20240730__20240730__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zjf1zIUFekU7" title="Sale of stock description of transaction"&gt;(i)
cash equal to 200% of the Note balance, or (ii) transaction consideration in the amount to be received by the Holder in such Sale
Transaction if the July 30 Note was converted pursuant to an optional conversion. &#x201c;Sale Transaction&#x201d; means a merger or
consolidation of the Company with or into any other entity, or a sale of all or substantially all of the Company&#x2019;s assets, or any other transaction or series of related transactions in which the Company&#x2019;s stockholders immediately prior
to such transaction(s) receive cash, securities or other property in exchange for their shares and, immediately after such
transaction(s), own less than 50% of the equity securities of the surviving corporation or its parent.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the occurrence of an Event of Default (defined below), the July 30 Holder may, by written notice to the Company, declare the Note to
be due immediately and payable with respect to the July 30 Note balance. An &#x201c;Event of Default&#x201d; means &lt;span id="xdx_906_eus-gaap--DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault_c20240730__20240730_zfJPzROqFKAj" title="Debt description of notice of default"&gt;(i)
failure by the Company to pay the July 30 Note balance on the Maturity Date, (ii) the Company becomes subject to a judgement of more
than $&lt;span id="xdx_904_eus-gaap--DebtDefaultLongtermDebtAmount_iI_pn3n3_c20240730_zP2KMCyVHcE6" title="Debt default long term debt amount"&gt;50,000&lt;/span&gt;,
(iii) voluntary bankruptcy, or (iv) involuntary bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii)
above, the July 30 Note balance shall automatically and immediately become due and payable, in all cases without any action on the
part of the July 30 Holder.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
July 30 Warrant becomes exercisable 12 months after its issuance and has term of &lt;span id="xdx_901_eus-gaap--DebtInstrumentTerm_dtY_c20240730__20240730_zJduixxhgpdk"&gt;10
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years. The July 30 Warrants are exercisable for
cash only and have no price-based antidilution. The first July 30 Warrant is for &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240730__20240730__us-gaap--StatementEquityComponentsAxis__custom--FirstWarrantMember_zqTbmwV8W7kc"&gt;2,133,334
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares at $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240730__us-gaap--StatementEquityComponentsAxis__custom--FirstWarrantMember_z8ZsNrZqH5Zd" title="Exercise price"&gt;1.875
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share. The second July 30 Warrant is for
&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240730__20240730__us-gaap--StatementEquityComponentsAxis__custom--SecondWarrantMember_zhP7ZBPUM3z"&gt;1,523,810
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares at $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240730__us-gaap--StatementEquityComponentsAxis__custom--SecondWarrantMember_zdDCUegw3YBe" title="Exercise price"&gt;2.625
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share. The third July 30 Warrant is for &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240730__20240730__us-gaap--StatementEquityComponentsAxis__custom--ThirdWarrantMember_zYV4mNMoM6M2"&gt;1,185,186
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares at $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240730__us-gaap--StatementEquityComponentsAxis__custom--ThirdWarrantMember_zbLOxZG0Utj" title="Exercise price"&gt;3.375
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the initial date, the Company has issued two instruments that include (i) a financial instrument that is considered as &#x201c;host&#x201d;
which comprised of July 30 Note and two embedded derivative financial instruments (i.e. an embedded conversion feature and an embedded
redemption feature to receive cash equals to &lt;span id="xdx_90F_ecustom--EmbeddedConversionFeaturePercentage_iI_pid_dp_c20240730_zHpOGMbkvSf2" title="Embedded conversion feature percentage"&gt;200&lt;/span&gt;% of July 30 Note balance upon Sale Transaction) and (ii) three series of detachable
warrants. At the initial date, the Company is required to estimate the fair value of both two instruments and allocate the total gross
proceeds received between them based on that relative fair value identified. The fair value of the embedded derivative financial instruments
(i.e. the conversion right and the redemption right) should be bifurcated from the host instrument and remeasured on recurring basis
at each reporting period under marked to market approach, the July 30 Note is accounted for under carrying amount whereby discount and
interest expenses are recorded over the economic life of the July 30 Note based on the effective interest rate method and the July 30
Warrants are classified into equity without any further subsequent measurement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
thousands of US Dollars)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 - SIGNIFICANT TRANSACTIONS (CONT.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;H.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Convertible
    Promissory Note and Warrant Agreements (Cont.)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
                                                         initial recognition, the management by using the assistance of an external appraiser allocated the gross cash proceeds received
                                                         based on the relative fair value of the July 30 Note and the detachable July 30 Warrants in total amount of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfDebt_c20240730__20240730_zcvcskdIz6L" title="Proceeds from notes"&gt;1,450&lt;/span&gt;
                                                         and $&lt;span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20240730__20240730_zBb7XG2JF2rc" title="Fair value of warrants"&gt;2,550&lt;/span&gt;,
                                                         respectively. The fair value of the convertible note was determined by using hybrid method that includes conversion
                                                         scenario and liquidation scenario taking into account, inter alia, a debt discount rate of &lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20240730_zr46TEhAsdIk" title="Debt discount rate"&gt;28.65&lt;/span&gt;%.
                                                         The fair value of the July 30 Warrants was determined by using Black-Scholes pricing model taking into account, inter alia, expected
                                                         stock price volatility of &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240730__20240730_z7P6OiQpLtof" title="Volatility"&gt;122.8&lt;/span&gt;%
                                                         and risk-free interest rate of &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240730__20240730_za4oQLVx6iI5" title="Risk- free interest rate"&gt;4.78&lt;/span&gt;%.
                                                         The amount allocated to July 30 Warrants was classified as a component of permanent equity (as their terms permit the holders to
                                                         receive a fixed number of shares of common stock upon exercise for a fixed exercise price).&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furthermore,
it was determined that the embedded conversion feature and embedded redemption feature are required to be bifurcated from the host loan
instrument. The fair value of the bifurcated derivatives was determined by the management using the assistance of an external appraiser
in a total amount of $&lt;span id="xdx_903_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_pn3n3_c20240730_zhLPZmjp7eU3" title="Fair value of embedded derivative liability"&gt;35
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;upon initial recognition and in subsequent periods
as derivative liability at fair value through profit and loss. The remaining amount of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240730_z41X6Q5ys25k"&gt;1,415
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;was allocated to the host loan instrument which
in subsequent periods is accounted for using the effective interest method over the term of the loan, until its stated maturity.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    following tabular presentation reflects the reconciliation of the carrying amount of the July 30 Note during the period of nine months
    ended September 30, 2024:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_898_ecustom--ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--JulyThirteenNotesMember_zYc0P3ckmT7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="display: none"&gt;&lt;span id="xdx_8B2_z3vRAylczGji"&gt;SCHEDULE
OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY  30 NOTES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--JulyThirtyNotesMember_zdScknDfgcK7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine-month period ended &lt;br/&gt;
September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ConvertibleDebt_iS_pn3n3_z52nzxn0zku7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Open balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0929"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ProceedsFromIssuanceOfDebt_pn3n3_zL8inGKJRWpb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Total proceeds received&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_zqFwYLU1yITe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total proceeds allocated to July 30 Warrants at initial recognition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,550&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_pn3n3_zv82Po9flfcg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total proceeds allocated to embedded redemption feature at initial recognition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(35&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DiscountAmortizationAndInterestExpenses_pn3n3_zW1ptRHkBZxf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Amortization of discount and interest expenses related to July 30 Note (Note 5 below)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;309&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ConvertibleDebt_iE_pn3n3_zC5jJ7G5R526" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,724&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zESJf0AQXKE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock_zXF9TfCc680g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tabular presentation reflects the reconciliation of the fair value of the embedded conversion feature and embedded redemption
feature during the period of nine months ended September 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zuF3YLAqrakf" style="display: none"&gt;SCHEDULE
OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20240930_zt5zN59dkSx8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine-month period ended &lt;br/&gt;
September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DerivativeLiabilities_iS_zozdHaCn3yp4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Open balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0943"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_pn3n3_zP200s6qmuRd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Proceeds allocated to embedded redemption feature at initial recognition&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--RevaluationExpensesRelatedToEmbeddedRedemptionFeature_pn3n3_zihVxNPa8Od1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Revaluation expenses related to embedded redemption feature (Note 5 below)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DerivativeLiabilities_iE_zkchSUvzHfM1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zapTcKaPmV92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 24, 2024, the Company held a special meeting of its stockholders under which shares of common stock issuable by the Company
upon conversion of the July 30 Note and exercise of the July 30 Warrants has been approved. However, through September 30, 2024, July
30 Holder has not elected to trigger the conversion of July 30 Note or the exercise of the July 30 Warrants into shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
thousands of US Dollars)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 - SIGNIFICANT TRANSACTIONS (CONT.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;I.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;August 23
    Conversion&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    August 23, 2024 (the &#x201c;Commitment Date&#x201d;), the Company and two of June 27 Investors entered into conversion agreement,
    under which the Company agreed to convert the principal nominal amount plus any accrued but unpaid interest pursuant to each of June
    27 Notes, totalling approximately $&lt;span id="xdx_90F_eus-gaap--InterestExpense_pn3n3_c20240823__20240823__us-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenNotesMember_zWxpyAz6cV45" title="Interest expense"&gt;20&lt;/span&gt; each (the &#x201c;Debt&#x201d;), held by the Investors to Common Stock at a conversion price
    of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240823__us-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenNotesMember_zVdF1YSkjFs9" title="Conversion price"&gt;1.02&lt;/span&gt; per share. On October 15, 2024, the Company issued &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20241015__20241015__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIHLNVy4FjEb" title="Stock issued during period shares issued for services"&gt;19,682&lt;/span&gt; shares of common stock for each of the two of the June 27 Investors
    in respect of each respective Debt converted.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    satisfaction of the Debt, the Company also issued to each of the two June 27 Investors three warrants (each an &#x201c;August 23 Warrant&#x201d;).
    Each August 23 Warrant becomes exercisable on &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240823__20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantMember_zOolTvNjVPF8" title="Warrants exercisable"&gt;August 16, 2025&lt;/span&gt; and has term of &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantMember_zPIvgDc6Wy7a" title="Warrants and rights outstanding term::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0959"&gt;10&lt;/span&gt;&lt;/span&gt; years. The August 23 Warrants are exercisable for
    cash only and have no price-based antidilution. The first August 23 Warrant is for &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantOneMember_zgKCXWgB51w2" title="Class of warrant or right number of securities called by warrants or rights"&gt;10,707&lt;/span&gt; shares of Common Stock and is exercisable
    at $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantOneMember_zqHZ1Vlj9dPb" title="Exercise price"&gt;1.875&lt;/span&gt; per share. The second August 23 Warrant is for &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantTwoMember_zT1svfPEATIc" title="Class of warrant or right number of securities called by warrants or rights"&gt;7,648&lt;/span&gt; shares of Common Stock, exercisable at $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantTwoMember_zMDZF2QlRRbe" title="Exercise price"&gt;2.625&lt;/span&gt; per share. The third
    August 23 Warrant is for &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantThreeMember_zcJiiOjJZ0Ja" title="Class of warrant or right number of securities called by warrants or rights"&gt;5,948&lt;/span&gt; shares of Common Stock, exercisable at $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240823__us-gaap--StatementEquityComponentsAxis__custom--AugustTwentyThreeWarrantThreeMember_zBHRahYCFjc2" title="Exercise price"&gt;3.375&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    above transaction was accounted for as settlements of financial liabilities under which the instruments issued or to be issued to
    the June 27 Investors (i.e. shares of common stock and August 23 Warrants) are eligible for equity classification and thus both have
    been recorded as part of the permanent equity based on the total fair value of $&lt;span id="xdx_904_eus-gaap--EquityFairValueDisclosure_iI_pn3n3_c20240823_zZiLMCIoNcoh" title="Equity fair value disclosure"&gt;238&lt;/span&gt; at the Commitment Date. The difference between
    the fair value of these equity instruments and the carrying amount of each of the respective Debt at the Commitment Date amounted
    to $&lt;span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240823_zsJluKmFvjaa" title="Debt instrument face amount"&gt;11&lt;/span&gt; was charged immediately to the finance expenses (see also Note 5 below).&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    the period commencing the issuance date through September 30, 2024, none of the August 23 Warrants have been exercised.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;J.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Sep 5 Conversion&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    September 5, 2024 (the &#x201c;Commitment Date&#x201d;), the Company and one of June 27 Investors and July 18 Investors entered into
    a conversion agreement, under which the Company agreed to convert outstanding board fees amounted $&lt;span id="xdx_90F_eus-gaap--InterestExpense_pn3n3_c20240905__20240905__us-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenNotesMember_zhbP7e0kpav1" title="Interest expense"&gt;113&lt;/span&gt; and the principal nominal
    amount plus any accrued but unpaid interest pursuant to June 27 Note and July 18 Note, totalling $&lt;span id="xdx_909_eus-gaap--InterestExpense_pn3n3_c20240905__20240905__us-gaap--StatementEquityComponentsAxis__custom--JulyEighteenNotesMember_zooXaIH17PN7" title="Interest expense"&gt;146&lt;/span&gt; (referring together as a &#x201c;Debt&#x201d;),
    held by the Investor to Common Stock at a conversion price of $&lt;span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240823__us-gaap--StatementEquityComponentsAxis__custom--JulyTwentySevenNotesMember_zsDO7fWyYe1g" title="Conversion price"&gt;1.02&lt;/span&gt; per share. On October 15, 2024, the Company issued &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20241015__20241015__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenNotesMember_zeUrn5PRxDO9" title="Stock issued during period shares issued for services"&gt;254,226&lt;/span&gt; shares
    of common stock for the June 27 Investor in respect of the Debt converted.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    satisfaction of the Debt, the Company also issued to June 27 Investor and July 18 Investor three warrants (each an &#x201c;September
    5 Warrant&#x201d;). Each September 5 Warrant becomes exercisable on &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240905__20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsMember_zkAfYk20Ghab" title="Warrants exercisable"&gt;August 16, 2025&lt;/span&gt; and has term of &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsMember_zV8yWD4JRDWh" title="Warrants and rights outstanding term::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0987"&gt;10&lt;/span&gt;&lt;/span&gt; years. The September 5 Warrants
    are exercisable for cash only and have no price-based antidilution. The first September 5 Warrant is for &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsOneMember_zMPLfHDDzBx4" title="Class of warrant or right number of securities called by warrants or rights"&gt;138,299&lt;/span&gt; shares of Common
    Stock and is exercisable at $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsOneMember_z77WflL0Wfy8" title="Exercise price"&gt;1.875&lt;/span&gt; per share. The second September 5 Warrant is for &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsTwoMember_z2GIl1yqeUb2" title="Class of warrant or right number of securities called by warrants or rights"&gt;98,785&lt;/span&gt; shares of Common Stock, exercisable at
    $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsTwoMember_zz1Ym84sgTie" title="Exercise price"&gt;2.625&lt;/span&gt; per share. The third September 5 Warrant is for &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsThreeMember_zaKm6gzzUXv5" title="Class of warrant or right number of securities called by warrants or rights"&gt;76,833&lt;/span&gt; shares of Common Stock, exercisable at $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240905__us-gaap--StatementEquityComponentsAxis__custom--SeptemberFiveWarrantsThreeMember_zShYVelRWV1e" title="Exercise price"&gt;3.375&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    above transaction was accounted for as settlements of financial liabilities under which the instruments issued or to be issued to
    the July 18 Investor (i.e. shares of common stock and September 5 Warrants) are eligible for equity classification and thus both
    have been recorded as part of permanent equity based on the total fair value of $&lt;span id="xdx_901_eus-gaap--EquityFairValueDisclosure_iI_pn3n3_c20240905_zIQnmVLV7pRd" title="Equity fair value disclosure"&gt;1,505&lt;/span&gt; at the Commitment Date. The difference between
    the fair value of these equity instruments and the carrying amount of the Debt at the Commitment Date amounted to $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240905_znjTytI72ePi" title="Debt instrument face amount"&gt;227&lt;/span&gt; was charged
    immediately to the finance expenses (see also Note 5 below).&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    the period commencing the issuance date through September 30, 2024, none of the September 5 Warrants have been exercised.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
thousands of US Dollars)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</GCTK:SignificantTransactionsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-032024-01-03_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact000776"
      unitRef="Shares">395294</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-02-13"
      decimals="INF"
      id="Fact000778"
      unitRef="Shares">718641</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-02-13_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000780"
      unitRef="Shares">876391</us-gaap:CommonStockSharesIssued>
    <GCTK:LockUpPeriodDescription
      contextRef="From2024-02-132024-02-13_custom_ExchangeAgreementMember"
      id="Fact000782">(a) sell or contract
    to sell Shares at a price higher than $0.50 per Share on any trading day up to 10% of the daily volume of Shares or (b) sell or contract
    to sell Shares at a price higher than $0.80 per Share on any trading day with no volume limitation.</GCTK:LockUpPeriodDescription>
    <us-gaap:SharePrice
      contextRef="AsOf2024-02-13_custom_ExchangeAgreementMember"
      decimals="INF"
      id="Fact000784"
      unitRef="USDPShares">1.00</us-gaap:SharePrice>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-02-192024-02-19_us-gaap_LeaseAgreementsMember"
      decimals="-2"
      id="Fact000786"
      unitRef="USD">2500</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="AsOf2024-02-19_us-gaap_LeaseAgreementsMember"
      id="Fact000788">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:SecurityDeposit
      contextRef="AsOf2024-02-19_us-gaap_LeaseAgreementsMember"
      decimals="-2"
      id="Fact000790"
      unitRef="USD">2500</us-gaap:SecurityDeposit>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-02-19"
      decimals="-3"
      id="Fact000792"
      unitRef="USD">79000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000794">&lt;p id="xdx_897_eus-gaap--LeaseCostTableTextBlock_zIzel0VXWKy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_z3vDuEBqrYq6" style="display: none"&gt;SCHEDULE
OF OPERATING
LEASE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240930_zZZP4RDv7wKg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zsaPUwH9wOCa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left; padding-bottom: 2.5pt"&gt;Operating right-of-use asset&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 18%; text-align: right"&gt;65&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zyV0tTXRkczh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Current operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zsi5QhiaesRb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Non-Current operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;40&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000796"
      unitRef="USD">65000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000798"
      unitRef="USD">25000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000800"
      unitRef="USD">40000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000802">&lt;p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zjcYrVnemZJ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Maturity
analysis of the Company&#x2019;s lease liability:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_ztlO01gzXIGk" style="display: none"&gt;SCHEDULE
OF MATURITY
ANALYSIS OF LEASE LIABILITY&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240930_zhZxTL7nJvg3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_hus-gaap--LeaseContractualTermAxis__custom--LessThanOneYearMember_zXc3Tv74rw9c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Less than one year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;30&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_hus-gaap--LeaseContractualTermAxis__custom--BetweenOneYearToTwoYearsMember_zC0BaIt2ItC1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Between 1-2 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_hus-gaap--LeaseContractualTermAxis__custom--MoreThanTwoYearsMember_zUYBx9ixmCL2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;More than 2 years&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zR8mOjemPfEj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total operating lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;73&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--LesseeOperatingLeaseLiabilityImputedInterest_iNI_di_zDVgdFWJRpO7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_zrTAHbTQkpxb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;65&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-09-30_custom_LessThanOneYearMember"
      decimals="-3"
      id="Fact000804"
      unitRef="USD">30000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-09-30_custom_BetweenOneYearToTwoYearsMember"
      decimals="-3"
      id="Fact000806"
      unitRef="USD">30000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-09-30_custom_MoreThanTwoYearsMember"
      decimals="-3"
      id="Fact000808"
      unitRef="USD">13000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000810"
      unitRef="USD">73000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <GCTK:LesseeOperatingLeaseLiabilityImputedInterest
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000812"
      unitRef="USD">-8000</GCTK:LesseeOperatingLeaseLiabilityImputedInterest>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000814"
      unitRef="USD">65000</us-gaap:OperatingLeaseLiability>
    <GCTK:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000816">&lt;p id="xdx_892_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock_zZMEFboNQckj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of the weighted average remaining lease terms and discount rate for the lease:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zg2FCIS7FFqb" style="display: none"&gt;SCHEDULE
OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Lease term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240930_zE2X8TvuDZW1" title="Lease term (years)"&gt;2.42&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20240930_zxtunKEZIuh9" title="Weighted average discount rate"&gt;9.03&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</GCTK:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-09-30" id="Fact000818">P2Y5M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000820"
      unitRef="Pure">0.0903</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-04-222024-04-22_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000822"
      unitRef="Shares">79366</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-04-22_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000824"
      unitRef="USDPShares">6.30</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-04-222024-04-22_us-gaap_PrivatePlacementMember"
      decimals="-3"
      id="Fact000826"
      unitRef="USD">500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2024-04-302024-04-30" id="Fact000828">one-for-five</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-06-27_custom_UnsecuredPromissoryNotesMember"
      decimals="-3"
      id="Fact000830"
      unitRef="USD">100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-06-27"
      decimals="-3"
      id="Fact000832"
      unitRef="Shares">300000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShortTermDebtDescription contextRef="From2024-06-272024-06-27" id="Fact000834">The
    June 27 Notes bear simple interest at a rate of 3% per annum and are due and payable in cash on the earlier of: (a) 12 months
    from the date of the June 27 Note; or (b) the date the Company raises third-party equity capital in an amount equal to or in excess
    of $1,000 (the &#x201c;Maturity Date&#x201d;). The Company may prepay the June 27 Notes at any time prior to the Maturity Date without
    penalty. If an event of default occurs, the then-outstanding principal amount of the June 27 Notes plus any unpaid accrued interest
    will accelerate and become immediately payable in cash.</us-gaap:ShortTermDebtDescription>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-27"
      decimals="INF"
      id="Fact000836"
      unitRef="USDPShares">4.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-06-272024-06-27"
      decimals="-3"
      id="Fact000840"
      unitRef="USD">15000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-06-272024-06-27"
      decimals="-3"
      id="Fact000842"
      unitRef="USD">85000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2024-06-27"
      decimals="INF"
      id="Fact000844"
      unitRef="Pure">0.2865</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-06-272024-06-27"
      decimals="INF"
      id="Fact000846"
      unitRef="Pure">2.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-06-272024-06-27"
      decimals="INF"
      id="Fact000848"
      unitRef="Pure">0.0452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <GCTK:ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock
      contextRef="From2024-01-012024-09-30_custom_JuneTwentySevenWarrantsMember"
      id="Fact000850">&lt;p id="xdx_899_ecustom--ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenWarrantsMember_ztHe4s0Y6vC" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zmhwp7QEQiti" style="display: none"&gt;SCHEDULE
OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--JuneTwentySevenWarrantsMember_zq6138sou90d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine-month period ended&lt;br/&gt;
 September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_zqYDDjqLHFkl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Open balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0852"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfWarrants_pn3n3_zyhzU0eZMena" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Total proceeds received&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ProceedsFromAllocatedWarrantsAtInitialRecognition_pn3n3_zX9355DzW9V4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
proceeds allocated to June 27 Warrants at initial recognition&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 18%"&gt;(85&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DiscountAmortizationAndInterestExpenses_pn3n3_zE75HDXl0Vsd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Discount amortization and interest expenses related to &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;June
27 Notes (Note 5 below)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--PartialConversionNotesAndAccruedInterest_pn3n3_zT1rqNwyyTs5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Partial conversion &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;June 27 Notes and accrued
Interest (Note 3I and Note 3J below)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(26&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--WarrantsAndRightsOutstanding_iE_pn3n3_zhz6ftz91vk2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</GCTK:ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-012024-09-30_custom_JuneTwentySevenWarrantsMember"
      decimals="-3"
      id="Fact000854"
      unitRef="USD">100000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <GCTK:ProceedsFromAllocatedWarrantsAtInitialRecognition
      contextRef="From2024-01-012024-09-30_custom_JuneTwentySevenWarrantsMember"
      decimals="-3"
      id="Fact000856"
      unitRef="USD">-85000</GCTK:ProceedsFromAllocatedWarrantsAtInitialRecognition>
    <GCTK:DiscountAmortizationAndInterestExpenses
      contextRef="From2024-01-012024-09-30_custom_JuneTwentySevenWarrantsMember"
      decimals="-3"
      id="Fact000858"
      unitRef="USD">16000</GCTK:DiscountAmortizationAndInterestExpenses>
    <GCTK:PartialConversionNotesAndAccruedInterest
      contextRef="From2024-01-012024-09-30_custom_JuneTwentySevenWarrantsMember"
      decimals="-3"
      id="Fact000860"
      unitRef="USD">-26000</GCTK:PartialConversionNotesAndAccruedInterest>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-09-30_custom_JuneTwentySevenWarrantsMember"
      decimals="-3"
      id="Fact000862"
      unitRef="USD">5000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-07-18_us-gaap_ConvertibleNotesPayableMember"
      decimals="-3"
      id="Fact000864"
      unitRef="USD">360000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-07-18_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="Fact000866"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2024-07-18_us-gaap_ConvertibleNotesPayableMember"
      decimals="-3"
      id="Fact000868"
      unitRef="USD">500000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2024-07-18_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="Fact000870"
      unitRef="USDPShares">1.56</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2024-07-182024-07-18_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="Fact000872"
      unitRef="USD">360</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <GCTK:ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock
      contextRef="From2024-01-012024-09-30_custom_JulyEighteenNotesMember"
      id="Fact000874">&lt;p id="xdx_89F_ecustom--ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--JulyEighteenNotesMember_z1cKGNZR7vUa" style="margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zwhuunhzDGij" style="display: none"&gt;SCHEDULE
OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--JulyEighteenNotesMember_z5oURXRylszg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine-month period ended &lt;br/&gt;
September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ConvertibleDebt_iS_pn3n3_z2iF2SE7fnzd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Open balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0876"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfDebt_pn3n3_zF7GWCyQYXw" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Total proceeds allocated to July 18 Notes at initial recognition&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;360&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestExpense_pn3n3_zpZevaxptRE3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest expenses related to July 18 Notes (Note 5 below)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--PartialConversionAndAccruedInterest_pn3n3_zv1dVDK0cmVl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Partial conversion July 18 Notes and accrued Interest (Note 3J below)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(101&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ConvertibleDebt_iE_z4h2ISWrdvL4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;264&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</GCTK:ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-01-012024-09-30_custom_JulyEighteenNotesMember"
      decimals="-3"
      id="Fact000878"
      unitRef="USD">360000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:InterestExpense
      contextRef="From2024-01-012024-09-30_custom_JulyEighteenNotesMember"
      decimals="-3"
      id="Fact000880"
      unitRef="USD">5000</us-gaap:InterestExpense>
    <GCTK:PartialConversionAndAccruedInterest
      contextRef="From2024-01-012024-09-30_custom_JulyEighteenNotesMember"
      decimals="-3"
      id="Fact000882"
      unitRef="USD">-101000</GCTK:PartialConversionAndAccruedInterest>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2024-09-30_custom_JulyEighteenNotesMember"
      decimals="-3"
      id="Fact000884"
      unitRef="USD">264000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-07-30_custom_ConvertiblePromissoryNotesMember_custom_WarrantsAgreementMember"
      decimals="-3"
      id="Fact000886"
      unitRef="USD">4000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-07-30_custom_ConvertiblePromissoryNotesMember_custom_WarrantsAgreementMember"
      decimals="INF"
      id="Fact000888"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentDescription
      contextRef="From2024-07-302024-07-30_custom_ConvertiblePromissoryNotesMember_custom_WarrantsAgreementMember"
      id="Fact000890">(i)
12 months anniversary of July 30 Note, or (ii) closing date of a Sale Transaction (defined below) (the &#x201c;Maturity
Date&#x201d;)</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentDescription
      contextRef="From2024-07-302024-07-30_custom_ConvertiblePromissoryNotesMember"
      id="Fact000892">(i)
is convertible at the discretion of the July 30 Holder at a price equal to the closing price of the Common Stock on the date of
conversion and, (ii) if the Closing Price of the Common stock exceeds $5.00
per share for a period of 5 consecutive trading days, will automatically convert at a price equal to the 5 daily Volume Weighted
Average Price (&#x201c;VWAP&#x201d;) of the Common Stock (subject to adjustment for any stock split, stock dividend, reverse stock
split, combination or similar transaction).</us-gaap:DebtInstrumentDescription>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-07-30_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="Fact000894"
      unitRef="USDPShares">5.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockDescriptionOfTransaction
      contextRef="From2024-07-302024-07-30_custom_ConvertiblePromissoryNotesMember"
      id="Fact000896">(i)
cash equal to 200% of the Note balance, or (ii) transaction consideration in the amount to be received by the Holder in such Sale
Transaction if the July 30 Note was converted pursuant to an optional conversion. &#x201c;Sale Transaction&#x201d; means a merger or
consolidation of the Company with or into any other entity, or a sale of all or substantially all of the Company&#x2019;s assets, or any other transaction or series of related transactions in which the Company&#x2019;s stockholders immediately prior
to such transaction(s) receive cash, securities or other property in exchange for their shares and, immediately after such
transaction(s), own less than 50% of the equity securities of the surviving corporation or its parent.</us-gaap:SaleOfStockDescriptionOfTransaction>
    <us-gaap:DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault contextRef="From2024-07-302024-07-30" id="Fact000898">(i)
failure by the Company to pay the July 30 Note balance on the Maturity Date, (ii) the Company becomes subject to a judgement of more
than $50,000,
(iii) voluntary bankruptcy, or (iv) involuntary bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii)
above, the July 30 Note balance shall automatically and immediately become due and payable, in all cases without any action on the
part of the July 30 Holder.</us-gaap:DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault>
    <us-gaap:DebtDefaultLongtermDebtAmount
      contextRef="AsOf2024-07-30"
      decimals="-3"
      id="Fact000900"
      unitRef="USD">50000000</us-gaap:DebtDefaultLongtermDebtAmount>
    <us-gaap:DebtInstrumentTerm contextRef="From2024-07-302024-07-30" id="Fact000901">P10Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-07-302024-07-30_custom_FirstWarrantMember"
      decimals="INF"
      id="Fact000902"
      unitRef="Shares">2133334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-07-30_custom_FirstWarrantMember"
      decimals="INF"
      id="Fact000904"
      unitRef="USDPShares">1.875</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-07-302024-07-30_custom_SecondWarrantMember"
      decimals="INF"
      id="Fact000905"
      unitRef="Shares">1523810</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-07-30_custom_SecondWarrantMember"
      decimals="INF"
      id="Fact000907"
      unitRef="USDPShares">2.625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-07-302024-07-30_custom_ThirdWarrantMember"
      decimals="INF"
      id="Fact000908"
      unitRef="Shares">1185186</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-07-30_custom_ThirdWarrantMember"
      decimals="INF"
      id="Fact000910"
      unitRef="USDPShares">3.375</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <GCTK:EmbeddedConversionFeaturePercentage
      contextRef="AsOf2024-07-30"
      decimals="INF"
      id="Fact000912"
      unitRef="Pure">2</GCTK:EmbeddedConversionFeaturePercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-07-302024-07-30"
      decimals="-3"
      id="Fact000914"
      unitRef="USD">1450000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-07-302024-07-30"
      decimals="-3"
      id="Fact000916"
      unitRef="USD">2550000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2024-07-30"
      decimals="INF"
      id="Fact000918"
      unitRef="Pure">0.2865</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-07-302024-07-30"
      decimals="INF"
      id="Fact000920"
      unitRef="Pure">1.228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-07-302024-07-30"
      decimals="INF"
      id="Fact000922"
      unitRef="Pure">0.0478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="AsOf2024-07-30"
      decimals="-3"
      id="Fact000924"
      unitRef="USD">35000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-07-30"
      decimals="-3"
      id="Fact000925"
      unitRef="USD">1415000</us-gaap:DebtInstrumentFaceAmount>
    <GCTK:ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock
      contextRef="From2024-01-012024-09-30_custom_JulyThirteenNotesMember"
      id="Fact000927">&lt;p id="xdx_898_ecustom--ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--JulyThirteenNotesMember_zYc0P3ckmT7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="display: none"&gt;&lt;span id="xdx_8B2_z3vRAylczGji"&gt;SCHEDULE
OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY  30 NOTES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--JulyThirtyNotesMember_zdScknDfgcK7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine-month period ended &lt;br/&gt;
September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ConvertibleDebt_iS_pn3n3_z52nzxn0zku7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Open balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0929"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ProceedsFromIssuanceOfDebt_pn3n3_zL8inGKJRWpb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Total proceeds received&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_zqFwYLU1yITe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total proceeds allocated to July 30 Warrants at initial recognition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,550&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_pn3n3_zv82Po9flfcg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total proceeds allocated to embedded redemption feature at initial recognition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(35&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DiscountAmortizationAndInterestExpenses_pn3n3_zW1ptRHkBZxf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Amortization of discount and interest expenses related to July 30 Note (Note 5 below)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;309&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ConvertibleDebt_iE_pn3n3_zC5jJ7G5R526" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,724&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</GCTK:ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-01-012024-09-30_custom_JulyThirtyNotesMember"
      decimals="-3"
      id="Fact000931"
      unitRef="USD">4000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-09-30_custom_JulyThirtyNotesMember"
      decimals="-3"
      id="Fact000933"
      unitRef="USD">-2550000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="From2024-01-012024-09-30_custom_JulyThirtyNotesMember"
      decimals="-3"
      id="Fact000935"
      unitRef="USD">-35000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <GCTK:DiscountAmortizationAndInterestExpenses
      contextRef="From2024-01-012024-09-30_custom_JulyThirtyNotesMember"
      decimals="-3"
      id="Fact000937"
      unitRef="USD">309000</GCTK:DiscountAmortizationAndInterestExpenses>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2024-09-30_custom_JulyThirtyNotesMember"
      decimals="-3"
      id="Fact000939"
      unitRef="USD">1724000</us-gaap:ConvertibleDebt>
    <GCTK:ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000941">&lt;p id="xdx_89E_ecustom--ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock_zXF9TfCc680g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tabular presentation reflects the reconciliation of the fair value of the embedded conversion feature and embedded redemption
feature during the period of nine months ended September 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zuF3YLAqrakf" style="display: none"&gt;SCHEDULE
OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20240930_zt5zN59dkSx8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine-month period ended &lt;br/&gt;
September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DerivativeLiabilities_iS_zozdHaCn3yp4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Open balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0943"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_pn3n3_zP200s6qmuRd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Proceeds allocated to embedded redemption feature at initial recognition&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--RevaluationExpensesRelatedToEmbeddedRedemptionFeature_pn3n3_zihVxNPa8Od1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Revaluation expenses related to embedded redemption feature (Note 5 below)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DerivativeLiabilities_iE_zkchSUvzHfM1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</GCTK:ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000945"
      unitRef="USD">35000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <GCTK:RevaluationExpensesRelatedToEmbeddedRedemptionFeature
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000947"
      unitRef="USD">2000</GCTK:RevaluationExpensesRelatedToEmbeddedRedemptionFeature>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000949"
      unitRef="USD">37000</us-gaap:DerivativeLiabilities>
    <us-gaap:InterestExpense
      contextRef="From2024-08-232024-08-23_custom_JuneTwentySevenNotesMember"
      decimals="-3"
      id="Fact000951"
      unitRef="USD">20000</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2024-08-23_custom_JuneTwentySevenNotesMember"
      decimals="INF"
      id="Fact000953"
      unitRef="USDPShares">1.02</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-10-152024-10-15_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact000955"
      unitRef="Shares">19682000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="From2024-08-232024-08-23_custom_AugustTwentyThreeWarrantMember"
      id="Fact000957">2025-08-16</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-08-23_custom_AugustTwentyThreeWarrantOneMember"
      decimals="-3"
      id="Fact000961"
      unitRef="Shares">10707000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-08-23_custom_AugustTwentyThreeWarrantOneMember"
      decimals="INF"
      id="Fact000963"
      unitRef="USDPShares">1.875</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-08-23_custom_AugustTwentyThreeWarrantTwoMember"
      decimals="-3"
      id="Fact000965"
      unitRef="Shares">7648000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-08-23_custom_AugustTwentyThreeWarrantTwoMember"
      decimals="INF"
      id="Fact000967"
      unitRef="USDPShares">2.625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-08-23_custom_AugustTwentyThreeWarrantThreeMember"
      decimals="-3"
      id="Fact000969"
      unitRef="Shares">5948000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-08-23_custom_AugustTwentyThreeWarrantThreeMember"
      decimals="INF"
      id="Fact000971"
      unitRef="USDPShares">3.375</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:EquityFairValueDisclosure
      contextRef="AsOf2024-08-23"
      decimals="-3"
      id="Fact000973"
      unitRef="USD">238000</us-gaap:EquityFairValueDisclosure>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-08-23"
      decimals="-3"
      id="Fact000975"
      unitRef="USD">11000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestExpense
      contextRef="From2024-09-052024-09-05_custom_JuneTwentySevenNotesMember"
      decimals="-3"
      id="Fact000977"
      unitRef="USD">113000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-09-052024-09-05_custom_JulyEighteenNotesMember"
      decimals="-3"
      id="Fact000979"
      unitRef="USD">146000</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2024-08-23_custom_JulyTwentySevenNotesMember"
      decimals="INF"
      id="Fact000981"
      unitRef="USDPShares">1.02</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-10-152024-10-15_us-gaap_SubsequentEventMember_custom_JuneTwentySevenNotesMember"
      decimals="-3"
      id="Fact000983"
      unitRef="Shares">254226000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="From2024-09-052024-09-05_custom_SeptemberFiveWarrantsMember"
      id="Fact000985">2025-08-16</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-09-05_custom_SeptemberFiveWarrantsOneMember"
      decimals="-3"
      id="Fact000989"
      unitRef="Shares">138299000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-09-05_custom_SeptemberFiveWarrantsOneMember"
      decimals="INF"
      id="Fact000991"
      unitRef="USDPShares">1.875</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-09-05_custom_SeptemberFiveWarrantsTwoMember"
      decimals="-3"
      id="Fact000993"
      unitRef="Shares">98785000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-09-05_custom_SeptemberFiveWarrantsTwoMember"
      decimals="INF"
      id="Fact000995"
      unitRef="USDPShares">2.625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-09-05_custom_SeptemberFiveWarrantsThreeMember"
      decimals="-3"
      id="Fact000997"
      unitRef="Shares">76833000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-09-05_custom_SeptemberFiveWarrantsThreeMember"
      decimals="INF"
      id="Fact000999"
      unitRef="USDPShares">3.375</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:EquityFairValueDisclosure
      contextRef="AsOf2024-09-05"
      decimals="-3"
      id="Fact001001"
      unitRef="USD">1505000</us-gaap:EquityFairValueDisclosure>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-09-05"
      decimals="-3"
      id="Fact001003"
      unitRef="USD">227000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact001005">&lt;p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zCOc37QMoXDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 - &lt;span id="xdx_822_zdDaUGCzfqad"&gt;COMMITMENTS AND CONTINGENT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    2004, the Israeli Innovation Authority (IIA) provided Integrity Israel with a grant of approximately $&lt;span id="xdx_908_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember_zaHViVdRghJ1"&gt;93&lt;/span&gt;
    (NIS &lt;span id="xdx_90E_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pp0p0_uIsrael_c20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember_zhBK2jlcIrLh"&gt;420,000&lt;/span&gt;),
    for develop a non-invasive blood glucose monitor (the &#x201c;Development Plan&#x201d;). Integrity Israel is required to pay royalties
    to IIA at a rate ranging between &lt;span id="xdx_90B_ecustom--RoyaltyPercentage_pid_dp_uPure_c20040303__20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember__srt--RangeAxis__srt--MinimumMember_zunJ0lR75WF5" title="Royalty percentage minimum"&gt;3&lt;/span&gt;-&lt;span id="xdx_903_ecustom--RoyaltyPercentage_pid_dp_uPure_c20040303__20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember__srt--RangeAxis__srt--MaximumMember_zxphyp4Enfx8" title="Royalty percentage maximum"&gt;5&lt;/span&gt;%
    of the proceeds from sale of the Company&#x2019;s products arising from the Development Plan up to an amount equal to $&lt;span id="xdx_906_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pp0p0_c20040304__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember_zPm8IVWj1hOj" title="Business combination contingent consideration liability"&gt;93&lt;/span&gt;,
    plus interest at LIBOR from the grant date. As to replacement of the LIBOR benchmark rate, even though the IIA has not
    declared the alternative benchmark rate to replace the LIBOR, the Company does not believe it will have a significant impact. As of
    September 30, 2024, the remaining contingent liability with respect to royalty payment on future sales equals approximately $&lt;span id="xdx_90D_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pp0p0_c20240930__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember_zGM71gfi1iJ4" title="Contingent consideration liability"&gt;73&lt;/span&gt;,
    excluding interest. Such contingent obligation has no expiration date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    October 7, 2022 (&#x201c;the Closing Date&#x201d;), the Company entered into Intellectual Property Purchase Agreement (the &#x201c;Agreement&#x201d;)
    with Paul Goode, which is the Company&#x2019;s Chief Executive Officer (the &#x201c;Seller&#x201d;), under which it was agreed that
    on and subject to the terms and conditions of the Agreement, at the Closing Date, Seller sold and assigned to the Company, all of Seller&#x2019;s right, title and interest in and to the following assets, properties and rights (collectively,
    the &#x201c;Purchased Assets&#x201d;): (i) all rights, title, interests in all current and future intellectual
property, including, but not limited to patents, trademarks, trade secrets, industry know-how and other IP rights relating to an implantable
continuous glucose sensor (collectively, the &#x201c;Conveyed Intellectual Property&#x201d;); and (ii) all the goodwill relating to the
Purchased Assets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    consideration for the sale of the Purchased Assets to the Company, at the Closing Date, the Company paid to Seller cash
    in the amount of one dollar and obligated to issue up to &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221007__20221007__us-gaap--TypeOfArrangementAxis__custom--IntellectualPropertyPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXEZOIwXqj5i" title="Number of common shares issued"&gt;200,000&lt;/span&gt; shares of Common Stock to be issued based upon specified performance
    milestones as set forth in the Agreement (the &#x201c;Purchase Price&#x201d;). In addition, if upon the final issuance, the aggregate
    &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221007__20221007__us-gaap--TypeOfArrangementAxis__custom--IntellectualPropertyPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zrtE6UgOrJne" title="Number of common shares issued"&gt;200,000&lt;/span&gt; shares represent less than &lt;span id="xdx_905_ecustom--AggregateSalesPriceOfUnitsPercentage_iI_pid_dp_uPure_c20221007__us-gaap--TypeOfArrangementAxis__custom--IntellectualPropertyPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zCCi3QJaefZ3" title="Commission as a percentage of aggregate sales price"&gt;1.5&lt;/span&gt;% of the then outstanding Common Stock of the Company, the final issuance will include such
    number of additional shares so that the total aggregate issuance equals &lt;span id="xdx_900_ecustom--AggregateSalesPriceOfUnitsPercentage_iI_pid_dp_uPure_c20221007__us-gaap--TypeOfArrangementAxis__custom--IntellectualPropertyPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__custom--TrueupSharesMember_z9Vfinwd0cze" title="Commission as a percentage of aggregate sales price"&gt;1.5&lt;/span&gt;% of the outstanding shares (the &#x201c;True-Up Shares&#x201d;).
    All shares of Common Stock of the Company that will be issued under the agreement shall be (i) restricted over a limited period
    as defined in the Agreement and (ii) subject to the lockup provisions.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
    the Company acquires net assets that do not constitute a business, as defined under ASU 2017-01 Business Combinations (Topic 805)
    Clarifying the Definition of a Business (such when there is no substantive process in the acquired entity) the transaction is accounted
    for as asset acquisition and no goodwill is recognized. The acquired In-Process Research and Development intangible asset (&#x201c;IPR&amp;amp;D&#x201d;)
    to be used in research and development projects which have been determined not to have alternative future use at the acquisition
    date, is expensed immediately.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
    the Closing Date, it was determined that the asset acquisition represents the purchase of IPR&amp;amp;D with no alternative future use.
    However, the achievement of each of the performance milestones is considered as a contingent event outside the Company&#x2019;s
    control and thus the contingent consideration which is equal to the fair value of the Purchase Price as measured at the Closing Date
    will be recognized when it becomes probable that each target will be achieved within the reasonable period. Such additional
    contingent consideration will be recognized in subsequent periods if and when the contingency (the achievement of targets) is
    resolved.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    June 2023, the Company achieved the first performance milestone out of the five performance milestones outlined in the Agreement
    executed between the Company and the Seller as of the Closing Date. As a result, upon the date of the fulfilment of the first performance
    milestone the Company was committed to issue &lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesRestrictedStock_pid_c20230601__20230620_z25ocrgRy8S8" title="Restricted shares to the seller"&gt;20,000&lt;/span&gt; restricted shares to the Seller. Accordingly, the Company recorded an amount
    of $&lt;span id="xdx_906_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_c20240101__20240930_zSuklHwUuhGb" title="Research and development expenses"&gt;131&lt;/span&gt; as research and development expenses with a similar amount as an increase to additional paid-in capital. The first performance
    milestone shares were issued on February 6, 2024.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    May 2024, the Company achieved the second performance milestone out of the five performance milestones outlined in the Agreement
    executed between the Company and the Seller as of the Closing Date. As result, the Company is committed to issue &lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesRestrictedStock_pid_c20240501__20240531_z0lpNVaxB1S6" title="Restricted shares"&gt;30,000&lt;/span&gt; restricted
    shares to the Seller. Accordingly, the Company recorded stock-based compensation expenses amounted to $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZzAsjd0Z9tl" title="Stock based compensation"&gt;192&lt;/span&gt; which represents the
    quoted price of its Common Stock at the Closing Date, after taking into consideration a discount for lack of marketability in a rate
    of &lt;span id="xdx_906_ecustom--MarketabilityDiscountRate_pid_dp_uPure_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSM3uI0t0A02" title="Discount rate"&gt;30&lt;/span&gt; % over the applicable restriction period. As of September 30, 2024, the second performance milestone shares were not yet issued.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of September 30, 2024, the achievement of all other remaining performance milestones was not considered probable and thus no
    stock-based compensation expenses were recorded with respect to thereof.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(in
thousands of US Dollars)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2004-03-04_custom_IsraeliInnovationAuthorityMember"
      decimals="-3"
      id="Fact001006"
      unitRef="USD">93000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2004-03-04_custom_IsraeliInnovationAuthorityMember"
      decimals="0"
      id="Fact001007"
      unitRef="Israel">420000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <GCTK:RoyaltyPercentage
      contextRef="From2004-03-032004-03-04_custom_IsraeliInnovationAuthorityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001009"
      unitRef="Pure">0.03</GCTK:RoyaltyPercentage>
    <GCTK:RoyaltyPercentage
      contextRef="From2004-03-032004-03-04_custom_IsraeliInnovationAuthorityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001011"
      unitRef="Pure">0.05</GCTK:RoyaltyPercentage>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2004-03-04_custom_IsraeliInnovationAuthorityMember29980703"
      decimals="0"
      id="Fact001013"
      unitRef="USD">93</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2024-09-30_custom_IsraeliInnovationAuthorityMember"
      decimals="0"
      id="Fact001015"
      unitRef="USD">73</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-10-072022-10-07_custom_IntellectualPropertyPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001017"
      unitRef="Shares">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-10-072022-10-07_custom_IntellectualPropertyPurchaseAgreementMember_us-gaap_CommonStockMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001019"
      unitRef="Shares">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <GCTK:AggregateSalesPriceOfUnitsPercentage
      contextRef="AsOf2022-10-07_custom_IntellectualPropertyPurchaseAgreementMember_us-gaap_CommonStockMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001021"
      unitRef="Pure">0.015</GCTK:AggregateSalesPriceOfUnitsPercentage>
    <GCTK:AggregateSalesPriceOfUnitsPercentage
      contextRef="AsOf2022-10-07_custom_IntellectualPropertyPurchaseAgreementMember_us-gaap_CommonStockMember_srt_MinimumMember_custom_TrueupSharesMember"
      decimals="INF"
      id="Fact001023"
      unitRef="Pure">0.015</GCTK:AggregateSalesPriceOfUnitsPercentage>
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock
      contextRef="From2023-06-012023-06-20"
      decimals="INF"
      id="Fact001025"
      unitRef="Shares">20000</us-gaap:WeightedAverageNumberOfSharesRestrictedStock>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact001027"
      unitRef="USD">131000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock
      contextRef="From2024-05-012024-05-31"
      decimals="INF"
      id="Fact001029"
      unitRef="Shares">30000</us-gaap:WeightedAverageNumberOfSharesRestrictedStock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001031"
      unitRef="USD">192000</us-gaap:ShareBasedCompensation>
    <GCTK:MarketabilityDiscountRate
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001033"
      unitRef="Pure">0.30</GCTK:MarketabilityDiscountRate>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact001035">&lt;p id="xdx_809_eus-gaap--FinancialInstrumentsDisclosureTextBlock_zwBry1e2Aijg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5 - &lt;span id="xdx_82D_z1HgvlIKamTb"&gt;FINANCE (INCOME) EXPENSES, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zauJhdSM0g7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zDk8QpTWxw05" style="display: none"&gt;SCHEDULE
OF FINANCE EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20240701__20240930_zFF3zx8ch3R" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20230701__20230930_zuGbgWYkprh8" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20240101__20240930_zGqfKKbestH2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20230101__20230930_z6aWwu5CAgM5" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three-month period ended&lt;br/&gt;
 September
    30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine-month period ended&lt;br/&gt;
 September
    30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Unaudited&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Unaudited&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DiscountAmortizationAndInterestExpensesOne_msFINztjv_zhyhrts5GOFj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt; width: 40%; text-align: left"&gt;Discount amortization and interest expenses related to June 27 Notes&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;16&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1040"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;16&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1042"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--InterestExpense_msFINztjv_zlTcp83Lkpjj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest expenses related to July 18 Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1045"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1047"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DiscountAmortizationAndInterestExpensesTwo_msFINztjv_z9b63atu2dth" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;Discount amortization and interest expenses related to July 30 Note&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;309&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1050"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;309&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1052"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--RevaluationExpensesRelatedToDerivativeFinancialLiabilities_pn3n3_msFINztjv_zezxB21JZ20i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;Revaluation expenses related to derivative financial liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1055"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1057"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities_pn3n3_msFINztjv_zmxtjfjUkxt3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;Revaluation expenses incurred from settlement of financial liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,505&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1060"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,505&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1062"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InterestExpenseDeposits_pn3n3_msFINztjv_zXVl7imz3jTk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest on bank deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(38&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherExpenses_pn3n3_msFINztjv_zd1FJnu5PiL" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;Exchange rate differentials, bank commissions and miscellaneous&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1070"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--FinanceIncomeNet_iNT_pn3n3_di_mtFINztjv_zV1QX83jCJJ6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance (income) expenses,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,848&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,822&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <srt:ScheduleOfCondensedFinancialStatementsTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact001037">&lt;p id="xdx_893_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zauJhdSM0g7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zDk8QpTWxw05" style="display: none"&gt;SCHEDULE
OF FINANCE EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20240701__20240930_zFF3zx8ch3R" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20230701__20230930_zuGbgWYkprh8" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20240101__20240930_zGqfKKbestH2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20230101__20230930_z6aWwu5CAgM5" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three-month period ended&lt;br/&gt;
 September
    30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine-month period ended&lt;br/&gt;
 September
    30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Unaudited&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Unaudited&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DiscountAmortizationAndInterestExpensesOne_msFINztjv_zhyhrts5GOFj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt; width: 40%; text-align: left"&gt;Discount amortization and interest expenses related to June 27 Notes&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;16&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1040"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;16&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1042"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--InterestExpense_msFINztjv_zlTcp83Lkpjj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest expenses related to July 18 Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1045"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1047"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DiscountAmortizationAndInterestExpensesTwo_msFINztjv_z9b63atu2dth" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;Discount amortization and interest expenses related to July 30 Note&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;309&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1050"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;309&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1052"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--RevaluationExpensesRelatedToDerivativeFinancialLiabilities_pn3n3_msFINztjv_zezxB21JZ20i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;Revaluation expenses related to derivative financial liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1055"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1057"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities_pn3n3_msFINztjv_zmxtjfjUkxt3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;Revaluation expenses incurred from settlement of financial liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,505&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1060"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,505&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1062"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InterestExpenseDeposits_pn3n3_msFINztjv_zXVl7imz3jTk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest on bank deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(38&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherExpenses_pn3n3_msFINztjv_zd1FJnu5PiL" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;Exchange rate differentials, bank commissions and miscellaneous&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1070"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--FinanceIncomeNet_iNT_pn3n3_di_mtFINztjv_zV1QX83jCJJ6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance (income) expenses,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,848&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,822&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</srt:ScheduleOfCondensedFinancialStatementsTableTextBlock>
    <GCTK:DiscountAmortizationAndInterestExpensesOne
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact001039"
      unitRef="USD">16000</GCTK:DiscountAmortizationAndInterestExpensesOne>
    <GCTK:DiscountAmortizationAndInterestExpensesOne
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact001041"
      unitRef="USD">16000</GCTK:DiscountAmortizationAndInterestExpensesOne>
    <us-gaap:InterestExpense
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact001044"
      unitRef="USD">5000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact001046"
      unitRef="USD">5000</us-gaap:InterestExpense>
    <GCTK:DiscountAmortizationAndInterestExpensesTwo
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact001049"
      unitRef="USD">309000</GCTK:DiscountAmortizationAndInterestExpensesTwo>
    <GCTK:DiscountAmortizationAndInterestExpensesTwo
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact001051"
      unitRef="USD">309000</GCTK:DiscountAmortizationAndInterestExpensesTwo>
    <GCTK:RevaluationExpensesRelatedToDerivativeFinancialLiabilities
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact001054"
      unitRef="USD">2000</GCTK:RevaluationExpensesRelatedToDerivativeFinancialLiabilities>
    <GCTK:RevaluationExpensesRelatedToDerivativeFinancialLiabilities
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact001056"
      unitRef="USD">2000</GCTK:RevaluationExpensesRelatedToDerivativeFinancialLiabilities>
    <GCTK:RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact001059"
      unitRef="USD">1505000</GCTK:RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities>
    <GCTK:RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact001061"
      unitRef="USD">1505000</GCTK:RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities>
    <us-gaap:InterestExpenseDeposits
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact001064"
      unitRef="USD">-7000</us-gaap:InterestExpenseDeposits>
    <us-gaap:InterestExpenseDeposits
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact001065"
      unitRef="USD">-1000</us-gaap:InterestExpenseDeposits>
    <us-gaap:InterestExpenseDeposits
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact001066"
      unitRef="USD">-38000</us-gaap:InterestExpenseDeposits>
    <us-gaap:InterestExpenseDeposits
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact001067"
      unitRef="USD">-2000</us-gaap:InterestExpenseDeposits>
    <us-gaap:OtherExpenses
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact001069"
      unitRef="USD">18000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact001071"
      unitRef="USD">23000</us-gaap:OtherExpenses>
    <GCTK:FinanceIncomeNet
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact001074"
      unitRef="USD">-1848000</GCTK:FinanceIncomeNet>
    <GCTK:FinanceIncomeNet
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact001075"
      unitRef="USD">1000</GCTK:FinanceIncomeNet>
    <GCTK:FinanceIncomeNet
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact001076"
      unitRef="USD">-1822000</GCTK:FinanceIncomeNet>
    <GCTK:FinanceIncomeNet
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact001077"
      unitRef="USD">2000</GCTK:FinanceIncomeNet>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact001079">&lt;p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zFTwVRbQnGqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6 - &lt;span id="xdx_82B_zqoEpMyZAPt"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed interim consolidated financial statements were available to be issued. Based upon this review, the Company did not identify any other significant subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below.&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Completion
of underwritten U.S. public offering&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 12, 2024, the Company completed a public offering (the &#x201c;Offering&#x201d;) under which the Company received gross proceeds
of $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20241112__20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpSI7AiY6Yh3" title="Gross proceeds from public offering"&gt;10,000&lt;/span&gt; in exchange for issuance of an aggregate of (i) &lt;span id="xdx_90A_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1tP9c9SG7M" title="Shares issued"&gt;2,437,340&lt;/span&gt; shares (the &#x201c;Shares&#x201d;) of its Common Stock, (ii) &lt;span id="xdx_90B_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zXoTQPrrcpu5" title="Shares issued"&gt;4,756,900&lt;/span&gt;
pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase up to an aggregate of &lt;span id="xdx_90B_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z1bGPQv2CdIa" title="Shares issued"&gt;4,756,900&lt;/span&gt; shares of Common Stock (the &#x201c;Pre-Funded
Warrant Shares&#x201d;) in lieu of Shares, (iii) Series A Warrants (the &#x201c;Series A Warrants&#x201d;) to purchase up to &lt;span id="xdx_909_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesACommonWarrantMember_zSc1j3V7lBt4" title="Shares issued"&gt;7,194,240&lt;/span&gt; shares
of Common Stock (the &#x201c;Series A Warrant Shares&#x201d;) and (iv) Series B Warrants (the &#x201c;Series B Warrants&#x201d; and, together
with the Series A Warrants, the &#x201c;Common Warrants&#x201d;) to purchase up to &lt;span id="xdx_90C_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBCommonWarrantMember_zCY3WAecN04a" title="Shares issued"&gt;7,194,240&lt;/span&gt; shares of Common Stock (&#x201c;the &#x201c;Series
B Warrant Shares&#x201d; together with the Series A Warrant Shares, the &#x201c;Warrant Shares&#x201d;). Each Share or Pre-Funded Warrant,
as applicable, was sold together with one Series A Warrant to purchase one share of Common Stock and one Series B Warrant to purchase
one Common Share. The public offering price for each Share and accompanying Common Warrants was $&lt;span id="xdx_90C_eus-gaap--SharePrice_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--PrefundedWarrantsMember_zzpcZaXFd25" title="Shares issued, per share"&gt;1.39&lt;/span&gt;, and the public offering price
for each Pre-Funded Warrant and accompanying Common Warrants was $&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z668fmof9Om7" title="Shares issued, per share"&gt;1.389&lt;/span&gt; (the &#x201c;Offering Price&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Pre-Funded Warrants have an exercise price of $&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zsVYEpqkpIf7" title="Share price"&gt;0.001&lt;/span&gt; per share, are exercisable immediately and expire when exercised in full. Each Series
A Common Warrant will have an exercise price per share of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesACommonWarrantMember_zXzfJApE7vL4" title="Warrant, exercise price"&gt;1.81&lt;/span&gt; and will be exercisable beginning on the date on which Stockholder
Approval (as defined below) is received and deemed effective (the &#x201c;Initial Exercise Date&#x201d; or the &#x201c;Stockholder Approval
Date&#x201d;). The Series A Warrants will expire on the five-year anniversary of the Initial Exercise Date. The Series B Warrants will
have an exercise price per share of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBCommonWarrantMember_z4d9LMCKojVg" title="Warrant, exercise price"&gt;1.81&lt;/span&gt; and will be exercisable beginning on the Initial Exercise Date. The Series B Warrants
will expire on the two and one-half year anniversary of the Initial Exercise Date. The issuance of Common Warrant Shares upon exercise
of the Common Warrants is subject to stockholder approval under applicable rules and regulations of The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;)
(&#x201c;Stockholder Approval&#x201d; and the date on which Stockholder Approval is received and deemed effective, the &#x201c;Stockholder
Approval Date&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
exercise price of Series A Warrants and Series B Warrants is subject to certain adjustments. If at the time of exercise there is no effective
registration statement registering, or the prospectus contained therein is not available for the issuance of the Series A Warrants Shares
and Series B Warrant Shares to the holders, then the Series A Warrants and Series B Warrants may also be exercised, in whole or in part,
at such time by means of a &#x201c;cashless exercise&#x201d;. In addition, the holders are entitled to an option to require the Company
to purchase the Series A Warrants and Series B Warrants for cash in an amount equal to their Black-Scholes Option Pricing Model value,
in the event that certain fundamental transactions (which some of them are not considered solely within the control of the Company) as
defined in the Series B Warrants agreement, occur. Additionally, holders of Series B Warrants may also effect an &#x201c;alternative cashless
exercise&#x201d; at any time while the Series B Warrants are outstanding following the Initial Exercise Date. Under the alternate cashless
exercise option, the holder of the Series B Warrant has the right to receive an aggregate number of shares equal to the product of (i)
the aggregate number of shares of Common Stock that would be issuable upon a cashless exercise of the Series B Warrant and (ii) 3.0.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
incremental and direct issuance costs are estimated at the total amount of $&lt;span id="xdx_90A_eus-gaap--PaymentsOfDebtIssuanceCosts_pn3n3_c20241112__20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPu6cLA8K3w9" title="Incremental and direct issuance costs"&gt;1,127&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
closing of the public offering occurred on November 14, 2024 (the &#x201c;Closing Date&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt 0pt 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
a private placement offering completed&#160; concurrently with the completion of the public offering, the July 30 Investor voluntarily
converted &#160;approximately $&lt;span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn3n3_c20241112__20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--JulyThirtyNotesMember_z9NM5WmfsPJ4" title="Debt conversion converted instrument amount"&gt;4,089&lt;/span&gt; of Debt, which represents the outstanding minimal amount of principal and accrued interest under
the July 30 Note as of November 12, 2024, on substantially the same terms as the public offering, resulting in the issuance of &lt;span id="xdx_906_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--JulyThirtyNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zILd82iiKKig" title="Stock issuance"&gt;2,640,717&lt;/span&gt;
shares of Common Stock (plus &lt;span id="xdx_908_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--JulyThirtyNotesMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesACommonWarrantMember_zJv0FEwEYMm3" title="Stock issuance"&gt;2,640,717&lt;/span&gt; accompanying Series A Warrants and &lt;span id="xdx_90C_eus-gaap--SharesIssued_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--JulyThirtyNotesMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCommonWarrantMember_zhrDrbg04nW7" title="Stock issuance"&gt;2,640,717&lt;/span&gt; accompanying Series B Common Warrants), based on
a conversion price of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--JulyThirtyNotesMember_zoxmTKBDtus" title="Conversion price, per share"&gt;1.55&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-11-122024-11-12_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact001081"
      unitRef="USD">10000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001083"
      unitRef="Shares">2437340</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact001085"
      unitRef="Shares">4756900</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact001087"
      unitRef="Shares">4756900</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_SeriesACommonWarrantMember"
      decimals="INF"
      id="Fact001089"
      unitRef="Shares">7194240</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_SeriesBCommonWarrantMember"
      decimals="INF"
      id="Fact001091"
      unitRef="Shares">7194240</us-gaap:SharesIssued>
    <us-gaap:SharePrice
      contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_PrefundedWarrantsMember29981921"
      decimals="INF"
      id="Fact001093"
      unitRef="USDPShares">1.39</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact001095"
      unitRef="USDPShares">1.389</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact001097"
      unitRef="USDPShares">0.001</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_SeriesACommonWarrantMember"
      decimals="INF"
      id="Fact001099"
      unitRef="USDPShares">1.81</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_SeriesBCommonWarrantMember"
      decimals="INF"
      id="Fact001101"
      unitRef="USDPShares">1.81</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-11-122024-11-12_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact001103"
      unitRef="USD">1127000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2024-11-122024-11-12_us-gaap_SubsequentEventMember_custom_JulyThirtyNotesMember"
      decimals="-3"
      id="Fact001105"
      unitRef="USD">4089000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_JulyThirtyNotesMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001107"
      unitRef="Shares">2640717</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_JulyThirtyNotesMember_custom_SeriesACommonWarrantMember"
      decimals="INF"
      id="Fact001109"
      unitRef="Shares">2640717</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_JulyThirtyNotesMember_custom_SeriesCommonWarrantMember"
      decimals="INF"
      id="Fact001111"
      unitRef="Shares">2640717</us-gaap:SharesIssued>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_custom_JulyThirtyNotesMember"
      decimals="INF"
      id="Fact001113"
      unitRef="USDPShares">1.55</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#xdx2ixbrl0286"
          xlink:label="xdx2ixbrl0286"
          xlink:type="locator"/>
        <link:footnote id="Footnote000529" xlink:label="Footnote000529" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents
    amount lower than $1.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0286"
          xlink:to="Footnote000529"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
